



3rd Schizophrenia International Research Society Conference

*Schizophrenia:
The Globalization of Research*



**FLORENCE, ITALY
14 - 18 APRIL 2012**



This meeting is jointly sponsored by the Vanderbilt University School
of Medicine and the Schizophrenia International Research Society





3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

Opening letter

Dear Attendees,

It is our great pleasure to welcome you to the 3rd Biennial Schizophrenia International Research Society (SIRS) Conference. SIRS is a non-profit organization dedicated to promoting research and communication about schizophrenia among research scientists internationally. We sincerely appreciate your interest in the Society and in our conference. The second congress in 2010 was a major success for the field attracting more than 1500 attendees from 53 countries. We anticipate an even higher attendance at this congress with most of the best investigators in the world in attendance.

SIRS was founded in 2005 with the goal of bringing together scientists from around the world to exchange the latest advances in biological and psychosocial research in schizophrenia. The Society strives to facilitate international collaboration to discover the causes of, and better treatments for, schizophrenia and related disorders. Part of the mission of the Society is to promote educational programs in order to effectively disseminate new research findings and to expedite the publication of new research on schizophrenia. In addition to the Biennial Congress, the Society hosted the first regional meeting in São Paulo, Brazil in August of 2011. The meeting was a great success with over 150 presenters and 400 attendees.

Under the outstanding leadership of Program Committee Chair Jim van Os and Co-Chair Dawn Velligan, we have an exciting scientific program planned for the 3rd Biennial Conference. The Program Committee selected thirty-five outstanding symposia session in addition to seven evening workshops out of 92 submissions. Special sessions including the Family Forum, Italian Symposium and the Basic Science session have been added to the conference schedule. The Program Committee also selected forty-eight superior oral presentations from more than 500 abstracts submitted. Plan to visit the poster sessions during lunch on Sunday, Monday and Tuesday.

Please remember to complete an evaluation at the end of the conference so the Society can continue to improve its educational offerings. If you are not already a member, please stop by the registration desk and inquire about member benefits and how to join. We hope you enjoy this conference and in addition to learning about the latest, cutting edge research in the field, you will enjoy the beautiful city of Florence and its rich history.

Sincerely,

The Organizers

Robin M. Murray, M.D., President

John M. Kane, M.D., President-Elect

Lynn E. DeLisi, M.D., Secretary

René Kahn, M.D., Ph.D., Treasurer

Wolfgang Fleischhacker, Meeting Liaison Chair

Jim van Os, Program Committee Chair

Dawn Velligan, Program Committee Co-Chair



Table of Contents

General Information	6
Saturday, 14 April	18
Sunday, 15 April	22
Monday, 16 April	33
Tuesday, 17 April	42
Wednesday, 18 April	54
Sunday Posters	60
Monday Posters	82
Tuesday Posters	104
Index of Presenters and Authors	126



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

Acknowledgements

The Schizophrenia International Research Society appreciates the generous support of the Society from our 2011 - 2012 Supporting Corporations.

Platinum



Silver



Additional Supporters

**Hoffman -
La Roche**

**Intra-cellular
Therapies**

Lundbeck

Sunovion

The Sponsors express appreciation to the following companies for their support of this educational activity by providing unrestricted educational grants:

AstraZeneca

Eli Lilly & Company

The Junior Travel Award Fellowship Program is sponsored by an R13 grant from the U.S. National Institute of Mental Health to Harvard Medical School (Lynn DeLisi, PI) (Grant ED: R13MH082446).



Schizophrenia International Research Society Officers, Board of Directors and International Advisory Committee

OFFICERS:

Robin M. Murray, President
John M. Kane, President-Elect
Lynn E. DeLisi, Secretary
René Kahn, Treasurer

BOARD OF DIRECTORS (2011 – 2012):

Jean Addington, Canada
Geraldo Busatto, Brazil
Mary Cannon, Ireland
Wolfgang Fleischhacker, Austria
Philip Harvey, USA
Shitij Kapur, UK
Jun Soo Kwon, Republic of Korea
John McGrath, Australia
Stephen Marder, USA
Xin Yu, China
Alison Yung, Australia

INCOMING OFFICERS:

John Kane, USA, President
René Kahn, Netherlands, President-Elect
Lynn E. DeLisi, USA, Secretary
Anthony Grace, USA, Treasurer
Robin M. Murray, UK, Past-President

INCOMING BOARD OF DIRECTORS:

Jean Addington, Canada
Celso Arango, Spain
Geraldo Busatto, Brazil
Jun Soo Kwon, Republic of Korea
Patrick McGorry, Australia
John McGrath, Australia
Stephen Marder, USA
Herbert Meltzer, USA
Xin Yu, China
Alison Yung, Australia

INTERNATIONAL ADVISORY COUNCIL:

Celso Arango, Spain
Francine Benes, USA
David Braff, USA
Mary Cannon, Ireland

William Carpenter, USA
David Castle, Australia
Eric Chen, China
Siow Ann Chong, Singapore
Christina Dalman, Sweden
Michael Davidson, Israel
J.F.W. Deakin, UK
Robin Emsley, South Africa
Wolfgang Gaebel, Germany
Wagner Gattaz, Brazil
Birte Glenthøj, Denmark
Anthony Grace, USA
Michael Green, USA
Kyung Sue Hong, Korea
Matti Huttunen, Finland
Dan Javitt, USA
Eve Johnstone, UK
Richard Keefe, USA
Veronica Larach Walters, Chile
David Lewis, USA
Mario Maj, Italy
Patrick McGorry, Australia
Paulo Menezes, Brazil
Preben Bo Mortensen, Denmark
Dieter Naber, Germany
Christos Pantelis, Australia
Josef Peuskens, Belgium
Sibylle Schwab, Australia
Cynthia Shannon Weickert, Australia
Iris Sommer, Netherlands
Martha Shenton, USA
Masatoshi Takeda, Japan
Nori Takei, Japan
Carol Tamminga, USA
Rangaswamy Thara, India
Si Tianmei, China
Jim van Os, The Netherlands
Dawn Velligan
Antonio Vita, Italy
John Waddington, Ireland
Mark Weiser, Israel
Til Wykes, UK



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

2012 Meetings Committees

TRAVEL AWARD SELECTION COMMITTEE

Celso Arango, Spain
Lynn L. DeLisi, USA
Robin Emsley, South Africa
John McGrath, Australia
Dieter Naber, Germany
Sibylle Schwab, Australia
Cyndi Shannon Weickert, Australia

2012 PROGRAM COMMITTEE

Jean Addington, Canada
Köksal Alptekin, Turkey
Alessandro Bertolino, Italy
Geraldo Busatto, Brazil
Mary Cannon, Ireland
Miranda Chakos, USA
Eric Chen, Hong Kong
Siow Ann Chong, Singapore
David Cotter, Ireland
Deepak Cyril D'Souza, USA
Christina Dalman, Sweden
Paola Dazzan, UK
Robin Emsley, South Africa
Anthony Grace, USA
Michael Green, USA
Philip Harvey, USA
Hyung Sue Hong, Korea
Eileen Joyce, UK
Shitij Kapur, UK
Richard Keefe, USA
Tilo Kircher, Germany
Jun Soo Kwon, Korea
John McGrath, Australia
Craig Morgan, UK
Vera Morgan, Australia
Dieter Naber, Germany
Douglas Noordsy, USA
Patricio O'Donnell, USA
Gary Remington, Canada
Dan Rujescu, Germany
Sibylle Schwab, Germany
Martha Shenton, USA
Si Tianmei, China
Antonio Vita, Italy
John Waddington, Ireland

Thomas Weickert, Australia
Mark Weiser, Israel
Stephen Wood, Australia
Til Wykes, UK
Xin Yu, China

CONGRATULATIONS TO THE 2012 TRAVEL FELLOWS:

Bagrat Abazyan, USA
Brandon Abbs, USA
Rashmin Achalia, India
Adegoke Adelufosi, Nigeria
Ahmet Aktener, Turkey
Natalie Beveridge, Australia
Savita Bhakta, USA
Rachael Blackman, USA
Emre Bora, Australia
Min Soo Byun, South Korea
Maurice Cabanis, Germany
Ricardo Carrion, USA
Christina Castellani, Canada
Tze Jen Chow, Malaysia
Monika Dmistrz-Weglarz, Poland
Charlotte Gayer-Anderson, UK
Felipe Gomes, Brazil
Kristen Haut, USA
Joshua Kantrowitz, USA
Taishiro Kishimoto, USA
Frankie Lee, Canada
Ashleigh Lin, UK
Lena Palaniyappan, UK
Weidan Pu, China
Meina Quan, USA
Maria Rubio, USA
Sonia Ruiz de Azúa, Spain
Saddichha Sahoo, India
Gregory Strauss, USA
Aleksandra Szaepankiewicz, Poland
Andrew Thompson, Australia
Antonella Trotta, UK
Laura Tully, USA
Hiroyuki Uchida, Japan
Eva Velthorst, Netherlands
Jared Young, USA



Continuing Medical Education

ACCME:

The 3rd Biennial Schizophrenia International Research Society Conference is jointly sponsored by the Vanderbilt University School of Medicine and SIRS. This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Vanderbilt University Medical School of Medicine and the SIRS. Vanderbilt University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Vanderbilt University School of Medicine designates this live activity for a maximum of 34.50 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity. There will be a \$50.00 USD charge for scientific registrants to obtain CME credits.

To obtain credit, registered participants must complete an online evaluation. The evaluation may be completed at www.schizophreniaconference.org.

Course Objectives:

After participating in this CME Activity, **Clinicians** should be able to describe and discuss:

- Strategies for determining an approach to manage patients with schizophrenia.
- The status of genetics findings and how they can be incorporated into strategies for managing patients with schizophrenia.
- The use of brain Imaging data about pathophysiology and disease progression to revise or continue a strategy for managing patients with schizophrenia.
- the implications of basic neuroscience findings for managing patients with schizophrenia.

After participating in this CME Activity, **Researchers** should be able to describe and discuss:

- Approaches to develop novel treatments for schizophrenia.
- Strategies for translating basic neuroscience into knowledge that can be used clinical practice.
- Differences in schizophrenia research across diverse cultures and geographic areas.
- Novel intervention studies that will promote the development of advanced knowledge about schizophrenia.
- Methods to advance the clinical application genetic research in schizophrenia.

Disclosures:

It is the policy of Vanderbilt University School of Medicine and Schizophrenia International Research Society to require disclosure of financial relationships from individuals in a position to control the content of a CME activity; to identify and resolve conflicts of interest related to those relationships; and to make disclosure information available to the audience prior to the CME activity. Presenters are required to disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentations. Disclosures for 2012 speakers, plenary, special session, symposia, workshop, oral presentations and poster presenters may be found online at www.schizophreniaconference.org. A copy of the disclosures will be available at the registration desk.



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

EACCME:

The 3rd Biennial Schizophrenia International Research Society Conference has been granted 24 European CME credits (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME). Physicians should claim only the credits commensurate with the extent of their participation in the activity. To obtain credit, registered participants must complete an online evaluation. The evaluation may be completed at www.schizophreniaconference.org. There will be a \$50.00 USD charge to obtain credit.

Italian Ministry of Health Credits:

Credits will be offered from the Italian Ministry of Health. For more information, please inquire at the Registration Desk in the Palazzo Entrance.

Conference Evaluation:

All conference attendees are urged to complete an evaluation of the meeting. Attendees who are requesting CME (ACCME or EACCME) credit for the meeting are required to complete the evaluation. This form is available online only. You may complete the evaluation in the Computer Center or on-line at www.schizophreniaconference.org. All evaluations must be completed by 19 May, 2012.

Videotaping Sessions:

Attendees may not videotape, audiotape, or photograph (camera or camera phone) presentations at the conference without prior permission from the session chair.

General Information

Registration

Registration for the 3rd Biennial Schizophrenia International Research Society Conference is located at the Main Entrance of Firenze Fiera Congress Center, Piazza Adua.

Date	Time
Saturday, 14 April	8:30 a.m. - 7:00 p.m.
Sunday, 15 April	8:00 a.m. - 6:30 p.m.
Monday, 16 April	8:00 a.m. - 6:30 p.m.
Tuesday, 17 April	8:00 a.m. - 6:30 p.m.
Wednesday, 18 April	8:00 a.m. - 4:00 p.m.

Registration Types:

Delegate: Scientific Attendee

Student: Full-time graduate students, medical students or students in the first two years of a post-doctoral fellowship program at a university in a field relevant to schizophrenia research. A letter from the student's immediate supervisor verifying his/her student status and relevant field will be required for registration.

Accompanying Guest: Non-scientific attendee who only attends social functions.

Accompanying Guest:

The €200 fee includes all lunches, coffee breaks and welcome reception.

Registration Timeframes:

Regular: Register August 2011 - 14 March 2012

Late: Register 15 March 2012 - onsite



Registration Fees:

Category	Up to 14 March 2012	15 March or later
SIRS 2011 and 2012 Member	400.00€	450.00€
SIRS 2012 New Member	440.00€	490.00€
SIRS 2011 and 2012 Student Member	150.00€	190.00€
SIRS 2012 New Student Member	190.00€	240.00€
Non-Member Delegate	650.00€	700.00€
Non-Member Student	230.00€	280.00€
Accompanying Guest	200.00€	200.00€

Abstracts:

Abstracts for all presentations are available online at www.schizophreniaconference.org.

Abstracts will be published electronically by *Schizophrenia Research* and will be available as an electronic flipbook and as a PDF document.

Awards

The Awards Committee and Board of Directors of the Schizophrenia International Research Society are pleased to announce the Society's first Honorary Award Winners.

OUTSTANDING BASIC RESEARCH:



John Waddington is Professor of Neuroscience in Molecular & Cellular Therapeutics at the Royal College of Surgeons in Ireland, Dublin. He graduated in Natural Sciences from the University of Cambridge in 1974, where he was enthused for our field by working with Trevor Robbins & Susan Iversen. He received his Ph.D. in Psychopharmacology from the University of London in 1981 for work undertaken with Tim Crow in the Division of Psychiatry, MRC Clinical Research Centre, Northwick Park Hospital, and was awarded DSc in Neuroscience from the same university in 1991. Over a 30-year career, his teams have devoted themselves to basic and clinical research relating to schizophrenia during which they have published more than 400 articles, chapters and books, including articles in *Nature*, *Science*, *PNAS*,

Lancet and *BMJ*. He has been a global ambassador for our field delivering more than 370 invited lectures that include the John Cade Lecture at the University of Melbourne and as Visiting Professor at Nihon University, Tokyo. He was elected to the Royal Irish Academy in 2003 and received the CINP-Lilly Neuroscience Basic Research Award in 2004. He has mentored numerous graduate students, post-docs and clinical fellows, many of whom have evolved to independent standing. Over the past several years, his group has been to the fore in studying mice mutant for genes associated with risk for schizophrenia. In particular, he is currently playing a leading role in the study of gene × environment interactions using mutant mice subjected to a variety of relevant biological and psychosocial insults over their developmental trajectory these studies now extend to the critical issue of identifying and characterizing gene × gene interactions. He has involved himself consistently in additional academic and professional responsibilities to support and advance our field: inter alia, he serves on the Editorial Boards of both SIRS-affiliated journals, *Schizophrenia Bulletin* and *Schizophrenia Research*; he



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

has organized symposia at SIRS conferences, including the Basic Science Special Session at this conference, and at the SIRS-affiliated International Congress on Schizophrenia Research, for which he serves on the Advisory Board and Young Investigator Review Committee. He was a member of the original ad hoc group that negotiated the formation of SIRS and is currently a member of the SIRS International Advisory Council and Elections Committee.

OUTSTANDING CLINICAL/COMMUNITY RESEARCH



Philip D. Harvey, Ph.D. is a professor of Psychiatry at the University of Miami Miller School of Medicine. He was formerly professor of Psychiatry at Emory University School of Medicine and Mt. Sinai School of Medicine and Chief Psychologist at Mt. Sinai Hospital. Dr. Harvey received his Ph.D. in Clinical Psychology from SUNY at Stony Brook in 1982. Dr. Harvey is the author of over 800 scientific papers and abstracts and he has written over 50 book chapters. He is a widely cited author whose work has been cited more than 500 times per year for the past decade, with over 1500 citations of his work in 2011 alone. Dr. Harvey has given more than 1,800 presentations at scientific conferences and medical education events. He has edited 5 books and written 4 books on topics of psychological assessment, schizophrenia, and aging. He has received a number of awards and is a member of the American Psychological Association, the American College of Neuropsychopharmacology (Fellow), the International College of Neuropsychopharmacology (Fellow), the Society for Research in Psychopathology (Founding Member), the Society for Biological Psychiatry, International Neuropsychological Society, the Schizophrenia International Research Society (Founding Director), and the International Society for Clinical Trials and Methodology (Founding Member).

His research has focused for years on cognition and functioning and he has written extensively on aging in schizophrenia, functional impairments in severe mental illness, the cognitive effects of typical and atypical antipsychotics, as well as studying the effects of cognitive enhancing agents in various conditions, including schizophrenia, dementia, affective disorders, and traumatic brain injury. Dr. Harvey's past research includes serving as a primary consultant on over 40 pharmacological treatment trials. He directs an annual conference on cognition that is an official satellite of the International Congress on Schizophrenia Research and the Schizophrenia International Research Society.



RISING STAR

Dr. Paolo Fusar Poli, Ph.D. is Senior Lecturer/Associate Professor at the Department of Psychosis Studies, Institute of Psychiatry, London and Consultant at the prodromal OASIS team, South London and Maudsley NHS Trust. Over the past few years he has developed a strong interest into the prodromal phases of psychosis and he has widely employed neuroimaging techniques to address functional, structural and neurochemical correlates of an enhanced clinical risk for the illness. He is particularly interested in the development of multimodal imaging approaches and in conducting large voxel-based meta-analyses in the field of early psychosis. To date, Dr. Fusar-Poli has published over than 150 PubMed papers.



Scientific Sessions

TRAVEL FELLOW ORIENTATION

Saturday, 14 April, 4:30 p.m. - 5:45 p.m.

Auditorium

Travel Awardees are required to attend.

Four presentations will be given at the Travel Fellow Orientation.

Successful Manuscript Publication

Lynn E. DeLisi

Financial Conflict of Interest

Stephen Marder

Career Development and Grant Writing in the American System

Robert McCarley

Grant Writing in the European System

Jim van Os

KEYNOTE LECTURE

Saturday, 14 April, 6:00 p.m. - 7:00 p.m.

Auditorium



Philip Campbell

Editor-in-Chief, Nature and the Nature Publishing Group

Mental Health Research: New Charity, New Strategy, New Science.

Dr. Philip Campbell is Editor-in-Chief of Nature and of the Nature Publishing Group. His areas of responsibility include the editorial content and management of Nature, and assuring the long-term quality of all Nature publications. He is based in London. There is a pressing need for continued funding in mental health research to drive new discoveries and find better treatments. Dr. Campbell will describe the processes involved in inaugurating a new major charity to fund mental health research, to be launched later this year. In order to develop sustainable funding in this area of research, a novel strategy is required. He will discuss the options and decision-making concerning a research funding strategy and the 'proposition' that can be responsibly offered to donors. These decisions revolve around the potential contributions of diverse disciplines, the tension between short- and long-term accomplishments, and the relevance of stigma. The combination of collaborative, synergistic effort and appropriate funding may pave the way to the development of new science in mental health research.



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

PLENARY SESSIONS

There will be four plenary sessions covering topics including new genetic advances, psychological and social treatments, models of immunology and experimental medicine and new pharmacologic treatments in the pipeline for schizophrenia.

Sunday, 15 April

Auditorium

8:30 a.m. - 12:00 p.m. *Psychological and Social Treatments Plenary Session*

Chair: Dawn Velligan

Co-Chair: Shitij Kapur

Christos Pantelis

Neuroimaging and Cognitive Rehabilitation; A Hypothesis Based on the Evidence for Progressive Brain Changes in Schizophrenia

Steffen Moritz

Metacognitive Training in Schizophrenia Patients (MCT)

Douglas Turkington

Cognitive Behavior Therapy for Positive and Negative Symptoms

Michael Green

Social Cognition Schizophrenia: Rationale and Strategies for Training Intervention

Monday, 16 April

8:30 a.m. – 12:00 p.m. *Genetics Plenary Session*

Chair: Jim van Os

Co-Chair: Lynn E. DeLisi

William Byerley

Genetics of Schizophrenia: Past Results and Future Approaches

Maria Karayiorgou

The Genetic Architecture of Schizophrenia: New Mutations and Emerging Paradigms

Robin M. Murray

Gene-Environment Interaction in Psychosis

Inez Myin-Germeys

Reactivity Phenotypes for Genetics Studies



Tuesday, 17 April

8:30 a.m. – 12:00 p.m. *Models from Immunology and Experimental Medicine Plenary Session*

Chair: René Kahn

Co-Chair: Carol Tamminga

Preben Bo Mortensen

Epidemiology

Alan Brown

Prenatal Infection, Immune Function and Schizophrenia

Peter McGuffin

What Genetic Studies Tell us about the Involvement of the Immune System in Schizophrenia

Barbara Sperner-Unterweger

Can Affective Disorders and Schizophrenia be Differentiated on an Immunological Basis?

Wednesday, 18 April

8:30 a.m. – 12:00 p.m. *New Treatments Plenary Session*

Chair: Wolfgang Fleischhacker

Co-Chair: Donald Goff

Donald Goff

Difficulties with Translational Research

John Kane

Methodologic Challenges in Clinical Trials in Schizophrenia

Colleagues in industry will provide brief updates on promising new compounds and strategic approaches to drug development.

Presentation from Pharma:

- Anjana Bose, Forest Pharmaceutical and Gedeon Richter
- Rob Conley, Eli Lilly and Company
- Gerhard Gross, Abbott
- David Hosford, Targacept
- Ron Marcus, Bristol Myers-Squibb
- Daniel Umbricht, Roche
- Kim Vanover, Intracellular Therapies



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

SPECIAL SESSIONS

Special sessions have been included in the conference program:

- *The Italian Research Experience Concerning First Episode Psychotic Patients*
Saturday, 14 April, 10:00 a.m. – 12:30 p.m., Sala Verde
Chair: Paul Fearon, Co-Chair: Alessandro Bertolino
Simultaneous Translation Provided
- *The Family Forum*
Saturday, 14 April, 2:00 p.m. – 4:30 p.m., Sala Verde
Chair: Lynn E. DeLisi, Co-Chair: Alice Mulè
Simultaneous Translation Provided
- *Basic Science Session*
Sunday, 15 April, 4:15 p.m. – 6:15 p.m., Palazzo Affari 1st Floor
Chair: John Waddington

SYMPOSIA SESSIONS

The title and location of each symposium is indicated in the program. The presentations in each session are scheduled at approximately 20 – 25 minute intervals. A general discussion period is scheduled after the last presenter in each session. Symposia are scheduled:

Sunday, 15 April	2:00 p.m. – 4:00 p.m. 4:15 p.m. – 6:15 p.m.
Monday, 16 April	2:00 p.m. – 4:00 p.m. 4:15 p.m. – 6:15 p.m.
Tuesday, 17 April	4:15 p.m. – 6:15 p.m.
Wednesday, 18 April	1:30 p.m. – 3:30 p.m.

WORKSHOPS

Seven workshops have been scheduled on Sunday and Tuesday evening. The title and location of each workshop is indicated in the program. The presentations within each session are scheduled at approximately 20 – 25 minute intervals. A general discussion period is scheduled after the last presentation within each workshop. Workshops are scheduled:

Sunday, 15 April	6:30 p.m. – 8:30 p.m.
Tuesday, 17 April	6:30 p.m. – 8:30 p.m.



ORAL PRESENTATIONS

Six concurrent oral presentation sessions are scheduled on Tuesday, 17 April from 2:00 p.m. – 4:00 p.m. Within the concurrent sessions, there are 8 individual presentations. Oral sessions scheduled:

Genetics and Environment

Co-Chairs: John McGrath and Dan Rujescu

Palazzo Affari, 2nd Floor

Neuroimaging

Co-Chairs: Paola Dazzan and Jun Soo Kwon

Palazzo Affari, Ground Floor

Neuropathology and Electrophysiology

Co-Chairs: Anthony Grace and John Waddington

Palazzo Affari, Lower Level

Neuropsychology and Development

Co-Chairs: Eileen Joyce and Richard Keefe

Sala Verde

Psychosocial and Comorbidities

Co-Chairs: Michael Green and Til Wykes

Palazzo Affari, 1st Floor

Treatments

Co-Chairs: Jean Addington and Robin Emsley

Auditorium

POSTERS

Three poster sessions have been scheduled. Presenters should put their poster up by 9:30 a.m. and remove the poster by 5:00 p.m. on the day it is scheduled. Poster presentations are grouped by general topic when possible. All three poster sessions are located in the Cavaniglia located across the street in the Fortezza de Basso. Lunch will be served each day with the poster session.

Poster viewing will be open until 5:00 p.m.

Sunday, 15 April	Poster Session I 12:00 p.m. – 2:00 p.m.
Monday, 16 April	Poster Session II 12:00 p.m. – 2:00 p.m.
Tuesday, 17 April	Poster Session III 12:00 p.m. – 2:00 p.m.



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

COMPUTER ACCESS

Complimentary wireless internet access is available in the conference center. To access the wireless internet, input "SIRS2012" as the username and "Florence" as the password. Conference attendees may also use the Computer Center located in Limonaia.

The Computer Center is provided this year for the convenience of meeting attendees who wish not to bring a laptop. Computers and printers will be available in the Limonaia for the following: email, internet access and meeting evaluation.

The Computer Center will be open the following hours:

Saturday, 14 April	9:00 a.m. – 7:00 p.m.
Sunday, 15 April	7:30 a.m. – 6:30 p.m.
Monday, 16 April	7:30 a.m. – 6:30 p.m.
Tuesday, 17 April	7:30 a.m. – 6:30 p.m.
Wednesday, 18 April	7:30 a.m. – 4:30 p.m.

SPEAKER READY ROOM

A speaker ready room is available in Sala 103 in the Palazzo Congressi. All presenters are required to come to the speaker ready room to upload your presentation, preferably 24-hours prior to the presentation. Presentations from individual computers are not permitted. Below are the hours for the Speaker Ready Room:

Saturday, 14 April	8:00 a.m. – 7:00 p.m.
Sunday, 15 April	7:30 a.m. – 7:00 p.m.
Monday, 16 April	7:30 a.m. – 7:00 p.m.
Tuesday, 17 April	7:30 a.m. – 7:00 p.m.
Wednesday, 18 April	7:30 a.m. – 3:30 p.m.



REFRESHMENT BREAKS

Coffee and light pastries are available Sunday - Wednesday at 8:00 a.m. The morning break will be located in the Passi Perduti, located outside the Auditorium. Afternoon breaks will be available Saturday - Wednesday outside the Palazzo Affari meeting rooms, the Auditorium and the Sala Verde.

LUNCHEONS


Buffet lunch will be served Sunday – Tuesday from 12:00 p.m. – 2:00 p.m. in the Cavaniglia during the poster sessions. Buffet lunch will be served on Wednesday from 12:00 p.m. – 1:30 p.m. in the Passi Perduti, located outside the Auditorium.




3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research


FLOOR PLAN



Poster Sessions and lunches will be held at the Fortezza da Basso in the Cavaniglia Pavilion. This is a short 3 to 5 minute walk from the Palazzo de Congressi.




Concurrent Symposia, Oral Presentations and Special Sessions will be held on the Lower Floor, Ground Floor, First Floor, Second Floor of the Palazzo degli Affari.



The Computer Center will be located in the Limonaia building just between the Palazzo Degli Affari and the Villa Vittoria.




Palazzo Congressi - Villa Vittoria AUDITORIUM




Keynote, Plenary Sessions and some Special Sessions, Symposia and Oral Presentations will be held in the Auditorium.

Palazzo Congressi - Villa Vittoria

First Floor



Second Floor



The Speaker Ready Room (Sala 103) and other small meeting rooms for journal meetings and committee meetings will be in the Villa Vittoria Building on the 1st Floor. The Villa Vittoria building is connected to the Auditorium. The Sala Verde room is on the 2nd floor of the Villa Vittoria building. The Italian Symposia Session, Family Forum, Symposia and Oral Presentations will be held in the Sala Verde.



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

Saturday, 14 April

	7:00-8:00	8:00-9:00	9:00-10:00	10:00-11:00	11:00-12:00	12:00-1:00	1:00-2:00	2:00-3:00	3:00-4:00	4:00-5:00	5:00-6:00	6:00-7:00	7:00-8:00	8:00-9:00
Auditorium										4:30-5:45 Travel Awardee Orientation		6:00-7:00 Keynote Lecture		
Sala Verde			9:30-10:00 Coffee Break	10:00 - 12:30 The Italian Research Experience Concerning First Episode Psychotic Patients			1:30-2:00 Coffee Break	2:00-4:30 Family Forum						
Palazzo Entrance							8:30-7:00 Registration							
Sala 103							8:00-7:00 Speaker Ready Room							
Limonaia							9:00-7:00 Computer Center							
Palaffari Lawn													7:00-9:00 Opening Night Reception	

Legenda:

Keynote Special Session Speaker Ready Registration Computer Center Opening Night Reception



Saturday, 14 April, Detailed Schedule of Events

Registration

Palazzo Entrance

8:30 AM - 7:00 PM

Coffee Available

Sala Verde

9:30 AM - 12:30 PM

Scientific Sessions

SPECIAL SESSION - The Italian Research Experience Concerning First Episode Psychotic Patients

10:00 AM - 12:30 PM

Sala Verde

Chair: Paul Fearon

Co-Chair: Alessandro Bertolino

Abstract: This symposium will pull together the Italian research experiences on patients with their first episode of psychosis. Dr. Alice Mulè will present her preliminary data on the incidence of psychotic disorders in Palermo, the main city of Sicily, discussing the main incidence differences found compared to those in other European countries. Dr. Sarah Tosato will discuss her findings from the Psychosis Incident Cohort Outcome Study – PICOS-Veneto focusing on social disability and needs for care in patients at their first episode of psychosis according to gender. Dr. Ilaria Tarricone will discuss how migration can impact on psychosis onset. Dr. Marta Di Forti will report her findings on the influence of cannabis consumption on patients affected by a first episode of psychosis.

Introduction

Robin M. Murray

Risk Factors for Psychosis in Migrants in Bologna

Ilaria Tarricone

The Influence of Gender on Clinical and Social Characteristics of Patients at Psychosis Onset: A Report from the Psychosis Incident Cohort Outcome Study (PICOS)-Veneto.

Sarah Tosato

Incidence of Psychotic Disorders in Palermo: Preliminary Results

Alice Mulè

Are Cannabis Users Different from other First Episode Psychotics?

Marta Di Forti

Discussant

Antonio Vita

Coffee Available

Sala Verde

1:30 PM - 4:30 PM



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

SPECIAL SESSION- Family Forum

2:00 PM - 4:30 PM

Sala Verde

Co-Chairs: Lynn E. DeLisi and Alice Mulè

Abstract: There often exists a large gap between what researchers know about the illness, schizophrenia, and what patients and their families experience during and by the consequences of this chronic disease. One purpose of the Schizophrenia International Research Society is to foster better communication between researchers and consumers and facilitate the dissemination of knowledge about schizophrenia, both to clinicians who treat it and to individuals who have the disease. This forum will bring together researchers with the families of people who have schizophrenia. Researchers will be present to communicate current knowledge about:

- What factors are relevant to developing schizophrenia
- Advances in early detection and attenuation of its chronic course
- What role genes play in its development
- What latest new treatments can be brought to the clinic

Speakers will include Sir Professor Robin Murray, from London, UK who will give an update on how far we have currently advanced in research; Professor Ilaria Taricone, from Bologna, Italy, who will speak on the role of families in facilitating recovery of their affected relatives; Professor John Kane who will speak on new treatments, and Professor Emmanuelle Peters who will specifically speak on Cognitive Therapy. This, in turn, will be followed by Elyn Saks, someone who has suffered and recovered from the disease, who will give a patient's perspective. Dr. Muggia will specifically address the Italian family and patient perspective. A panel of other researchers and family members will bring together the audience and speakers to discuss the major current issues and obstacles that exist and the ways in which they can be approached.

Understanding Schizophrenia Today

Robin Murray

Study of Role of Families in Patient Compliance

Ilaria Tarricone

Update on Drug Treatment

John Kane

The Sufferer's Perspective

Elyn Saks

Italian Family and Caregivers Group

Ernesto Muggia

Cognitive Therapy

Emmanuelle Peters

Panel

Mirella Ruggeri, Marta Di Forti, Dawn Velligan



SPECIAL SESSION – Travel Fellow Orientation

4:30 PM - 5:45 PM

Auditorium

Chair: Lynn E. DeLisi

The Travel Fellow Orientation has been organized for 2012 Travel Awardees and their mentors, but is open to all junior investigators attending the SIRS Biennial Conference.

Successful Manuscript Publication

Lynn E. DeLisi

Financial Conflict of Interest

Stephen Marder

Career Development and Grant Writing in the American Grant System

Robert McCarley

Grant Writing in the European System

Jim van Os

KEYNOTE LECTURE - Mental Health Research: New Charity, New Strategy, New Science

Auditorium

Philip Campbell, Editor-in-Chief, Nature Magazine and Nature Publishing Group

There is a pressing need for continued funding in mental health research to drive new discoveries and find better treatments. Dr. Campbell will describe the processes involved in inaugurating a new major charity to fund mental health research, to be launched later this year. In order to develop sustainable funding in this area of research, a novel strategy is required. He will discuss the options and decision-making concerning a research funding strategy and the 'proposition' that we can responsibly offer to donors. These decisions revolve around the potential contributions of diverse disciplines, the tension between short- and long-term accomplishments, and the relevance of stigma. The combination of collaborative, synergistic effort and appropriate funding may pave the way to the development of new science in mental health research.

OPENING RECEPTION

7:00 PM - 9:00 PM

Palazzo Affari Lawn, Passi Perduti in case of inclement weather



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

Sunday, 15 April

	7:00 - 8:00	8:00 - 9:00	9:00 - 10:00	10:00 - 11:00	11:00 - 12:00	12:00 - 1:00	1:00 - 2:00	2:00 - 3:00	3:00 - 4:00	4:00 - 5:00	5:00 - 6:00	6:00 - 7:00	7:00 - 8:00	8:00 - 9:00
Auditorium			8:30-12:00 Psychological and Social Treatments					2:00-4:00 The Abnormal Life of the D2 Receptor in Schizophrenia	4:00-4:15 Coffee Break	4:15-6:15 Intervening in People At-Risk of Psychosis: What is the Evidence?				
Palazzo Affari Ground Floor								2:00-4:00 Convergent Evidence Linking Advanced Paternal Age and Neurodevelopmental Disorders	4:00-4:15 Coffee Break	4:15-6:15 Cellular Trafficking in Schizophrenia: Is It Important?	6:15-6:30 Coffee Break	6:30-8:30 Homicide and Schizophrenia		
Palazzo Affari 1st Floor								2:00-4:00 Long Acting Injectable Antipsychotic Medications in Schizophrenia: Do Recent Studies Change Our Understanding of Their Role in Our Treatment Armamentarium?	4:00-4:15 Coffee Break	4:15-6:15 Basic Science Special Session	6:15-6:30 Coffee Break	6:30-8:30 Treatment Options for Refractory Positive and Negative Symptoms in Schizophrenia		
Palazzo Affari 2nd Floor								2:00-4:00 Hormonal Influences in Schizophrenia: Key in the Mechanism of Illness or an Illusory Correlation?	4:00-4:15 Coffee Break	4:15-6:15 Understanding the Path to Better Functioning in Schizophrenia	6:15-6:30 Coffee Break	6:30-8:30 Cannabis and Psychosis - The State of the Art		
Palazzo Affari Lower								2:00-4:00 Immune Response in Schizophrenia: Host-Environment Interactions	4:00-4:15 Coffee Break	4:15-6:15 Progressive Changes in Brain Structure and Function in Psychosis	6:15-6:30 Coffee Break	6:30-8:30 How Early and Late Social Environment Shapes Risk and Onset of Psychotic Disorders		
Sala Verde								2:00-4:00 Is Schizophrenia a Unique Illness of the Brain, or the More Severe Part of a Spectrum of Psychopathology?	4:00-4:15 Coffee Break	4:15-6:15 Psychosis - From Epidemiology to Mechanisms				
Cavaniglia						12:00-2:00 Sunday Poster Session								
Palazzo Entrance							8:00-6:30 Registration							
Sala 103							7:30-7:00 Speaker Ready Room							
Limonaia							7:30-6:30 Computer Center							
Passi Perduti				8:00-11:00 Coffee Break										

Legenda:

Keynote Special Session Speaker Ready Registration Computer Center Symposia Workshop Poster Session



Sunday, 15 April, Detailed Schedule of Events

Registration

Palazzo Entrance

8:00 AM - 6:30 PM

Coffee/Pastries

Passi Perduti – Adjacent to the Auditorium

8:00 AM - 11:00 AM

Scientific Sessions

PLENARY SESSION- Psychological and Social Treatments

Auditorium

Chair: Dawn Velligan

Co-Chair: Shitij Kapur

8:30 AM - 12:00 PM

Abstract: While it is suggested that cognitive deficits are stable throughout all stages of the schizophrenia, the evidence for progressive brain changes identified with neuroimaging would suggest that function might also be affected. If there is evidence of cognitive change with illness progression, this could influence the approach taken to managing these deficits. To date few studies have examined neuroimaging changes associated with cognitive rehabilitation strategies. These studies provide some evidence for positive effects on brain structure and function (e.g. Wykes et al, 2002; Eack et al, 2010; Bor et al, 2011). However, studies have not compared strategies to remediate these deficits versus cognitive adaptation approaches. I will present findings regarding progressive brain structural changes in the early course of the illness involving medial temporal and frontal regions, and relate these findings to results from the Melbourne long-term follow-up studies demonstrating progressive deterioration in relevant neurocognitive domains (associative memory and set-shifting ability), while other domains such as spatial working memory are stable across illness stages (Pantelis et al, 2009). These findings are best understood when placed in the context of brain maturational trajectories for these abilities and may be differentially amenable to alternate intervention strategies (Pantelis et al, 2009a, 2009b). I will suggest that: (i) cognitive remediation approaches should target those abilities that have matured, are relatively unimpaired at psychosis onset, but which show later deterioration; (ii) cognitive adaptation (i.e. an approach that compensates for the deficits through environmental manipulation) (Velligan et al, 2009) would be more appropriate for those abilities that have never fully matured and are impaired at all illness stages.

It is hypothesized that the former would have beneficial effects in minimizing or ameliorating progressive brain changes in schizophrenia. Bor, J., Brunelin, J., d'Amato, T., Costes, N., Suaud-Chagny, M. F., Saoud, M., & Poulet, E. (2011). How can cognitive remediation therapy modulate brain activations in schizophrenia? An fMRI study. *Psychiatry Research*, 192(3), 160-166. Eack, S. M., Hogarty, G. E., Cho, R. Y., Prasad, K. M., Greenwald, D. P., Hogarty, S. S., & Keshavan, M. S. (2010). Neuroprotective effects of cognitive enhancement therapy against gray matter loss in early schizophrenia: results from a 2-year randomized controlled trial. *Archives of General Psychiatry*, 67(7), 674-682. Pantelis, C., Wood, S. J., Proffitt, T. M., Testa, R., Mahony, K., Brewer, W. J., Buchanan, J. A., Velakoulis, D., & McGorry, P. D. (2009a). Attentional set-shifting ability in first-episode and established schizophrenia: Relationship to working memory. *Schizophrenia Research*, 112(1-3), 104-113. Pantelis, C., Yucel, M., Bora, E., Fornito, A., Testa, R., Brewer, W. J., Velakoulis, D., & Wood, S. J. (2009b). Neurobiological Markers of Illness Onset in Psychosis and Schizophrenia: The Search for a Moving Target. *Neuropsychology Reviews*, 19, 385-398. Velligan, D. I., Draper, M., Stutes, D., Maples, N., Mintz, J., Tai, S., & Turkington, D. (2009). Multimodal cognitive therapy: combining treatments that bypass cognitive deficits and deal with reasoning and appraisal biases. *Schizophrenia Bulletin*, 35(5), 884-893. Wykes, T., Brammer, M., Mellers, J., Bray, P., Reeder, C., Williams, C., & Corner, J. (2002). Effects on the brain of a psychological treatment: cognitive remediation therapy: functional magnetic resonance imaging in schizophrenia. *The British Journal of Psychiatry*, 181, 144-152.



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

Presenters:

- *Neuroimaging and Cognitive Rehabilitation; A Hypothesis Based on the Evidence for Progressive Brain Changes in Schizophrenia*
Christos Pantelis
- *Metacognitive Training in Schizophrenia Patients (MCT)*
Steffen Moritz
- *Cognitive Behavior Therapy for Positive and Negative Symptoms*
Douglas Turkington
- *Social Cognition Schizophrenia: Rationale and Strategies for Training Intervention*
Michael Green

Travel Awarder and Mentor Lunch

Scherma, Fortezza da Basso

12:00 PM - 1:00 PM

Poster Session #1 and Lunch

Cavaniglia

Buffet Lunch will be served daily at the poster sessions.

Please see page 60 - 81 a complete listing of posters.

12:00 PM - 2:00 PM

Coffee Available

Passi Perduti – Adjacent to the Auditorium

Palazzo Affari Foyers

Sala Verde

1:45 PM - 4:15 PM

CONCURRENT SYMPOSIA

The Abnormal Life of the D2 Receptor in Schizophrenia

Auditorium

Chair: Anissa Abi-Dargham

Co-Chair: Anil Malhotra

2:00 PM - 4:00 PM

D2 and DA Release in Comorbid Dependence and Schizophrenia

Anissa Abi-Dargham

Striatal D2 Receptors regulate Dendritic Morphology of Striatal Neurons via Kir2 Channels

Christoph Kellendonk

The Association of DRD2 with Prefrontal Activity as Modulated by Pharmacologic D2 Receptor Stimulation and Genetic Variation of GSK3b

Alessandro Bertolino

Dopamine Receptor Genetic Variation and Antipsychotic Drug Response

Anil Malhotra

Discussant: Robin M. Murray



Immune Response in Schizophrenia: Host-Environment Interactions

2:00 PM - 4:00 PM

Palazzo Affari, Lower Level

Chair: Nicola Cascella

Co-Chair: Akira Sawa

Is Maternal Influenza Specific to Schizophrenia among Offspring Outcomes?

Alan Brown

Antibodies to Retroviruses in Recent Onset Psychosis and Multi-Episode Schizophrenia

Faith Dickerson

DISC1 Is Involved in Innate Immune Response in the Brain

Michael Pletnikov

Microglia and the Complement Cascade: Shaping Neural Circuits in the Developing Brain

Dorothy Schafer

Increased Prevalence of Transglutaminase 6 Antibodies in Sera from Schizophrenia Patients

Nicola Cascella

Discussant: Akira Sawa

**Convergent Evidence Linking Advanced Paternal Age
and Neurodevelopmental Disorders**

2:00 PM - 4:00 PM

Palazzo Affari, Ground Floor

Chair: John J. McGrath

Co-Chair: Dolores Malaspina

Advanced Paternal Age Contributes to a Specific Subtype of Schizophrenia

Dolores Malaspina

Advanced Paternal and Grandpaternal Age as a Risk Factor for Psychiatric Disorders

Christina M. Hultman

Increased De Novo Copy Number Variants in the Offspring of Older Males

John J. McGrath

Paternal Age Effect and Selfish Mutations

Anne Goriely

Discussant: Avi Reichenberg



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

Long Acting Injectable Antipsychotic Medications in Schizophrenia: Do Recent Studies Change Our Understanding of Their Role in Our Treatment Armamentarium?

2:00 PM - 4:00 PM

Palazzo Affari, 1st Floor

Chair: Nina R. Schooler

Co-Chair: John Kane

New Results Alter Balance of Evidence in Meta-analysis of Long-Acting Injectables vs. Oral Antipsychotics in Schizophrenia

Taishiro Kishimoto

An Open, Randomized, Controlled Comparison of Long-acting Injectable Risperidone vs. Oral Olanzapine in Schizophrenia & Schizoaffective Disorder

Nicholas A. Keks

Relapse Prevention with Risperidone Long-Acting Injectable vs. Oral Quetiapine. Results of an Open-label RCT

Wolfgang Gaebel

PROACTIVE: Initial Results of an RCT Comparing Long-Acting Injectable Risperidone to 2nd Generation Oral Antipsychotics

Nina R. Schooler

Discussant: Donald C. Goff

Hormonal Influences in Schizophrenia: Key in the Mechanism of Illness or an Illusory Correlation?

2:00 PM - 4:00 PM

Palazzo Affari, 2nd Floor

Chair: Thomas W. Weickert

Co-Chair: Maarten van den Buuse

Oestrogens and Schizophrenia

Anita Reocher-Rossler

The Paradox of Testosterone Signaling in Males with Schizophrenia

Cynthia S. Weickert

Sex Differences and Role of Oestrogen and Testosterone in Animal Models of Schizophrenia: Interaction with NMDA Receptors

Maarten van den Buuse

Genetic and Molecular Mechanisms of Prosocial Neuropeptides in Human Brain – Implications for Schizophrenia Treatment

Andreas Meyer-Lindenberg

Discussant: Sven Mueller



**Is Schizophrenia a Unique Illness of the Brain, or
the More Severe Part of a Spectrum of Psychopathology?**

2:00 PM - 4:00 PM

Sala Verde

Chair: Michael Davidson

Co-Chair: Mark Weiser

Non-Specificity of Risk Factors for Schizophrenia: Population-Based Studies

Mark Weiser

Brain Changes in Schizophrenia and Bipolar Disorder: Is there a Genetic Overlap?

René Kahn

Similarities in the Gene and Protein Expression Substrates of Schizophrenia and Bipolar Disorder

Vahram Haroutunian

Schizophrenia and Bipolar Disorder Genetics: Overlapping and Distinguishing Features

Michael O'Donovan

Discussant: Jim Van Os

Coffee Break

4:00 PM - 4:15 PM

Passi Perduti – Adjacent to the Auditorium

Palazzo Affari Foyers

Sala Verde

CONCURRENT SYMPOSIA

Intervening in People At-Risk of Psychosis: What is the Evidence?

4:15 PM - 6:15 PM

Auditorium

Chair: Patrick D. McGorry

Co-Chair: Andreas Bechdolf

Early Detection and Intervention Evaluation for People At-Risk of Psychosis

Anthony P. Morrison

The Results of a Specific CBT Intervention in Young Help-Seeking Patients with Social Decline and an Ultra-High Risk for Developing a First Episode of Psychosis

Mark Van der Gaag

Randomized Controlled Trial of Interventions for Young People at Ultra-High Risk of Psychosis: 12-Month Outcome

Patrick D. McGorry



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

Rationale and Baseline Characteristics of PREVENT: A Second Generation Intervention Trial in Subjects At-Risk (prodromal) of Developing First Episode Psychosis Evaluating Cognitive Behaviour Therapy, Aripiprazole and Placebo for the Prevention of Psychosis

Andreas Bechdorf

How Effective are Omega-3 Fatty Acids for the Treatment of the Psychosis Prodrome?

Paul G. Amminger

Discussant: Jim van Os

Progressive Changes in Brain Structure and Function in Psychosis

4:15 PM - 6:15 PM

Palazzo Affari, Lower Level

Chair: Philip K. McGuire

Co-Chair: Christos Pantelis

Changes in Brain Structure Before and After the Onset of Psychosis - Evidence from Meta-Analyses and a Proposed New Multi-Centre Longitudinal Study

Matthew J. Kempton

Neurochemical Abnormalities in Schizophrenia and Progressive Changes from the Prodrome to the Onset of the First Psychotic Episode

Oliver D. Howes

Progressive Structural and Functional Brain Changes in Individuals with an At-Risk Mental State of Psychosis

Stefan J. Borgwardt

Progressive Changes in Brain Structure in Schizophrenia – Clinical Outcome, Medication and Heritability

René S. Kahn

Discussant: Lynn E. DeLisi

Cellular Trafficking in Schizophrenia: Is It Important?

4:15 PM - 6:15 PM

Palazzo Affari, Ground Floor

Chair: David R. Cotter

Co-Chair: James Meador-Woodruff

Plastic Modulation of Neurotransmission by Endocytic Sorting of Synaptic Vesicle Proteins

Volker Haucke

Clathrin-Mediated-Endocytosis and Clathrin-Dependent Membrane and Protein Trafficking; Core Pathophysiological Processes in Schizophrenia and Bipolar Disorder?

David R. Cotter

Altered Intracellular Trafficking of NR1 Subunit in Schizophrenia

Chang-Gyu Hahn



Decreased S-Palmitoylation of Proteins as a Potential Mechanism for Abnormal Receptor Trafficking in Frontal Cortex in Schizophrenia

James Meador-Woodruff

Discussant: William G. Honer

Understanding the Path to Better Functioning in Schizophrenia

4:15 PM - 6:15 PM

Palazzo Affari, 2nd Floor

Chair: Stephen R. Marder

Co-Chair: Elyn R. Saks

High Achieving Individuals with Schizophrenia: Techniques Developed to Manage Symptoms

Elyn R. Saks

“Superphrenia”? The Epidemiological, Neuropsychological and Clinical Characteristics of Schizophrenia with Superior Intellectual Functioning

James MacCabe

Maximizing Successful Return to School or Work after an Initial Episode of Schizophrenia

Keith Nuechterlein

Predictors of Good Functional Outcome in Early Psychosis

Jean Addington

Discussant: Shôn Lewis

Psychosis – From Epidemiology to Mechanisms

4:15 PM - 6:15 PM

Sala Verde

Chair: Wim Veling

Co-Chair: Peter Jones

Neural Mechanisms Mediating Urbanicity and Migration Risk

Andreas Meyer-Lindenberg

Virtual Reality in Psychosis: Experiments with Social Risk Environments

Wim Veling

Psychotic Reactivity to Stress: A Combined PET – ESM Approach

Inez Myin-Germeyns

Is the Epigenetic Machinery Involved in Mediating the Effects of Stress and Childhood Trauma on Negative Affect and Psychosis?

Bart Rutten

Discussant: John McGrath



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

SPECIAL SESSION

Basic Science Special Session

4:15 PM - 6:15 PM

Palazzo Affari, 1st Floor

Chair: John Waddington

The Psychobiology of Environmental Enrichment and 'Brain Reserve' in Genetic Mouse Models of Schizophrenia

Anthony Hannan

Bridging Epidemiology and Rodent Models: Maternal Inflammation and Psychobiology of Offspring

Urs Meyer

MRI as a Translational Tool in Mouse Models of Neurodevelopmental Disorder

Grainne McAlonan

The Enduring Challenge of Modeling the Negative Symptoms of Schizophrenia in Animals

Jared Young

Coffee Break

6:15 PM - 6:30 PM

Palazzo Affari Foyers

WORKSHOPS

How Early and Late Social Environment Shapes Risk and Onset of Psychotic Disorders

6:30 PM - 8:30 PM

Palazzo Affari, Lower Level

Chair: Marta Di Forti

Co-Chair: Helen L. Fisher

Effect of Childhood Abuse on Cognitive Function in First-Episode Psychosis Patients and Community Controls

Lucia Sideli

Prevalence of Bullying amongst First-Episode Psychosis Patients and Unaffected Controls

Antonella Trotta

Cannabis using First Episode Psychosis (FEP) have Normal Pre-morbid IQ

Laura Ferraro

Cannabis Use and Age of Onset in First Episode of Psychosis: a Gender Issue?

Fabio Allegri

Discussant: Ilaria Tarricone



Homicide and Schizophrenia

6:30 PM - 8:30 PM

Palazzo Affari, Ground Floor

Chair: Anthony W. Harris

Co-Chair: Vaughan Carr

Homicide in First Episode Psychosis

Olav B. Nielssen

Homicide in Schizophrenia and Total Homicide

Matthew M. Large

Homicide after Discharge from Psychiatric Hospitals

Seena Fazel

Homicide Recidivism in Schizophrenia

Matthew M. Large

Stranger Homicide in Schizophrenia

Olav B. Nielssen

Discussant: John McGrath

**Treatment Options for Refractory Positive
and Negative Symptoms in Schizophrenia**

6:30 PM - 8:30 PM

Palazzo Affari, 1st Floor

Chair: Stefan Leucht

Co-Chair: Georgios Petrides

Pharmacological Augmentation Strategies for Schizophrenia Patients with Insufficient Response to Clozapine

Stefan Leucht

Cognitive Behavioural Therapy (CBTp) for Psychosis - New Developments

Iris Sommer

Possibilities and Impossibilities of TMS for the Treatment of Hallucinations

Donald Goff

New Approaches with Glutamatergic Agents and Folate

Elizabeth Kuipers

Electroconvulsive Therapy (ECT) for Medication Resistant Schizophrenia

Georgios Petrides

Discussant: John Kane



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

Cannabis and Psychosis - The State of the Art

6:30 PM - 8:30 PM

Palazzo Affari, 2nd Floor

Chair: Philip K. McGuire

Co-Chair: Jim van Os

Cannabis, CNS Rhythms & Positive Psychotic Symptoms

Paul Morrison

The Effects of Delta-9-Tetrahydrocannabinol and Cannabidiol on Brain Function in Man

Sagnik Bhattacharyya

The Paradox of Cannabis Sativa: The Plant that can Induce Psychotic Symptoms and also Treat them

Jose A. Crippa

A Twin Study on Abnormalities of Endocannabinoid Functioning in Schizophrenia and Bipolar Disorder

F. Markus Leweke

Discussant: Shitij Kapur

Sunday, 15 April

	7:00 - 8:00	8:00 - 9:00	9:00 - 10:00	10:00 - 11:00	11:00 - 12:00	12:00 - 1:00	1:00 - 2:00	2:00 - 3:00	3:00 - 4:00	4:00 - 5:00	5:00 - 6:00	6:00 - 7:00	7:00 - 8:00	8:00 - 9:00
Auditorium			8:30-12:00	Genetics Plenary										
Palazzo Affari Ground Floor								2:00-4:00	Recent Directions in the Treatment of Early-Onset Psychoses	4:00-4:15	4:15-6:15	6:15-6:30		
								2:00-4:00		4:00-4:15	4:15-6:15	6:15-6:30		
Palazzo Affari 1st Floor								2:00-4:00	Risk Factors and Prevention of Psychosis: New NAPLS 2 Data	4:00-4:15	4:15-6:15	6:15-6:30		
								2:00-4:00		4:00-4:15	4:15-6:15	6:15-6:30		
Palazzo Affari 2nd Floor								2:00-4:00	Dual Process Theory: Automatic and Controlled Processes and their Implications for Psychosocial Treatment Development	4:00-4:15	4:15-6:15	6:15-6:30		
								2:00-4:00		4:00-4:15	4:15-6:15	6:15-6:30		
Palazzo Affari Lower								2:00-4:00	Neural Network Changes in Schizophrenia: Evidence for Dysconnectivity in the Brain	4:00-4:15	4:15-6:15	6:15-6:30		
								2:00-4:00		4:00-4:15	4:15-6:15	6:15-6:30		
Sala Verde								2:00-4:00	Multimodal Neuroimaging of Prodromal Psychosis	4:00-4:15	4:15-6:15			
								2:00-4:00		4:00-4:15	4:15-6:15			
Cavaniglia						12:00-2:00								
						Monday Poster Session and Lunch								
Palazzo Entrance							8:00- 6:30							
							Registration							
Sala 103							7:30-7:00							
							Speaker Ready Room							
Limonaia							7:30- 6:30							
							Computer Center							
Passi Perduti														
								8:00-11:00						
								Coffee Break						

Legenda:

■ Keynote
 ■ Special Session
 ■ Speaker Ready
 ■ Registration
 ■ Computer Center
 ■ Symposia
 ■ Workshop
 ■ Poster Session



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

Monday, 16 april, Detailed Schedule of Events

Registration

Palazzo Entrance

8:00 AM - 6:30 PM

Coffee/Pastries

Passi Perduti – Adjacent to the Auditorium

8:00 AM - 11:00 AM

Scientific Sessions

PLENARY SESSION - Genetics

Auditorium

Chair: Jim van Os

Co-Chair: Lynn E. DeLisi

8:30 AM - 12:00 PM

Abstract: Schizophrenia is a complex neuropsychiatric disorder that afflicts 1% of the world's population. The global costs of illness are estimated to be over 1 trillion dollars per year. Family, twin and adoption studies conducted over the past half century indicate that hereditary factors account for at least 70% of susceptibility to illness. Genome wide association studies (GWAS) have provided compelling evidence that a handful of common variants underlie a few percent of the genetic inheritance. Another major dividend of GWAS has been the identification of rare susceptibility factors, so called copy number repeats (CNVs) that may explain an additional 2 to 3% of the genetic variance to illness. Most of the remaining heritability (~95%) may be explained by a large number of rare variants, potentially in hundreds to thousands of genes. Next generation sequencing studies are now underway to map additional loci predisposing to schizophrenia.

Panelists:

- *Genetics of Schizophrenia: Past Results and Future Approaches*
William Byerley
- *The Genetic Architecture of Schizophrenia: New Mutations and Emerging Paradigms*
Maria Karayiorgou
- *Gene-Environment Interaction in Psychosis*
Robin M. Murray
- *Reactivity Phenotypes for Genetics Studies*
Inez Myin-Germeys

Poster Session #2 and Lunch

Cavaniglia

Buffet Lunch will be served daily at the poster sessions.

Please see page 82 - 103 for a complete listing of posters.

12:00 PM - 2:00 PM

Coffee Available

Passi Perduti – Adjacent to the Auditorium

Palazzo Affari Foyers

Sala Verde

1:45 PM - 2:15 PM



CONCURRENT SYMPOSIA

Genetic and Non-Genetic Factors Underlying Sensitivity to Cannabis-Induced Psychosis

2:00 PM - 4:00 PM

Auditorium

Chair: Robin M. Murray

Co-Chair: Deepak Cyril D'Souza

Cannabis and Psychosis: Is the Association Moderated by Environmental Risk Factors?

Rebecca Kuepper

Genetic Moderation of the Psychotomimetic and Amnestic Effects of Delta-9-Tetrahydrocannabinol in the Laboratory

Deepak Cyril D'Souza

The AKT1 (rs2494732) Genotype Moderates the Risk of Psychotic Disorders in Cannabis Users

Marta Di Forti

Combined Effects of COMT and AKT1 Moderate Risk for Cannabis-Induced Psychotic Disorder: Evidence from Two Large, Independent Samples

Ruud van Winkel

Discussant: Paul Morrison

Neural Network Changes in Schizophrenia: Evidence for Dysconnectivity in the Brain

2:00 PM - 4:00 PM

Palazzo Affari, Lower Level

Chair: Hilleke Hulshoff Pol

Co-Chair: Andreas Meyer-Lindenberg

The Human Connectome: A Complex Network

Olaf Sporns

Economical Network Models of the Connectome in Schizophrenia

Edward Bullmore

Imaging Connectomics and Schizophrenia

Alex Fornito

On Brain Networks and Cognition

Martijn Van den Heuvel

Discussant: Andreas Meyer-Lindenberg



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

Recent Directions in the Treatment of Early-Onset Psychoses

2:00 PM - 4:00 PM

Palazzo Affari, Ground Floor

Chair: Celso Arango

Co-Chair: Christoph Correll

One Year Follow-Up Longitudinal Study with a Large Sample of Antipsychotic-Naïve Children and Adolescents Exposed to Antipsychotics

Celso Arango

Efficacy and Safety of Antipsychotics in Early-Onset Schizophrenia: A Meta-Analysis of Randomized Controlled Trials

Christoph Correll

Safety and Tolerability of Different Antipsychotics and Use of Clozapine in Early Onset Schizophrenia

Sanjiv Kumra

Neuroplasticity-Based Cognitive Training in Ultra-High Risk Adolescents and Recent Onset Patients with Schizophrenia

Sophia Vinogradov

Discussant: Carmen Moreno

Risk Factors and Prevention of Psychosis: New NAPLS 2 Data

2:00 PM - 4:00 PM

Palazzo Affari, 1st Floor

Chair: Barbara A. Cornblatt

Co-Chair: Jean Addington

Altered Functional and Structural Brain Developmental Trajectories in Youth at Clinical Risk for Psychosis

Tyrone D. Cannon

Neurophysiological Abnormalities during Stimulus Processing in Youth at Clinical High Risk for Psychosis: An Interim Analysis of the NAPLS Data

Daniel Mathalon

Neuropsychology of the Prodrome to Psychosis in the NAPLS 2 Consortium: Relationship to Family History and Conversion to Psychosis

Larry J. Seidman

Clinical and Social Risk Factors and Conversion in Young People at Clinical High Risk for Psychosis

Jean Addington

Social and Role Functioning as Predictors of Psychosis and Disability

Barbara A. Cornblatt

Discussant: Stephan Ruhrmann

Monday, 16 April



**Dual Process Theory: Automatic and Controlled Processes
and their Implications for Psychosocial Treatment Development**

2:00 PM - 4:00 PM

Palazzo Affari, 2nd Floor

Chair: Dawn I. Velligan

Co-Chair: Til Wykes

Automatic and Controlled Processes in Social Cognition Training
David Roberts

Integrated Neurocognitive Therapy (INT): How does the Integration of Automatic and Controlled Approaches Work?
Daniel R. Mueller

Cognitive Behavior Therapy for Positive and Negative Symptoms of Schizophrenia
Douglas Turkington

Cognitive Adaptation Training: Targeted Use of Automatic and Controlled Processes to Improve Functional Outcomes
Dawn I. Velligan

Discussant: Morris Bell

Multimodal Neuroimaging of Prodromal Psychosis

2:00 PM - 4:00 PM

Sala Verde

Chair: Paolo Fusar-Poli

Co-Chair: Stefan Borgwardt

The Relationship Between Structural, Functional and Effective Connectivity in Subjects of High Genetic Risk in Schizophrenia
Stephen Lawrie

Cortical and Subcortical Function in People at High Clinical Risk of Psychosis: Multimodal Imaging Findings
Chris Chaddock

Elucidating Multimodal Biomarkers of the At-Risk Mental State and the Prodromal Phase of Psychosis Using Pattern Recognition Methods
Nikos Koutsouleris

Thalamic Glutamate Levels as a Predictor of Cortical Response During Executive Functioning in Subjects at High Risk for Psychosis
Paolo Fusar-Poli

Different Duration of At-risk Mental State Associated with Structural and Neurofunctional Abnormalities - A Multimodal Imaging Study
Stefan Borgwardt

Discussant: Philip McGuire



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

Coffee Break

4:00 PM - 4:15 PM

Passi Perduti – Adjacent to the Auditorium
Palazzo Affari Foyers
Sala Verde

CONCURRENT SYMPOSIA

Schizophrenia: A Clinical Disorder being Shattered into Many Molecular Entities?

4:15 PM - 6:15 PM

Auditorium

Chair: Aiden Corvin

Co-Chair: David Porteous

Next Generation Sequencing of the DISC1 Locus in Major Mental Illness and Cognition

David Porteous

Investigating CNVs in Schizophrenia

Dan Rujescu

Family Studies of Cognitive Disorders

Dick McCombie

Exome Sequencing in Schizophrenia to Map Disease Variants, Genes and Networks

Shaun Purcell

Family Based Sequencing of Extended Pedigrees and Trios with Schizophrenia

Shane McCarthy

Discussant: Aiden Corvin

Do Schizophrenia and Bipolar Disorder Have Opposite Associations with Intelligence?

4:15 PM - 6:15 PM

Palazzo Affari, Lower Level

Chair: James MacCabe

Co-Chair: Avi Reichenberg

Premorbid Intellectual Functioning and Social Adjustment and Risk of Developing Schizophrenia, Psychotic or Non-Psychotic Bipolar Disorder: A Population Longitudinal Study

Avi Reichenberg

Neurocognitive Functioning in Twins Discordant for Schizophrenia and Bipolar Disorder

Rachel G. Higer

Monday, 16 April



Intelligence in Bipolar Disorder: Normal, Impaired or Enhanced?

James H. MacCabe

Creativity and Psychosis

Simon Kyaga

Discussant: Mary Cannon

**Integrating Social and Biological Factors to Predict the
Course and Outcome of Psychosis: Evidence from Two Large
Epidemiological First Episode Psychosis Cohorts (AESOP and PICOS)**

4:15 PM - 6:15 PM

Palazzo Affari, Ground Floor

Chair: Paola Dazzan

Co-Chair: Mirella Ruggeri

The Impact of Cannabis Use on Age of Onset in First-Episode Psychotic Patients

Sarah Tosato

*Predictors of Two-Year Outcomes in First-Episode Psychotic Patients Treated in Community Mental
Health Services*

Antonello Lasalvia

*Biological Predictors of Clinical Outcome after the First Psychotic Episode: Initial Findings from
AESOP-10*

Paola Dazzan

Ethnicity and the Long-Term Course and Outcome of Psychosis: Initial Findings from AESOP-10

Craig Morgan

Discussant: Mirella Ruggeri

**Role for Oxidative Stress, Inflammation, and Misfolded
Protein in the Early Pathology of Schizophrenia**

4:15 PM - 6:15 PM

Palazzo Affari, 1st Floor

Chair: Akira Sawa

Co-Chair: Carsten Korth

*Oxidative Stress and Inflammation in the Pathology of Schizophrenia: Data from Patient Neuron
Biology and Brain Imaging*

Akira Sawa

Characterization of Molecular Changes in CSF of Patients with Recent Onset Schizophrenia

Jennifer Coughlin

*N-Acetylcysteine Normalizes Neurochemical Changes in the Glutathione-Deficient Schizophrenia
Mouse Model during Development*

Anita Kulak



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

Systematic Search for Misfolded Proteins in Schizophrenia
Carsten Korth

Misfolding of Risk Factors for Schizophrenia in Frontotemporal Lobar Degeneration
Motomasa Tanaka

Discussant: Nicola Cascella

Personalizing Social and Cognitive Remediation – Is the Whole Greater Than the Sum of the Parts?

4:15 PM - 6:15 PM

Palazzo Affari 2nd, Floor

Chair: Anthony W. F. Harris

Co-Chair: Pamela J. Marsh

*Bolstering Work: Potential Benefits of Cognitive and Social Cognitive Interventions to Employment
Interventions for People with Early Psychosis*
Kelly Allott

SoCog: A Novel Social Cognitive Training Program for People with Schizophrenia
Pamela J. Marsh

*Personalized Skills-training Interventions Combined with Cognitive Remediation enhances
Community Outcome*
Alice Medalia

*Implementing Cognitive Remediation Therapy Outside the Ivory Tower: Maintaining Momentum with
a New Treatment in a Large Mental Health Service*
Francis Dark

Social Cognitive Skills Training for Schizophrenia: Initial Efficacy and Ways to Augment the Effects
William Horan

Discussant: Anthony W. F. Harris

Characteristics of People At-Risk of Psychosis

4:15 PM - 6:15 PM

Sala Verde

Chair: Andreas Bechdolf

Co-Chair: Mark Weiser

Adverse Life Events in Help-Seeking and Non-Help-Seeking UHR Individuals
Lucia Valmaggia

*Basic Self-Disturbance Predicts Psychosis Onset in the Ultra High Risk for Psychosis ('Prodromal')
Population*
Barnaby Nelson



*Axis I and II Comorbidity in People At-Risk of Psychosis in the Early Initial Prodromal State:
Correlations with Symptoms, Functioning and Transition to Psychosis*
Andreas Bechdorf

*The Relationship between Transition to Psychosis, and Functional Outcome in a Group at Ultra High
Risk for Psychotic Disorder*
Barnaby Nelson

*Comparison of Clinical and Sociodemographic Risk Factors between Adult and Early Onset
Psychosis*
Marco Armando

Discussant: Mark Weiser

Coffee Available

Passi Perduti – Adjacent to the Auditorium

6:00 PM - 6:30 PM

SPECIAL SESSION

SIRS Business Meeting and Awards Presentation
Auditorium

6:15 PM - 7:15 PM



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

Tuesday, 17 April

	7:00 - 8:00	8:00 - 9:00	9:00 - 10:00	10:00 - 11:00	11:00 - 12:00	12:00 - 1:00	1:00 - 2:00	2:00 - 3:00	3:00 - 4:00	4:00 - 5:00	5:00 - 6:00	6:00 - 7:00	7:00 - 8:00	8:00 - 9:00
Auditorium			8:30-12:00 Models from Immunology & Experimental Medicine					2:00-4:00 Treatments	4:00-4:15 Coffee Break	4:15-6:15 Physical Exercise in Schizophrenia: Subjective, Symptomatic, Cardiometabolic and Neurobiological Effects				
Palazzo Affari Ground Floor								2:00-4:00 Neuroimaging	4:00-4:15 Coffee Break	4:15-6:15 A Bright Future for Blood Biomarkers in Schizophrenia	6:15-6:30 Coffee Break	6:30-8:30 Aerobic Exercise in Schizophrenia: Clinical Consequences and Neurobiological Effects of a Novel Treatment Strategy		
Palazzo Affari 1st Floor								2:00-4:00 Psychosocial and Comorbidities	4:00-4:15 Coffee Break	4:15-6:15 The Effects of Psychopharmacologic Treatment on the Brain in Schizophrenia	6:15-6:30 Coffee Break	6:30-8:30 Cardiovascular Risk in Schizophrenia – The Problem and Some Solutions		
Palazzo Affari 2nd Floor								2:00-4:00 Genetics and Environment	4:00-4:15 Coffee Break	4:15-6:15 ICOSR Symposia: Systems Neuroscience Underlying Schizophrenia Models	6:15-6:30 Coffee Break	6:30-8:30 Relapse Prevention in Schizophrenia: An Update on Preclinical Data, Pharmacological and Psychotherapeutic Options		
Palazzo Affari Lower								2:00-4:00 Neuropathology and Electrophysiology	4:00-4:15 Coffee Break	4:15-6:15 What Explains the Schizophrenia Epidemic among Immigrants to Europe?	6:15-6:30 Coffee Break			
Sala Verde								2:00-4:00 Neuropsychology and Development	4:00-4:15 Coffee Break	4:15-6:15 The NMDA Deficiency Hypothesis of Schizophrenia: Emerging from Preclinical Concepts to Clinical Evidence				
Cavaniglia						12:00-2:00 Tuesday Poster Session and Lunch								
Palazzo Entrance							8:00-6:30 Registration							
Sala 103							7:30-7:00 Speaker Ready Room							
Limonaia							7:30-6:30 Computer Center							
Passi Perduti							8:00-11:00 Coffee Break							
Sala 101							7:30-8:30 ICOSR Advisory Board Meeting							

Legenda:

Keynote Special Session Speaker Ready Registration Computer Center Symposia Workshop Poster Session



Tuesday, 17 april, Detailed Schedule of Events

Registration

Palazzo Entrance

8:00 AM - 6:30 PM

Coffee/Pastries

Passi Perduti – Adjacent to the Auditorium

8:00 AM - 11:00 AM

Committee Meeting

ICOSR Advisory Board Meeting – by Invitation
Sala 103

7:30 AM - 8:30 AM

Scientific Sessions

PLENARY SESSION- Models from Immunology and Experimental Medicine

8:30 AM - 12:00 PM

Auditorium

Chair: Carol Tamminga

Co-Chair: René Kahn

Abstract: Evidence is growing for the role of immunological factors in schizophrenia. This evidence is based on epidemiological and postmortem data, and covers treatment trials and basic research. This panel will address these various aspects and explain how immune processes may play a role in the pathogenesis of schizophrenia. Epidemiological data will be presented as well as data from trials, more fundamental studies and the panel will start with presentation on the enormous progress that has been made in multiple sclerosis. The model of MS could well present an excellent example of the kind of studies that need to be conducted in schizophrenia. All in all, this symposium will present an opportunity for researchers and clinical psychiatrists to get an update on the newest research on immune factors in schizophrenia thereby providing a new concept and offering hope for the development of new treatments in schizophrenia.

Panelists:

- *Epidemiology*
Preben Bo Mortensen
- *Prenatal Infection, Immune Function and Schizophrenia*
Alan Brown
- *What Genetic Studies Tell us about the Involvement of the Immune System in Schizophrenia*
Peter McGuffin
- *Can Affective Disorders and Schizophrenia be Differentiated on an Immunological Basis?*
Barbara Sperner-Unterweger



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

Poster Session #2 and Lunch

12:00 PM - 2:00 PM

Cavaniglia

Buffet Lunch will be served daily at the poster sessions.

Please see page 104 - 125 for a complete listing of posters.

Coffee Available

1:45 PM - 2:15 PM

Passi Perduti – Adjacent to the Auditorium

Palazzo Affari Foyers

Sala Verde

ORAL PRESENTATIONS

2:00 PM - 4:00 PM

Treatment

Auditorium

Co-Chairs: Jean Addington and Robin Emsley

- 2:00 PM** *Multiple-treatments Meta-analysis on the Efficacy, Acceptability and Tolerability of 15 Antipsychotic Drugs in Schizophrenia*
Stefan Leucht
- 2:15 PM** *Cognitive Remediation Therapy (CRT) Impacts on Functional and Structural Connectivity in Schizophrenia: A Multimodal Imaging Study*
Rafael Penadés
- 2:30 PM** *Augmenting Social Skills Training with Cognitive Remediation in Schizophrenia*
Matthew Kurtz
- 2:45 PM** *Non-steroidal Anti-inflammatory Drugs in Schizophrenia: Ready for Practice or a Good Start? A Meta-analysis*
Iris E. Sommer
- 3:00 PM** *Predictors of Cognitive Improvement and Normalization Under Cognitive Remediation in Patients with Schizophrenia*
Antonio Vita
- 3:15 PM** *Treatment of Insight in Psychosis: A Meta-analysis*
Marieke Pijnenborg
- 3:30 PM** *Metformin for Treatment of Atypical Antipsychotic-Induced Weight Gain and Endocrinological Side Effects in Patients with First Episode Schizophrenia: Results from Randomized, Double blind, Placebo-Controlled Study*
Ren-Rong Wu



3:45 PM *Effects of Benzodiazepine and Other Hypnotic Use on Efficacy Results in placebo Controlled Antipsychotic Trials: Lessons Learned from the NewMeds Repository of RCT Data from AstraZeneca, Janssen, Eli Lilly, Lundbeck, and Pfizer*
Jonathan Rabinowitz

Neuropathology and Electrophysiology

Palazzo Affari, Lower Level

Co-Chairs: Anthony Grace and John Waddington

2:00 PM *Aberrant Prediction Error Signalling, Salience Attribution and Presynaptic Dopamine Synthesis in the Prodrome of Psychosis*
Christopher A. Chaddock

2:15 PM *Shedding Light on the Molecular Basis for NMDAR Hypofunction in Schizophrenia*
Vibeke S. Catts

2:30 PM *Dopamine and Schizophrenia. Do all Roads Lead to Dopamine or is the Start of the Journey? Evidence from Animal Models*
Darryl W. Eyles

2:45 PM *Elucidating the Role of Aggregated, Cell-invasive DISC1*
Verian Bader

3:00 PM *The Effects of Regular Long-term Cannabis Use on Auditory Mismatch Negativity (MMN)*
Lisa-marie Greenwood

3:15 PM *Processing Information from Face and Voice in Schizophrenia*
Margaret A. Niznikiewicz

3:30 PM *Startle Reactivity and Prepulse Inhibition in Subjects at Ultra High Risk for Psychosis: Correlation with Striatal D2/3 Receptor binding Following Dopamine Depletion*
Mariken B. De Koning

3:45 PM *Selective Remediation of Cognitive Deficits in Pharmacological and Neurodevelopmental Animal Models of Schizophrenia by a Novel mGlu5 Positive Allosteric Modulator*
Francois Gastambide

Neuroimaging

Palazzo Affari, Ground Floor

Co-Chairs: Paola Dazzan and Jun Soo Kwon

2:00 PM *Repeated Observation of Abnormal Gyrfication Localized to the Frontoinsular Cortex from Four Independent Samples with Schizophrenia*
Lena Palaniyappan

2:15 PM *Decreased White Matter Integrity in Psychotic Disorder: Association with Childhood Trauma?*
Machteld Marcelis



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

- 2:30 PM** *Effects of Eight Weeks of Atypical Anti-psychotic Medication Treatment on Middle Frontal Thickness in Drug-Naïve First Episode Psychosis Patients*
Vina M. Goghari
- 2:45 PM** *Free-Water Imaging Reveals a Global Inflammatory Effect and Local Axonal Degeneration in First Episode Schizophrenia*
Ofer Pasternak
- 3:00 PM** *Biological Basis of Sensitivity to the Effects of cannabis on Psychosis: AKT1 and DAT1 Genotype Modulates the Effects of Delta-9-Tetrahydrocannabinol on Midbrain and Striatal Function*
Sagnik Bhattacharyya
- 3:15 PM** *Alterations of the Brain Reward System in Antipsychotic Naïve Schizophrenia Patients Before and After Antipsychotic Treatment*
Mette Ø. Nielsen
- 3:30 PM** *Alterations in Magnetoencephalographic Gamma Oscillatory Patterns during Resting-State in Patients with Childhood-Onset Schizophrenia, Non-Psychotic Siblings and Healthy Controls*
Nora S. Vyas
- 3:45 PM** *Auditory Cortical Dysfunction as a Basis for Auditory Hallucinations*
Peter W. Woodruff

Psychosocial and Comorbidities

Palazzo Affari, First Floor

Co-Chairs: Michael Green and Til Wykes

- 2:00 PM** *Cognitive Remediation and Competitive Employment: Differential Benefits for Schizophrenia Patients with Poor Community Function*
Morris D. Bell
- 2:15 PM** *Specialized Addiction Treatment Versus Treatment as Usual for Patients with Cannabis Use Disorder and Psychosis – Results from the CapOpus Randomized, Parallel-group, Observer-blinded Clinical Trial*
Carsten R. Hjorthøj
- 2:30 PM** *Computerized Functional Capacity Assessment in Schizophrenia: Evidence for Convergent Validity*
Philip D. Harvey
- 2:45 PM** *Different Sensitivity to PCP-induced Schizophrenia-like Symptoms in Adult Female Rats Pre-exposed to Δ 9-Tetrahydrocannabinol During Adolescence*
Erica Zamberletti



- 3:00 PM** *Shining Light on Sleep-wake and Cortical Gamma Oscillations in Schizophrenia: The Role of Parvalbumin GABA Neurons*
Robert W. McCarley
- 3:15 PM** *Emotion Recognition in Schizophrenia: No Evidence for an Association with Social Functioning*
Mayke Janssens
- 3:30 PM** *Are Patients with Schizophrenia Happy?*
Ofer Agid
- 3:45 PM** *Violent Crimes in People with Schizophrenia*
Nomi Werbeloff

Genetics and Environment

Palazzo Affari, Second Floor

Co-Chairs: John McGrath and Dan Rujescu

- 2:00 PM** *Common Polygenic Variation Contributing to Schizophrenia Risk Explains Variation in Total Brain Volume*
Afke Terwisscha van Scheltinga
- 2:15 PM** *Persistence of the Extended Psychosis Phenotype in Young People: Link Between Vulnerability and Clinical Need*
Johanna T. W. Wigman
- 2:30 PM** *Complete Genome Sequence Based Genetic Analysis of Monozygotic Twins Discordant for Schizophrenia*
Christina A. Castellani
- 2:45 PM** *Novel Data from a Large Population Prevalence Survey: A Unique Opportunity to Inform Psychosis Research Directions and Mental Health Reform*
Vera A. Morgan
- 3:00 PM** *Absolute Risk of Suicide Following First Hospital Contact with Mental Disorder*
Merete Nordentoft
- 3:15 PM** *Maternal Antibodies to Infectious Agents and Risk for Non-affective Psychoses in the Offspring – a Case-control Study Using Archived Blood Samples from Neonatal Life*
Åsa Blomström
- 3:30 PM** *Structural Elucidation of DISC1 Pathway Proteins Using Electron Microscopy, Chemical Cross-linking and Mass Spectroscopy*
Nicholas J. Bradshaw
- 3:45 PM** *Expression and Function of CHRNA7 and Its Partial Duplication, CHRFAM7A, in Schizophrenia*
Sherry Leonard



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

Neuropsychology and Development

Sala Verde

Co-Chairs: Richard Keefe and Eileen Joyce

- 2:00 PM** *Neurocognition in the Extended Psychosis Phenotype: Performance of a Community Sample of Adolescents with Psychotic Experiences on the MATRICS Neurocognitive Battery*
Ian Kelleher
- 2:15 PM** *Ontogeny of Cognitive Impairment Following Prenatal Infection*
Juliet Richetto
- 2:30 PM** *Interaction Between Childhood Adverse Events, BDNF Val66Met and Impaired Cognition in Patients with Schizophrenia and Affective Psychoses*
Monica Aas
- 2:45 PM** *Identifying Neurocognitive Impairments Prior to Psychosis: New Meta-Analyses of Neurocognition in the Psychosis Risk Syndrome and in Youth at Familial Risk for Schizophrenia*
Larry J. Seidman
- 3:00 PM** *The Relationship of Subclinical Psychotic Experiences to Internalising and Externalising Psychopathology in Childhood*
Kristin R. Laurens
- 3:15 PM** *Prospective Investigation of Cognitive and Affective Pathways from Childhood Trauma to Psychosis-like Experiences in a UK Birth Cohort*
Helen L. Fisher
- 3:30 PM** *Childhood and Adolescence Symptoms Predicting First Episode Psychosis in the General Population Based Northern Finland 1986 Birth Cohort*
Pirjo H. Mäki
- 3:45 PM** *Hearing and Speech Impairment at Age 4 and Risk of Later Non-affective Psychosis*
Annica Fors

Coffee Break

Passi Perduti – Adjacent to the Auditorium

Palazzo Affari Foyers

Sala Verde

4:00 PM - 4:15 PM

Tuesday, 17 April



CONCURRENT SYMPOSIA

Physical Exercise in Schizophrenia: Subjective, Symptomatic, Cardiometabolic and Neurobiologic Effects

4:15 PM - 6:15 PM

Auditorium

Chair: Douglas L. Noordsy

Co-Chair: Frank G. Pajonk

Effects of Exercise Therapy on Cardiovascular Fitness and the Metabolic Syndrome in Schizophrenia: A Randomized Clinical Trial

Thomas W. Scheewe

International Organization of Physical Therapy in Mental Health-Consensus on Physical Activity within Multidisciplinary Rehabilitation Programmes for Minimising Cardio-Metabolic Risk in Patients with Schizophrenia

Davy Vancampfort

Voluntary Wheel Running Rescues Cellular and Behavioral Schizophrenic-like Phenotype in Mice

Susanne A. Wolf

The Effects of Physical Exercise on Neural Plasticity and Clinical Symptoms in Schizophrenia

Frank G. Pajonk

Discussant: Douglas L. Noordsy

What Explains the Schizophrenia Epidemic among Immigrants to Europe?

4:15 PM - 6:15 PM

Palazzo Affari, Lower Level

Chair: Jean-Paul Selten

Co-Chair: Wim Veling

Age at Migration and Psychotic-Like Experiences: Clues in Childhood to Explain the Increased Risk for Psychosis among Ethnic Minorities

Wim Veling

Psychotic Experiences in the General Population and Ethnicity: Findings from the SELCoH Study

Craig Morgan

Does a Recently Occurring Vitamin D Deficit Explain the Increased Risk for Schizophrenia and Other Psychoses in First-Generation Black Immigrants?

Marie-Jose Dealberto

The Epidemic is Explained in part by Selective Migration

Carsten Pedersen

Testing the Social Defeat Hypothesis in Another Minority: Are Psychotic Symptoms more Prevalent in the Non-Heterosexual Population?

Jean-Paul Selten

Discussant: John McGrath



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

A Bright Future for Blood Biomarkers in Schizophrenia

4:15 PM - 6:15 PM

Palazzo Affari, Ground Floor

Chair: Cynthia Shannon Weickert

Co-Chair: Marquis P. Vawter

Brain Derived Neurotrophic Factor: Illustrative of a Putative Biomarker for Schizophrenia

Peter F. Buckley

Disease Biomarkers for Schizophrenia - From Laboratory to Patient Bedside

Sabine Bahn

Transcriptional Signatures from Blood and Brain

Marquis P. Vawter

MicroRNA Biomarkers of Schizophrenia in Blood

Murray Cairns

Discussant: Cyndi Shannon Weickert

The Effects of Psychopharmacologic Treatment on the Brain in Schizophrenia

4:15 PM - 6:15 PM

Palazzo Affari, 1st Floor

Chair: Lynn E. DeLisi

Co-Chair: Eva M. Meisenzahl

Effects of Antipsychotics on Functional and Structural Plasticity in the Human Brain

Andreas Meyer-Lindenberg

The Effects Psychopharmacologic Treatment on the Brain in Schizophrenia

Nancy C. Andreassen

Why Antipsychotics are Good for the Brain

Rene S. Kahn

Differential Effects of Neuroleptic Treatment and Clinical Improvement in First-Episode Schizophrenia

Eva M. Meisenzahl

Discussant: Robert McCarley

ICOSR Symposia: Systems Neuroscience Underlying Schizophrenia Models

4:15 PM - 6:15 PM

Palazzo Affari, 2nd Floor

Chair: Carol Tamminga

Co-Chair: Anthony Grace

New Insights into the Pathophysiology, Treatment and Prevention of Schizophrenia Gleaned from Animal Models

Anthony Grace



Alterations in Brain Structure, Function and Chemistry Prior to the Onset of Psychosis

Philip McGuire

Analysis of CNVs Points to Specific Abnormalities of Synaptic Function in Schizophrenia

Michael O'Donovan

The Role of the Hippocampal Subfield System in Schizophrenia Psychosis

Carol Tamminga

Discussant: Charles Schulz

**The NMDA Deficiency Hypothesis of Schizophrenia:
Emerging from Preclinical Concepts to Clinical Evidence**

4:15 PM - 6:15 PM

Sala Verde

Chair: Marc Laruelle

Co-Chair: Shitij Kapur

Loss of Prefrontal Cortical Excitation-Inhibition Balance in a Developmental Animal Model of Schizophrenia

Patricio O'Donnell

Glutamate Receptor Subtypes Mediating Synaptic Activation of Prefrontal Cortex Neurons

Guillermo Gonzalez-Burgos

Abnormal Neural Synchrony in Schizophrenia: A Translational Perspective

Peter J. Uhlhaas

A Translational Success Story: Facilitating NMDA Receptor Signaling with the Glycine Reuptake Inhibitor RG1678

Daniela Alberati

Glutamate-dopamine Interactions in Schizophrenia: Insight from Molecular Imaging Studies

Marc Laruelle

Discussant: Shitij Kapur

Coffee Break

6:15 PM - 6:30 PM

Palazzo Affari Foyers

WORKSHOPS

**Aerobic Exercise in Schizophrenia: Clinical Consequences and
Neurobiological Effects of a Novel Treatment Strategy**

6:30 PM - 8:30 PM

Palazzo Affari, Ground Floor

Chair: Peter G. Falkai



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

Co-Chair: William G. Honer

Effects of Indoor Cycling on Hippocampal Structure, Metabolism and Clinical Features of Schizophrenia

Peter G. Falkai

The Impacts of Yoga and Aerobic Exercise on Neuro-Cognition and Brain Structure in Early Psychosis – A Preliminary Analysis of the Randomized Controlled Clinical Trial

Jingxia Lin

Effects of Physical Exercise on Psychotic Symptoms, Cognition and Brain Structure: Results of a Randomized Clinical Trial in Chronic Schizophrenia

René Kahn

Does Exercise Alter the Metabolic Effects of Olanzapine in an Animal Model?

Alasdair M. Barr

Discussant: William G. Honer

Cardiovascular Risk in Schizophrenia – The Problem and Some Solutions

6:30 PM - 8:30 PM

Palazzo Affari, 1st Floor

Chair: Fiona P. Gaughran

Co-Chair: Shubulade Smith

IMPACT– Motivating a Change in Health Behaviour

Shubulade Smith and Fiona P. Gaughran

Systematic Evaluation of Guidelines for Monitoring Cardio-metabolic Risk in Schizophrenia

Marc De Hert

Shared Genetic Risks for Schizophrenia and Cardiovascular Disease

Urban Osby

The Role of Medication in Increasing and Managing Cardiovascular Risk in Psychosis

Azizah Attard

Discussant: Robin M. Murray

Relapse Prevention in Schizophrenia: An Update on Preclinical Data, Pharmacological and Psychotherapeutic Options

6:30 PM - 8:30 PM

Palazzo Affari, 2nd Floor

Chair: Stefan Leucht

Co-Chair: Christoph Correll

Preclinical Data on Relapse Prevention with Antipsychotic Drugs

Shitij Kapur



Meta-analysis on Relapse Prevention with Antipsychotic Drugs compared to Placebo in Schizophrenia

Stefan Leucht

Relapse Prevention in Schizophrenia: A Systematic Review and Meta-analysis of Second-generation Antipsychotics versus First-generation Antipsychotics

Christoph Correll

Release Presentation in Schizophrenia: Meta - Analysis of Depot Antipsychotics vs. Oral Antipsychotics

Taishiro Kishimoto

The Role of CBT in Relapse Prevention of Schizophrenia

Elizabeth Kuipers

Discussant: John M. Kane



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

Wednesday, 18 April

	7:00 - 8:00	8:00 - 9:00	9:00 - 10:00	10:00 - 11:00	11:00 - 12:00	12:00 - 1:00	1:00 - 2:00	2:00 - 3:00	3:00 - 4:00	4:00 - 5:00	5:00 - 6:00	6:00 - 7:00	7:00 - 8:00	8:00 - 9:00
Auditorium				8:30-12:00 New Treatments				1:30-3:30 The Abnormal Life of the D2 Receptor in Schizophrenia		3:45-4:45 Summary and Closing Session				
Palazzo Affari Ground Floor								1:30-3:30 Convergent Evidence Linking Advanced Paternal Age and Neurodevelopmental Disorders						
Palazzo Affari 1st Floor								1:30-3:30 Long Acting Injectable Antipsychotic Medications in Schizophrenia: Do Recent Studies Change Our Understanding of Their Role in Our Treatment Armamentarium?						
Palazzo Affari 2nd Floor								1:30-3:30 Hormonal Influences in Schizophrenia: Key in the Mechanism of Illness or an Illusory Correlation?						
Palazzo Affari Lower								1:30-3:30 Immune Response in Schizophrenia: Host-Environment Interactions						
Sala Verde								1:30-3:30 Is Schizophrenia a Unique Illness of the Brain, or the More Severe Part of a Spectrum of Psychopathology?						
Palazzo Entrance							8:00- 4:00 Registration							
Sala 103							7:30-3:30 Speaker Ready Room							
Limonaia							7:30- 4:30 Computer Center							
Passi Perduti							8:00-11:00 Coffee Break							
Sala 101													5:00-6:30 Elsevier Editorial Board Meeting	

Legenda:

■ Keynote
 ■ Special Session
 ■ Speaker Ready
 ■ Registration
 ■ Computer Center
 ■ Symposia
 ■ Workshop
 ■ Poster Session



Wednesday, 17 April, Detailed Schedule of Events

Registration

Palazzo Entrance

8:00 AM - 4:00 PM

Coffee/Pastries

Passi Perduti – Adjacent to Auditorium

8:00 AM - 11:00 AM

Scientific Sessions

PLENARY SESSION – New Treatments

Auditorium

Chair: Wolfgang Fleischhacker

Co-Chair: Don Goff

8:30 AM - 12:00 PM

Main Address:

Don Goff, *Difficulties with Translational Research*

John Kane, *Methodologic Challenges in Clinical Trials in Schizophrenia*

Abstract: The New Treatments for Schizophrenia plenary session will feature brief presentations by colleagues in industry to provide updates on promising new compounds and strategic approaches to drug development which will compliment introductory presentations on methodological issues, regulatory hurdles, and new approaches for drug development. The goal of the session is to stimulate discussion by presenting new preclinical or clinical data representing innovative strategies for treating psychosis, negative symptoms or cognitive impairment in schizophrenia. Data that are already familiar to this international audience of clinical scientists will not be presented.

Panelists:

- Anjana Bose, *Forest Pharmaceuticals and Gedeon Richter*
- Robert Conley, *Eli Lilly & Company*
- Gerhard Gross, *Abbott*
- David Hosford, *Targacept*
- Ron Marcus, *Bristol Myers-Squibb*
- Daniel Umbricht, *Roche*
- Kim Vanover, *Intracellular Therapies*



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

Lunch

12:00 PM - 1:30 PM

Palazzo Affari Lawn, Passi Perduti (in case of inclement weather)

Coffee Available

1:30 PM - 4:00 PM

Passi Perduti – Adjacent to the Auditorium
Palazzo Affari Foyers
Sala Verde

CONCURRENT SYMPOSIA

Nature and Nurture in Schizophrenia: Are There Common Underlying Mechanisms?

1:30 PM – 3:30 PM

Auditorium
Chair: Oliver D. Howes
Co-Chair: Jean Paul Selten

Developmental Disruption and Stress: What Animal Models Tell Us about Schizophrenia
Anthony Grace

An Experimental Social Defeat Paradigm to Study Environmental Effects in Psychosis
Jim van Os

The Link between Cannabis and Schizophrenia: Dopaminergic or Cannabinoid System?
Oliver D. Howes

Neural Mechanisms of Urbanicity and Migration: Social Risk Factors for Schizophrenia?
Andreas Meyer-Lindenberg

Discussant: Shitij Kapur

Emerging Clinical Evidence on Oxytocin in Schizophrenia

1:30 PM - 3:30 PM

Palazzo Affari, Lower Level
Chair: Deanna Kelly
Co-Chair: David Feifel

Oxytocin Improves Emotion Recognition in Patients with Schizophrenia
Bruno Averbeck

Intranasal Oxytocin Reduces Core Symptoms of Schizophrenia
David Feifel

Oxytocin Treatment Improves Social Cognition, PANSS Social Item Scores and Verbal Learning in Schizophrenia
Cort Pedersen



Sex-specific Associations Between Peripheral Oxytocin, Symptoms, and Emotion Perception in Schizophrenia
Leah Rubin

Adjunctive Intranasal Oxytocin to Improve Social Cognition and Functioning in Schizophrenia
Mary Lee

Discussant: Deanna Kelly

Affective Dysfunction and Associated Developmental Vulnerabilities across the Extended Psychosis Continuum

1:30 PM – 3:30 PM

Palazzo Affari, Ground Floor

Chair: Max Birchwood

Co-Chair: Maria Michail

Subclinical Psychotic Experiences and Affective Dysregulation in Adolescents and Young Adults
Ashleigh Lin

Prevalence of Psychotic-Like Experiences in Young Adults with Social Anxiety Disorder and Correlations with Affective Dysregulation
Marco Armando

An Investigation of Social Anxiety Disorder in People with First-Episode Psychosis and those at Ultra High Risk
Maria Michail

Developmental Vulnerabilities and Affective Dysregulation in Psychosis Continuum
Ruchika Gajwani

Discussant: Emmanuelle Peters

Is the Psychosis Continuum For Real? The Cognitive, Environmental, and Neural Correlates of 'Real' Psychotic Experiences in the General Population

1:30 PM – 3:30 PM

Palazzo Affari, 1st Floor

Chair: Emmanuelle Peters

Co-Chair: Iris Sommer

The Route to Psychosis: What Differentiates Individuals with Psychotic Experiences with and without a 'Need-For-Care'?
Emmanuelle Peters

Childhood Trauma and Auditory Verbal Hallucinations
Kirstin Daalman
What Makes Voices Distressing? A Comparison of Patients Who Hear



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

Voices and Non-Psychiatric Voice Hearers
Mike Jackson

Auditory Hallucinations Elicit Similar Brain Activation in Psychotic and Non-Psychotic Individuals
Iris Sommer

Dopaminergic Function in the Psychosis Spectrum: An [18F]-DOPA Imaging Study in Healthy Individuals with Auditory Hallucinations
Paul Shotbolt

Discussant: Anthony David

**Subclinical Psychotic Experiences – Time to Move beyond Counting.
Advancing Clinical Research into Risk Factors,
Associated Psychopathology and Outcomes**

1:30 PM - 3:30 PM

Palazzo Affari, 2nd Floor

Chair: Mary Cannon

Co-Chair: James Scott

A Systematic Review and Meta-Analysis of the Psychosis Continuum: Epidemiological Evidence on the Pathway from Proneness to Persistence to Disorder
Richard Linscott

Exposure to Child Maltreatment and Hallucinations during Adolescence: A Prospective Study
James Scott

Childhood Trauma and Subclinical Psychotic Experiences in Young Adulthood: 20-year Longitudinal Analyses of Two Cohort Studies
Cherrie Galletly

Psychotic Symptoms in Adolescence Index Risk for Self Harm and Suicidal Behaviour: Findings from Two Population-Based Case-Control Clinical Interview Studies
Ian Kelleher

The Association between Self-reported Attenuated Psychotic Symptoms and Suicidal Behavior, and Hospitalization for Non-psychotic Psychiatric Disorders
Mark Weiser

Discussant: Peter Jones



Role of Glia in Schizophrenia

1:30 PM - 3:30 PM

Sala Verde

Chair: Natalya A. Uranova

Co-Chair: Mikhail V. Pletnikov

*Proteome Analyses of Post-Mortem Brain Tissue from Patients with Schizophrenia
Suggest Dysfunction of Oligodendrocytes and Astrocytes and Potential Biomarker Candidates*
Daniel Martins-de-Souza

*Reduced Oligodendroglial Density in Neocortex and Lack of
Insight in Schizophrenia*
Natalya A. Uranova

*Protective Effects of Haloperidol and Clozapine on Energy-Deprived OLN-93
Oligodendrocytes*
Johann Steiner

*DISC1 Interacts with Serine Racemase to Modulate D-Serine
Production in Astrocytes*
Mikhail V. Pletnikov

Discussant: Vahram Haroutunian

Summary and Closing Session

3:45 PM - 4:45 PM

Auditorium

Chair: Jim van Os



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

Posters, Sunday 15 April

12:00 PM - 2:00 PM

Cavaniglia

1. *Prevalence and Factors Associated with Tardive Dyskinesia among Indian Patients with Schizophrenia*
Rashmin M. Achalia, Santosh K. Chaturvedi, Geetha Desai, Om Prakash

2. *Childhood Adversity and Cannabis use in the Development of Positive Psychotic-like Experiences: Moderation Effects of the COMT Gene*
Silvia Alemany, Bárbara Arias, Mar Fatjó-Vilas, Mari Aguilera, Helena Villa, Jorge Moya, Manuel I. Ibáñez, Generós Ortet, Lourdes Fañanás

3. *Trauma and Psychotic-like Experiences: Mediating Psychological Mechanisms*
Neus Barrantes-Vidal, Tamara Sheinbaum, Sergi Ballespí, Erika Bedoya, Agnès Ros, Mercè Mitjavila, Thomas R. Kwapil

4. *Relationship between Attachment and Schizotypy Dimensions in Spanish and American Samples*
Tamara Sheinbaum, Thomas R. Kwapil, Erika Bedoya, Agnès Ros, Neus Barrantes-Vidal

5. *DISC1 and Serine Racemase Interact in Astrocytes to Regulate D-serine Production*
Bagratt Abazyan, Ting Martin Ma, Jun Nomura, Sofya Abazyan, Akira Sawa, Solomon H. Snyder, Mikhail V. Pletnikov

6. *Studying Gene-Environment Interaction in Aged Mice Overexpressing the Schizophrenia Susceptibility Gene Tcf4*
Dorota M. Badowska, Magdalena M. Brzozka, Peter Falkai, Moritz J. Rossner

7. *Local Changes in Hippocampal Neural Synchronisation in the Maternal Immune Activation Model of Schizophrenia*
Amy R. Wolff, Desiree D. Dickerson, David K. Bilkey

8. *Non-human Primate Performance on the Dot Pattern Expectancy Task after Ketamine Administration*
Rachael K. Blackman, Matthew V. Chafee

9. *Repeated Forced Swimming Reduces Glutamate Uptake in Hippocampal Slices and Affects Differently the Rats Behavior in Two Models Related to Cognitive Symptoms of Schizophrenia: Novel Object Recognition and Pre-pulse Inhibition*
Milene Borsoi, Alice Fialho Viana, Camila Boque Antonio, Andressa Braga, Paula Lunardi, Cristiane Batassini, Carlos Alberto Gonçalves, Stela Maris Kuze Rates

10. *Magnetic Resonance Imaging Characterization of Early Postnatal Phencyclidine Treatment as a Rat Model of Schizophrenia*
Brian V. Broberg, Kristoffer H. Madsen, Niels Plath, Christina K. Olsen, Birte Y. Glenthøj, Olaf B. Paulson, Börje Bjelker, Lise V. Søgaard



11. *Housing Conditions Modulate the Cognitive Performance in Transgenic Mice Overexpressing the Schizophrenia Susceptibility Gene Tcf4*

Magdalena M. Brzózka, Dorota Badowska, Peter Falkai, Moritz J. Rossner

12. *Effects of Repeated Electroconvulsive Shock on Methamphetamine-Induced Behavioral Abnormalities in Mice*

Yu-Lin Chao, Hwei-Hsien Chen, Chia-Hsiang Chen

13. *Expression and Distribution Profiles of Glutamatergic Receptors in the MAME17 Neurodevelopmental Rat Model of Schizophrenia*

Marie-Caroline Cotel, Eva Hradetzky, Sabine Bahn, Mark Tricklebank, Michael J. O'Neill

14. *Neural Systems Underlying Schizophrenia-Related Behavioural Phenotypes in Mice*

Neil Dawson, David M. Thomson, Brian J. Morris, Judith A. Pratt

15. *Phenotypic Effects in Adulthood of Repeated Psychosocial Stress during Adolescence in Mice Mutant for the Schizophrenia Risk Gene Neuregulin-1: A Putative Model of Gene × Environment Interaction*

Lieve Desbonnet, Colm O'Tuathaigh, Gerard Clarke, Claire Leary, Emilie Petit, Niamh Clarke, Orna Tighe, Donna Lai, Richard Harvey, John F. Cryan, Timothy G. Dinan, John L. Waddington

16. *Synergistic Interactions between Prenatal Infection and Pubertal Stress in the Development of Schizophrenia-relevant Abnormalities*

Sandra Giovanoli, Joram Feldon, Urs Meyer

17. *Transient Neuroinflammation Mediates Pathological Synergisms between Prenatal Infection and Pubertal Stress*

Sandra Giovanoli, Juliet Richetto, Harald Engler, Manfred Schedlowski, Marco A. Riva, Urs Meyer

18. *Modulations of Neural Circuits by Cognitive Behavioural Therapy in Patients with Schizophrenic Disorders*

Maurice Cabanis, Axel Krug, Martin Pyka, Henrik Walter, Georg Winterer, Bernhard Müller, Jutta Herrlich, Georg Wiedemann, Kai Vogeley, Alexander Rapp, Andreas Wittorf, Stefan Klingberg, Tilo Kircher

19. *Impaired Cerebellar Functional Connectivity in Schizophrenia Patients and their Healthy Siblings*

Guusje Collin, Hilleke E. Hulshoff Pol, Sander V. Haijma, Wiepke Cahn, Rene S. Kahn, Martijn P. Van den Heuvel

20. *Dopaminergic Modulation of the Reward System in Schizophrenia: a Placebo-controlled Dopamine Depletion fMRI Study*

Fabiana da Silva Alves, Nicole Schmitz, Nico Abeling, Johan van der Meer, Aart Nederveen, Lieuwe de Haan, Don Linszen, Therese van Amelsvoort

21. *Dynamic Causal Modeling in Subjects at High Genetic Risk of Schizophrenia*

Maria R. Dauvermann, Thomas W. Moorhead, Liana Romaniuk, Heather C. Whalley, Stephen M. Lawrie

22. *Hyperactivation in Working Memory Circuits in Siblings of Schizophrenia Patients: an fMRI Study*

Max de Leeuw, Matthijs Vink, Bram B. Zandbelt, René S. Kahn



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

23. *The Association Between Self-Reflective Processing and Insight in Psychosis in Schizophrenia Patients: an fMRI Study*
Annerieke de Vos, Lisette van der Meer, Marieke Pijnenborg, Willem A. Nolen, Anthony S. David, André Aleman
24. *Failure to Deactivate Medial Prefrontal Cortex Associated with Clinical not Genetic Risk for Psychosis*
Irina Falkenberg, Chris Chaddock, Gemma Modinos, Matthew Broome, Philip McGuire, Paul Allen
25. *A Genetic Variant of the Dopamine D2 Receptor Gene Predicts Prefrontal Activity during Working Memory Retrieval in Humans*
Leonardo Fazio, Gianluca Ursini, Tiziana Quarto, Paolo Taurisano, Raffaella Romano, Barbara Gelao, Marina Mancini, Annamaria Pocelli, Annabella Di Giorgio, Apostolos Papazacharias, Grazia Caforio, Antonio Rampino, Annalisa Incampo, Teresa Popolizio, Giuseppe Blasi, Alessandro Bertolino
26. *Delineating the Functional Neuroanatomy of Illness Denial or Anosognosia in Schizophrenia*
Philip Gerretsen, Ariel Graff-Guerrero, David Mamo, Bruce G. Pollock, Mahesh Menon
27. *Aberrant Functional Connectivity of Right Anterior Insula during a Working Memory Task in Schizophrenia*
Lena Palaniyappan, Thomas P. White, Peter F. Liddle
28. *Neural Correlates of Action Imitation in Relation to Schizotypal Personality*
Joel S. Peterman, Katharine N. Thakkar, Sohee Park
29. *Exploring Genetic and Environmental Influences on Brain Function in Schizophrenia*
Marco M. Picchioni, Timothea Touloupoulou, Andreina Pauli, Isabel Valli, Ulrich Ettinger, Cynthia Fu, Mei Hua-Hall, Fergus Kane, Eugenia Kravariti, Sri Kaladindi, Elvira Bramon, Muriel Walshe, Mick Brammer, Vincent Giampietro, Robin Murray, Philip McGuire
30. *Neural Correlates of Irony Comprehension: Decreased Medial Prefrontal BOLD Response in Schizophrenia*
Alexander M. Rapp, Karin Langohr, Dorothee E. Mutschler, Michael Erb
31. *Changes in Spontaneous Brain Activity Patterns in Antipsychotic Naïve Schizophrenia Patients before and after Antipsychotic Treatment*
Egill Rostrup, Mette O. Nielsen, Jaychandra M. Raghava, Birte Glenthøj
32. *The Neural Bases of Reversal Learning Deficits in Unmedicated Schizophrenia Patients*
Florian Schlagenhauf, Quentin Huys, Lorenz Deserno, Michael Rapp, Anne Beck, Andreas Heinz
33. *Changes in Resting State Connectivity Following Treatment in First Episode Schizophrenia*
S. Charles Schulz, Chen DaChun, Xue-Dong Yang, Thomas Kosten, Xiang Yang Zhang, Kelvin O. Lim
34. *Assessment of Positive and Negative Symptoms using an fMRI Reward-paradigm in a Sample of Healthy Subjects with Different Levels of Symptom Expression*
Joe J. Simon, Sheila Cordeiro, Hans-Christoph Friederich, Marc-André Weber, Robert C. Wolf, Matthias Weisbrod, Stefan Kaiser



35. *Prefrontal Cortex and Goal-Directed Behavior in Schizophrenia: Neural Mechanisms Underlying Inflexibility*

Tatiana Sitnikova, Alexandre Gramfort, Robert W. Boyle, Corinne Cather, Oliver Freudenreich, Matti S. Hämäläinen, Bruce R. Rosen, Donald C. Goff

36. *Abnormal Relationship between Circulating BDNF Levels and Prefrontal Cortex Activity during Probabilistic Feedback Learning in Schizophrenia*

Ashley J. Skilleter, Ans Vercammen, Cyndi S. Weickert, Thomas W. Weickert

37. *Association of DRD2 Genetic Variation and Schizotypy with Attentional Processing and D2 Receptors Availability*

Paolo Taurisano, Marina Mancini, Raffaella Romano, Gianluca Ursini, Artor N. Asabella, Barbara Gelao, Leonardo Fazio, Luciana Lo Bianco, Annabella Di Giorgio, Rita Masellis, Grazia Caforio, Lorenzo Sinibaldi, Teresa Popolizio, Giuseppe Blasi, Giuseppe Rubini, Alessandro Bertolino

38. *Multimodal Emotional Integration Task: An fMRI Paradigm for Emotional Processing in Early Psychosis and Ultra-High Risk State*

Huai-Hsuan Tseng, Jonathan Roiser, Bradley Platt, Sunjeev Kamboj, Philip McGuire, Paul Allen

39. *Morphological and Functional Abnormalities of Salience Network in the Early-stage of Paranoid Schizophrenia*

Weidan Pu, Li Li, Huiran Zhang, Jingping Zhao, Baoci Shan, Zheneng Liu

40. *Longitudinal Change in Levels of n-acetyl-aspartate in Early Onset Psychosis and Healthy Controls*

Marta Rapado-Castro, Santiago Reig, Montse Graell, Josefina Castro-Fornielles, Ana González-Pinto, Soraya Otero, Inmaculada Baeza, Joost Janssen, Mara Parellada, Dolores Moreno, Manuel Desco, Celso Arango

41. *Sex Differences in Verbal Memory Circuitry in Schizophrenia: Structural, Functional, and Hormonal Contributors*

Brandon R. Abbs, Lichen Liang, Jason S. Bitterman, Nikos Makris, Larry J. Seidman, Jill M. Goldstein

42. *Impact of Clozapine Treatment on Regional Brain Volume: A Longitudinal Study of Treatment Resistant Schizophrenia*

Mohamed Ahmed, Dara M. Cannon, Laurena Holleran, Heike Schmidt, John McFarland, Camilla Langan, Louise Emsell, Gary McDonald, Cathy Scanlon, Peter McCarthy, Gareth J. Barker, Colm McDonald

43. *Negative Symptoms in the Early Stages of Psychosis are Associated with Changes in the Cingulate*

Jacqueline Aston, Erich Studerus, Charlotte Rapp, Hilal Bugra, Stefan Borgwardt, Anita Riecher-Rössler

44. *Neurological Soft Signs and Gray Matter Changes: A Longitudinal Analysis in First Episode Schizophrenia*

Silke Bachmann, Li Kong, Philipp Thomann, Marco Essig, Johannes Schroeder

45. *White Matter and Clinical Symptomatology in the Early Stages of Schizophrenia*

Khalima A. Bolden, Helene Mirzakhanian, Kristin Cadenhead, Lisa T. Eyler, Gregorgy G. Brown



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

46. *Diffusion Tensor Imaging Demonstrates Reduced White Matter Integrity in Schizophrenia that is Related to Poorer Memory Performance*

Amity E. Green, Rodney J. Croft, Jerome J. Maller, Paul B. Fitzgerald

47. *DTI-based Study to Analyse White Matter Integrity in Schizophrenia and Bipolar Disorder using Tract-Based Spatial Statistics*

Alexandra Hellerbach, Bruno Dietsche, Davide Laneri, Heidelore Backes, Mirjam Stratmann, Tilo Kircher, Axel Krug, Jens Sommer

48. *Neurobiological Correlates of Slow Wave Sleep Reduction in First Episode Schizophrenia*

Julie Poulin, Konsale M. R. Prasad, Jeffrey A. Nutche, Jean M. Miewald, Debra Montrose, Matcheri S. Keshavan

49. *Changes in DLPFC-Striatum Connections in First Episode Schizophrenia: A Cross-Sectional and Longitudinal DTI Study*

Meina Quan, Marek Kubicki, Ryan Eckbo, Zora Kikinis, Robert W. McCarley, James J. Levitt, Martha E. Shenton

50. *Structural Brain Heterogeneity in Schizophrenia: A Gray Matter Texture Analysis on MR Images*

Eugenia Radulescu, Balaji Ganeshan, Nicholas Medford, Sukhwinder S. Shergill, Hugo D. Critchley

51. *Cannabis Use and Brain Structural Alterations of Cingulate Cortex and Hippocampus in First Episode Psychosis Patients and at Risk Mental State Subjects*

Charlotte Rapp, Hilal Bugra, Corinne Tamagni, Erich Studerus, Anna Walter, Stefan Borgwardt, Anita Riecher-Rössler

52. *Duration of Untreated Illness/Psychosis and Cognitive Functioning*

Charlotte Rapp, Erich Studerus, Hilal Bugra, Marlon Pflueger, Jacqueline Aston, Corinne Tamagni, Anna Walter, Stefan Borgwardt, Anita Riecher-Rössler

53. *Human Cortical Development and Intelligence: a Longitudinal MRI Study in over 1000 Scans*

Hugo G. Schnack, Neeltje E. van Haren, Rachel M. Brouwer, Sarah Durston, Alan C. Evans, Dorret I. Boomsma, Rene S. Kahn, Hilleke E. Hulshoff Pol

54. *Disrupted White Matter Connectivity is Associated with Reduced Cortical Thickness in the Cingulate Cortex in Schizophrenia*

Kathrin Koch, C. Christoph Schultz, Gerd Wagner, Claudia Schachtzabel, Jürgen R. Reichenbach, Heinrich Sauer, Ralf GM Schlösser

55. *Meta-analysis of Insula Grey Matter Volume in Schizophrenia*

Alana M. Shepherd, Sandra L. Matheson, Kristin R. Laurens, Vaughan J. Carr, Melissa J Green

56. *Insular Volume Abnormalities Associated with Different Transition Probabilities to Psychosis – A Voxel-based Morphometry Study*

Renata Smieskova, Anita Riecher-Rössler, Jacqueline Aston, Andor Simon, Kerstin Bendfeldt, Claudia Lenz, Rolf-Dieter Stieglitz, Paolo Fusar-Poil, Philip McGuire, Stefan J. Borgwardt

57. *Self Organizing Map Analysis of Regional Brain Volume Revealed Subgroups in Schizophrenia*

Genichi Sugihara, Naoya Oishi, Shinsuke Fujimoto, Jun Miyata, Toshiya Murai



58. *Longitudinal Volume Changes of the Pituitary Gland in the Course of Schizophrenia*

Tsutomu Takahashi, Michio Suzuki, Shi-Yu Zhou, Kazue Nakamura, Atsushi Furuichi, Mikio Kido, Yasuhiro Kawasaki, Kyo Noguchi, Hikaru Seto, Masayoshi Kurachi

59. *Better Theory-of-mind Skills in Children Hearing Voices Mitigate the Risk of Secondary Delusion Formation*

Agna A. Bartels-Velthuis, Els M. Blijd-Hoogewys, Jim Van Os

60. *Cognitive Reserve as a Predictor of Two Year Neuropsychological Performance in Early Onset First-Episode Schizophrenia*

Elena de la Serna, Susana Andrés-Perpiñá, Olga Puig, Inmaculada Baeza, Igor Bombin, David Bartrés-Faz, Celso Arango, Ana Gonzalez-Pinto, Mara Parellada, María Mayoral, Montserrat Graell, Soraya Otero, Josefina Castro-Fornieles

61. *Cytokine Profile in Acutely States of Child and Adolescent Psychiatric Disorders: A Comparison with Healthy Controls; Preliminary data.*

Maria Gariup, Tamara Garcia, Gemma Trias, Carles Serra, Astrid Morer

62. *Self-perception vs. Peer Reputation of Bullying Victimization in Relation to Non-clinical Psychotic Experiences*

Paula M. Gromann, Frits Goosens, Tjeert Olthof, Jeroen Pronk, Lydia Krabbendam

63. *Family Load Estimates of Schizophrenia with Different Age at Onset. Findings from a Nation-wide Population Study of Three Generations*

Dorte Helenius, Povl Munk-Jørgensen, Hans-Christoph Steinhausen

64. *Plasma Clozapine and Norclozapine in Relation to Prescribed Dose and Other Factors in Patients Aged < 18 Years: Data from a Therapeutic Drug Monitoring Service, 1994-2010*

Maxine X. Patel, Lewis Couchman, Sally V. J. Bowskill, Simon Handley, Robert J. Flanagan

65. *Shared Risk Factors for Mental Health Problems and Cannabis Use in Adolescence*

Willemijn A. van Gastel, Clothilde J.E. Bun, Wanda Tempelaar, Christian D. Schubart, Carolien M. Plevier, René S. Kahn, Marco P. M. Boks

66. *Covert Recognition of Familiar, Famous and Unfamiliar Faces in Schizophrenia*

Aurely Ameller, Laetitia Delbos, Anne-Laure Côte, Pierre Thomas, Delphine Pins

67. *Cognitive Exceptionality and Impairment in Schizophrenia*

Narmeen Ammari, Walter Heinrichs, Geoffrey Hall, Ashley A. Miles

68. *Diagnostic Value of a Simplified Screening Test for Metabolic Syndrome in a Cohort of Patients with Schizophrenia-spectrum Disorders*

Salcey G. Amzand, Bert L. Luteijn, Elsje van der Ven, Clazina D. Dogterom, Jan P. Bogers, Jean-Paul Selten

69. *Deficit and Nondeficit Schizophrenia: Boundaries Revisited*

Clarissa R. Dantas, Bruno R. Barros, Claudio E.M. Banzato



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

70. *Predicting Deficit/Nondeficit Categorization from the Scale for the Assessment of Negative Symptoms (SANS)*

Bruno R. Barros, Claudio E. M. Banzato, Clarissa R. Dantas

71. *Similarities and Differences between First Episode Schizophrenia and Schizoaffective Disorders*

Sue M. Cotton, Martin Lambert, Benno G. Schimmelmann, Andrew Mackinnon, John Gleeson, Michael Berk, Leanne Hides, Andrew Chanen, Patrick D. McGorry, Philippe Conus

72. *Autism Spectrum Disorders and Schizophrenia, a Comparative Study*

Maria Hallerbäck, Tove Lugnegård, Christopher Gillberg

73. *At-Risk Criteria of Psychosis: Reliability between Interview Modes*

Chantal Michel, Benno G. Schimmelmann, Stephan Kupferschmid, Marcel Siegwart, Frauke Schultze-Lutter

74. *The Impact of Cultural Competency on Reducing Ethnic Disparities in Psychiatric Diagnosis: A Regional Variation Analysis*

John E. Zeber, John F. McCarthy, Jodi M. Gonzalez, David S. Greenawalt, Alejandro Interian, Laurel A. Copeland

75. *Ictal EEG Fractal Dimension Early in the Course of ECT in Schizophrenia Patients Predicts Clinical Outcome at Two Weeks*

H. A. Abhishekh, M. Anusha, J. Thirthalli, V. H. Puthane, K. Muralidharan, B. N. Gangadhar

76. *Semantic and Associative Priming in Schizophrenia: Behavioural and Electrophysiological (N400) Differences*

Simon T. E. Baker, Rachel A. Batty, Susan L. Rossell, Neil Thomas, Andrew J. P. Francis

77. *Positive Affect and Appetitive Motivation in Schizophrenia as Quantified by the Post-Auricular Reflex*

Taylor L. Benson, Stephen D. Benning, Heathman S. Nichols, Holden D. Bitner, Rachel V. Aaron, Sohee Park

78. *Robust EEG Biomarkers of Decision-making; A Possible Probe for Dysfunction in Schizophrenia*

Amy R. Bland, Alexandre Schaefer, Bill J. F. W. Deakin

79. *The Mismatch Negativity in Different Stages of Schizophrenia*

Mitja Bodatsch, Anke Brockhaus-Dumke, Frauke Schultze-Lutter, Ralf Müller, Joachim Klosterkötter, Stefan Ruhrmann

80. *Disruption of Prefrontal Fast-Spiking Interneurons in the DISC1-DN Mouse Model of Schizophrenia*

Ross A. Cardarelli, Akira Sawa, Patricio O'Donnell

81. *Genetic Variation in ABCB1 Associated with P300 Amplitude in Schizophrenia*

Jeroen Decoster, Marc De Hert, Wolfgang Viechtbauer, Guy Nagels, Inez Myin-Germeys, Joseph Peuskens, Jim van Os, Ruud van Winkel

82. *Association of Treatment Delay, Migration and Urbanicity in Psychosis*

Nynke Boonstra, Bouke Sterk, Lex Wunderink, Sjoerd Sytema, Lieuwe de Haan, Durk Wiersma



83. *Family History of Mental Illnesses in First- and Second-Generation Migrants: Evidence from the AESOP First-Onset Study*

Francois Bourque, Susana Borges, Jane Boydell, Paul Fearon, Gerard Hutchinson, Kevin Morgan, Gillian Doody, Peter B. Jones, Robin M Murray, Paola Dazzan, Craig Morgan

84. *The Prevalence of Diabetes Mellitus is Increased in Relatives of Patients with a Psychotic Disorder*

Hanneke Welie, Eske Derks, Kim Verweij, Harold de Valk, Rene Kahn, Wiepke Cahn

85. *The CCC2000 Birth Cohort Study: Theory of Mind in Children at Risk of Psychosis*

Lars Clemmensen, Anja Munkholm, Charlotte Eberhardt, Jim van Os, Anne Mette Skovgaard, Pia Jeppesen

86. *Premature Aging as a Proposed Explanation for Excess of Death in Schizophrenia*

Dan Cohen, Christiane Gasse, Thomas Laursen

87. *Effect of Geographical Ancestry and Ethnicity on Tardive Dyskinesia Severity*

Vincenzo De Luca, Clement Zai, Gary Remington, James L. Kennedy

88. *Childhood Infection and Schizophrenia and Other Psychosis: A Systematic Review and Meta-Analysis of Population-based Studies*

Golam M. Khandaker, Glyn Lewis, Christina Dalman, Peter B. Jones

89. *Prenatal Maternal Infection, Neurodevelopment and Adult Schizophrenia: A Systematic Review of Population-based Studies*

Golam M. Khandaker, Jorge Zimbron, Glyn Lewis, Peter B. Jones

90. *AESOP-10: A 10-Year Follow-up Study of First-Episode Psychosis – Rationale, Method, and Preliminary Findings*

Craig Morgan

91. *Childhood and Adulthood Social Disadvantage in First Episode Psychosis Patients: Is the Latter a Consequence of the Former?*

Simona A. Stilo, Marta Di Forti, Alessandra Paparelli, Aurora Falcone, Valeria Mondelli, Paola Dazzan, Anthony David, Robin M. Murray, Craig Morgan

92. *Ethnicity, Separation and Psychosis: Exploring the Odds*

Simona A. Stilo, Adanna Onyejiaka, Charlotte Gayer-Anderson, Susana Borges, Grant McQueen, Chelsea Gardner, Sophie Sowden, Francois Bourque, Rowena Handley, Helen Fisher, Valeria Mondelli, Marta Di Forti, Robin M. Murray, Carmine Pariante, Paola Dazzan, Craig Morgan

93. *Cancer Mortality in Patients with Psychiatric Diagnoses: A Higher Hazard of Cancer Death does not Lead to a Higher Cumulative Risk of Dying from Cancer*

Ng Chong Guan, Fabian Termorshuizen, Wijnand Laan, Hugo M. Smeets, Nor Zuraida Zainal, René S. Kahn, Niek J. de Wit, Marco P. M. Boks

94. *Trauma and Risk of Developing Psychosis in a High Clinical Risk Population: Results from a Medium to Long Term Follow-up Study*

Andrew Thompson, Barnaby Nelson, Hok Pan Yuen, Paul, G. Amminger, Patrick, D. McGorry, Ashleigh Lin, Stephen Wood, Alison R. Yung



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

95. *Is Clozapine Treatment Associated with Lower Mortality Rates in Schizophrenia? Preliminary Evidence from a Register Based Study*

Annet H. van Bergen, Fabian Termorshuizen, Hugo M. Smeets, Iris E. Sommer, René S. Kahn, Marco P. M. Boks

96. *Comparing the Clinical Presentation of First Episode Psychosis across Different Migrant and Ethnic Minority Groups in Montreal, Canada*

Elsje van der Ven, Francois Bourque, Ridha Joober, Jean-Paul Selten, Ashok Malla

97. *The Curacao Extrapyramidal Syndromes Study, an 18 Year Prospective Study of Inpatients with Severe Mental Illness*

Peter N. van Harten, Hans W. Hoek, Glenn E. Matroos, Jim van Os

98. *Hearing in Persons with Schizophrenia – Findings from a Population-based Survey*

Satu Viertiö, Jonna Perälä, Samuli I. Saarni, Seppo Koskinen, Jaana Suvisaari

99. *CNR1 and Risk of the Metabolic Syndrome in Patients with Schizophrenia*

Weiping Yu, Marc De Hert, Tim Moons, Stephan J. Claes, Christoph U. Correll, Ruud van Winkel

100. *Privacy and Confidentiality: Beliefs, Expectations, and Protections in an Indian Context*

Nagendra N. Mishra, Triptish Bhatia, Vishwajit L. Nimgaonkar, Lisa S. Parker, Smita N. Deshpande

101. *Psychological Mechanisms as Potential Endophenotypes for Bipolar Disorder: A Study of Twin and Sibling Pairs*

Stephanie Beards, Manasi Sharma, Anna Georgiades, Fergus Kane, Sridevi Kalidindi, Katja Schulze, Muriel Walshe, Mei-Hua Hall, Irene Rebollo-Mesa, Jan Scott, Robin M. Murray, Fruhling Rijdsdijk, Eugenia Kravariti

102. *The Association of NRG1, DTNBP1, RGS4, G72/G30, DISC1 and BDNF Candidate Genes with Cognition in Patients with Schizophrenia and Healthy Controls*

János M. Réthelyi, Patrícia Polgár, Judit Benkovits, Kinga Farkas, Attila J. Pulay, Pál Czobor, István Bitter

103. *COMT Met158 allele is Associated with Violence in Schizophrenia: A Meta-analysis*

Savita G. Bhakta, Jian-Ping Zhang, Anil K. Malhotra

104. *Risk Stratification Incorporating Cognitive Endophenotypes for Schizophrenia (SZ) in India*

Triptish Bhatia, Elizabeth A. Gettig, Jon Berliner, Nagendra N. Mishra, Kapila Garg, Vishwajit L. Nimgaonkar, Smita N. Deshpande

105. *Monozygotic Twins Discordant for Bipolar Disorder Show Functional DNA Methylation Changes in Whole Blood and Brain*

Marco P. Boks, Ruth Pidsley, Kristel van Eijk, Emma L Dempster, Netherlands Brain Bank, Simone de Jong, Hilleke E. Hulshoff Pol, Neeltje E. van Haren, Robin Murray, René S. Kahn, Jonathan Mill, Roel A. Ophoff

106. *In a Normal Population Sample Schizophrenia Associated Copy Number Variations in Genomic Regions 1q21. 1, 15q11. 2 are more Frequent in Female and are Associated with Lower Socioeconomic Status, Obesity and Higher Cholesterol Levels*

Elemi J. Breetvelt, Maartje F. Aukes, Marco P. Boks, René S. Kahn, Roel A. Ophoff



107. *Genetic and Functional Analysis of EGR Family Genes in Schizophrenia*

Min-Chih Cheng, Yang-An Chuang, Shih-Hsin Hsu, Chia-Hsiang Chen

108. *Altered Language Network Activity in Young People at Genetic Risk for Schizophrenia*

Lynn E DeLisi, Heidi W. Thermenos, Larry J. Seidman, Susan Whitfield-Gabrieli, Richard Juelich, Gul A. Jabbar, KK Salwen, Martha Shenton, Marek Kubicki, John D. E. Gabrieli, Theo Manschreck, Alan Francis, Matcheri Keshavan

109. *Neuro-immune Crosstalk: Genetic Underpinnings of Immune System Activation with Respect to Frontal Lobe Cognitive Functions in Schizophrenia*

Dorota Frydecka, Lidia Karabon, Edyta Pawlak, Aleksander Beszlej, Andrzej Kiejna

110. *Using a Translational Approach to Study Behavioral Disorders' Pathophysiology: Dopamine System is Affected in a Glutamatergic Animal Model of Psychosis*

Felice Iasevoli, Gianmarco Latte, Livia Avvisati, Carmine Tomasetti, Rodolfo Rossi, Luigi Aloj, Andrea de Bartolomeis

111. *Epistatic Interaction of COMT and DTNBP1 Modulates Working Memory Performance in Mice and Related Prefrontal Physiology in Humans*

Francesco Papaleo, Madeline Burdick, Joseph Callicott, Daniel Weinberger

112. *Glial-derived Neurotrophic Factor (GDNF) Serum Levels in Schizophrenic Women during 8-weeks of Treatment*

Aleksandra Rajewska-Rager, Maria Skibinska, Pawel Kapelski, Anna Leszczynska-Rodziewicz, Joanna Pawlak, Hauser Joanna

113. *Brain-derived Neurotrophic factor (BDNF), Neurotrophin 3 (NTF3), Neurotrophin 4 (NTF4) and Glial-derived Neurotrophic Factor (GDNF) Serum Levels in Schizophrenia*

Anna Leszczynska-Rodziewicz, Maria Skibinska, Pawel Kapelski, Aleksandra Rajewska-Rager, Joanna Pawlak, Joanna Hauser

114. OPEN BOARD

115. *An Environmental Analysis of Genes Associated with Schizophrenia: Hypoxia and Vascular Factors as Interacting Elements in the Neurodevelopmental Model*

Bart P. F. Rutten, Jim van Os, Gabriel Esquivel, Harry W. M. Steinbusch, Rainald Schmidt-Kastner

116. *Decreased Inhibitory Neurotransmission Markers in the Amygdala of Alzheimer Patients Suffering from Psychosis*

Ana R. Saez, Javier Gilabert-Juan, Jose L. Ivorra, Josep M. Haro, Alfonso Monje, Isidre Ferrer, Juan Nacher, Julio Sanjuan, M. Dolores Moltó

117. *Analysis of Candidate Genes Conferring Susceptibility to Schizophrenia in a Sample from Indonesia with 1081 Cases and 1111 Controls Reveals Association with rs1344706 Located in the ZNF804A Gene*

Sibylle G. Schwab, Nan Dai, WenWen Qin, Mutiara D. B. Wildenauer, Agung A. A. Kusumawardhani, Indonesia Schiz. Gen Consortium, Dieter B. Wildenauer



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

118. *Intermediate Phenotype Analysis of Patients, Unaffected Siblings and Healthy Controls Identifies VMAT2 as a Candidate Gene for Psychotic Disorder and Neurocognition*

Claudia Simons, Ruud van Winkel

119. *Genetic Modulation of the Long-term Effects of Cannabis on Brain Structure, Function and Symptomatology*

Nadia Solowij, Francesca Fernandez, Robin Murray, Murat Yücel

120. *The Genetics of Language Lateralization and Left-handedness: Linkage Analysis in a Dutch Population Isolate*

Metten Somers, Roel A. Ophoff, Rita M. Cantor, Maartje F. Aukes, Kristel van Eijk, Meenakshi Dauwan, Ruben van 't Slot, Esther Janson, Marco P. Boks, René .S. Kahn, Iris E. Sommer

121. *Multilocus Analysis of Candidate Genes Involved in Neurodevelopment with Schizophrenia Susceptibility*

Aleksandra Szczepankiewicz, Maria Skibinska, Pawel Kapelski, Monika Wilkosc, Piotr Czerski, Monika Dmistrz-Weglarz, Joanna Hauser

122. *Impact of Positive and Negative Symptoms and Cognitive Impairment on Health Outcomes and Healthcare Resource Utilization in European Patients with Schizophrenia*

Namita L. Tundia, Menaka Bhor, Amy M. Duhig, Steven Hass, Richard Perry, Gary Milligan

123. *Peripheral Blood Mononuclear Cells CB1 and CB2 Receptor Levels in First Episodes of Psychosis*

Miquel Bioque, Karina MacDowell, Borja Bueno, Ana Meseguer, Bibiana Cabrera, Juan C. Leza, Miguel Bernardo

124. *Decreased Hand Blood Flow Correlates with Symptom Severity and is Acutely Increased by Atypical Antipsychotic Medication in Patients with Schizophrenia and Schizoaffective Disorder*

Esther Blessing, Linda Kader, Youichirou Ootsuka, William W. Blessing, Christos Pantelis

125. *Association of Hyperprolinemia with Schizophrenia: Implications for the Etiology, Clinical Management and Treatment of Schizophrenia Patients*

Catherine L. Clelland, Valerie Drouet, Ian Orozco, Alexandra Kelly, Angela Kaon, Li Liu, Raymond Suckow, Laura L. Read, Robert Nadrich, Amit Rajparia, James D. Clelland

126. *Dopaminergic Function in Treatment Resistant Schizophrenia: New Evidence from an [18F]-DOPA PET Study*

Arsime Demjaha, Robin Murray, Shitij Kapur, Oliver Howes

127. *Analyses of Monoamine Metabolites in the Cerebrospinal Fluid of Patients with Schizophrenia*

Kotaro Hattori, Daimei Sasayama, Toshiya Teraishi, Takashi Fujii, Hiroshi Kunugi

128. *Nitric Oxide Synthase Activity is Differentially Altered between Acute and Subchronic Phencyclidine Treatments in Discrete Mouse Brain Regions*

Graham Lee, David M. Thomson, Allan McVie, Colin J. Suckling, Brian J. Morris, Judith A. Pratt

129. *Dynamic Changes in microRNA Expression in the Developing Human Prefrontal Cortex*

Natalie J. Beveridge, Danielle M. Santarelli, Paul A. Tooney, Maree J. Webster, Cynthia S. Weickert



130. *Prenatal Vitamin D Deficiency Alters Dopamine and Glutamate Metabolism in Rat Brain*
Thomas H. Burne, James P. Kesby, Karly Turner, Alexander Suzy, John J. McGrath, Darryl W. Eyles
131. *Prediction of Functional Outcome in Individuals at Clinical High-Risk for Psychosis*
Ricardo E. Carrion, Danielle McLaughlin, Terry E. Goldberg, Doreen Olvet, Andrea Auther, Barbara A. Cornblatt
132. *The Group of Schizophrenias: Evidence for Differential Developmental Trajectories in Schizophrenia and Bipolar Disorder*
Nicolas A. Crossley, Mark Weiser, Michael Davidson, Abraham Reichenberg
133. *Serum NT3 and NT4 Levels and the Positive and Negative Syndrome Scale (PANSS) Scores – Pilot Study*
Monika Dmitrzak-Weglaz, Maria Skibinska, Paweł Kapelski, Aleksandra Szczepankiewicz, Joanna Pawlak, Joanna Hauser
134. *Hostility Bias in Healthy Persons: It's Association with 'Theory of Mind' Skills*
Suk Kyoan An, Su Young Lee, Imhong Jeon, Kyung Ran Kim, Jin Young Park, Eun Lee, Jun Soo Kwon
135. *Myelin Pathology and its Relationship to Iron Homeostasis in Schizophrenia*
Lorna A. Farrelly, Melanie Föcking, Jane English, Gerard Cagney, David Cotter
136. *Disruption of Cdc42 and Duo/PAK1 Pathway Drives Myosin Light Chain Phosphorylation in Schizophrenia*
María D. Rubio, Vahram Haroutunian, James H. Meador-Woodruff
137. *The Phrenic Component of Acute Schizophrenia – A Name and its Physiological Reality*
Karl-Juergen Bär, Steffen Schulz, Sandy Berger, Voss Andreas
138. *Semantic Fluency is Impaired but Phonological Fluency is Intact -the Key to Pathophysiology*
Timothy J. Crow, Simon L. Collinson, Anthony C. James
139. *Study Using Magnetoencephalography of Spontaneous Neural Activity in a Schizophrenic Patients*
Josep Tarragó, Cristina Alonso, Rafal Novack, Oscar Pino, Jose E. Rojo
140. *Meta-analysis of Cognitive Deficits in Ultra-High Risk to Psychosis*
Emre Bora, Christos Pantelis
141. *Theory of Mind Impairment at Risk Conditions to Psychosis and in First-Degree Relatives of Schizophrenia: Systematic Review and Meta-analysis*
Emre Bora, Christos Pantelis
142. *Social Cognition in Impaired Patients: Which Role for Facial Emotion Recognition and Theory of Mind ?*
Perrine Brazo, Virginie Beaucousin, Laurent Lecardeur, Sonia Dollfus
143. *Visual Backward Masking Deficits in Schizotypy*
Celine Cappe, Christine Mohr, Daniela Herzig, Michael Herzog



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

144. *Breaking Down Thinking Speed: Components of Processing Time and their Relationship to Symptoms and other Cognitive Domains in Schizophrenia*

Matteo Cella, Til Wykes

145. *Impairment in Cognitive Flexibility in Patients with Bipolar Disorder Versus Patients with Schizophrenia*

Goultchira Chakirova, Jessika E. D. Sussmann, Adam Hampshire, T. William J. Moorhead, Killian A. Welch, Anna Peel, Prerona Mukherjee, Heather C. Whalley, Adrian M. Owen, Jeremy Hall, Eve C. Johnstone, Stephen M. Lawrie, Andrew M. McIntosh, Verity J. Brown

146. *Semantic Inhibition Performances in Bipolar Disorders and Schizophrenia: A Meta-analysis of Hayling Sentence Completion Test*

Raymond C. Chan, Li L. Song, Kui Wang, Eric F. Cheung, Simon S. Lui, David Shum

147. *The Emotional Stroop in First Episode Schizophrenia*

Sieds Dieleman, Frederik M. Veen van der, Christian H. Roder

148. *IQ Measure: Relation with Refractory Schizophrenia*

Graça Maria R. Oliveira, Monica Kayo, Sandra M. K. Iso, Helio Elkis

149. *Facial Affective Expressiveness in Patients with Schizophrenia*

Helena Fatouros Bergman, Jochen Spang, Jörg Merten, Gunilla Preisler, Andrzej Werbart

150. *Goal-representation and Action Control in Patients with Schizophrenia and Predominant Negative Symptoms*

Anja Fritzsche, Tania Lincoln

151. *Clinical and Neurocognitive Assessment of Schizophrenic Patients who Suffer Repeated Relapse and Hospitalization*

Manuela Perez Garcia, Julio Brenlla Gonzalez, Mario Parmo Fernandez, Alfonso Mozos Ansorena, Begoña Portela Traba

152. *Further Evidence for an Impaired Discrimination between Imagined and Performed Actions in Schizophrenia*

Łukasz Gawęda, Steffen Moritz, Andrzej Kokoszka

153. *The Role of DRD2 rs1076560 and AKT1 rs1130233 Variants in the Modulation of Attention in Patients with Schizophrenia and Healthy Subjects*

Barbara Gelao, Giuseppe Blasi, Maria Teresa Attotto, Annamaria Porcelli, Marina Mancini, Paolo Taurisano, Leonardo Fazio, Gianluca Ursini, Antonio Rampino, Rita Masellis, Raffaella Romano, Lucia Colagiorgio, Enrico D'Ambrosio, Annabella Di Giorgio, Grazia Caforio, Alessandro Bertolino

154. *Neurocognitive Profiles of Marginalized Persons with Comorbid Psychosis and Polysubstance Abuse*

Kristina Gicas, Heather A. Baitz, Chantelle J. Giesbrecht, Fidel Vila-Rodriguez, William Panenka, G. William MacEwan, Alasdair M. Barr, Donna J. Lang, Allen E. Thornton, William G. Honer



155. *Child Maltreatment, COMT variability and Adult Cognition: Gene-Environment Interaction using a Twin Study*

Ximena Goldberg, Mar Fatjó-Vilas, Silvia Alemany, Aldo Córdova, Igor Nenadic, Cristobal Gastó, Lourdes Fañanás

156. *Neuropsychological Performance of Individuals at Ultra High Risk or First Episode Psychosis*

Priscila D. Gonçalves, Paula A. Martins, Pedro Gordon, Mario Louzã

157. *Metacognition in Non-psychotic Help-seeking Adolescents: Associations with Prodromal Symptoms, Distress, and Psychosocial Deterioration*

Danny Koren, Ravit Scheyer, Noa Reznik, Merav Adres, Alan Apter, Larry J. Seidman

158. *Cognitive Reserve as a Moderator of Outcome in Chronic Schizophrenia*

Natalia Ojeda, Pedro Sanchez, Javier Peña, Edorta Elizagarate, Jesus Ezcurra, Miguel Gutierrez

159. *Executive Attention Impairment in First Episode of Schizophrenia*

Gricel P. Orellana, Marcela Peña, Andrea Slachevsky

160. *Hearing Voices; Abnormal Perception of "Biological" Sound in Schizophrenia and Schizotypy*

Sohee Park, Amanda Cumming, Heathman Nichols

161. *The Characteristics of Reversal Response Initiation and Associative Learning of Reward Approach and Loss Aversion in Schizophrenia*

Sunyoung Park, Jae-Jin Kim, Seok-Hyeong Kim, Jung-Hwan Kim, Min-Seong Koo, Il Ho Park

162. *Affect Recognition in People at Clinical High Risk of Psychosis*

Danijela Piskulic, David Penn, Diana Perkins, Scott Woods, Lu Liu, Jean Addington

163. *Applicability of the MATRICS Consensus Cognitive Battery in Singapore*

Attilio Rapisarda, Thomas Lim, Matthew Lim, Simon Collinson, Michael Kraus, Richard Keefe

164. *The Cognitive Substrates of Thought Disorder Using Analogue Modeling*

Susan L. Rossell, Erica Neill, Celia Morgan

165. *An Investigation of a Novel Transdiagnostic Model of Delusions in a Group with Positive Schizotypal Symptoms*

Susan L. Rossell

166. *Relationship between Cognitive and Psychosocial Functioning in First Psychotic Episodes: 5 Year Follow-Up Study*

Itxaso González-Ortega, Sara Barbeito, Sonia Ruiz de Azúa, Patricia Vega, Susana Alberich, Ariadna Besga, Ruben González-Oliveros, Ana González-Pinto

167. *A Virtual Reality Investigation of Spontaneous Navigation Strategies in Schizophrenia*

Leanne K. Wilkins, Todd A. Girard, Jelena King, Matt King, Katie Herdman, Bruce Christensen, Veronique Bohbot



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

168. *Normalization Effect of Cognitive-Behavioral Therapy for Auditory Hallucinations on Limbic and Frontal Hyperactivation in Front of an Emotional Auditory Paradigm*

Eduardo J. Aguilar, Gracián García-Martí, Luis Martí-Bonmatí, Douglas Turkington, Mercedes Renovell, Julio Sanjuán

169. *COMBIMOD: Interest of a French Integrative Programme in the Improvement of Cognitions among Patients with Schizophrenia: Preliminary Results*

Marie-Cécile Bralet, Delphine Catinaud, Abderahman Jlidi, Christophe Hochard, Corinne Gautier, Thierry Lambert, Sandrine Orrens, Laurence Gerret

170. *Assessment and Treatment of Metacognitive Impairment in People with Psychosis*

Steven de Jong, Marieke Pijnenborg, André Aleman, Mark van der Gaag, Paul H. Lysaker

171. *Yoga as Adjunctive Cognitive Remediation for Schizophrenia in India*

Triptish Bhatia, Akhilesh Agrawal, Gyandeepak Shah, Wood Joel, Jan Richards, Raquel E. Gur, Ruben C. Gur, Vishwajit L. Nimgaonkar, Smita N. Deshpande

172. *A Multi-centre Randomised Controlled Trial of Cognitive Therapy to Prevent Harmful Compliance with Command Hallucinations*

M. Birchwood, E. Peters, T. Wykes, N. Tarrier, S. Lewis, G. Dunn, L. Davies, H. Lester, M. Michail, S. L. Griffiths

173. *Group Cognitive-behavioral Therapy for Early Psychosis*

Nam-In Kang, Kil-Sang Yoon, Tae-Won Park, Jong-Chul Yang, Keun-Young Oh, Young-Chul Chung

174. *Can Prenatal Supplementation of Omega-3 Prevent the Early Prodrome of Schizophrenia in Adolescence in a Mouse Model?*

Qi Li, Xiaofan Zhan, Ran Wei, Sylvia Lam, Basil Paul, Pak C. Sham, Siew E. Chua, Grainne M. McAlonan

175. *Clozapine Administration in Adolescence Improves the Social Function of the Adult Offspring in an Animal Model of the Schizophrenia*

Qi Li, Ran Wei, Kelvin Kwok, Joseph Lau, Siew E. Chua, Grainne M. McAlonan

176. *Long-term Effects (up to 4 years) of Aripiprazole on Maintenance Treatment for Schizophrenia or Schizoaffective Disorder: A Pooled Open-label Extension of Two Clinical Trials*

Ross A. Baker, Na Jin, Mirza W. Ali, Robert A. Forbes, Steven J. Offord, William H. Carson, Raymond Sanchez, Robert D. McQuade, Zia Rahman

177. *Is the Dreaming Mentation Directly Influenced by the Psychotic Mental State?*

Anna Castelnovo, Rebecca Ranieri, Silvio Scarone

178. *Theory of the Mind Skills in Schizophrenia: Exploring Economic Behavior in the Dictator (DG) and in the Ultimatum Game (UG)*

Anna Castelnovo, Rebecca Ranieri, Silvio Scarone



179. *Proteomic Analysis of the Corpus Callosum Reveals Down-regulation of the Glycolysis Protein Pathway and further Implicates CME in Schizophrenia*

Jane A. English, Kieran Wynne, Gerard Cagney, David R. Cotter

180. *Vitamin D Deficiency in First Episode Psychosis*

Matthieu P. Crews, Poonam Gardner-Sood, Stefania Bonaccorso, Shubulade Smith, Robin M. Murray, Oliver Howes, Fiona Gaughran

181. *Ongoing Data Quality Monitoring of Videotaped Patient Interviews in Global Schizophrenia Clinical Trials: Initial Findings*

David Daniel, Alan Kott

182. *Compulsory Psychiatric Treatment in Canada: 100 Cases*

Luc Nicole, Marie Boivin, Kathe Villeneuve, Benedicte Nicole, Christian Desmarais

183. *Metabolic Syndrome in Patients with Schizophrenia and Actions from Mental Health Services*

Jose M. Pelayo-Teran, Yolanda Zapico-Merayo, Ana R. Alonso-Fernandez, Pedro Trabajo-Vega, Eva Povedano, Nicolas Martin-Navarro, Jovita Martinez-Diaz, Mario M. Martinez-Perez, Consolacion Rodriguez-Fonseca, Camino Fernandez-Borregan, Alfonso Hurtado-Casanova, Raul Arenas-Fernandez

184. *The EMEA ADHES Survey: Schizophrenia Through the Carers' Eyes*

A. Svettini, B. Johnson, C. Magro, J. Saunders, K. Jones, S. Silk, L. Hargarter, A. Schreiner

185. *The EMEA ADHES Survey in Schizophrenia: Nurses' Perceptions of the Extent and Burden of Partial and Non-adherence to Medication in Patients with Schizophrenia*

R. Emsley, K. Alptekin, J.M. Azorin, F. Cañas, V. Dubois, P. Gorwood, D. Naber, J. M. Olivares, G. Papageorgiou, M. Roca, P. Thomas, L. Hargarter, A. Schreiner

186. *The EMEA ADHES Survey in Schizophrenia: Nurses' Views on the Treatment Options for Improving Partial or Non-adherence in Patients with Schizophrenia*

R. Emsley, K. Alptekin, J. M. Azorin, F. Cañas, V. Dubois, P. Gorwood, D. Naber, J. M. Olivares, G. Papageorgiou, M. Roca, P. Thomas, L. Hargarter, A. Schreiner

187. *Evaluating Injection Site Pain with Long-acting Atypical Antipsychotics Using Clinical Trial Databases of Subjects with Schizophrenia*

Jennifer Kern Sliwa, Srihari Gopal, Dong-Jing Fu, Isaac Nuamah, Larry Alphs

188. *Maintenance Treatment with Risperidone Long-Acting Injection vs. Placebo in Subjects Recently Diagnosed with Bipolar Disorder: A Subgroup Analysis*

Larry Alphs, Dong-Jing Fu, Jennifer Kern Sliwa, Yi-Wen Ma, Cynthia A. Bossie

189. *Prediction of Relapse after a First Episode of Psychosis: A Follow-up Clinical Study*

Daniel Berge, Anna Mane, Purificación Salgado, Romina Cortizo, Patricia C. Garnier, Antoni Bulbena

190. *Olanzapine Long-acting Injection: Review of First Experiences of Post-injection Delirium/Sedation Syndrome in Routine Clinical Practice*

Chris J. Bushe, Chetan C Shatapathy, Ernie Anand, Marta Casillas, Elena Perrin, Holly Detke



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

191. *How well do Psychosis Risk Criteria Predict Psychosis Relative to their Absence? A 10-year Audit of an Early Psychosis Service*

Vaughan J. Carr, Terry J. Lewin, Agatha M. Conrad, Sean A. Halpin, Ulrich Schall, Ketrina A. Sly

192. *Relationship of Premorbid Functioning with Negative Symptoms and Cognition in First-episode Schizophrenia: A Three-year Prospective Follow-up Study*

Wing-Chung Chang, Christy Hui, Jennifer Tang, Gloria Wong, Sherry Chan, Eric Y. H. Chen

193. *Baseline Characteristics of First-episode Psychosis Patients in Cape Town*

Bonginkosi Chiliza, Laila Asmal, Robin Emsley

194. *Functional Status Rating Scales as Predictors of Everyday Functioning in People with Schizophrenia: Global vs. Subscales Ratings*

Davide Prestia, Samir Sabbag, Philip D. Harvey

195. *Examining Levels of Antipsychotic Adherence to Better Understand Nonadherence in Patients with Schizophrenia*

Gagan Fervaha, Celine Teo, Steve Mann, Margaret Hahn, George Foussias, Ofer Agid, Gary Remington

196. *FFM Personality Traits and Subclinical Psychotic Symptoms in Patients with Psychotic Disorders, their Siblings and Healthy Subjects: Preliminary Findings*

Lindy Boyette, Carin Meijer, Lieuwe de Haan

197. *Self Relevance of Patients with Schizophrenia*

Kit Wa Chan, Tianyin Liu, Gloria H. Y. Wong, Christy L. M. Hui, Wing Chung Chang, May M. L. Lam, Eric Y. H. Chen

198. *Childhood Trauma and Auditory Verbal Hallucinations*

Kirstin Daalman, Kelly M. Dieren, Eske M. Derks, Remko van Lutterveld, René S. Kahn, Iris E. Sommer

199. *Effect of Medication in Cognition and Insight in Psychotic Patients*

J. Cobo, L. Nieto, S. Ochoa, J. Usall, I. Baños, B. Gonzalez, I. Ruiz, E. Pousa, C. García-Ribera, A. I. Ruiz

200. *Splitting the Mind and Body: Disturbances in Body Ownership as a Core Feature of the Schizophrenia Spectrum*

Lindsey G McIntosh, Taylor L Benson, Joel S. Peterman, Sohee Park

201. *Frequency of Auditory and Visual Hallucinations over the Course of 20-Years in Patients with Schizophrenia, Schizoaffective Disorder, and Bipolar Disorder with Psychosis*

Vina M. Goghari, Martin Harrow

202. *Comparing the Prodrome of Schizophrenia-spectrum Psychoses and Bipolar Disorders With and Without Psychotic Features*

Frauke Schultze-Lutter, Benno G. Schimmelmann, Joachim Klosterkötter, Stephan Ruhrmann



203. *Time Course of Dropout Rates in Schizophrenia Trials Conducted from 1966 to 2010: A Systematic Review and Meta-analysis*

Ofer Agid, Cynthia O. Siu, Robert B. Zipursky, Gary Remington

204. *Change in Psychopharmacotherapy of Schizophrenia Patients within a Period of 10 Years*

Deniz Ceylan, Ahmet Yiğit Aktener, Berna Binnur Akdede Kıvırcık, Köksal Alptekin

205. *TRIES: An Open, Randomized, Prospective, Multicenter Study, Searching the Best Switch Policy of Sertindole in Patients with Schizophrenia*

Köksal Alptekin, Berna Akdede, Haldun Soygur, TRIES Study Group

206. *Lamotrigine Augmentation in Patients with Schizophrenia Who Show Partial Response to Clozapine Treatment*

Sefa Vayisoğlu, A. Elif Anıl Yağcıoğlu, Süha Yağcıoğlu, Sevilay Karahan, Oğuzhan Karıcı, Can Gürel, M. Kâzım Yazıcı

207. *Long-term Functional Improvements in the 2-Year Treatment of Schizophrenia Outpatients with Olanzapine Long-acting Injection*

Haya Ascher-Svanum, Diego Novick, Josep M. Haro, Jordan Bertsch, David McDonnell, Holland Detke

208. *New Results Alter Balance of Evidence in Meta-analysis of Long-Acting Injectable vs. Oral Antipsychotics in Schizophrenia*

Taishiro Kishimoto, Alfred Robenzadeh, Stanley Ng, Koichiro Watanabe, Masaru Mimura, Claudia Leucht, Stefan Leucht, John M. Kane, Christoph U. Correll

209. *Central Glycine Increase in Rats, Monkeys and Healthy Volunteers after Two Glycine Reuptake Inhibitors, RG1678 and RG7118*

Flavia Pizzagalli, Meret Martin-Facklam, Carsten Hofmann, Christophe Boetsch, Larry Ereshefsky, Alain Patat, Bruno Boutouyrie-Dumont, Joseph G. Wettstein, Daniela Alberati

210. *Identification of a Putative Serum Biomarker Predicting Response to the Glycine Reuptake Inhibitor RG1678 in Improving Negative Symptoms in Patients with Schizophrenia*

Anne Vogt, Daniel Umbricht, Daniela Alberati, Jens Robert Wendland, Enrico Domenici, Fabian Model, Johann Karl, Peter Kastner, Giuseppe Palermo, Carsten Horn, Dominique de Quervain, Andreas Papassotiropoulos, Gabriel Vargas, George Garibaldi, Luca Santarelli

211. *The Behavioral Profile of TP-10 in Rodents and Non-human Primates Supports PDE10A Inhibition as a Novel Treatment Approach for Schizophrenia*

Eric P. Prinssen, Daniela Alberati, Bruno Pouzet, Theresa M. Ballard, Tanya L. Wallace, Daniel Schlatter, Elodie Meyer, Paricher Malherbe, Matthias Koerner, Rosa Maria Rodriguez Sarmiento, Ruben Alvarez Sanchez, Alexander Flohr, Joseph G. Wettstein, Herve Schaffhauser

212. *The Influence of the Route of Administration on the Efficacy of Long-term Oral Antipsychotic treatment in Schizophrenia*

Rebecca Ranieri, Anna Castelnovo, Silvio Scarone



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

213. *Trends in the Pharmacological Treatment of Involuntarily Committed Patients with a Schizophrenia, Schizotypal or Delusional Disorder Over an 11 Year Observation Period*

Anna-Sophia Rauch, Monika Edlinger, Thomas Wolfinger, Georg Kemmler, Nursen Yalcin, W. Wolfgang Fleischhacker, Alex Hofer

214. *Study on the Control of Symptoms and Impact on Functioning in Hospital Intervention during a First Psychotic Episode*

Rosa E. Rodriguez-Huesca, Jose M. Manzano

215. *Prehypertension, Hypertension, Diabetes, Obesity and Cardiometabolic Changes Associated with Antipsychotic Use in Schizophrenia*

Sahoo Saddichha, Sayeed Akhtar

216. *Risk of New-onset Diabetes after Long-term Treatment with Clozapine in Comparison to Other Antipsychotics in Patients with Schizophrenia*

Peter F. Schulte, Johanna T. Bocxe, Hieronymus J. Doodeman, Ingrid M. van Haelst, Dan Cohen

217. *Leptin Reversed the Sensorimotor Gating Disturbance in a Rat Developmental Model of Schizophrenia*

Ali Shahbazi, Somayeh Dashti, Nahid Aboutaleb

218. *Bayesian Analysis of Weighted-Z Tests in Adaptive Trial Design*

Cynthia Siu, Carla Brambilla, Fabrizio Ruggeri

219. *Differences Between Patients Undergoing Augmentation or Switching of Antipsychotic Medications During Treatment of Schizophrenia*

Virginia L. Stauffer, Haya Ascher-Svanum, Alan J. M. Brnabic, Anthony H. Lawson, Bruce J. Kinon, Peter D. Feldman, Katarina Kelin

220. *A Phase 1b Study Investigating the Potential Interaction between LY2140023 and Second Generation Antipsychotics in Subjects with Schizophrenia or Schizoaffective Disorder*

Virginia L. Stauffer, Mosun Ayan-Oshodi, Eshetu T. Wondmagegnehu, Jennifer Witcher, Tong Shen, Eunice Soek Mun Yuen, Ludmila Kryzhanovskaya, Lev Gertsik, David P. Walling

221. *Acute and Chronic Administration of Cotinine to DBA/2 Mice Increase Conditioning Amplitude in the Sensory Inhibition Model*

Karen E. Stevens, Lijun Zheng, Kevin S. Choo

222. *Prediction of Remission in a Sample of Subjects with Schizophrenic Disorder*

Paolo Stratta, Alessandro Rossi

223. *A Novel Interactive Social Cognition Task Reveals Decreased Adaptation of Verbal Productions as a Function of Interlocutor's Likely Knowledge in People with Recent-onset Schizophrenia*

Amélie M. Achim, Sophie Couture, Marie-Audrey Lavoie, Marion Fossard

224. *Improving Functional Outcome Using Compensatory Strategies in Comorbid Intellectual Disability and Psychosis: A Case Study*

Kelly A. Allott, Shona M. Francey, Dawn I. Velligan



225. *Exploring the Relationship Between Schizotypy and well-being in a Student Population*

David S. Barron, Nina Smyth, Kevin D. Morgan, Tony Towell, Angela Clow

226. *Social Cognition Training as an Intervention for Improving Functional Outcome in First Episode Psychosis: A Pilot Study*

Cali F. Bartholomeusz, Kelly Allott, Eoin Killackey, Stephen J. Wood, Andy Thompson

227. *Relationships of Object Relations to Empathy and Social Skills Performance in Schizophrenia and Healthy Controls*

Morris D. Bell, Silvia Corbera, Satoru Ikezawa, Bruce E. Wexler

228. *Affective Prosody Perception in Remitted Patients with Schizophrenia Compared to Healthy Controls*

Falko Biedermann, Susanne Baumgartner, Alexandra Kaufmann, Christine Hoernagl, Christian Georg Widschwendter, Nursen Yalcin, Wolfgang W. Fleischhacker, Alex Hofer

229. *Predictors of Recovery and Social Functioning in Early Psychosis*

Geneviève Bourdeau, Tania Lecomte, Paul H. Lysaker

230. *Enhancing Adherence to Antipsychotic Medication: Where are we Going Wrong?*

Ellie Brown, Richard Gray

231. *Motivation and Metacognition as Predictors of Occupational Functioning in Remitted Schizophrenia Patients*

Cumhur Tas, Elliot C. Brown, Aysen E. Danaci, Lysaker H. Paul, Martin Brüne

232. *How Separable are the Domains of Social Cognitive Deficits in Schizophrenia?*

Elliot C. Brown, Cumhur Tas, Aysen E. Danaci, Martin Brüne

233. *An Investigation into Covert Signal Detection and Selective Attention Control in Individuals Diagnosed with Schizophrenia Using a Covert Cueing Paradigm*

Elizabeth Bryant, Mohammed M. Al-Uzri, Maria Dale, Timothy Millward, Vesna Acovski, Chris Stowers, Steven S. Shimozaiki

234. *Social Skills and Social Functioning Related to Type and Severity of Psychiatric Symptoms*

Emma Casas-Anguera, Gemma Prat, Susana Ochoa, Maria Escandell Jose, Ramon Martín Jose, Sonia Vilamala, Mar Garcia-Franco

235. *Smoking and Other Cardiovascular Disease Risk Behaviours among People with Severe Mental Disorders*

Amanda Baker, Robyn Richmond, Frances Kay-Lambkin, David Castle, Sacha Filia, Jill Williams, Vanessa Clark

236. *Listeners' Impressions of Speakers with Schizophrenia: Impact for Social Functioning*

Maud Champagne-Lavau, Anne-Sophie Lienhart, Julie Girer, Hélène Wilquin, Mariapaola D'Imperio



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

237. *Effects of Extended Case Management on Functioning in People with Early Psychosis- Preliminary Findings of the EASY3 Randomised Controlled Study*

Gloria H. K. Chan, Olivia T. T. Jim, Carol W. S. AuYang, Christy L. M. Hui, Gloria H. Y. Wong, May M. L. Lam, W. C. Chang, Eric Y. H. Chen

238. *Emotion Recognition and Social Functioning Deficits in Schizophrenia*

Cameron M. Clark, Vina M. Goghari, Frédéric Gosselin

239. *Family History of Psychosis, Social Risk Factors and Risk of Developing Psychosis*

Jacqueline Stowkowy, Jean Addington

240. *Subjective Quality of Life of Nigerian Outpatients with Schizophrenia: Sociodemographic and Clinical Correlates*

Adegoke O. Adelufosi, Adegboyega Ogunwale, Olukayode Abayomi, Temilola J. Mosanya

241. *Social Cognition and Quality of Life in Schizophrenia*

Arija Maat, Anne-Kathrin Fett, Eske Derks, GROUP Investigators

242. *Recovery Based Practice in Acute Psychosis – The Current State of Play, Future Directions*

David Ash, Jonathan Crichton

243. OPEN BOARD

244. *Early Psychosis Intervention: Service Model Determines Case Detection Rate but What the Clinician Does Determines 6 to 12 Month Outcomes*

Stanley V. Catts, Brian I. O'Toole, Vaughan J. Carr, Terry Lewin, Amanda Neil, Meredith G. Harris

245. *Metabolic Monitoring for Black vs White Veterans with Schizophrenia*

Laurel A. Copeland, John E. Zeber, Karon L. Phillips, Richard A. Beswick

246. *Early Patterns of Symptom Profiles Using the Positive and Negative Syndrome Scale (PANSS) to Inform Decisions on the Expected Response to Treatment during Clinical Trials*

Christian Yavorsky, Anzalee Khan, Mark Opler, Guillermo DiClemente, Ashleigh DeFries, Sofija Jovic

247. *Neuro-cognitive Presentations of Methamphetamine Abusers with and without Psychosis Compared to Schizophrenics*

Chih-Ken Chen, Liang-Jen Wang, Yi-Chih Chen, Ming-Chy Huang, Shih-Ku Lin

248. *Intervention in Schizophrenia in an Underserved Community: Addressing Comorbid Substance Abuse*

Leonardo Cortese, Saadia Ahmad, Jeffrey Gempl, Giovanni Vilella, Corina Velehorsch

249. *Dangerousness of Inpatients with Schizophrenia – an Evaluation of Daily Clinical Routine*

Monika Edlinger, Anna-Sophia Rauch, Georg Kemmler, Nursen Yalcin, W.Wolfgang Fleischhcker, Alex Hofer

250. *Cannabis Abuse and Psychotic Symptoms in Patients with their First Episode of Psychosis*

Miriam Sirianni, Marta Di Forti, Pasquale De Fazio, Simona A. Stilo, Sonia M. Pintore, Craig Morgan, Robin M. Murray



251. *Event-related Potentials and Brain Rhythm Oscillations Changes in First-episode Schizophrenia during Working Memory Activation*

Pascal Missonnier, Maryse Badan Bâ, Panteleimon Giannakopoulos, Marco Merlo

252. *Plasma Ndel1 Activity is Reduced in Patients with Schizophrenia.*

Ary Gadelha, Mauricio F. M. Machado, Camila M. Yonamine, João Ricardo Sato, Vitor Oliveira, Rodrigo A. Bressan, Mirian A.F. Hayashi

253. *Prediction of Psychosis in Clinical High-risk Patients by Schizotypal Personality Questionnaire*

Raimo K. R. Salokangas, Peter Dingemans, Markus Heinimaa, Tanja Svisrskis, SinkkaLuutonen, Joachim Klosterkötter, Stephan Ruhrmann, Georg Juckel, Heinrich Graf von Reventlow5, Don Linszen, Max Birchwood6, Paul Patterson

254. *Childhood Adversity and Premorbid Schizotypal Traits: Findings from the AESOP First-episode Psychosis Case-control Study*

Tjasa Velikonja, Craig Morgan, Paola Dazzan, Kevin Morgan, Paul Fearon, Gillian Doody, Peter Jones, Robin Murray, Helen L. Fisher

255. *Clinical Features of Patients with Schizophrenia who Showed Symptomatic Remission*

Yeon Ho Joo, Jung Sun Lee, So Yeon Park

256. *Structural Brain Correlates of Sensorimotor Gating in Schizophrenia Patients and Healthy Controls: A 6 Year Follow-up Study of Initially Antipsychotic Naïve, First-Episode Schizophrenia patients*

Trine Bjørg Hammer, William Baaré, Arnold Skimminge, Birte Glenthøj, Bob Oranje

257. *Task-dependent Modulation of Cortical Excitability and Intracortical Inhibition in Schizophrenia*

Agathe Saby, Pavel G. Lindberg, Benoît Crepon, Marie-Odille Krebs, Raphaël Gaillard, Isabelle Amado

258. *Variation in Functional Ratings of Patients with Schizophrenia among Different Types of Informants and the Relationship to Objective Measures of Ability*

Sara J. Czaja, David A. Loewenstein, Jonathan E. Sherin, Philip D. Harvey

259. *Maternal Antibodies to Dietary Antigens and Risk for Non-affective Psychoses in the Offspring*

Susanne Wicks, Håkan Karlsson, ÅsaBlomström, Shuoja Yang, Robert H. Yolken, Christina Dalman

260. *The Expression of Pro-inflammatory Cytokines in Patients with Schizophrenia*

Kara O'Connell, JoginThak, KumleshDev

261. *Severe Weight Gain in Association with Duration of Antipsychotic use; A Meta-analysis of RCT's between 1999 and 2009*

Maarten Bak, Annemarie Fransen, Jim van Os, MarjanDrukker

262. *Lexical-semantics and Schizotypy: What Deficits do High Schizotypes have with Word Processing?*

Giorgia Wagner, Eric Tan, Susan Rossell

263. *Spinocerebellar Ataxia Type 17: a Putative Neurochemical and Behavioural Model of Schizophrenia-like Phenotype Development*

Davide Amato, Sally Makady, Fabio Canneva, Stephan von Hörsten, Christian P. Müller

264. *Disrupted Functional Connectivity During Memory Encoding and Retrieval in Patients with First-Episode Schizophrenia*

Kristen M. Haut, Theo G. Van Erp, Barbara J Knowlton, Keith H. Nuechterlein, Kenneth L. Subotnik, Joseph Ventura, Tyrone D. Cannon

265. *Computational Approach to Understanding Cortical Circuit Deficits of Schizophrenia*

Peter J. Siekmeier, Tsung-Ung W. Woo



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

Posters, Monday 16 April

12:00 PM - 2:00 PM

Cavaniglia

Monday Poster Session and Lunch

1. *Insecure Attachment Style Mediates the Association between Childhood Adversity and Subclinical Psychotic Symptoms in a Non-clinical Sample*

Tamara Sheinbaum, Thomas R. Kwapil, Agnès Ros, Sergi Ballespí, Mercè Mitjavila, Neus Barrantes-Vidal

2. *Sudden, Acute Stress during Early Development Confers the Greatest Risk of Schizophrenia and Bipolar Disorder – A Population-based Study*

Mary C. Clarke, Antti Tanskanen, Matti O. Huttunen, Mary Cannon

3. *Beyond White Blood Cell Monitoring: Screening in the Initial Phase of Clozapine Therapy*

Dan Cohen, Jan P. Bogers, Daniel van Dijk, Bert Bakker, Peter F. Schulte

4. *Sex Differences in Plasma Clozapine/Norclozapine and Olanzapine Concentrations in Clinical Practice: Data from a Therapeutic Drug Monitoring Service*

Lewis Couchman, Sally V. Bowskill, James H. MacCabe, Maxine X. Patel, Robert J. Flanagan

5. *Gender Differences in the Association between Childhood Adversity, Social Support, and Psychosis*

Charlotte E. Gayer-Anderson, Helen L. Fisher, Paola Dazzan, Paul Fearon, Kevin Morgan, Gillian Doody, Peter B. Jones, Robin M. Murray, Craig Morgan

6. *A New Treatment Algorithm for Tardive Dyskinesia or Dystonia*

Peter N. van Harten, Charlie L. Mentzel, Diederik E. Tenback, Rob Bakker, Marina Tijssen, Jim Jim

7. *Neurochemical Changes in Schizophrenia are Primed by the Synergistic Action of Prenatal Immune Challenge and Restraint Stress*

Jessica Deslauriers, Annie Larouche, Philippe Sarret, Sylvain Grignon

8. *Suicide-related Behaviors Induced by Social Isolation in a Model of Schizophrenia*

Jessica Deslauriers, Karine Belleville, Karyn Kirby, Nicolas Beaudet, Philippe Sarret, Sylvain Grignon

9. *Antagonists at N-Methyl-D-Aspartate Receptor (NMDA-R) with Different Clinical Profile Affect Differently the Transcripts of Constitutive and Inducible Early Genes at Postsynaptic Density*

Felice Iasevoli, Chiara Sarappa, Anna Eramo, Elisabetta F. Bonaguro, Federica Marmo, Andrea de Bartolomeis

10. *Effects of Maternal Immune Activation on Gene Expression Patterns in the Fetal Brain*

Krassimira A. Garbett, Elaine Y. Hsiao, Sára Kálmán, Paul H. Patterson, Károly Mirnics

11. *The Sp4 Hypomorphic Mouse as a Model Relevant to Schizophrenia*

Xianjin Zhou, Mark A. Geyer



12. *A Dual Model of Schizophrenia in Rats Reveals Deficiencies in the Structure and Inhibitory Neurotransmission of the Medial Prefrontal Cortex*

Javier Gilabert-Juan, Maria Belles, Ana R. Saez, Hector Carceller, Maria D. Molto, Juan Nacher

13. *Receptor Binding Profiles of Antipsychotic Medications and Glucose Dysregulation: An Acute Animal Model*

Melanie D. Guenette, Adria Giacca, Margaret Hahn, Celine Teo, Loretta Lam, Araba F. Chintoh, Tamara Arenovich, Gary Remington

14. *How does Maternal Inflammation in the Mouse Result in Alterations in GAD67 and Reelin Expression in the Hippocampus?*

Louise Harvey, Nadia Zeramdini, Ridha Joober, Patricia Boksa

15. *Sulforaphane as a Potential Therapeutic Drug for Schizophrenia*

Kenji Hashimoto, Hongxian Chen, Yuko Fujita, Jichun Zhang, Tamaki Ishima, Yumi Shirai, Jin Wu

16. *Cariprazine, a D3/D2 Dopamine Receptor Partial Agonist Antipsychotic, Displays Greater D3 Receptor Occupancy in Vivo Compared with Other Antipsychotics*

Bela Kiss, Ferenc Horti, Amrita Bobok

17. *Oxygen Restriction of Neonate Rats Elevates HIF-1 α , IL-6, NF- κ B and Caspase-3 Protein Levels: Possible Relationship to Neurodevelopmental Disorders*

Sylvia Lam, Qi Li, Ran Wei, Xiaofan Zhang, Siew Chua, Grainne M McAlonan

18. *Effects of Direct and Indirect Cannabinoids Agonists on Contextual Fear Conditioning in a New Animal Model of Schizophrenia: The SHR Strain*

Raquel Levin, Valéria Almeida, Fernanda Fiel Peres, Neide Derci da Silva, Ana Maria Vendramini, Mariana Bendlin Calzavara, Vanessa Costhek Abílio

19. *X-linked Tspyl2deficit Mouse is Associated with a Phenotype of Schizophrenia*

Q. Li, Kwun K. Wong, Ran Wei, Sylvia Lam, Xiao F. Zhang, Pak C. Sham, Siew E. Chua, Siu Y. Chan, Grainne M. McAlonan

20. *Maternal Immune Activation in the Early or Late Pregnancy Leads to the Different Behavioral Abnormalities of the Adult Offspring Relevant to the Schizophrenia*

Qi Li, Ran Wei, Xiao Fan Zhang, Sylvia Lam, Siew E. Chua, Grainne M. McAlonan

21. *Functional Hemispheric Lateralization for Language in Patients with Schizophrenia*

Mathieu Alary, Annick Razafimandimby, Nicolas Delcroix, Sonia Dollfus

22. *Brain Activation to Facial Emotion in Individuals Reporting Psychotic-like Experiences: A fMRI Community-based Twin Study*

Silvia Aleman, Alex Mas, Ximena Goldberg, Carles Falcón, Núria Bargalló, Cristobal Gastó, Lourdes Fañanás

23. *Interaction between DRD2 Genetic Variation and Bromocriptine Stimulation on Prefrontal Response during Attentional Control in Healthy Individuals*

Linda A. Antonucci, Paolo Taurisano, Barbara Gelao, Leonardo Fazio, Pierluigi Selvaggi, Tiziana Quarto, Gianluca Ursini, Antonio Rampino, Raffaella Romano, Apostolos Papazacharias, Annabella Di Giorgio, Grazia Caforio, Teresa Popolizio, Lorenzo Sinibaldi, Giuseppe Blasi, Alessandro Bertolino



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

24. *Defective Joint Action Processing in Schizophrenia*

Bianca Backasch, Farahnaz Klöhn-Saghatolislam, Martin Pyka, Benjamin Straube, Tilo Kircher, Dirk Leube

25. *Resting-state Brain Activity in Schizophrenia and its Relationship to Cognitive Functioning and Psychopathological Symptoms*

Heidlore Backes, Bruno Dietsche, Mirjam Stratmann, Carsten Konrad, Tilo Kircher, Axel Krug

26. *Effect of Low Frequency rTMS Treatment on Inner Speech Related Activity in Schizophrenia Patients with Auditory Verbal Hallucinations*

Leonie Bais, Ans Vercammen, Marianne Oldehinkel, Rikus Knegtering, André Aleman

27. *Neural Correlates of ToM in Schizophrenia: A Meta-analysis of Functional Neuroimaging Studies*

Nadia Baklouti, Annick Razafimandimby, Sonia Dollfus

28. *Interaction between COMT Val158Met Polymorphism and Susceptibility for Schizophrenia during Emotion Processing*

Luciana Lo Bianco, Francesca Ferrante, Paolo Taurisano, Annabella Di Giorgio, Barbara Gelao, Leonardo Fazio, Gainluca Ursini, Raffaella Romano, Apostolos Papazacharias, Grazia Caforio, Lorenzo Sinibaldi, Teresa Popolizio, Cesario Bellantuono, Giuseppe Blasi, Alessandro Bertolino

29. *Evaluation of Cortex-based Alignment for fMRI Studies of Working Memory in Schizophrenia*

Robert A. Bittner, David E. J. Linden, Wolf Singer, Rainer Goebel, Corinna Haenschel

30. *Dopamine Synthesis Capacity in Regular Cannabis Users who Experience Transient Psychotic Symptoms on Cannabis: An [18F]-DOPA PET Imaging Study*

Michael A.P. Bloomfield, Celia J. A. Morgan, Alice Egerton, Shitij Kapur, H. Val Curran, Oliver D. Howes

31. *Reduced Connectivity in the Default Mode Network of Schizophrenia Patients with Poor Insight*

Edith J. Liemburg, Lisette Van der Meer, Marte Swart, Branislava Curcic, Richard Bruggeman, Henderikus Knegtering, André Aleman

32. *Brain Response to Psychological Stress in Patients with Schizophrenia: Preliminary Results*

Mariana N. Castro, Mirta F. Villarreal, Oscar I. Jáuregui, Fernando Binder, Delfina de Achával, Elsa Y. Costanzo, Karl-Jürgen Bär, Salvador M. Guinjoan

33. *Fingerprint of Antipsychotic Drug Action Revealed by Arterial Spin Labeling-based phMRI*

Thomas Mueggler, Celine Risterucci, Andreas Bruns, Basil Kuennecke, Edilio Borroni, Joseph G. Wettstein, Jean-Luc Moreau, Markus von Kienlin

34. *Working Memory-related Brain Activity in Antipsychotic-naïve Schizophrenia Patients after Seven Months of Quetiapine Treatment*

Ayna B. Nejad, Bjørn H. Ebdrup, Hans Rasmussen, Bodil Aggernæs, William F. C. Baaré, Hartwig R. Siebner, Birte Y. Glenthøj

35. *Studying Episodic Memory Cerebral Network: A Novel Event-related Task for fMRI*

Maria A. Nettis, Annabella Di Giorgio, Enrico D'Ambrosio, Leonardo Fazio, Paolo Taurisano, Tiziana Quarto, Marco Colizzi, Teresa Popolizio, Giuseppe Blasi, Alessandro Bertolino



36. *Altered Emotion Processing in Schizophrenia Patients- A Functional Imaging Study*
Anne Pankow, Eva Friedel, Anne Beck, Michael Rapp, Florian Schlagenhauf, Andreas Heinz
37. *Deficiently Enhanced Anterior Cingulate Activity during Reversal Response Initiation of Reward Approach and Loss Aversion in Schizophrenia*
Il Ho Park, Hae-Jeong Park, Min-Seong Koo, Ji-Won Chun, Seok-Hyeong Kim, Jae-Jin Kim
38. *Anterior Cingulate Biochemistry Predicts Symptom Severity in Schizophrenia: A Magnetic Resonance Spectroscopy (1H-MRS) Study*
Liv E. Falkenberg, René Westerhausen, Else-Marie Løberg, Rune Kroken, Erik Johnsen, Kasten Specht, Kenneth Hugdahl
39. *Striatal Glutamate and the Conversion to Psychosis: A Prospective 1H-MRS Imaging Study*
Camilo de la Fuente-Sandoval, Pablo León-Ortiz, Rafael Favila, Sylvana Stephano, Mariana Azcárraga, Ariel Graff-Guerrero
40. *Longitudinal Hemodynamic Changes and Prediction of Functional Outcome in At-risk Mental State and First-episode Psychosis*
Shinsuke Koike, Yoshihiro Satomura, Yukika Nishimura, Yosuke Takano, Norichika Iwashiro, Motomu Suga, Ryu Takizawa, Tsuyoshi Araki, Kiyoto Kasai
41. *Comparison of Cerebral Glutamate and GABA in Schizotypal Personality Disorder using Spectral Editing and 2D Correlated Spectroscopy*
Alexander Lin, Hui J. Liao, Ana Cadena, Saadallah Ramadan, Israel Molina, Robert W. McCarley
42. *Cannabis Effects on Brain Structure in First-episode Psychosis*
Paulo J. Cunha, Jose A. Crippa, Fabio L. Duran, Marcia Scazufca, Paulo R. Menezes, Robin M. Murray, Geraldo F. Busatto, Maristela S. Schaufelbeger
43. *Structural Brain Changes in First-episode Schizophrenia: A 4-5 Year Follow-up Study Using MRI*
Maristela S. Schaufelberger, Pedro G. Rosa, Marcus V. Zanetti, Fabio L. Duran, Paulo R. Menezes, Marcia Scazufca, Robin M. Murray, Geraldo F. Busatto
44. *Regional Cortical Thinning in Subjects with High Genetic Loading for Schizophrenia*
Min Soo Byun, June Sic Kim, Wi Hoon Jung, Joon Hwan Jang, Jung-Seok Choi, Sung Nyun Kim, Chi-Hoon Choi, Chun Kee Chung, Suk Kyoan An, Jun Soo Kwon
45. *White Matter and Genetic Risk for Schizophrenia: A Twin DTI Study*
Francesco Carletti, Marco Picchioni, Irina Falkenberg, Timothea Touloupoulou, Gareth J. Barker, Philip K. McGuire
46. *Grey Matter Density and Cortical Thickness Vary with Different Orbitofrontal Sulcogyral Patterns*
Goulthira Chakirova, Thomas W.J. Moorhead, Heather C. Whalley, Jessica E. Sussmann, David C. Glahn, Anderson M. Winkler, Killian A. Welch, Stephen Giles, Andrew C. Stanfield, Verity J. Brown, Jeremy Hall, Eve C. Johnstone, Stephen M. Lawrie, Andrew M. McIntosh
47. *White Matter Abnormalities in Schizophrenia: a Volume Preserved Warping (VPW) Analysis*
Tiziano Colibazzi, Bruce Wexler, Dongrong Xu, Xuejun Hao, Ravi Bansal, Bradley Peterson



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

48. *Frontostriatal Dependency in Grey Matter Volume is Reduced in Schizophrenia*

Guusje Collin, Martijn P. Van den Heuvel, Marcel A. De Reus, Heleen B. M. Boos, Wiepke Cahn, Hilleke E. Hulshoff Pol, René S. Kahn

49. *Neuroanatomical Alterations in Regions Mediating Language in Young Adults at High Risk for Inheritance of Schizophrenia (GHR)*

Alan N. Francis, Gul A. Jabbar, Heidi W. Thermenos, Larry J. Seidman, Richard Juelich, Ashley Proal, Marek Kubicki, Martha Shenton, Matcheri Keshavan, Lynn E. DeLisi

50. *White Matter Integrity in Schizophrenia and Bipolar Disorder in Association with Symptom Severity*

Bruno Dietsche, Davide Laneri, Heide Lore Backes, Alexandra Hellerbach, Mirjam Stratmann, Tilo Kircher, Jens Sommer, Axel Krug

51. *Microstructural White Matter Biomarkers for Psychotic Disorder: A Family-based Diffusion Tensor Imaging Study*

Patrick A. E. Domen, Stijn Michielse, Ed Gronenschild, Petra Habets, Alard Roebroek, Koen Schruers, Jim van Os, Machteld Marcelis

52. *Grey Matter Correlates of Mismatch Negativity Amplitudes in At-risk Mental State*

Tim Ehlikes, Rebbekah Atkinson, Philip B. Ward, Georgie Paulik, Jackie Curtis, Patricia T. Michie, Paul E. Rasser, Juanita Todd, Helen Stain, Ulrich Schall

53. *Relationship between Working Memory Performance and Prefrontal Volumes in Schizophrenia: A Family Study*

Vina M. Goghari, Angus W. MacDonald, Scott R. Sponheim

54. *To Trust or not to Trust: The Dynamics of Social Interactions in Early Psychosis*

Anne-Kathrin J. Fett, Sukhi S. Shergill, Dan W. Joyce, Paula M. Gromann, Lydia Krabbendam

55. *Cortical Thinning Over Two Years following the First Episode of Psychosis: Relationship to Treatment Duration and Cognitive Impairment*

Leticia B. Gutierrez Galve, Claudia A.M. Wheeler-Kingshott, Daniel R. Altmann, Gary Price, Elvina M. Chu, Verity C. Leeson, Gareth J. Barker, Thomas R. E. Barnes, Maria A. Ron, Eileen M. Joyce

56. *Classification of Schizophrenia Patients and Healthy Controls from Structural MRI Scans Verified in Two Large Independent Samples*

Mireille Nieuwenhuis, Neeltje E. van Haren, Hilleke E. Hulshoff Pol, Wiepke Cahn, René S. Kahn, Hugo G. Schnack

57. *Fibre Tractography Reveals Early White Matter Changes in Adolescents Reporting Subclinical Psychotic Symptoms: A Pilot Investigation*

Erik O'Hanlon, Sarah Roddy, Lauren Tiedt, Matthew Hosheit, Javeria Tabisch, Ian Kelleher, Thomas Frodl, Mary Cannon

58. *Increased Assortativity of Gyrfication based Brain Connectome in Schizophrenia*

Lena Palaniyappan, Bert Park, Peter F. Liddle



59. *Reduced Anterior Cingulate Cognitive Activation is Associated with Prefrontal – Temporal Cortical Thinning in Schizophrenia*

C. Christoph Schultz, Kathrin Koch, Gerd Wagner, Igor Nenadic, Claudia Schachtzabel, Daniel Güllmar, Jürgen R. Reichenbach, Heinrich Sauer, Ralf G. Schlösser

60. *Psychotic-like Experiences, Psychotic Symptoms and Clinical Correlates in Preadolescent Children in the CCC2000 Birth Cohort Study*

Pia Jeppesen, Lars Clemmensen, Anja Munkholm, Charlotte Eberhardt, Else M. Olsen, Hanne Elberling, Charlotte U. Rask, Torben Joergensen, Jim van Os, Anne M. Skovgaard

61. *Disturbances of the Basic Self as a Core Marker of Vulnerability to Schizophrenia: Preliminary Results from a 2-year Follow-up Study among Non-psychotic Help-seeking Adolescents*

Danny Koren, Noa Reznik, Merav Adres, Ravit Scheyer, Alan Apter, Josef Parnas

62. *Disturbances of the Basic Self and Prodromal Symptoms among Non-psychotic Help-seeking Adolescents*

Danny Koren, Noa Reznik, Merav Adres, Ravit Scheyer, Tamar Steinberg, Alan Apter, Josef Parnas

63. *Changes in Leptin, Adiponectin and Ghrelin in Antipsychotic-naïve Adolescents Taking Second-generation Antipsychotics: Comparative Effects in Patients with Psychotic and Nonpsychotic Disorders*

Laura Pina-Camacho, Elena Mérida, Covadonga M. Díaz-Caneja, Cecilia Tapia-Casellas, Pamela Rodríguez-Latorre, Jessica Merchán-Naranjo, David Fraguas, Carmen Moreno, Mara Parellada, Celso Arango

64. *Recruitment Status of the TEA Trial: Tolerance and Effect of Antipsychotics in Children and Adolescents with Psychosis: An investigator-initiated, Phase IV, Randomised Double-blind Multi-centre Trial of the Benefits and Harms of Aripiprazole versus Quetiapine in Children and Adolescents with Psychosis*

Anne K. Pagsberg, Anders Fink-Jensen, Ditte Rudaa, Karsten G. Jensen, Dea G. Klauber, Marie Stentebjerg-Olesen, Christian Gluud, Christoph U. Correll, Birgitte Fagerlund, Jens R. Jepsen, Niels Bilenberg, Peter Jantzen, Ann-Sophie Saldeen, Torben S. Carlsen, Thomas Werge, Pia Jeppesen

65. *Psychophysiological and Neurocognitive Profiling of Attentional Deficits in Children and Adolescents with Psychosis or ADHD*

Jacob Rydkjær, Jens Richardt Jepsen, Anne Katrine Pagsberg, Birgitte Fagerlund, Birte Y. Glenthøj, Bob Oranje

66. *Persistent Positive Symptoms in Persons at High Risk of Psychosis*

Mitja Bodatsch, Frauke Schultze-Lutter, Don Linszen, Raimo Salokangas, Max Birchwood, Georg Juckel, Anthony Morrison, Andreas Heinz, Heinrich von Reventlow, Joachim Klosterkötter, Stefan Ruhrmann

67. *First-Rank Symptoms in Schizophrenia; Disturbed Sense of Agency vs. Auditory Hallucinations*

Jet D. Heering, Neeltje E. M. van Haren, Carin J. Meijer, Lieuwe de Haan

68. *Diagnostic Stability of First Episode Psychosis at 10 Year Follow-up – Preliminary Results from the AESOP Cohort*

Benjamin A. Lomas, Gillian Doody

69. *A Longitudinal Follow-up of Diagnostic Outcomes of Childhood-onset Schizophrenia after Inpatient Evaluation and Medication Washout*

Rachel Miller, Tasia Richards, Peter Gochman, Deanna K. Greenstein, Nitin Gogtay, Judith L. Rapoport



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

70. *Coping in Individuals at Clinical High Risk for Psychosis, Schizophrenia Patients and Healthy Control Subjects*

Alexandra S.C. Nikolaidēs, Julia Paruch, Joachim Klosterkoetter, Stephan Ruhrmann

71. *Reliability of the Assessment of Subjective Experience and of Mental Status*

Julie Nordgaard, Josef Parnas

72. *Dissecting the 'Totality' of First Episode Psychosis: Do Schizophrenia, Bipolar Disorder and Psychotic Depression Reflect Categorical Distinctions or Dimensional Intersections?*

Olabisi Owøye, Tara Kingston, Patricia A. Baldwin, David Browne, Paul J. Scully, Anthony Kinsella, Vincent Russell, Eadbhard O' Callaghan, John L. Waddington

73. *A New Mobile Assessment Technology for Psychosis: Introducing ClinTouch*

Jasper E. Palmier-Claus, Shôn Lewis, Christine Barrowclough, Matt Machin, Graham Dunn, John Ainsworth

74. *Can D2/3 Blockade Improve Basic Information Processing in First Episode Schizophrenia?*

Signe W. Düring, Birte Glenthøj, Bob Oranje

75. *Age Effects on P50 Suppression in Healthy Male Volunteers*

Mikkel Erlang, Birte Glenthøj, Bob Oranje

76. *Acute Ketamine Infusion in Healthy Volunteers: Effects on Early Visual Processing*

Ivan G. Koychev, Andrew Shepherd, Wael El-Deredy, Bill Deakin, Corinna Haenschel

77. *Serotonergic Dysfunction of Patients with Schizophrenia and Bipolar Disorder as Assessed by the Loudness Dependence of the Auditory Evoked Potential (LDAEP)*

Kyung-Sang Lee, Seung-Hwan Lee, Jung-Seo Yi

78. *Preferential Patterns of Gamma Band Activity to Socially-Relevant Stimuli in Schizophrenia Patients*

Seung-Hwan Lee, Gwon Hi Park, Sangrae Kim, Ji-Hye Park, Do-Won Kim, Chang-Hwan Im

79. *Association between Sensorimotor Gating and Mismatch Negativity*

Bob Oranje, Mikkel E. Sørensen, Birte Y. Glenthøj

80. *Is there an Overlap between Autism and Schizophrenia: The Search for Shared Psychophysiological Endophenotypes*

Gitte F. Madsen, Niels Bilenberg, Bob Oranje

81. *The Interactions between Higher-order and Sensory-based Operations during Abnormal Emotional Prosody Processing in Schizophrenia: An Electrophysiological Investigation*

Ana P. Pinheiro, Andreia Rauber, Robert W. McCarley, Óscar F. Gonçalves, Margaret Niznikiewicz

82. *Genetic Factors and Gene-environment Interactions: A Descriptive Study*

Rebecca Ranieri, Anna Castelnovo, Silvio Scarone

83. *Are Immigrants to Canada at Increased or Decreased Risk for Schizophrenia?*

Marie-Jose Dealberto

84. *Longitudinal Association of Stress Measures with Symptoms in Youth at Clinical High Risk for Psychosis*

Jordan E. DeVlyder, Shelly Ben-David, Scott Schobel, David Kimhy, Cheryl M. Corcoran



85. *Paternal Age and Risk of Psychosis in Adoptees*

Mats Ek, Susanne Wicks, Cecilia Magnusson, Christina Dalman

86. *Clinical and Social Correlates of Late Onset First-episode Psychosis: Findings from the AESOP Study*

Susana Borges, Helen L. Fisher, Paul Fearon, Kevin Morgan, Gillian Doody, Peter B. Jones, Robin M. Murray, Craig Morgan, Paola Dazzan

87. *Childhood Adversity and Compulsory Admission during Presentation of First Episode Psychosis*

Jonathan L. Garabette, Grant McQueen, Charlotte Gayer-Anderson, Susana Borges, Adanna Onyejiaka, Monica Charalambides, Chelsea Gardner, Dionne Harleston, Helen Fisher, Valeria Mondelli, Marta Di Forti, Robin M. Murray, Carmine Pariante, Craig Morgan, Paola Dazzan, Rowena Handley

88. *The Impact of Childhood Support on Life Events and Risk of Psychosis*

Chelsea A. Gardener, Charlotte E. Gayer-Anderson, Stephanie F. Beards, Adanna N. Onyejiaka, Susana Borges, Sophie Sowden, Emma Palmer, Kathryn Hubbard, Rowena Handley, Helen Fisher, Valeria Mondelli, Marta Di Forti, Robin M. Murray, Craig Morgan, Paola Dazzan, Carmine Pariante

89. *Improving Participation Rates in Population based Schizophrenia Research by Using Home Interviews*

Marianne Haapea, Erika Jääskeläinen, Juha Veijola, Matti Isohanni, Jouko Miettunen

90. *Control Sampling and Selection Bias in Case-control Studies of Psychosis*

Kathryn Hubbard, Emma C. Palmer, Anisa Kurti, Tjasa Velikonja, Simona Stilo, Helen Fisher, Valeria Mondelli, Marta Di Forti, Robin M. Murray, Carmine Pariante, Paola Dazzan, Rowena Handley, Craig Morgan

91. *Diethylstilbestrol and Risk of Psychiatric Disorders: New Research Strategy*

Oussama Kebir, Marie-Odile Krebs

92. *Childhood Adversity and Suicidal Behaviour in First Episode Psychosis Patients*

Arune Keraite, Rowena Handley, Paul Fearon, Kevin Morgan, Gillian Doody, Peter B. Jones, Robin M. Murray, Craig Morgan, Paola Dazzan

93. *Cardiovascular Drug Use in Patients with Schizophrenia or Bipolar Disorder*

Thomas M. Laursen, Preben B. Mortensen, James H. MacCabe, Dan Cohen, Christiane Gasse

94. OPEN BOARD

95. *Head Injury and Inflammatory Reactions as Risk Factors for Psychiatric Disorders: A Nationwide Register-based Study*

Sonja Orlovskaja, Michael E. Benros, Preben B. Mortensen, Merete Nordentoft

96. *Age of Onset in First Episode Psychosis: The Influence and Interactions of the Environmental Risk Factors*

Brian N. O'Donoghue, John P. Lyne, Eric Roche, Niall Turner, Eadbhard O'Callaghan, Mary Clarke, Abbie Lane

97. *Depression, Hopelessness and Suicidality in First Episode Psychosis and the Relationship with the Social Class of Origin*

Brian N. O'Donoghue, John P. Lyne, Felicity Fanning, Niall Turner, Eadbhard O'Callaghan, Mary Clarke, Abbie Lane



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

98. *Validation of Suicide as Cause of Death in Cases of Undetermined Manner of Death in Schizophrenia in Sweden*

Eric M. Olsson, Diana Hukic, Lise-Lotte Nilsson, Henrik Druid, Martin Schalling, Urban Ösby

99. *Neighbourhood-level Socio-environmental Factors and Incidence of First Episode Psychosis by Place at Onset in Rural Ireland*

Sami Omer, James B. Kirkbride, Dennis G. Pringle, Vincent Russell, Eadbhard O'Callaghan, John L. Waddington

100. *Severe Trauma and First Episode Psychosis in the UK*

Adanna N. Onyejiaka, Helen Fisher, Charlotte E. Gayer-Anderson, Anisa Kurti, Susana Borges, Grant McQueen, Arune Keraite, Dionne Harleston, Monica Charalambides, Rowena Handley, Valeria Mondelli, Marta Di Forti, Robin M. Murray, Carmine Pariante, Paola Dazzan, Craig Morgan

101. *Mental Health Literacy: Are Psychoses Catching Up with Depression?*

Frauke Schultze-Lutter, Chantal Michel, Renata Kulcsarova, Franziska Durstewitz, Nina Schnyder, Benno G. Schimmelmann

102. *COMT Genotype Modulates the Effects of Childhood Adversity on Cognition and Symptoms in Schizophrenia*

Melissa J. Green, T-Yunn Chia, Murray J. Cairns, Jing Q. Wu, Paul Tooney, Rodney J. Scott, Vaughan J. Carr

103. *Interaction between COMT Genotype, Cannabis Use, and BFQ Measures of Sociability*

Marco Colizzi, Gianluca Ursini, Annamaria Porcelli, Marina Mancini, Barbara Gelao, Antonio Rampino, Lorenzo Sinibaldi, Maria T. Attrotto, Lucia Colagiorgio, Giuseppe Rizzo, Giancarlo Maddalena, Rita Masellis, Annabella Di Giorgio, Grazia Caforio, Giuseppe Blasi, Alessandro Bertolino

104. *The Case that Psychosis is Transmitted Epigenetically on an XY Template*

Timothy J. Crow

105. *The Relevance of the Protocadherin11XY Gene Pair*

Timothy J. Crow, Thomas H. Priddle

106. *Startle Reactivity and Prepulse Inhibition of the Acoustic Startle Response are Modulated by COMT Val158Met Polymorphism in Adults with 22q11 Deletion Syndrome*

Mariken B. De Koning, Erik Boot, Oswald J. N. Bloemen, Esther D. A. Van Duin, Kathryn M. Abel, Lieuwe De Haan, Don H. Linszen, Thérèse A. M. J. Van Amelsvoort

107. *Genetic Variation Underlying Psychosis-inducing Effects of Cannabis: Critical Review and Future Directions*

Jeroen Decoster, Jim van Os, Inez Myin-Germeys, Marc De Hert, Ruud van Winkel

108. *Modulatory Effect of the Interleukin -1 β Gene on Dorsolateral Prefrontal Cortex Function in Schizophrenia but not in Healthy Subjects: A Genetic Neuroimaging Study*

Mar Fatjó-Vilas, Edith Pomarol-Clotet, Raymond Salvador, Gemma C Monté, Jesús J. Gomar, Salvador Sarró, Jordi Ortiz-Gil, Candibel Aguirre, Ramón Landín-Romero, Amalia Guerrero-Pedraza, Sergi Papiol, Josep Blanch, Peter J. McKenna, Lourdes Fañanás



109. *Neuritin-1 Gene is Associated with Risk for Schizophrenia-spectrum Disorders and their Age at Onset*
Mar Fatjó-Vilas, Salvador Miret, M. José Muñoz, Bárbara Arias, Manuel Ignacio Ibáñez, Luisa Lázaro, Victor Peralta, Manuel J. Cuesta, Generós Ortet, Lourdes Fañanás

110. *No Association between SNAP-25 Gene Polymorphisms and Weight Gain in Antipsychotic Treatment of Schizophrenia*
Aziz Ferchiou, Anne Dumaine, Mohamed Lajnef, Christophe Lançon, Pierre Michel Llorca, Stéphane Jamain, Marion Leboyer, Alexandre Méary

111. *Aberrant Tyrosine Transport across the Fibroblast Membrane in Patients with Schizophrenia – Indications of Maternal Inheritance*
Lena Flyckt, Gunnar Edman

112. *Immune-Related Differential Expression Profile in Peripheral Blood Mononuclear Cells in Schizophrenia*
Erin J. Gardiner, Murray J. Cairns, Natalie J. Beveridge, Bing Liu, Vaughan Carr, Rodney Scott, Paul Tooney

113. *COMT Modulates the Effects of Lifetime Cannabis Use on Cognition and Symptom Profiles in Schizophrenia*
Melissa J. Green, T-Yunn Chia, Murray J. Cairns, Paul Tooney, Rodney J. Scott, Vaughan J. Carr

114. *Genome-wide Supported Variants (MIR137) Predicts Membership of a Cognitive Subtype of Schizophrenia*
Melissa J. Green, Murray J. Cairns, Jin Qin Wu, Milan Dragovic, Assen Jablensky, Paul Tooney, Rodney Scott, Vaughan J. Carr

115. *Increased Expression of Putative DNA Demethylation Genes in Psychosis*
Alessandro Guidotti, Erbo Dong, David P. Gavin, Dennis R. Grayson

116. *ZNF804A and Social Cognition in Patients with Schizophrenia and Healthy Participants*
April Hargreaves, Derek W. Morris, Rose Emma, Michael Gill, Aidan Corvin, Gary Donohoe

117. *Association between the ARHGEF11 Gene and Schizophrenia in a Japanese Population*
Yutaka Mizuki, Manabu Takaki, Yuko Okahisa, Masafumi Kodama, Hiroshi Ujike, Yosuke Uchitomi

118. *A Polymorphism in the CNR1 Gene is Associated with Gene Expression and Schizophrenia*
Yuko Okahisa, Hiroshi Ujike, Masafumi Kodama, Manabu Takaki, Yutaka Mizuki, Shinji Sakamoto, Nao Imai, Yosuke Uchitomi, Makoto Arai, Masanari Itokawa

119. *Candidate Genes for Schizophrenia in a Mixed Brazilian Population Using Pooled DNA*
Vanessa K. Ota, Ary Gadelha, Renata Pellegrino, Fernanda T. Bellucco, Denise M. Christofolini, Marcos L. Santoro, Diogo R. Lara, Gustavo L. Ottoni, Ândrea K. Ribeiro-dos-Santos, Sidney Santos, Jair J. Mari, Marília A. Smith, Rodrigo A. Bressan, Maria I. Melaragno, Sintia I. Belangero

120. *Long-Term Healthcare Costs and Functional Outcomes Associated with Lack of Remission in Schizophrenia*
Virginia S. Haynes, Baojin Zhu, Virginia Stauffer, Bruce J. Kinon, Lei Xu, Haya Ascher-Svanum

121. *Protein Profiling of Patients with Acute Psychosis vs. Psychiatric Controls: A Proteomic Approach*
Valentina Mantua, Ginevra Orsolini, Laura Giusti, Mauro Mauri, Antonio Lucacchini



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

122. *Correlations between Clinical Symptoms and Level of Serum Antibodies to Herpes Group Viruses in Paranoid Schizophrenia*

Irina I. Mikhailova, Vera A. Orlova, Vitalij L. Minutko

123. *BDNF Levels in Schizophrenia – Do Evolution and Type of Schizophrenia Matter?*

Cristina V. Oliveira, Alicia Valiente, Ana Meseguer, Clemente Garcia-Rizo, Amalia Lafuente, Miguel Bernardo

124. *Relationship between Oxidative Stress/Inflammation and Cognitive Impairment in First Episode Psychosis*

Sonia Ruiz de Azua, Patricia Vega, Monica Martinez-Cengotitabengoa, Sara Barbeito, Belen Garcia-Lecumberri, Mahmoud Karim Haidar, Margarita Saenz-Herrero, Ana Gonzalez-Pinto

125. *Interleukin-6 Levels in Cerebrospinal Fluid of Patients with Schizophrenia*

Daimei Sasayama, Kotaro Hattori, Haruko Tanaka, Hiroaki Hori, Toshiya Teraishi, Miho Ota, Naoji Amano, Hiroshi Kunugi

126. *In Vitro and In Vivo Characterization of a New Selective Phosphodiesterase 10 Radioligand*

Hervé Schaffhauser, Michael Honer, Jens Uwe Peters, Luca Gobbi, Thomas Hartung, Agnès Nilly, Patricia Glaentzlin, Céline Sutter, Edilio Borroni, Joseph G. Wettstein, Alexander Flohr

127. *Clinical and Brain Imaging Correlates of Neurological Soft Signs in Schizophrenia: A Contribution to the Neurodevelopmental Model of Schizophrenia*

Olivier Gay, Marion Plaze, Catherine Oppenheim, Sabine Mouchet-Mages, Raphael Gaillard, Jean-Pierre Olie, Marie-Odile Krebs, Arnaud Cachia

128. *Neurodevelopmental Liability to Schizophrenia: the Complex Mediating Role of Age at Onset and Premorbid Adjustment*

Ximena Goldberg, Mar Fatjó-Vilas, Rafael Penadés, Salvador Miret, María J. Muñoz, Helen Vossen, Lourdes Fañanás

129. *A Quantitative Meta-analysis of Population-based Studies of Premorbid Intelligence and Schizophrenia*

Golam M. Khandaker, Jennifer H. Barnett, Ian R. White, Peter B. Jones

130. *Cortical Gyrfication and Neurological Soft Signs in Schizophrenia: Markers of Developmental Load*

Marie-Odile Krebs, Olivier Gay, Marion Plaze, Jean Pierre Olié, Catherine Oppenheim, Arnaud Cachia

131. *Premorbid and Post-onset Cognitive Functioning in Schizophrenia and Bipolar Disorders: A Meta-analysis.*

Antonella Trotta, James H. MacCabe, Robin M. Murray

132. *Proteomic Investigation of the Postsynaptic Density in the Brain in Schizophrenia*

Melanie Foecking, Patrick Dicker, Jane English, Ger Cagney, David Cotter

133. *Alteration of the Expression Balance of hnRNP C1 and C2 Changes the Expression of Myelination- and Schizophrenia-related Genes in the Human Neuroblastoma Cell Line*

Keiko Iwata, Hideo Matsuzaki, Nori Takei, Norio Mori

134. *A Cross Sectional Study of Novel P300 in Prodromes and First Episode Schizophrenia*

Elisabetta C. del Re, Margaret Niznikiewicz, Tracy Petryshen, Robert W. McCarley



135. *Neurological Soft Signs and Prepulse Inhibition of the Startle Reflex in Psychosis: A Pilot Study*

Elisa Ira, Sarah Tosato, Chiara Bonetto, Martina Zaroni, Rodolfo Mazzoncini, Lisa Martini, Angela Garozzo, Antonio Lasalvia, Michele Tansella, Mirella Ruggeri

136. *Computational Models of Hallucinations*

Renaud Jardri, Sophie Deneve

137. *Effects of High and Low-frequency rTMS on P50: Preliminary results*

Clement Nathou, Olivier Etard, Gregory Simon, Annick Razafimandimby, Sonia Dollfus

138. *Symptomatic Remission in Schizophrenia: Relation of Cognitive Functions and Clinical Features*

Ahmet Yiğit Aktener, Berna Binnur Akdede, Banu Değirmecioğlu, Köksal Alptekin

139. *Emotional Prosody Modulates Attention in Schizophrenia Patients with Hallucinations*

Lucy Alba-Ferrara, Marco Hirnstein, Susanne Weis, Markus Hausmann

140. *Impaired Saccadic Adaptation in Schizophrenic Patients with High Neurological Soft Signs Scores*

Isabelle Amado, Anne Le Seac'h, Hernan Picard, Raphael Gaillard, Marie-Odile Krebs, Cecile Beauvillain

141. *The Zoo Map Test Reveals Heterogeneity in Action Planning Profiles in Schizophrenia*

Alice Rampazzo, Dominique Willard, Aurélie Lagodka, Raphaël Gaillard, Nicolas Franck, Marie-Odile Krebs, Isabelle Amado, Philippe Allain

142. *Metacognition of Agency in Patients with Schizophrenia*

Elisabeth Bacon, Janet Metcalfe

143. *At Risk for Psychosis: The Role of Cognition*

Mark A. Colijn, Mariapaola Barbato, Richard S. E. Keefe, Diana O. Perkins, Scott W. Woods, Jean Addington

144. *Can Neuropsychological Profile (RBANS) Predict Co-Morbid Traumatic Brain Injury and Psychosis?*

Rachel A. Batty, Susan L. Rossell, Neil Thomas, Andrew J. P. Francis, Malcolm Hopwood

145. *Enhanced Visuospatial Imagery Manipulation in Schizophrenia*

Taylor L. Benson, Sohee Park

146. *Are Auditory Processing Deficits a Sensory Substrate of Receptive Prosodic Dysfunction and Auditory Hallucination in Schizophrenia?*

Christopher J. Groot, Susan Rossell, Henry J. Jackson

147. *Psychometric Properties of Korean Version of Launay-Slade Hallucination Scale-Revised in Non-clinical and Clinical Population*

Hee-Yeon Jung, Yeni Kim, Samuel Hwang, Se-Hyun Kim, Jae-Seung Chang

148. *Cognitive Reserve: Does it Modify the Effect of Age on Cognitive Remediation Therapy Outcome in Schizophrenia?*

Dimitrios Kontis, Vyv Huddy, Clare Reeder, Sabine Landau, Til Wykes



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

149. *COMT and MTHFR Polymorphisms Interaction on Working Memory in Schizophrenia: An Exploratory Study*

Dimitrios Kontis, Eirini Theochari, Helen Fryssira, Spyridon Kleisas, Christalena Sofocleous, Stamatina Kalogerakou, Angeliki Andreopoulou, Spyridoula Vassilouli, Dimitrios Kypraios, Anthia Gazi, Lucia Boniatsi, Eleftheria Tsaltas

150. *Crystallized Verbal Skills in Schizophrenia: Relationship to Neurocognition, Symptoms and Functional Status*

Matthew M. Kurtz, Jad Donato, Jennifer Rose

151. *No Evidence for Familial Covariation of Neurocognition and Negative Symptoms in Psychotic Disorders*

Tineke Lataster, Armin Shazad, Cecile Henquet, Piotr Quee, Inez Myin-Germeys, GROUP Investigators

152. *Identifying Social Cognition as a Specific Component of Schizophrenia: The Association of Social Cognitive Capacities between Schizophrenic Patients and their Non-affected Mother*

Marie-Audrey Lavoie, Philip L. Jackson, Amélie M. Achim

153. *Social Cognition in Early-Onset-Schizophrenia, High Functioning Autism and Asperger Syndrome*

Eva Le Gall, Galina Iakimova, Sylvie Serret, Florence Askenazy

154. *The Comparative Strength of Multiple Predictors of Real World Functioning in Patients with Schizophrenia*

David Loewenstein, Sara Czaja, Philip Harvey

155. *Theory of Mind and Context Processing in Schizophrenia: The Role of Social Knowledge*

Maud Champagne-Lavau, Anick Charest, Guy Blouin, Jean-Pierre Rodriguez

156. *Neurocognitive Impairments in Adolescents with At-Risk States of Psychosis*

Chantal M. Michel, Benno G. Schimmelmann, Nicole Leibundgut, Frauke T. Schultze-Lutter

157. *Different Vulnerability Indicators for Psychosis and their Neuropsychological Characteristics in the Northern Finland 1986 Birth Cohort*

Sari Mukkala, Tuula Ilonen, Tanja Nordström, Jouko Miettunen, Jari Koskela, Jukka Loukkola, Jenny H. Barnett, Graham K. Murray, Erika Jääskeläinen, Pirjo Mäki, Anja Taanila, Irma Moilanen, Peter B. Jones, Markus Heinimaa, Juha Veijola

158. *Flexible Object Working Memory Capacity in Schizophrenia and Healthy Participants in a Self-order Task*

Heathman S. Nichols, Jared X. Van Snellenberg, Edward E. Smith, Sohee Park

159. *Early Visual Processing in Early and Adult Onset Schizophrenia: A Source Analysis of the N80 Visual Evoked Potential*

Daniel Nunez, Andre Rupp, Matthias Weisbrod, Rieke Oelkers-Ax

160. *A Cluster Approach for Determining Groups of Patients with First Psychotic Episode and their Relationship with Symptoms, Social and Neuropsychological Functioning*

Susana Ochoa, Judith Usall, Elena Huerta-Ramos, Montserrat Dolz, Ana Barajas, Iris Baños, Bernardo Sánchez, Janina Carlson, Alexandrina Foix, Trinidad Pelaez, Marta Coromina, Marta Pardo



161. *Neurocognitive Profile and its Association with Psychopathology in First-degree Relatives of Patients with Schizophrenia: A Case-control Study*

Silvia Scala, Antonio Lasalvia, Cristofalo Doriana, Bonetto Chiara, Ruggeri Mirella

162. *Disturbed Self-agency in Schizophrenia Due to Abnormal Implicit (but not explicit) Processing of Action-outcome Information*

Robert A. Renes, Lisanne Vermeulen, Rene S. Kahn, Henk Aarts, Neeltje E. van Haren

163. *Neural Correlates of CBT in Patients with Positive Symptoms during a Jumping to Conclusions Task*

Axel Krug, Henrik Walter, Georg Winter, Wolfgang Wölwer, Bernhard Müller, Jutta Herrlich, Georg Wiedemann, Kai Vogeley, Andreas Wittorf, Alexander Rapp, Stefan Klingberg, Maurice Cabanis, Tilo Kircher

164. *Feasibility of Mindfulness Based Therapy in Patients Recovering from a First Psychotic Episode, A Pilot Study*

Carin J. Meijer, Renate van der Valk, Susanna van der Waerd, Ingrid van den Hout, Lieuwe de Haan

165. *Efficacy and Safety of Deep Brain Stimulation in Patients with a Psychiatric Illness and Tardive Dyskinesia and/or Dystonia; A Systematic Review*

C.L. Mentzel, D.E. Tenback, P. N. van Harten

166. *Negative Schematic Beliefs about Self and Others Differentially Predict Suspiciousness in at-risk States*

Hendrik Müller, Michael Wagner, Wolfgang Maier, Marion Lautenschlager, Walter de Millas, Birgit Janssen, Wolfgang Gaebel, Tanja Michel, Frank Schneider, Martin Lambert, Dieter Naber, Georg Juckel, Thomas Wobrock, Michael Riedel, Joachim Klosterkötter, Andreas Bechdolf

167. *Effects of Cognitive Remediation on Cognition in Young People at Clinical High Risk of Psychosis*

Danijela Piskulic, Mariapaola Barbato, Jean Addington

168. *Attention and Memory Training in Stable Schizophrenic Patients: A Double-blind, Randomized, Controlled Trial Using Simple Resources*

Livia M. Pontes, Camila B. Martins, Isabel C. Napolitano, Juliana R. Fonseca, Graca M. Oliveira, Sandra M. Iso, Anny K. Menezes, Adriana D. Vizzotto, Elaine S. di Sarno, Marcelo Nogueira, Helio Elkis

169. *Involvement of Patients and Relatives in Scientific Research Projects: Experiences from the GROUP Study*

Agna A. Bartels-Velthuis

170. *Coping Strategies in Carers of Patients with First Episode Psychosis*

Sue M. Cotton, McCann Terence, John Gleeson, Kingsley Crisp, Catania Lisa, Daniel Lubman

171. *Psychiatrists' Perceptions of the Clinical Importance, Assessment and Management of Patient Functioning in the Treatment of Schizophrenia: Results of an EMEA-wide Survey*

Philip Gorwood, Georg Juckel, Tom Burns, Alessandro Rossi, Luis San, Pierre Cherubin, Ludger Hargarter, Andreas Schreiner

172. *Effects of Family Member Participation on Structural Transparency and Content of Discourse in Schizophrenia*

Pertti O. Hella, Jussi Niemi, Lidia Otsa, Jani-Matti Tirkkonen

173. *The Association of Insight with Self- and Clinician-Rated Side Effects and HRV Measures*

Samuel S. Hwang, Jae Seung Chang, Yong Sik Kim



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

174. *Vitamin D Levels in Severely Mentally Ill Patients and Staff Members in a Long Stay Psychiatric Unit*
Tijmen Bostoen, Jan P. A. M. Bogers

175. *Adjunctive Lisdexamfetamine Dimesylate Treatment of Predominant Negative Symptoms of Schizophrenia in Clinically Stable Adults Maintained on Atypical Antipsychotic Agents: A 14-Week Trial*
Robert Lasser, Bryan Dirks, Henry Nasrallah, Courtney Kirsch, Joseph Gao, Mary Ann Knesevich, Jean-Pierre Lindenmayer

176. *The Birth of the New Korean Term for Schizophrenia: JoHyeonByung(Attunement Disorder)*
Yu Sang Lee, Jun Soo Kwon, Jae-Jin Kim, Il Ho Park, Seon-Cheol Park

177. *The Australian Schizophrenia Research Biobank (ASRB): An Audit of the First Five-years of Recruitment Resource Access*
Carmel M. Loughland, Kathryn McCabe, Jason Bridge, Frans Henskens, Stanley Catts, Assen Jablensky, Patricia Michie, Bryan Mowry, Christos Pantelis, Ulrich Schall, Rodney Scott, Paul Tooney, Liesl Duffy, Vaughan Carr

178. *The Australian Schizophrenia Research Biobank (ASRB): IT Development and Management of a Live E-research System*
Frans Henskens, David Paul, Carmel Loughland, Jason Bridge, Kathryn McCabe, Stanley Catts, Assen Jablensky, Patricia Michie, Bryan Mowry, Christos Pantelis, Ulrich Schal, Paul Tooney, Liesl Duffy, Vaughan Carr

179. OPEN BOARD

180. *The Role of Category Fluency in Schizophrenia Research: A Novel Approach to Answer the Question of whether Performance on this Task Reflects Executive or Semantic Deficits*
Erica Neill, Susan L. Rossell

181. *Body Mass Index (BMI) as a Predictor of Metabolic Syndrome (MetS) in Patients with Schizophrenia*
Milawaty Nurjono, Jimmy Lee

182. *The Effect of Telepsychiatric Follow-up on the Family Burden, Emotional Expression and Depression Levels in the Caregivers of Turkish Patients with Schizophrenia*
Birgul Ozkan, Emine Erdem, Saliha Ozsoy, Gokmen Zararsiz

183. *Cognitive Bizarreness as a Transnosographic Marker of Psychosis*
Rebecca Ranieri, Anna Castelnovo, Matteo Mercatili, Armando D'agostino, Silvio Scarone

184. *Evaluating Readiness for Work and Useful Activities in Patients with Schizophrenia: "The Readiness for Work Questionnaire" WoRQ*
Dragana Bugarski-Kirola, Steven G. Potkin, George Garibaldi

185. *Remission with Continued Paliperidone Palmitate Treatment in Stable Subjects with Schizophrenia*
Joseph Hulihan, Cynthia A. Bossie, Dong-Jing Fu, Jennifer Kern Sliwa, Yi-Wen Ma, Larry D. Alphas

186. *Effectiveness vs Efficacy Rankings by a Modified PRECIS Tool for Schizophrenia Trials of Long-Acting Injectable vs. Daily Oral Antipsychotic Treatments*
Cynthia A. Bossie, Larry Alphas, Joseph F. Hulihan



187. *Midlife Progression and its Clinical Correlates in Schizophrenia: A 43-year Follow-up in the Northern Finland 1966 Birth Cohort*

Matti Isohanni, Erika Jääskeläinen, Irene Isohanni, Kristiina Moilanen, Antti Alaräisänen, Jouko Miettunen

188. *A Rasch Model Analysis to Assess Cross-cultural Differences among Items the Positive and Negative Syndrome Scale (PANSS) in Schizophrenia*

Christian Yavorsky, Anzalee Khan, Stacy Leicht, Brian Rothman, Mark Opler, Ashleigh DeFries

189. *Comparing Symptom Response among Antipsychotic Medications in CATIE*

Stephen Z. Levine, Haya Ascher-Svanum, Douglas E. Faries, Anthony H. Lawson, Jonathan Rabinowitz

190. *Some Notes of Caution on 'Time-to-Discontinuation' as a Primary Outcome Measurement*

Patricia R.N. Nazir, Jan Pieter Maes, Chantal N. Delger, Arthur R. Van Gool

191. *The Strauss and Carpenter Prognostic Scale in Subjects Clinically at High Risk of Psychosis*

Dorien H. Nieman, Eva Velthorst, Hiske E. Becker, Lieuwe de Haan, Don Linszen, Max Birchwood, Paul Patterson, Raimo KR Salokangas, Markus Heinimaa, Georg Juckel, Heinrich Graf von Reventlow, Anthony Morrison, Frauke Schultze-Lutter, Joachim Klosterkötter, Stephan Ruhrmann

192. *Improvement in Negative Symptoms and Functional Outcome after Group Cognitive Remediation Treatment (REHACOP program): A Randomized Controlled Trial*

Natalia Ojeda, Pedro Sanchez, Javier Peña, Edorta Elizagarate, Eneritz Bengoetxea, Jesus Ezcurra, Miguel Gutierrez

193. *Negative Thought Disorder and its Relationship to Schizotypy: Evidence from the New York High-Risk Project*

Diane C. Gooding, Salome Ott, Simone A. Roberts, L. Erlenmeyer-Kimling

194. *Depressive Symptoms are Associated with (sub) Clinical Psychosis Vulnerability in Patients with Non-affective Psychotic Disorder, Siblings and Healthy Controls*

Rianne M.C. Klaassen, Manuela Heins, Nico van beveren, Bert L. Luteijn, Mark V. D. Gaag, Inez Myin-Germeys, Lieuwe de Haan

195. *Psychometric Properties and Validity of Short Forms of the Wisconsin Schizotypy Scales in Two Large Samples*

Thomas R. Kwapil, Georgina M. Gross, Paul J. Silvia, Neus Barrantes-Vidal

196. *Interpersonal Appraisals and Subjective Stress Predict Psychotic Symptoms in Daily Life*

Thomas R. Kwapil, Tecelli Dominguez, Erika Bedoya, Neus Barrantes-Vidal

197. *Factor Structure of Schizotypy and Associations with Psychopathology and Functioning in a Group previously at Ultra-high Risk for Psychosis*

Ashleigh Lin, Johanna T. W. Wigman, Barnaby Nelson, Stephen, J. Wood, Wilma, A. M. Vollebergh, Jim van Os, Alison R. Yung

198. *Reliability and Validity of the Spanish Versions of AVHRS y PUVI: Two Instruments for Assessing Auditory Hallucinations from a Dimensional Perspective*

Esther Lorente-Rovira, Eva Grasa, Iluminada Corripio, Susana Ochoa, Pelaez Trinidad, Victor Liaño, M. Jose Escartí, Mercedes Renovell, Julio Sanjuan, Jack Jenner



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

199. *Rates and Time Course of Extrapyrimal Symptoms: A Comparison of Oral and Long-Acting Intramuscular (LAI) Paliperidone Randomized Controlled Studies*

Srihari Gopal, Yanning Liu, Larry Alphas, Adam Savitz, Isaac Nuamah, David Hough

200. *Insulin-resistance and Metabolic Disturbances Related to Second-generation Antipsychotics in a Sample of Treatment-naïve Adolescents Compared to Adults*

Covadonga M. Díaz-Caneja, Laura Pina-Camacho, Margarita García-Amador, Cecilia Tapia-Casellas, Pamela Rodríguez-Latorre, Pilar Sáiz, Iluminada Corripio, Bárbara Arias, Ana González-Pinto, Julio Sanjuán, Aurelio García, Miguel Ángel Jiménez-Arriero, Celso Arango

201. *Improving Side Effect Monitoring in People Prescribed Long-acting Antipsychotic Injections: A UK Quality Improvement Programme*

Thomas R.E. Barnes, Carol Paton

202. *Estrogen Augmentation in Schizophrenia: A Quantitative Review of Current Evidence*

Marieke J. Begemann, Caroline F. Dekker, Mari van Lunenburg, Iris E. Sommer

203. *A Randomized Controlled Trial of Allopurinol vs. Placebo Added on to Antipsychotics in Patients with Schizophrenia or Schizoaffective Disorder*

Shimon Burshtein, Ari A. Gershon, Katya Rubinstein, Camelia Petcu, John M. Davis, Mark Weiser

204. *Effects of Papaverine on Contextual Fear Conditioning Deficit Presented by an Animal Model of Schizophrenia: the Spontaneously Hypertensive Rats*

Bianca A. Camerini, Natalia C. Zanta, Felipe M. Hungria, Claudio F. Souza, Vanessa C. Abílio, Rodrigo A. Bressan, Mariana B. Calzavara

205. *IV Droperidol or Olanzapine as Adjuncts to Midazolam for the Acutely Agitated Patient: A Multi-centre, Randomised, Double-blind, Placebo-controlled, Clinical Trial*

Esther Chan, David McD Taylor, David Kong, Jonathan Knott, Georgina Phillips, David Castle

206. *The Pharmacokinetic Profile of CLZ might Explain the Variability in the Acute Response in Treatment Refractory Schizophrenia*

Rosa Catalan, Rafael Penadés, Mireia Vázquez, Merce Torra, Guillen Masana, Alex Pons, Miquel Bernardo

207. *Switching to Olanzapine Long-acting Injection from either Oral Olanzapine or any other Antipsychotic: Comparative Post-hoc Analyses*

Antonio Ciudad, Marta Casillas, Alexander Schacht, Ernie Anand, Elena Perrin

208. *Effectiveness of Lurasidone vs. Quetiapine XR For Relapse Prevention in Schizophrenia: A 12-Month, Double-Blind Study*

Antony Loebel, Josephine Cucchiaro, Jane Xu, Kaushik Sarma, Andrei Pikalov, John M. Kane

209. *Efficacy of Lurasidone in Schizophrenia: Results of a Factor Analysis of 5 Pooled Short-Term Studies*

Josephine Cucchiaro, Robert Silva, Yongcai Mao, Antony Loebel, Stephen R. Marder

210. *Bimodal Rhythms of General Births, Schizophrenia, Super-Sanity and the "Two Classes of Men"*

Giovanni Marzullo

211. *Analysis of Suicidality, Stress and Treatment with Clozapine in Schizophrenia*

Gina N. Polsinelli, Vincenzo De Luca, Martha McKay, Isaac Sakinofsky, Joanna Henderson



212. *Results of a Phase 2a Proof-of-Concept Trial with a PDE10A Inhibitor in the Treatment of Acute Exacerbation of Schizophrenia*

Nicholas DeMartinis, Anindita Banerjee, Vikas Kumar, Stacey Boyer, Christopher Schmidt, Santiago Arroyo

213. *Discontinuing Anticholinergic Agents Prescribed for Extrapyrarnidal Side Effects in Schizophrenia or Schizoaffective Disorder Treated with Antipsychotics: Effects on Movement Disorders, Cognition and Psychopathology*

Julie E. Desmarais, Howard C. Margoless, Linda Beauclair, Lawrence Annable, Marie-Claire Bélanger, Theodore T. Kolivakis

214. *Within-Drug Benefit/Risk Evaluation of Olanzapine Long-Acting Injection at 1 and 2 Years of Treatment*

Holland C. Detke, John Lauriello, John Landry, Susan B. Watson, David P. McDonnell

215. *Comparison of Outcomes in Patients with Early Phase Versus Later Phase Schizophrenia*

Holland C. Detke, Christoph U. Correll, Chunxu Liu, John Landry, Peter D. Feldman, David P. McDonnell

216. *Is Haloperidol More Effective than Other First-generation Antipsychotics in Schizophrenia? A Meta-analysis of Randomized Controlled Trials*

Markus Dold, Stefan Leucht

217. *Efficacy and Acceptability of Benzodiazepine Augmentation of Antipsychotics in Schizophrenia and Schizophrenia-like Psychoses: A Meta-analysis of Randomized Controlled Trials*

Markus Dold, Stefan Leucht

218. *Glucagon-like Peptide-1 Analogues Against Antipsychotic-induced Overweight: Potential Physiological Benefits*

Bjørn H. Ebdrup, Filip K. Knop, Pelle L. Ishøy, Egill Rostrup, Birgitte Fagerlund, Henrik Lublin, Birte Glenthøj

219. *Serotonin 5-HT_{2A} Receptor Antagonists for Treatment of Schizophrenia*

Bjørn H. Ebdrup, Hans Rasmussen, Jørn Arnt, Birte Glenthøj

220. *Management of Involuntarily Admitted Patients with Schizophrenia*

Beatrice Frajo-Apor, Nina Schabetsberger, Georg Kemmler, W. Wolfgang Fleischhacker

221. *Exploring the Biology of the Clinical Inverse U-shape Dose-response in Schizophrenia or Cognitive Deficits Using Mechanistic Disease Modeling*

Hugo Geerts, Patrick Roberts, Athan Spiros

222. *Cannabidiol Attenuates the Impairments in Prepulse Inhibition Induced by Repeated Treatment with MK-801 in Mice*

Felipe V. Gomes, Ana C. Issy, Elaine Del-Bel, Francisco S. Guimarães

223. *Single Dose Administration of Olanzapine: Effects on Glucose Metabolism, Endocrine and Inflammatory Markers in Healthy Volunteers*

Margaret K. Hahn, Tamara Arenovich, Tom Wolever, Adria Giacca, Tony Cohn, Roger McIntyre, Celine Teo, Leigh Clarke, Valerie Powell, Araba Chintoh, Steve Mann, Sylvia Gomes, Gary Remington

224. *The Putative Antipsychotic Alstonine Decreases Glutamate Uptake in Rat Hippocampal Slices*

Ana P. Herrmann, Paula Lunardi, Luísa K. Pilz, Viviane M. Linck, Christopher O. Okunji, Carlos A. Gonçalves, Elaine Elisabethsky



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

225. *Several Prescription Patterns of Antipsychotic Drugs Influence Cognitive Functions in Japanese Chronic Schizophrenia Patients*

Hikaru Hori, Reiji Yoshimura, Asuka Katsuki, Atsuko Ikeouchi-Sugita, Wakako Umene-Nakano, Jun Nakamura

226. *Safety, Tolerability and Pharmacokinetics of RG1678, a Novel Glycine Reuptake Inhibitor, After Multiple Doses in Healthy Volunteers*

Meret Martin-Facklam, Alain Patat, Carsten Hofmann, Christophe Boetsch, Ludger Banken, Ursula Biedinger, Bruno Boutouyrie-Dumont

227. *Locus of Control and Self-esteem in Patients at their First Psychotic Episode*

Simone Ciufolini, Craig Morgan, Kevin D. Morgan, Paul Fearon, Peter B. Jones, Gill Doody, Robin M. Murray, Paola Dazzan

228. *The Use of Social Skills Inventory in Patients with Refractory and non-Refractory Schizophrenia*

Silvia Scemes, Monica Kayo, Mariangela Gentil Savoia, Bernardo Santos, Paulo Mestriner, Helio Elkis

229. *Longitudinal Changes In Everyday Functioning In Older Patients With Schizophrenia: The Role Of Changes In Functional Capacity*

Concetta Feo, Davide Prestia, Christopher R. Bowie, Philip D. Harvey

230. *Does the Schizophrenic Patient Really Improve with a Mensual Depot Treatment? A Prospective Study in an Outpatient Treatment Program; Multiprofessional View*

Isabel Fernandez, Silvia Alvarez, Paloma Alvarez, Juana Morena, Sandra Garcia

231. *Personality Traits of People with Severe Mental Illness Registered in Supported Employment Programs and their Relation to Baseline Motivation to Find a Job and Job Acquisition at 1-month Follow-up: Preliminary Results*

Guillaume Fortin, Tania Lecomte, Marc Corbière

232. *Achieving Insight: Is Good Executive Functioning Enough?*

James Gilleen, Kathryn Greenwood, Anthony. S. David

233. *The Impact of Family Factors on the Psychosocial and Clinical Functioning of African American Consumers with Schizophrenia*

Joseph M. Guada, Maanse Hoe, Reta Floyd, Jack Barbour, John Brekke

234. *Relationship between ToM and Attribution in Violent Male Patients with Schizophrenia*

Stephanie T. Harris, Clare Oakley, Avi Reichenberg, Declan Murphy, Marco Picchioni

235. *Impact of Stress on Paranoia in Patients with Psychosis, First-degree Relatives and Healthy Controls*

Maike M. Hartmann, Ulf Köther, Steffen Moritz, Tania M. Lincoln

236. *Deficits and Biases of the Facial Emotion Recognition in Patients with Schizophrenia*

Im hong Jeon, Seul Bi Lee, Jin Young Park, Jee In Kang, Eun Lee, Suk Kyo An



237. *The Influence of Attachment Style on Therapeutic Alliance: A Study of Psychotic Patients and Care Workers*

Nikie Korver-Nieberg, Simone Vriend, Patricia Tollenaar, Reinaud van de Fliert, Carin Meijer, Lieuwe de Haan

238. *The Relationship between Adult Attachment, Parental Bonding and Psychotic like Experiences, Preliminary Results*

Nikie Korver-Nieberg, Julia Meijer, Carin Meijer, Lieuwe de Haan

239. *Randomized Trial of In-person versus Electronic Intervention for Medication Adherence*

Natalie J. Maples, Xueying Li, Jim Mintz, Dawn I. Velligan

240. *Differential Associations between Cognition and Outcome in Early Psychosis: A Cohort Study of Early Psychosis Patients in the Netherlands*

Luyken Stouten, Wim Veling, Mischa Van der Helm, Winfried Laan, Mark Van der Gaag

241. *Cognitive and Clinical Predictors of Functional Capacity in First Episode Schizophrenia – The Importance of Working Memory*

Lone Vesterager, Torben Christensen, Birthe Olsen, Marianne Melau, Hysse Forchhammer, Merete Nordentoft

242. *Clinical and Morphometric Predictors of Quality of Life at Three Year Longitudinal Follow up of a First Episode Psychosis Cohort*

Shane J. McInerney, Cathy Scanlon, John Mc Farland, Heike Schmidt, Mohamed Ahmed, Dara Cannon, Colm McDonald

243. *The Brain-Gut Connection: Constipation in Schizophrenia*

Sudhakar Sivapalan, Thomas J. Raedler

244. *Monitoring Physical and Metabolic Parameters in a First Psychotic Episode*

Rosa E. Rodriguez-Huesca, Carmelo Cepeda

245. *Thought Disorder in Schizophrenia: Implications for Subjective versus Objective Quality of Life*

Eric J. Tan, Susan L. Rossell

246. *Poverty and Mental Illness*

Cheryl Forchuk, Phyllis Montgomery, Robin Coatsworth-Puspoky, Ruth Schofield, Stewart Perry, Pam Lahey, Benita Cohen, Betty Edwards

247. *Influences of Mental Health Characteristics and Admission Experiences on Perceived Coercion*

Seung Hyun Kim

248. *Psychotic Experiences and Help-seeking in a Representative Community Sample*

John G. Mills, Craig Morgan, Souci Frissa, Maria Verdecchia, Robert Stewart, Nicola T. Fear, Abraham Reichenberg, Bwalya Kankulu, Jennifer Clark, Billy Gazard, Robert Medcalf, Matthew Hotopf, Stephani L. Hatch, SELCoH study team



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

249. *Compliance in Schizophrenia Patients: The Role Of Therapeutic Alliance - Introduction Of A New Rating Instrument*

Christian G. Widschwendter, Alex Hofer, Susanne Baumgartner, Georg Kemmler, Monika Edlinger, Wolfgang W. Fleischhacker, Maria A. Rettenbacher

250. *Patients with their First Episode of Psychosis (FEP) Who Use Cannabis have Normal Premorbid IQ*

Laura Ferraro, Di Forti Marta, La Barbera Daniele, Russo Manuela, Reichenberg Avi, Murray Robin

251. *Comorbidity Action Research in Northern Adelaide, South Australia*

Cherrie A. Galletly, Charlotte de Crespigny, Peter Athanasos, John Moss, Nicholas Proctor, Andris Banders, Paul Delfabbro, Imelda Cairney, Cate Rowlands, Peter Tyllis, Dennis Liu, Deb Lee, Rosie King, Bev Hissee, Miriam Posselt, Hepsi Francis

252. *Validity of Timeline Follow-Back for Use of Cannabis and Other Illicit Substances in Patients with Psychosis*

Carsten R. Hjorthøj, Anne R. Hjorthøj, Allan Fohlmann, Anne-Mette Larsen, Mikkel Arendt, Merete Nordentoft

253. *Clinical Differences in Acute-phase Non-affective Psychotic Disorders with and without Substance Use*

Siri Helle, Erik Johnsen, Rolf Gjestad, Rune A. Kroken, Hugo A. Jørgensen, Else-Marie Løberg

254. *Towards a Phenomenological Understanding of Psychosis: Trait Perfectionism in Persons with Psychotic Illnesses*

Sabrina Hassan, Rohan Ganguli, Gordon L. Flett, Paul L. Hewitt

255. *Attributional Style in Paranoid Patients: The Role of Personal Beliefs and Paranoia*

M. Dolores Cantero, Almudena Duque, Carmen Valiente, Filiberto Fuentenebro, Patricia Villavicencio

256. *Effect of Lurasidone on Weight and Metabolic Parameters: A Comprehensive Database Analysis*

Andrei Pikalov, Josephine Cucchiaro, Masaaki Ogasa, Robert Silva, Jay Hsu, Jane Xu, Antony Loebel

257. *Dysfunctional Neural Networks of Time Perception in Schizophrenia During Cognitive Task: An ALE-Meta-Analysis*

Jose Antonio Gómez¹, Felipe Ortuño¹, Francisco Guillen-Grima², Maria Vallejo¹

258. *Childhood Trauma as a Precursor of Dissociative Symptoms in Schizophrenia Spectrum Patients and Healthy Controls*

Carlos Peña-Salazar¹, María-José Álvarez¹, Pere Roura-Poch², Caroline Gourdier¹, Helga Masramon¹, Francesc X. Arrufat¹

259. *Phenotypically Continuous with Clinical Psychosis, Discontinuous in Need for Care: Evidence for an Extended Psychosis Phenotype*

Martine M. van Nierop, Jim van Os, Nicole Gunther, Inez Myin-Germeys, Ron de Graaf⁴, Margreet ten Have, Saskia van Dorsselaer, Maarten Bak, Ruud van Winkel

260. *Imaging-genetic Study of COMT Effect on Cortical Morphology in a Large Sample of Healthy Subjects*

Arnaud Cachia, Anne Franceschini, Marie-Odile Krebs, Axel Krug, Tilo Kircher



261. *A Prospective Study of Factors Associated to Readmissions in Adult Schizophrenics Patients Discharged from a Short-stay psychiatric Inpatient Unit of a University General Hospital*
Fermin Mayoral, Olga Perez, Marina Romero, Javier Hernandez, Francisca Rius

262. *The Effect of Asenapine on Depressive Symptoms in Patients with Acute Schizophrenia, Results from Post Hoc Analyses*
John Kane, J-K Jensen

263. *Cariprazine Attenuates PCP-Induced Increases in Extracellular Prefrontal Cortical Glutamate Levels and Improves PCP-Induced Deficits in Cognition and Social Behavior*
Nika Adham, István Gyertyán, Béla Kiss, Nagi Idris, Samantha McLean, Ben Grayson, Takashi Yoshitake, Jan Kehr, Jo Neill

264. *Cortisol Levels and Cortisol/DHEAS Ratio as Potential Predictors of Anterior Cingulate Volume Change over the first 12 Weeks of Early Psychosis*
Renate LEP Reniers, Belinda Garner, Christina Phassoulitis, Lisa J. Philips, Connie Markulev, Christos Pantelis, Sarah Bendall, Patrick D McGorry, Stephen J. Wood

265. *Childhood Cognitive Function and Adult Psychopathology: Associations with Psychotic and Non-psychotic Symptoms in the General Population*
Jennifer H. Barnett, Fiona McDougall, Man Xu, Tim J. Croudace, Marcus Richards, Peter B. Jones

266. *Investigation of Neuronal Plasticity in Response to Combination Treatment with Lurasidone and Valproic Acid in Rats*
Francesca Calabrese, Alessia Luoni, Gianluigi Guidotti, Giorgio Racagni, Fabio Fumagalli, Marco A. Riva

267. *Multivariate Pattern Classification of Individuals with Psychosis Proneness from Functional Imaging during Emotional Processing*
Gemma Modinos, William Pettersson-Yeo, Paul Allen, Philip K. McGuire, André Aleman, Andrea Mechelli



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

Posters, Tuesday 17 April

12:00 PM - 2:00 PM

Cavaniglia

1. *Relationship between Childhood Adversity and Clinical and Cognitive Features in Schizophrenia*

Kathryn McCabe, Elizabeth Maloney, Helen Stain, Carmel Loughland, Vaughan Carr

2. *Childhood Bullying and the Association with Psychosis in Nonclinical and Clinical Samples: A Review and Meta-analysis*

Daniella S. van Dam, Elsje van der Ven, Eva Velthorst, Jean-Paul Selten, Craig Morgan, Lieuwe de Haan

3. *Childhood Trauma, Earlier Parental Experiences and Adult Attachment in Patients with Psychosis, Nonclinical Siblings and Healthy Controls*

Daniella S. van Dam, Nikie Korver-Nieberg, Eva Velthorst, Carin J. Meijer, Lieuwe de Haan

4. *Parental Bonding and Beliefs about Self and Others: Differential Patterns in Depressive and Paranoid Patients*

Gonzalo Hervás, Nuria Romero, Regina Espinosa, Carmen Valiente, Patricia Villavicencio

5. *Understanding Possible Relationships between Experiences of Trauma and Psychosis*

Covadonga Chaves, M. Dolores Cantero, Carmen Valiente, Carmelo Vázquez, Patricia Villavicencio

6. *Antidepressant and neuroplastic Properties of Chronic Lurasidone Treatment in Serotonin Transporter Knockout Rats*

Alessia Luoni, Sjoerd Hulsken, Giorgio Racagni, Judith Homberg, Marco A. Riva

7. *Clozapine Reverses Recognition Memory but not Social Interaction Deficits in a "Dual-hit" Rat Model of Schizophrenia*

Allison L. McIntosh, Theresa M. Ballard, Lucinda J. Steward, Paula M. Moran, Kevin C. Fone

8. *Evidence of Mismatch Negativity (MMN) in Epidural Auditory Event-related Potentials in the Rat to Frequency and Duration Deviants: Relevance to Animal Models of Schizophrenia*

Patricia T. Michie, Tamo Nakamura, William R. Fulham, Juanita Todd, Timothy W. Budd, Ulrich Schall, Michael Hunter, Deborah M. Hodgson

9. *Social Isolation Rearing in Rats Induces Schizophrenia-like Behaviours that are Reversed by Sub-chronic Treatment with Clozapine or N-acetyl Cysteine*

Marisa Möller, Brian H. Harvey, Robin Emsley

10. *Social Isolation Rearing in Rats Alters Plasma Tryptophan Metabolism and is Reversed by Sub-chronic Clozapine Treatment*

Marisa Möller, Jan L. Du Preez, Brian H. Harvey

11. *The Effects of the Dopamine D1 Receptor Agonist on Attentional Set-shifting Task Performance in Rats*

Agnieszka Nikiforuk



12. *Expression of Neurotransmitter Receptor and Regulator Genes in Two Brain Regions and Peripheral Blood in a New Animal Model of Schizophrenia: The Spontaneously Hypertensive Rats (SHR)*

Marcos L. Santoro, Camila M. Santos, Vanessa K. Ota, Mariana C. Diana, Ary Gadelha, Vinicius C. Mrad, Leticia M. N. Spindola, Jair J. Mari, Rodrigo Bressan, Marilia A. C. Smith, Vanessa C. Abilio, Sintia I. N. Belangero

13. *A Novel Semi-automated Attentional Set Shifting Task for Mice*

Diego Scheggia, Audrey Bebensee, Fabio Benfenati, Daniel R. Weinberger, Francesco Papaleo

14. *Differential Impact of GAD67 Downregulation in CCK+ and NPY+ Interneurons*

Martin J. Schmidt, Monika Everheart, Krassimira Garbett, Szatmar Horvath, Karoly Mirnic

15. *Environment-environment Interactions in a Schizophrenia-related Disease Model: Impact of Poly IC and THC on the Developing Brain*

Gillian M. Stenson, Judith A. Pratt, Ros R. Brett

16. *Alteration of Several Schizophrenia Candidate Genes Expression in Medial Prefrontal Cortex in Perinatal Asphyxia Rodent Model*

Tomoyasu Wakuda, Keiko Iwata, Katsuaki Suzuki, Nori Takei, Norio Mori

17. *Time- and Gender-dependent Effects on Response to Social and Non-social Odors in Adult Mice Exposed to Valproic Acid Prenatally*

Ran Wei, Qi Li, Grainne M. McAlonan

18. *Effects of Papaverine on Social Behaviors in an Animal Model of Schizophrenia: The Spontaneously Hypertensive Rats*

Natalia C. Zanta, Bianca A. Camerini, Felipe M. Hungria, Cláudio F. Souza, Vanessa C. Abílio, Rodrigo A. Bressan, Mariana B. Calzavara

19. *Chronic Exposure to Cigarette Smoke during Gestation Results in Altered Cholinesterase Enzyme Activity and Behavioral Deficits in Adult Rat Offspring: Potential Relevance to Schizophrenia*

Alexandra I. Zugno, Daiane Fraga, Renata D. Luca, Fernando Ghedim, Pedro Deroza, Andreza Cipriano, Alexandre Silverio, Renan Souza, João Quevedo

20. *Altered Default Network Resting State Functional Connectivity in Patients with a First Episode of Psychosis*

Anna Alonso-Solís, Iluminada Corripio, Pilar de Castro-Manglano, Santiago Duran-Sindreu, Manuel García-García, Erika Proal, Fidel Nuñez-Marín, Cesar Soutullo, Enric Alvarez, Beatriz Gómez-Ansón, Clare Kelly, F. Xavier Castellanos, Eva Grasa

21. *Brain Activity during Moral Judgment Tasks in Individuals with Schizophrenia, their Unaffected Siblings, and Healthy Controls*

Delfina de Achával, Mirta F. Villarreal, Elsa Y. Costanzo, Mariana N. Castro, Ramón C. Leiguarda, Charles B. Nemeroff, Salvador M. Guinjoan

22. *Functional Brain Imaging Correlates of Identifying Intention to Communicate in Schizophrenia*

Mary-Claire Hanlon, Gavin J. Cooper, W. Ross Fulham, Robyn Langdon, Ulrich A. Schall



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

23. *Neural Substrates of Empathic Accuracy in People with Schizophrenia*

Philippe-Olivier Harvey, Jamil Zaki, Junghee Lee, Kevin Ochsner, Michael F. Green

24. *From Lab to Life: Prefrontal Dopaminergic Hyporeactivity to Psychosocial Stress Predicts Psychotic Experiences in Response to Daily Life Stress in Individuals with a Familial Risk of Psychosis*

Dennis Hernaus, Johan Lataster, Dina Collip, Jenny Ceccarini, Linda Booij, Jim van Os, Jens Pruessner, Koen van Laere, Inez Myin-Germeys

25. *Deficit of Integrative Emotional Processing in Patient with Schizophrenia: An fMRI Study*

Seon-Koo Lee, Ji Won Chun, Hae-Jeong Park, Jae-Jin Kim

26. *Attenuated Frontal Activations and Reduced Functional Connectivity Elicited by an Overt Semantic Verbal Fluency Task in Patients with Schizophrenia*

Axel Krug, Heidelore Backes, Bruno Dietsche, Arne Nagels, Justus Marquetand, Mirjam Stratmann, Tilo Kircher

27. *Neural Correlates of Reality Judgment Abnormality in Patients with Schizophrenia*

Jung Suk Lee, Ji Won Chun, Sang-hoon Lee, Dong-II Kang, Hae-Jeong Park, Jae-Jin Kim

28. *Gender-dependent Differences in the Neural Responses to Fear Acquisition: A Voxel-based Diffusion Tensor Imaging (DTI) Study*

Qi Li, Abby Y. Ding, Ran Wei, Wendy Kong, Sylvia Lam, Xiao F. Zhang, Siew E. Chua, Ed X. Wu, Grainne M. McAlonan

29. *Out of our Minds: The Auditory 'Where' Pathway Projects Hallucinated Voices into External Auditory Space*

Jasper Looijestijn, Kelly Diederer, Rutger Goekoop, Iris Sommer, René Kahn, Jan Dirk Blom

30. *Neuroimaging Correlates of Working Memory in Postpartum Psychosis*

Astrid M. Pauls, Mitul A. Mehta, Owen G. O'Daly, Susan Pawlby, Simone Ciufolini, Costanza Vecchio, Steven C. R. Williams, Carmine M. Pariante, Paola Dazzan

31. *Functional Connectivity in Relation to Different Genetic Risk Levels for Psychotic Disorder: A Resting State fMRI Study*

Sanne C. T. Peeters, Vincent van de Ven, Petra Habets, Patrick Domen, Rainer Goebel, Jim van Os, Machteld Marcelis

32. *Neural Mechanisms Supporting the Cognitive Control of Emotional Information in Schizophrenia*

Laura M. Tully, Sarah Hope Lincoln, Todd Wright, Christine I. Hooker

33. *Schizophrenia, Social Cognition, Emotional Processing and the Role of the Left Ventrolateral Prefrontal Cortex*

Lisette Van der Meer, Marieke Pijnenborg, Willem A. Nolen, André Aleman

34. *Brain Activity during Emotion Regulation in Individuals at Ultra-high Risk for Psychosis*

Jorien Van der Velde, Esther Opmeer, Edith Liemburg, Roeline Nieboer, Lex Wunderink, Andre Aleman



35. *Auditory Verbal Hallucinations in Non-psychotic Individuals – A Graph Theoretical Study*

Remko van Lutterveld, Wim Otte, Kelly Diederer, René Kahn, Kees Stam, Iris Sommer

36. *Reduced Proactive Inhibitory Control in Schizophrenia Patients and their Unaffected Siblings*

Matthijs Vink, Bram B. Zandbelt, M. van Buuren, Rene S. Kahn

37. *Neural Correlates of Physical and Social Causality Judgement in Patients with Schizophrenia*

Kim C. Wende, Arne Nagels, Mirjam Stratmann, Anjan Chatterjee, Tilo Kircher, Benjamin Straube

38. *MRS Study of Glutamate, GABA, and NAAG in Schizophrenia*

Laura M. Rowland, Kimberly Kontson, Jef T. West, He Zhu, Richard A. Edden, Henry H. Holcomb, Peter B. Barker

39. *Associations between Focal Brain Structural Changes, Phospholipid Metabolism and Glutamatergic Neurotransmission – A Combined 31P/1H MR Spectroscopy Investigation in Patients with First Acute Onset Schizophrenia*

Stefan Smesny, Alexander Gussew, Reinhardt Rzanny, Berko Milleit, Juergen Reichenbach, Heinrich Sauer

40. *Fractional Anisotropy Reductions in Cingulum Bundle and Corpus Callosum in at Risk Mental State*

Naoyuki Katagiri, Masaaki Hori, Takahiro Nemoto, Naohisa Tsujino, Keiko Morita, Junichi Saito, Keigo Shimoji, Nobuyuki Shiraga, Shigeki Aoki, Masafumi Mizuno

41. *Longitudinal Voxel-based Morphometric Study Examining Progressive Gray Matter Changes in First-episode Schizophrenia*

Yasuhiro Kawasaki, Yukihiisa Matsuda, Tsutomu Takahashi, Mikio Kido, Kazue Nakamura, Atsushi Furuichi, Michio Suzuki

42. *Prefrontal Cortex and Hippocampal Volumes in Aggressive and Non-Aggressive Patients with a Psychotic Disorder*

Laura Koenders, Marise W. J. Machielsen, Jet D. Heering, Claudia Vingerhoets, Dick J. Veltman, Lieuwe de Haan

43. *White Matter Abnormalities in Middle-aged Subjects with Schizophrenia - The Northern Finland 1966 Birth Cohort*

Jenni S. Koivukangas, Juha Veijola, Osmo Tervonen, Marianne Haapea, Jouko Miettunen, Matti Isohanni, Vesa Kiviniemi, Erika Jääskeläinen, Peter B. Jones, Anna Barnes, Juha Nikkinen

44. *Association between Reduced Thalamo-prefrontal Integrity and Cortical Thickness Reduction in Schizophrenia*

Manabu Kubota, Jun Miyata, Akihiko Sasamoto, Hidefumi Yoshida, Ryosaku Kawada, Shinsuke Fujimoto, Yusuke Tanaka, Nobukatsu Sawamoto, Hidenao Fukuyama, Hidehiko Takahashi, Toshiya Murai

45. *Differences in Structural Brain Volumes between Patients with an Early Psychotic Disorder With and Without Comorbid Cannabis Use Disorders*

Marise Machielsen, Floor van der Meer, Angelique van Gasselt, Jet Heering, Dick Veltman, Lieuwe de Haan



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

46. *Altered White Matter Connections in Never-medicated Patients with Schizophrenia*

René C. W. Mandl, Monica Rais, G. Caroline van Baal, Neeltje van Haren, Wiepke Cahn, René S. Kahn, Hilleke E. Hulshoff Pol

47. *White Matter Alterations in Schizophrenia: A Diffusion Tractography Study of Cingulum Bundle*

Alessia Mirigliani, Mariana Gallo, Antonino Buzzanca, Fabio Di Fabio, Marianna Frascarelli, Fabrizio Parente, Francesca Caramia, Massimo Biondi

48. *A Multimodal Study of Emotion Processing in Prodromal and First-Episode Psychosis*

Helene Mirzakhanian, Khalima Bolden, Kristin Cadenhead, Lisa Eyler, Pedro Roman, Gregory Brown

49. *Neuroanatomy of Auditory Verbal Hallucinations in Schizophrenia: A Quantitative Meta-analysis of Voxel-based Morphometry Studies*

Gemma Modinos, Sergi G. Costafreda, van Tol Marie-José, Philip K. McGuire, André Aleman, Paul Allen

50. *Morphological Characteristics of Anterior Cingulate Cortex in Schizophrenia and Subjects at Genetic High Risk for Psychosis*

Hyeyoun Park, JaeYeon Hwang, Wi Hoon Jung, Geumsook Shim, JoonHwan Jang, JunSoo Kwon

51. *Correlates of Autobiographical Memory from Different Lifetime Periods in Patients with Chronic Schizophrenia*

Christina Herold, Lena Schmid, Marc Lässer, Ulrich Seidl, Philipp Thomann, Marco Essig, Johannes Schröder

52. *Increased Hypothalamus and Mammillary Bodies Volumes in Chronic Schizophrenia*

Stefania Tognin, Gianluca Rambaldelli, Marcella Bellani, Cinzia Perlini, Veronica Marinelli, Robert Terlevic, Michele Tansella, Paolo Brambilla

53. *Cortical Thickness and Cortical Surface in Schizophrenia: Two Distinct but Relevant Processes?*

Neeltje E. van Haren, Hugo G. Schnack, Wiepke Cahn, Hilleke E. Hulshoff Pol, Rene S. Kahn

54. *Pituitary Gland Volume in Individuals with an At-risk Mental State: A Longitudinal MRI Analysis*

Anna Walter, Anita Riecher-Rössler, Erich Studerus, Renata Smieskova, Corinne Tamagni, Charlotte Rapp, Stefan Borgwardt

55. *T2 Relaxation Times in the Superior Temporal Gyrus of Individuals at Ultra-High Risk for Psychosis and Their Association With Auditory Hallucinations*

Stephen J. Wood, Ashleigh Lin, Damian Kennedy, Barnaby Nelson, Christos Pantelis, Alison R. Yung

56. *A Diffusion Tensor Imaging (DTI) study of White Matter Integrity in Parkinson's Disease (PD)*

Nailin Yao, Shirley Pang, Kevin Yu, Charlton Cheung, Richard Chang, Henry Mak, Grainne McAlonan, SL Ho, Siew Chua

57. *Thought and Language Disorders in Young Patients with Schizophrenia, Schizoaffective Disorder and Bipolar Disorder*

Telma Pantano, Fu I. Lee, Eliana Curatolo, Camila B. Martins, Helio Elkis



58. *Direct Comparison of Memory Impairment in Youth at Familial Risk for Schizophrenia or Affective Psychosis*

Silvia Scala, Andrea Pousada-Casal, Heidi W. Thermenos, Ming T. Tsuang, Stephen V. Faraone, Larry J. Seidman

59. *The Outcome of Early Onset Schizophrenia based on a Systematic Meta-analysis of the Literature*

Lars Clemmensen, Ditte Lammers, Hans-Christoph Steinhausen

60. *The Relationship Between Childhood Trauma and Adult Onset Schizophrenia: What We Now Know*

Ashley K. Storrs

61. *Modified Cognitive Behavioral Therapy in Adolescents with Persistent Psychotic Symptoms- Results of a Randomized Controlled Trial*

Tanja Tecic, Jörn Güttgemanns, Gerd Lehmkuhl, Katarina Mueller, Dieter Stoesser, Georg Wiedemann, Stefan Klingberg, Andreas Bechdolf

62. *Copenhagen High Risk Study II: Childhood and Development. 7-year old Children of Parents with Schizophrenia*

Anne A. E. Thorup, Jens R. Jepsen, Kerstin Plessen, Merete Nordentoft

63. *Prevalence of Bullying Amongst First-episode Psychosis Patients and Unaffected Controls*

Antonella Trotta, Marta Di Forti, Craig Morgan, Paola Dazzan, Carmine Pariante, Anthony David, Alice Mulè, Caterina La Cascia, Daniele La Barbera, Robin M. Murray, Helen L. Fisher

64. *Cognitive Insight and Attenuated Positive Symptoms in At-risk Mental State*

Tomohiro Uchida, Noriyuki Omuro, Masahiro Katsura, Yumiko Hamaie, Emi Sunakawa, Kazunori Matsumoto, Hiroo Matsuoka

65. *Functional Impairment: Should it be an Obligate Part of Clinical Criteria for an Increased Risk of Developing Psychosis?*

Stefan Ruhrmann, Frauke Schultze-Lutter, Mitja Bodatsch, Don Linszen, Raimo Salokangas, Max Birchwood, Georg Juckel, Anthony Morrison, Andreas Heinz, Shon Lewis, Heinrich von Reventlow, Joachim Klosterkötter

66. *A Five Factor Solution of the Scale of Prodromal Symptoms (SOPS)*

Stefan Ruhrmann, Frauke Schultze-Lutter, Mitja Bodatsch, Don Linszen, Raimo Salokangas, Max Birchwood, Georg Juckel, Anthony Morrison, Andreas Heinz, Shon Lewis, Heinrich von Reventlow, Joachim Klosterkötter

67. *Prevalence of Prediabetes in Patients Treated with Antipsychotics*

Pauline M. Steylen, Frank M. van der Heijden, Willem M. Verhoeven

68. *A New Perspective on Anhedonia in Schizophrenia*

Gregory P. Strauss, Lauren T. Catalano, James M. Gold

69. *Sensitivity for Stress in Early Psychosis Patients: A Clinical Profile*

Renate van der Valk, Maaïke Rouwenhorst, Carin Meijer, Lieuwe de Haan



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

70. *Ethnicity and Baseline Symptomatology in Patients with an At Risk Mental State for Psychosis*

Eva Velthorst, Dorien H. Nieman, Wim Veling, Rianne M. Klaassen, Sara Dragt, Judith Rietdijk, Helga Ising, Lex Wunderink, Don H. Linszen, Lieuwe de Haan, Mark van der Gaag

71. *Disability in People Clinically at High Risk of Psychosis*

Eva Velthorst, Dorien H. Nieman, Don H. Linszen, Hiske E. Becker, Lieuwe de Haan, Peter M. Dingemans, Max Birchwood, Paul Patterson, Raimo K. Salokangas, Markus Heinimaa, Andreas Heinz, Georg Juckel, Heinrich Graf von Reventlow, Paul French, Helen Stevens, Frauke Schultze-Lutter

72. *Relationship between MMN and Facial Emotion Recognition in Patients with Schizophrenia*

Sung-Hyouk Park, Chan-Hyung Kim, David Braff, Gregory Light

73. *Spatial and Temporal Properties of Affect Perception Deficits in Schizophrenia: A TMS Study*

Yuri Rassovsky, Junghee Lee, Poorang Nori, Allan D. Wu, Marco Iacoboni, Michael F. Green

74. *Mismatch Negativity Peak Latency and Negative Symptoms in Schizophrenia*

Gudrun Sartory, Christian Kärger, Daniela Kariofillis, Bernhard Müller

75. *Cognitive and Electrophysiological Correlates of Noise Power in Schizophrenia*

Alvaro Diez, Vanessa Suazo, Pilar Casado, Manuel Martin-Loeches, Vicente Molina

76. *Noise Power as a Measure of Event Related and Spontaneous Brain Activity: A Longitudinal Study*

Vanessa Suazo, Alvaro Diez, Pilar Casado, Manuel Martin-Loeches, Vicente Molina

77. *Characterization of the Novel Procognitive Antipsychotic EGIS 11150 in the Hippocampus and Neocortex in Vitro*

Isla H. B. Thomson, Ferenc A. Antoni, Michael Spedding, Miles A. Whittington, Mark O. Cunningham

78. *High Rates of Cardiometabolic Risk Factors in People with Psychotic Disorders*

Cherrie A. Galletly, Debra L. Foley, Anna Waterreus, Gerald F. Watts, David Castle, John McGrath, Andrew Mackinnon, Vera A. Morgan

79. *Longitudinal Youth-At-Risk Study (LYRIKS): Examining the Prodrome from Another Perspective*

Jimmy Lee, Attilio Rapisarda, Mike Kraus, Siow-Ann Chong, Richard Keefe

80. *Familial and Genetic Factors in the Course and Trajectories of Serious Mental Illness: A National Population-based Twin Study*

Stephen Z. Levine, Rinat Yoffe, Inna Pugachova, Avi Reichenberg

81. *Subdomains of Negative Symptoms in Schizophrenia: A Two-factor Model Confirmed by Confirmatory Factor Analysis*

Edith J. Liemburg, Stynke Castelein, Roy Stewart, Mark van der Gaag, André Aleman, GROUP Investigators, Henderikus Knegtering



82. *Comparison of Early Episode and Chronic Patients Diagnosed with Schizophrenia: Symptoms and Childhood Trauma*

Wang Zheng, Xuezhi Min, Puwei Dan, Yang Bo, Li Li, Yiwen Ying, Wang Peng, Liu hang, Wuguo Wei, LiuzheNing, Robert A Rosenheck

83. *At-risk Criteria of Psychosis and Help-seeking Behaviour in the General Population: Preliminary Results from a Telephone Survey*

Chantal Michel, Benno G. Schimmelmann, Rebecca Wyler, Frauke Schultze-Lutter

84. *Young People at Risk for Psychosis: Case Finding and Sample Characteristics of the Oulu Brain and Mind Study*

Juha Veijola, Pirjo Maki, Erika Jaaskelainen, Jenni Koivukangas, Irma Moilanen, Anja Taanila, Tanja Nordstrom, Tuula Hurtig, Vesa Kiviniemi, Sari Mukkala, Markus Heinimaa, Paivi Lindholm, Peter Jones, Jenny Barnett, Graham Murray, Jouko Miettunen

85. *Temperament in Individuals with Psychotic Disorders Before and After the Onset of Illness*

Jouko Miettunen, Pauliina Juola, Eka Roivainen, Juha Veijola, Antti Alaräisänen, Matti Isohanni, Erika Jääskeläinen

86. *First Episode of Psychosis (FEP): An Incidence Pilot Study Using the South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLAM BRC) Case Register*

Jason Tsang, Charlotte Gayer-Anderson, Francois Bourque, Jennifer O'Connor, Jonathan Garabette, Alex Tulloch, Adanna Onyejiaka, Susana Borges, Sherifat Oduola, Grant McQueen, Chelsea Gardener, Andrea Fernandes, Matthew Hotopf, Matthew Broadbent, Robert Stewart, Craig Morgan

87. *The EU-Gene Environment Interaction Study (EU-GEI): Incidence of Psychosis in 6 Countries – Rational, Methods and Progress at 12 Months*

EU-GEI Work Package 2 Study Grp-C. Morgan

88. *Incidence of Psychotic Disorders in Palermo: Preliminary Data*

Alice Mulè, Lucia Sideli, Caterina La Cascia, Marta Di Forti, Robin MG Murray, Daniele La Barbera

89. *Emergency Caesarean Section as a Risk Factor for Schizophrenia*

Alessandra Paparelli, Muriel Walshe, Iliaria Tarricone, Jane Boydell, Tawaliku Akib, Gabriella Pollutri, Simona A. Stilo, Elvira Bramon, Marta Di Forti, Jhon Powell, Robin Murray

90. *Migration, Ethnicity and Psychosis: Evidence for a Socio-developmental Pathway*

Ulrich Reininghaus, Tom Craig, Helen Fisher, Gerard Hutchinson, Paul Fearon, Kevin Morgan, Paola Dazzan, Gillian Doody, Peter Jones, Julian Leff, Robin Murray, Craig Morgan

91. *Use of Antipsychotic Medication and Suicidality – The Northern Finland Birth Cohort 1966*

Ina Rissanen, Erika Jääskeläinen, Matti Isohanni, Hannu Koponen, Matti Joukamaa, Antti Alaräisänen, Jouko Miettunen

92. *Psychopathological Significance of At-risk Criteria of Psychosis in the General Population: Preliminary Results from a Telephone Survey*

Benno G. Schimmelmann, Chantal Michel, Frauke Schultze-Lutter



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

93. *At-risk Criteria of Psychosis and Quality of Life in the General Population: Preliminary Results from a Telephone Survey*

Benno G. Schimmelmann, Chantal Michel, Frauke Schultze-Lutter

94. *Prevalence of At-risk Criteria of Psychosis in the General Population: Preliminary Results from a Telephone Survey*

Frauke Schultze-Lutter, Chantal Michel, Benno G. Schimmelmann

95. *Prevalence and Burden of At-risk Criteria of Psychosis and Help-seeking Behaviour: Design and Response of a Population Survey*

Frauke Schultze-Lutter, Chantal Michel, Benno G. Schimmelmann

96. *Does Exposure to Herpes Simplex Virus, Type 1 Cause Cognitive Dysfunction among Schizophrenia and Control Individuals: An Indian study*

Pramod Thomas, Triptish Bhatia, Jan Richard, Deepak Gauba, Joel Wood, Colleen Long, Konasale Prasad, Raquel Gur, Ruben Gur, Robert Yolken, Vishwajit L. Nimgaonkar, Smita N. Deshpande

97. *Childhood Abuse and Symptom Severity and Disability in First Episode Psychosis*

Sophie Sowden, Susana Borges, Simona Stilo, Adanna Onyjiaka, Charlotte Gayer-Anderson, Grant McQueen, Arune Keraite, Chelsea Gardener, Helen Fisher, Valeria Mondelli, Marta Di Forti, Robin M. Murray, Carmine Pariante, Craig Morgan, Rowena Handley, Paola Dazzan

98. *Increased Familiarity of Intellectual Deficits in Early-Onset Schizophrenia Spectrum Disorders*

Ximena Goldberg, Mar Fatjó-Vilas, María J. Muñoz, Silvia Campanera, Salvador Miret, María J. Miñano, Mari Aguilera, María L. Miralles, María E. Navarro, Luisa Lázaro, Marc Guitart, Neus Barrantes-Vidal, Lourdes Fañanás

99. *Replication of Previous GWAS Studies in Schizophrenia Show Common Risk SNPs with Bipolar Disorder*

Jose L. Ivorra, Jose C. Gonzalez, Javier Costas, Celso Arango-Lopez, Miguel Bernardo, Julio Bobes, Jorge Cervilla, Ana Gonzalez-Pinto, Jose M. Haro-Abad, Maria D Molto, Victor Perez-Sola, Tomas Palomo, Ana R. Saez, Jeronimo Saiz-Ruiz, Julio Sanjuan

100. *Application of a Molecular Pathway Based Approach to the Study Gene-Environment Interactions*

Conrad Iyegbe, Emma Knowles, Rowena Handley, Heather Taylor, Simona Stilo, Helen Fisher, Paola Dazzan, Craig Morgan, Selcoh study group, Marta DiForti, Andy Simmons, Stepheni Hatch, Matthew Hotopf, John Powell, Avi Reichenberg, Robin Murray

101. *COMT Val158Met Genotype and Schizotypy Dimensions*

Araceli Rosa, Artal Moreno, Agnès Ros-Morente, Thomas R. Kwapil, Neus Barrantes-Vidal

102. *Family Association Study of Candidate Genes in Schizophrenia*

Pawel Kapelski, Maria Skibinska, Aleksandra Szczepankiewicz, Monika Dmitrzak-Węglarz, Piotr Czerski, Joanna Hauser

103. *Serotonin Transporter Gene Polymorphism (5-HTTLPR) and Depressive Symptoms in Schizophrenia*

Dalibor Karlovic, Ante Silic, Ana Kovak-Mufic, Mario Stefanovic, Jelena Culej, Nada Vrkić

104. *Association of Estrogen Receptor Genes and Schizophrenia: A Preliminary Study*

Jung Jin Kim, Jung Ah Min, Chi Un Pae, Chang Uk Lee, Chul Lee



105. *Cross-phenotype Analysis for Schizophrenia Susceptibility Genes based Upon Type II Diabetes GWASs*
Kenji Kondo, Masashi Ikeda, Yusuke Kajio, Yasuhisa Fukuo, Norio Ozaki, Nakao Iwata

106. *GABA Transporter SLC6A11 Gene Polymorphism Associated with Tardive Dyskinesia*
Woo-Young Son, Heon-Jeong Lee, Ho-Kyoung Yoon, Seung-Gul Kang, Young-Min Park, Hee-Jung Yang, Jung-Eun Choi, Hyonggin An, Han-Kyu Seo, Leen Kim

107. *Evidence of an Association between Dysbindin Gene and Age at Onset in Schizophrenia*
Kyuyoung Lee, Eunjeong Joo, Yongsik Kim

108. *The Influence of DISC1 Ser704Cys Polymorphism on the Cortical Thickness of Salience Network (insula and anterior cingulate) in Psychosis*
Lena Palaniyappan, Vijender Balain, Molly Simmonite, Liam Carrol, Peter McGuffin, Katherine Aitchison, Peter F. Liddle

109. *Historical Study of Influence of Non-genetic Factors on Twin Concordance for Schizophrenia*
Edward J. Pepper

110. *No Association between the Presence of Val66Met Polymorphism and Schizophrenia: A Case-control Study*
Alicia Valiente, Amalia Lafuente, Patricia Gasso, Ana Mesguer, Cristina Oliveira, Miquel Bioque, Bibiana Cabrera, Alicia Duran, Clemente Garcia-Rizo, Miguel Bernardo

111. *Identification of a Genetic Panel to Predict Schizophrenia Risk*
Joanne Voisey, Cameron P. Hurst, Bruce R. Lawford, Ross McD. Young, Charles P. Morris

112. *No Evidence that Common Genetic Risk Variants are shared between Schizophrenia and Autism*
Jacob Vorstman, Richard Anney, Eske Derks, Louise Gallagher, Michael Gill, Maretha de Jonge, Herman van Engeland, René S. Kahn, Roel Ophoff, Autism Genome Project (AGP), International Schizophrenia Consortium (ISC)

113. *Estrogen Receptor Alpha Genotype and Cognitive Impairment in Schizophrenia*
Selena Hu, Merribe Kyaw, Ans Vercammen, Loretta Moore, Cynthia S. Weickert, Thomas W. Weickert

114. *Deep Re-sequencing of DPYSL2 Exons Reveals Novel SNPs and Variation in Splicing and Exon Usage Patterns in Schizophrenia Patients and Controls*
Catherine L. Winchester, Graham M. Hamilton, Brian Morris, Judy A. Pratt, Robert Hunter, Mark E.S. Bailey

115. *Association Analysis Polymorphisms of the Glutamic Acid Recept Gene with Schizophrenia*
Junzhe Xu, Magan Helm, Vivian Chang, Anna Li, Daniel Li, Steven Dubovsky

116. *Genetic and Functional Analysis of the Gene Encoding GAP-43 in Schizophrenia*
Shen Yu-Chih, Chen Chia-Hsiang

117. *Neuroinflammation in Temporal Cortex of Patients with Recent Onset Schizophrenia*
Thalia F. van der Doef, Maqsood Yaqub, Matthijs G. Bossong, Ronald Boellaard, Neeltje E. van Haren, Albert D. Windhorst, Wiepke Cahn, Adriaan A. Lammertsma, René S. Kahn, Bart N. van Berckel



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

118. *Bone Mineral Density as a Marker of Cumulative Endogenous Estrogen Exposure: Relationship to Background Genetic Risk for Psychotic Disorder*

Christine van der Leeuw, Patrick Domen, Petra Habets, Marinus van Kroonenburgh, Jim van Os, Machteld Marcelis

119. *The Role of Stress in Patients with Postpartum Psychosis*

Costanza Vecchio, Astrid Pauls, Patricia Zunszain, Valeria Mondelli, Simone Ciufolini, Susan Pawlby, Gertrude Seneviratne, Heather Taylor, Mitul Mehta, Steven Williams, Eugenio Aguglia, Carmine Pariante, Paola Dazzan

120. *Parallel Increases in [3H]Muscimol and [3H]Flumazenil Binding in the Dorsolateral Prefrontal Cortex in Schizophrenia are Linked to GABAA Receptor $\alpha 4$ and $\gamma 2S$ mRNA Subunit Levels Respectively*

Mathieu Verdurand, Stu G. Fillman, Cynthia Shannon Weickert, Katerina Zavitsanou

121. *Alterations in the Reward Processing Related to Dopamine D2/D3 Binding Potential in Antipsychotic Naïve Schizophrenia Patients*

Sanne Wulff, Mette Ø. Nielsen, Hans Rasmussen, Lars T. Jensen, Egill Rostrup, Erik Frandsen, Lars H. Pinborg, Claus Svarer, Gitte Moos Knudsen, Birte Glenthøj

122. *First Results from an Antisaccade Task and Memory-guided Saccade Task in a Neurodevelopmental Approach to Schizophrenia*

Rémi Gadel, Cécilia Coen, Magali Seassau, Yannick Morvan, Raphael Gaillard, Emilie Magaud, Isabelle Amado, Marie-Odile Krebs

123. *Interneuron Development in Disc1 Mutant Mice*

Frankie H. F. Lee, Clement C. Zai, Sabine P. Cordes, John C. Roder, Albert H. C. Wong

124. *Effect of Omega 3 Supplementation in an Animal Model Schizophrenia Induced by Ketamine*

Isabelle M. Miranda, Lara Canever, Renata De Luca, Redro F. Deroza, Clarissa S. Gama, Alexandra I. Zugno

125. *Self-disorders and Sensory Integration Disturbances in Schizophrenia: Do They Connect? An Integrating Model of 'Self'-development, Sensory Integration and Schizophrenia*

Lot Postmes

126. *Serum Levels of Brain-Derived Neurotrophic Factor (BDNF) in Schizophrenic Women during Course of Treatment*

Maria Skibinska, Pawel Kapelski, Aleksandra Rajewska-Rager, Joanna Pawlak, Joanna Hauser

127. *Do Neurological Soft Signs in At-risk Mental State Individuals Predict Transition to First Episode Psychosis?*

Corinne Tamagni, Erich Studerus, Ute Gschwandtner, Anna Walter, Charlotte Rapp, Hilal Bugra, Anita Riecher-Rössler

128. *Modeling Brain Circuitry in Schizophrenia from Interneuron Development in Mice*

Ksenija Vucurovic, Tania Vitalis, Arthur Kaladjian



129. *The Characteristics of People at Ultra High-risk for Psychosis on the Personality, Temperament, and Relationship Style with the Effect of 6-month Pharmacotherapy*

Tae Young Lee, Geumsook Shim, Joon Hwan Jang, Sung Nyun Kim, Hye Youn Park, Min Soo Byun, Jung Hyun Yu, Jun Soo Kwon

130. OPEN BOARD

131. *Neuropathology of Vitamin D Receptor and Retinoid X Receptors in Schizophrenia*

Shan-Yuan Tsai, Duncan Sinclair, Cynthia S. Weickert

132. *Prediction of Transition to Psychosis using Neuropsychology, Symptomatology, Environmental Factors, Premorbid Adjustment and Neurophysiology*

Dorien H. Nieman, Sara Dragt, Mirjam J. van Tricht, Hiske E. Becker, Don H. Linszen, Lieuwe de Haan

133. *Decreased Attention to Informative Social Cues in Schizophrenia Patients*

Alexandra S. C. Nikolaidis, Julia Paruch, Susanne Miess, Joachim Klosterkoetter, Stephan Ruhrmann

134. *Gamma Oscillations in MEG-Data in Chronic Schizophrenia and During Ketamine Administration: Evidence for the Role of NMDA-Receptor Deficits in the Pathophysiology of Schizophrenia*

Davide Rivolta, Andreas Sauer, Michael Wibrall, Limin Sun, Wolf Singer, Peter J. Uhlhaas

135. *Elevated Low-frequency Power Across Sensory and Cognitive Conditions in Schizophrenia*

Elyse M. Sullivan, Ann Summerfelt, Patricio O'Donnell, Elliot Hong

136. *Facial Affect Recognition in Patients with Schizophrenia and a History of Violence*

Stephanie T. Harris, Clare Oakley, Avi Reichenberg, Declan Murphy, Simon Sugraddze, Marco Picchioni

137. *A Meta-Analysis of IQ Change in Schizophrenia and Healthy Individuals*

Anna M. Hedman, Neeltje E. M. van Haren, Caroline G. M. van Baal, René S. Kahn, Hilleke E. Hulshoff Pol

138. *Hemispheric Asymmetry in First-episode Psychosis and Schizotypy: What's Left for Cannabis?*

Daniela A. Herzig, Sarah Sullivan, Glyn Lewis, Rhiannon Corcoran, Richard Drake, Christine Mohr

139. *Sex Differences in Schizophrenia – Is there a Link to Brain Asymmetry?*

Marco Hirnstein, René Westerhausen, Kenneth Hugdahl

140. *Test-retest Reliability of the Danish Adaption of the National Adult Reading Test in Patients with Psychosis and Cannabis Use Disorder*

Carsten R. Hjorthøj, Lone Vesterager, Merete Nordentoft

141. *Schizotypy and Genetic Loading for Schizophrenia Impact upon Neuropsychological Status in Bipolar II and Unipolar Major Depressive Disorders*

Hiroaki Hori, Junko Matsuo, Toshiya Teraishi, Daimei Sasayama, Yumiko Kawamoto, Yukiko Kinoshita, Kotaro Hattori, Miyako Hashikura, Teruhiko Higuchi, Hiroshi Kunugi



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

142. *Auditory Attention Bias to Potential Threats, and its Relationship to Positive Symptoms in Schizophrenia*
Norichika Iwashiro, Noriaki Yahata, Tomoya Watanabe, Tsuyoshi Kawamura, Satoru Yuasa, Yu Kawamuro, Kiyoto Kasai, Hidenori Yamasue

143. *Neurocognitive Deficits in Chronic, Young Adult Early-Onset Schizophrenia Patients*
Jens Richardt M. Jepsen, Birgitte Fagerlund, Anne Katrine Pagsberg, Anne Marie R. Christensen, Merete Nordentoft, Erik L. Mortensen

144. *Systematizing Social Cognition: A Cognitive Neuropsychiatric Program of an Integrated Intervention Addressing Emotion Recognition and Social Interaction Using Interactive Multimedia, in Patients with Schizophrenia*
Jean-Pierre Lindenmayer, Susan R. McGurk, Anzalee Khan, Amod Thanju, Saurabh Kaushik, Lisa Hoffman, Gladys Valdez, Deborah Wance, Edith Herrmann

145. *Longitudinal Study of Cognition in Schizophrenia and Bipolar Disorder: A 5 Years Follow-up Study*
Eva M. Sánchez-Morla, Ana I. Aparicio, Román Solano-Ruipérez, M. Luz Alcalde, José Luis Santos

146. *Deficit and Non-deficit Schizophrenia: Longitudinal Course of Neurocognitive Impairment. A Prospective 5 Years Follow-up Study*
José Luis Santos, Ana I. Aparicio, Román Solano-Ruipérez, M. Luz Alcalde, Eva M. Sánchez-Morla

147. *Mechanisms of Functional Recovery in Cognitive Remediation Therapy for Schizophrenia Patients*
Stefanie J. Schmidt, Daniel R. Mueller, Volker Roder

148. *Facing the Inversion Effect: Do Schizotypal and Autistic Traits Contribute differently to the "Face(-like) Inversion Effect"?*
G. Sierro, Y. Schrag, C. Mohr

149. *Shared Impairment of Prospective Memory in Patients with Schizophrenia and Bipolar Disorder*
Simon S. Y. Lui, Raymond C. K. Chan, Ya Wang Wang, Amy C. Y. Liu, William W. H. Chui, Qi-yong Gong, David Shum, Eric F. C. Cheung

150. *Fragmented Perception: Slower Space-based but Faster Object-based Attention in First Psychosis*
Henderikus G. Smid

151. *Neurocognitive Profile in Individuals at Ultra-high Risk for Psychosis and with First-episode Psychosis: It's Relations with Intelligence*
Ja Y. Sun, Jin Y. Park, Kyung R. Kim, Eun Lee, Hyun S. Cho, Suk K. An

152. *Cognitive Functioning as an Intermediate Phenotype in a Finnish Isolate with High Lifetime Risk of Schizophrenia*
Minna Torniainen, Juho Wedenoja, Jaana Suvisaari, Annamari Tuulio-Henriksson

153. *Neurocognitive Profiling in a Large Cohort of First Episode Patients Suggests Three Specific Subgroups*
Frank D. van Es, H.G.O.M. Smid, Henrikus Knegtering, Edith Liemburg, Edwin R. van den Heuvel, Durk Wiersma, André Aleman, Richard Bruggeman



154. *The Central Role of Attention and Information Processing Deficits in the Profile of Cognitive Dysfunction in Schizophrenia*

Keith Wesnes, Chris Edgar, Lawrence Brownstein, Howard Hassman, Eden Evins

155. *Evaluation of a Rule Switching Test Designed to Assess Executive Control*

Keith Wesnes, Chris Edgar, Richard Wojciak, Alicia Craig-Rodriguez, Maria Pinho, David Kreftetz, Daniel Gruener, Lawrence Brownstein, Howard Hassman

156. *Action Fluency Impairment and Temporal Synchronization in Patients with Schizophrenia*

Helene Wilquin, Yvonne Delevoye-Turrell, Anne Giersch

157. *Spurious Signal Detection and Delusions of Reference in First-episode Schizophrenia*

Gloria H. Y. Wong, H. Tao, Z. He, W. C. Chang, Sherry W. K. Chan, Christy L. M. Hui, Z. Xue, Z. Liu, Eric Y. H. Chen

158. *Social Skills Training with Inpatients Using a Soap-Opera TV Show: A Brazilian Experience*

Juliana Emy Yokomizo, Graça Maria Ramos Oliveira, Paulo Clemente Sallet

159. *Initial Testing of a Novel Social Cognitive Treatment for Schizophrenia*

David L. Roberts, Petra Kleinlein, Jamie Stevens

160. *Silencing Dopamine D2 Receptors by Use of siRNA in the Nucleus Accumbens Shell Reduced Impairment of Prepulse Inhibition Induced by Apomorphine in Rat*

Mohammad-Reza Noori-Daloi, Ali Shahbazi, Siamak Alizadeh Zendehrood, Fatemeh Zare Mehrgerdi, Somayeh Niknazar, Mohammad Mostawfi, Hajar Hashemi Sotoobadi, Asghar Korzehbor, Majid Mojarad, Ali Rashidi Nejad

161. *Towards Recovery: Empowerment and Quality of Life in Chronic Psychiatric Inpatients*

A. P. M. Stiekema, L. van der Meer, P. J. Quee, F. Jörg, R. Bruggeman, H. Kneegting, A. M. Dethmers, C. M. Rietberg, A. Aleman, R. A. Schoevers

162. *Effect of Sports Participation on Brain Activations during Sports Observation in Schizophrenia*

Hidehiko Takahashi, Tetsuya Suhara, Yoshiro Okubo

163. *Neuroplasticity-Based Cognitive Training in Schizophrenia: A Final Report on the Effects 6-12 Months Later*

Melissa Fisher, Coleman Garrett, Phillip Alexander, Karuna Subramaniam, Sophia Vinogradov

164. *Working out First Episode Schizophrenia: Neuroanatomical, Cognitive and Clinical Changes following an Aerobic Exercise Intervention*

Philip B. Ward, Simon Rosenbaum, Pamela K. Ward, Lauren Taylor, Jim Lagopoulos, Andrew Watkins, Ben Barry, E. Gail Trapp, Jackie Curtis

165. *How do Clinical, Social and Role Functioning of At-Risk Mental States (ARMS) and First Episode of Psychosis (FEP) Patients Relate to their Relatives' Expressed Emotion (EE)?*

Cristina Medina-Pradas, Tecelli Domínguez-Martínez, Thomas R. Kwapi, Neus Barrantes-Vidal



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

166. *Comparison of Semantic Memory Function in Schizophrenia and Two Analogues: Schizotypy and Ketamine*

Erica Neill, Susan L. Rossell

167. *Difference in Sexual Dysfunction among Schizophrenic Male Patients on Comminuted Therapy*
Vladica Lj. Sibinovic, Violeta M. Slavkovic, Suzana M. Tomic-Golubovic, Goran R. Selimovic

168. *Additive Interaction between Lifetime Cannabis Use and Childhood Trauma in Increasing the Risk for Psychosis; A Replication Analysis on a Sample of First Episode of Psychosis Patients*

Lucia Sideli, Marta Di Forti, Daniele La Barbera, Caterina La Cascia, Alice Mulè, Robin M. Murray

169. *Retrieval-induced Forgetting in Schizophrenic Patients*

Fiorentina Sterkaj, Trudi Edginton, Kevin Morgan, David Groome

170. *Proline and Schizophrenia: A Population-based Study*

Jaana M. Suvisaari, Tuulia Hyötyläinen, Matej Oresic

171. *Is Aloud Allowed? Differentially Impaired Meaning Attribution in Schizophrenia*

Eric J. Tan, Susan L. Rossell, Gregory W. Yelland

172. *Effect of Cannabis Use on Age of Onset; Findings from a Sample of Italian First Episode Psychotic Patients*

Maria Valentina Rumeo, Lucia Sideli, Alice Mulè, Marta Di Forti, Daniele La Barbera, Robin M. Murray

173. *E-mental Healthcare Applications Supporting Self-management in People with a Psychotic Disorder: A Systematic Review of the Literature*

Lian van der Krieke, Ando C. Emerencia, Lex Wunderink, Durk Wiersma, Sjoerd Sytema

174. *The Influence of Top-down Processing in Auditory Verbal Hallucinations*

Sanne Verkooijen, Kirstin Daalman, Eske M. Derks, René Kahn, André Aleman, Iris E. Sommer

175. *The Impact of Speaking Out: The Voices of Schizophrenia*

Emily C. Walker

176. *NSA-16 Revisited: Identifying Latent Factors of Negative Symptoms in Schizophrenia*

D. Popp, J. B. W. Williams, E. A. Cohen, M. J. Detke

177. *The Use of the NSA-16 by Videoconferencing in a Clinical Trial*

J. B. W. Williams, D. Popp, D. A. Osman, E. A. Cohen, M. J. Detke

178. *The Association between Thought-language Disorder and Negative Symptoms in Schizophrenia*

Berna Yalınçetin, Levent Var, Banu Değirmencioğlu, Şilay Sevilmiş, Elif Yavaş, Halis Ulaş, Selma Polat, Berna Binnur Akdede, Köksal Alptekin

179. *Association between Duration of Untreated Psychosis and Short- and Long-term Outcome in Schizophrenia within the Northern Finland 1966 Birth Cohort*

Matti Penttillä, Jouko Miettunen, Hannu Koponen, Merja Kyllönen, Juha Veijola, Matti Isohanni, Erika Jääskeläinen



180. *Changes in Endocrine Profile after Six Months of Treatment in a Canadian First Episode Psychosis Program*

Sharman Robertson, Paul Roy, Angela Stevens, Sahba Sabet-Rasekh

181. *Predictors of Real-World Outcomes in Schizophrenia Patients, their Family Members and Control Subjects*

Katya Rubinstein, Abraham Reichenberg, Daniella Margalit, Michael Davidson, Mark Weiser

182. *Change in Delusional Dimensions, Reasoning Biases and Emotions in the First 8 Weeks of Antipsychotic Treatment*

Suzanne H. So, Philippa A. Garety, Emmanuelle R. Peters, Shitij Kapur

183. *Predictors of Disengagement from Treatment in an Early Psychosis Program*

Jacqueline Stowkowy, Donald Addington, Lu Liu, Brett Hollowell, Jean Addington

184. *Cannabis Use in Patients at Clinical High Risk of Psychosis: Impact on Prodromal Symptoms and Transition to Psychosis – A Systematic Review*

Floor J. van der Meer, Eva Velthorst, Carin J. Meijer, Marise W. Machielsen, Paolo Fusar-Poli, Lieuwe de Haan

185. *The Association between Thought-Language Disorder and Remission in Schizophrenia*

Levent Var, Berna Yalınçetin, Halis Ulaş, Selma Polat, Şilay Sevilmiş, Berna Binnur Akdede, Köksal Alptekin

186. *Involuntary Admission in FEP and Evolution after 8 Years of Follow-up*

Sara Barbeito, Sonia Ruiz de Azua, Patricia Vega, Itxaso González, Miguel Gutiérrez, Ana González Pinto

187. *The Evolution of Adherence in First-episode Psychotic Patients after 8 Years*

Patricia Vega, Sonia Ruiz de Azua, Amaia Ugarte, Miryam Fernandez, Itxaso González-Ortega, Santiago Ron, Purificación López, Ana González-Pinto

188. *Long-term Impact of a Discontinuation Trial: Remission and Recovery Rates at 7 Years Follow-up of a First Episode Cohort Included in a Treatment Strategy Trial Comparing Maintenance Treatment with Discontinuation Strategy*

Lex Wunderink, Roeline Nieboer, Fokko Nienhuis, Nynke Boonstra, Durk Wiersma

189. *Talking with a Psychiatric Patient: Theoretic and Pragmatic Aspects of the Psycho-diagnostic Interview*

Julie Nordgaard, Josef Parnas

190. *Auditory Verbal Hallucinations in Patients with Borderline Personality Disorder are Similar to those in Schizophrenia*

Christina W. Slotema, Kirstin Daalman, Jan Dirk Blom, Kelly M. Diederen, Hans W. Hoek, Iris E. Sommer

191. *Temperament and Character Dimensions in Ultra-high Risk for Psychosis and First-episode Schizophrenia*

Yun Young Song, Jee In Kang, Su Young Lee, Eun Lee, Suk Kyoan An, Jun Soo Kwon

192. *From Intrusions to Obsessions to Psychosis: Mediated by Delusions?*

Frank Van Dael, Jim van Os, Roselind Lieb, Hans-Ulrich Wittchen, Inez Myin-Germeys



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

193. *Verbal Information Disclosure/non-disclosure in Psychosis: A Preliminary Result*

Jia-Qi Xu, Christy Lai-Ming Hui, Gloria Hoi-Yan Wong, May Mei-Ling Lam, Eric Yu-Hai Chen

194. *Antipsychotic-mood Stabilizers Association has Limited Efficacy in Psychosis but is more Frequent in People Receiving High Doses of Antipsychotics: Results from a Real-world Naturalistic Study*

Felice Iasevoli, E. Di Giovambattista, M. Marconi, M. P. Rapagnani, F. Felicetti, M. Perongini, Alessandro Valchera

195. *QTc Interval Prolongation in a Naturalistic Sample of Patients Acutely Admitted to Hospital for Psychosis and Treated with Second Generation Antipsychotics*

Erik Johnsen, Kristina Aanesen, Sanjeevan Sriskandarajah, Rune A. Kroken, Else-Marie Løberg, Hugo A. Jørgensen

196. *High Dose D-serine in the Treatment of Schizophrenia*

Joshua T. Kantrowitz, Tamara Friedman, Erin Oakman, Nayla Scaramello, Desiree Gomez, Gail Silipo, Daniel C. Javitt

197. *Long-Term Treatment with Lurasidone in Schizophrenia: Results of an 8-week Double-blind Acute Study Followed by a 44-Week Open-Label Extension*

Masaki Kato, Masaaki Ogasa, Hiroki Ogo, Yoko Ishige, Hiroshi Sawabe, Cynthia Siu, Antony Loebel

198. *Differential Diagnosis and Treatment of Depressive Symptoms in Patients with Schizophrenia*

Alexandra Kaufmann, Nadja Frei, Falko Biedermann, W. Wolfgang Fleischhacker, Alex Hofer

199. *Clinical Trials of Potential Cognitive-Enhancing Drugs in Schizophrenia: What Have We Learned So Far?*

Richard S. E. Keefe, Robert W. Buchanan, Stephen R. Marder, Nina R. Schooler, Ashish Dugar, Milana Zivkov, Michelle Stewart

200. *Symptom Structures of Atypical Antipsychotics-Induced Obsessive Compulsive Symptoms in Schizophrenia Patients*

Joo Hyun Kim, Seunghyong Ryu, Hee Jung Nam, Meerae Lim, Ji Hyun Baek, Yeon Ho Joo, Jun Soo Kwon, Kyooseob Ha, Kyung Sue Hong

201. *The Effect of Paliperidone ER on Subjective Well-being and Attitudes Toward Medication among Patients with Schizophrenia*

Sung-Wan Kim, Jin-Sang Yoon, Il-Seon Shin, Jae-Min Kim, Kyung-Yeol Bae, Seok-Heon Kim, Ji-Eun Jang, Hee-Ju Kang, Yo-Han Lee, Yong-Min Ahn, Yong Sik Kim

202. *Antipsychotic Polypharmacy in Schizophrenic Inpatients at a University Psychiatric Hospital in Korea: A Comparison of 2005 and 2010*

Chan-Hyung Kim, Daeyoung Roh, Ghin-Goo Chang

203. *The Relationship between Antipsychotic D2 Occupancy and Change in Frontal Metabolic and Cognitive Function: ADual [11C]-raclopride and [18F]-FDG Study with Aripiprazole*

Euitae Kim, Oliver D. Howes, Jae Min Jeong, Federico E. Turkheimer, Shitij Kapur, Jun Soo Kwon



204. *Time to Discontinuation of Antipsychotic Drugs in a Schizophrenia Cohort: Influence of Current Treatment Strategies*

Rune A. Kroken, Eirik Kjelby, Tore Wentzel-Larsen, Liv S. Mellesdal, Hugo A. Jørgensen, Erik Johnsen

205. *Development of a Brief Questionnaire for (un)desired Effects of Antipsychotics*

Irene M. Lako, Edith J. Liemburg, Edwin R. van den Heuvel, Henrikus Knegtering, Cees J. Slooff, Durk Wiersma, Richard Bruggeman, Katja Taxis

206. *Antipsychotic-like Effects Independent of D2 Receptors Blockade: The Case of Alstonine*

Viviane M. Linck, Ana P. Herrmann, Marta C. Antonelli, Christopher O. Okunji, Elaine Elisabetsky

207. *A Double-Blind, Placebo Controlled Trial of Betahistine to Ameliorate Antipsychotic Associated Weight Gain in Adolescents and Young Adults: Preliminary Safety and Efficacy Data*

Allison S. Larr, Julia Vakhrusheva, Peter Marino, Lawrence Maayan

208. *Plasma Clozapine and Norclozapine in Relation to Prescribed Dose and Other Factors in Patients Aged 65 Years and Over: Data from a Therapeutic Drug Monitoring Service, 1996-2010*

James H. MacCabe, Sally Bowskill, Lewis Couchman, Robert J. Flanagan

209. *Effects of Dopamine D3 Receptor Stimulation on Reward Learning: Implications for Adjunct Treatment of Antipsychotic-induced Motivational Impairments*

Patrick N. McCormick, Paul Fletcher, Gary J. Remington

210. *Olanzapine Influences Insulin Signaling Pathway Independently by its Effects on Weight and Fat Deposition*

Valeria Mondelli, Christopher Anacker, Annamaria Cattaneo, Anthony Vernon, Sridhar Natesan, Mike Modo, Paola Dazzan, Shitij Kapur, Carmine M. Pariante

211. *Adjunctive Lisdexamfetamine Dimesylate Treatment of Predominant Negative Symptoms of Schizophrenia: Analysis by Atypical Antipsychotic Agent*

Henry A. Nasrallah, Robert Lasser, Bryan Dirks, Courtney Kirsch, Ben Adeyi, Brian Scheckner, Jean-Pierre Lindenmayer

212. *Risk of Relapse and Hospitalization in the 2-Year Open-Label Treatment of Outpatients with Schizophrenia Randomized to Olanzapine Long-Acting Injection or Oral Olanzapine*

Diego Novick, Haya Ascher-Svanum, Jordan Bertsch, Holland C. Detke, David McDonnell, Josep Maria Haro

213. *Efficacy of an NMDA Receptor Antagonist in the Treatment of Tardive Dyskinesia: A Randomized, Double-blind, Placebo-controlled Study*

Sofia Pappa, Sofia Tzouli, Venos Mavreas, Spyros Konitsiotis

214. *Risperidone and Total 9-hydroxyrisperidone in Relation to Prescribed Dose and Other Factors: Data from a UK Therapeutic Drug Monitoring Service, 2002-2010*

Maxine X. Patel, Sally J. V. Bowskill, Simon Handley, Danielle Fischer, Robert J. Flanagan

215. *A Systematic Review of the Evidence of Clozapine's Anti-aggressive Effects*

Catherine L. Frogley, David Taylor, Marco Picchioni



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

216. *A Retrospective Study of Clozapine in Emotionally Unstable Personality Disorder*

Catherine L. Frogley, Katina Anagnostakis, Shawn Mitchell, Fiona Mason, Marco M. Picchioni

217. *Predicting Dopamine D2 Receptor Occupancy following Antipsychotic Dose Reduction: A Pilot PET Study*

Hiroyuki Uchida, Robert R. Bies, Takefumi Suzuki, Ariel Graff-Guerrero, Bruce G. Pollock, Benoit H. Mulsant, David C. Mamo

218. *Dopamine D2 Receptor Occupancy and Cognition in Schizophrenia: Analysis of the CATIE Data*

Hiroyuki Uchida, Hitoshi Sakurai, Robert R. Bies, Scott Stroup, Richard S. E. Keefe, Takefumi Suzuki, Takashi Tsuboi, Masaru Mimura, Bruce G. Pollock, David C. Mamo

219. *A Post-hoc Analysis of the Negative Symptom Factor Score in a Proof-of-concept with a Glycine Reuptake Inhibitor (GRI) in Schizophrenia*

Daniel Umbricht, Ellen L. Lentz, Luca Santarelli, Justine Lalonde

220. *Intranasal Oxytocin Effects on Social Anxiety and Depression in Schizophrenia: Results from a Double Blind Placebo Controlled Trial*

Heidi J. Wehring, Mary R. Lee, Robert P. McMahon, Alan Bellack, Jared Linthicum, Stephanie Feldman, Gopal Vyas, Charles Richardson, Robert W. Buchanan, Carlo Contoreggi, Ann Marie Kearns, Deanna L. Kelly

221. *A Survey on Attitudes of Korean Psychiatrists toward Long-acting injectable Antipsychotics: An Interim Analysis*

Jin-Sang Yoon, Sung-Wan Kim, Kyung-Yeol Bae, Joon-An Yoo, Seon-Young Kim, Ji-Eun Jang, Seok-Heon Kim, Yo-Han Lee

222. *Delayed 'eureka' of Alpha 7 Nicotinic Acetylcholine Receptor Knockout Mice in a Probabilistic Reversal Learning Paradigm*

Jared W. Young, Mary E. Kamenski, Mark A. Geyer

223. *Gender Differences and Effects of Acute and Chronic Oxytocin on Social Interaction in Mice*

Xiaofan Zhang, Qi Li, Sylvia Lam, Siew Chua, Grainne McAlonan

224. *Multi-centered Research of the Effectiveness of Combined Therapies for People with Schizophrenia- A Comprehensive Psycho-educational Approach and Scheme Set (COMPASS) while using Risperidone Long-acting Injection Therapy*

Yueren Zhao, Nakao Iwata

225. *Specific Executive Dysfunctions as Possible Predictors of Community Functioning*

Kaidi Kiis

226. *The Eyes Have It: Evidence of Heightened Sensitivity to Other People's Eye-gaze in Schizophrenia*

Robyn A. Langdon, Philip B. Ward

227. *Increased Social Withdrawal and Isolation in the Context of Intact Hedonic Capacity in People at Ultra-high Risk for Psychosis: An Experience Sampling Study*

Tineke Lataster, Judith Drees, Margreet Oorschot, Michael Wagner, Inez Myin-Germeys



228. *Personality Characteristics and its Relations with Anhedonia and Global Functioning in Individuals at Ultra-High Risk for Psychosis and Patients with First-Episode Schizophrenia*

Mikyung Lee, Ki Pyoung Kim, Suk K. An

229. *The Association between Working Alliance, Compliance, Self-efficacy, and Social Function in a Cohort of 397 Patients with First-episode Psychosis*

Marianne Melau, Susanne Harder, Pia Jeppesen, Anne Thorup, Merete Nordentoft

230. *Persons with Schizophrenia and Four Types of Family Involvement*

Carpentier Normand

231. *Evaluating Readiness for Work in Patients with Schizophrenia: "the Readiness for Work Questionnaire" WoRQ*

Steven G. Potkin, Dragana Burgarski-Kirola, George Garibaldi

232. *Psychosocial Unmet Needs and Social Functioning: It's Relationship in Persons with Severe Mental Health Disorders*

Gemma Prat, Pere Bonet, Myriam Valencia

233. *Empathy Deficits are Uniquely Associated with Poor Functioning in Schizophrenia*

Matthew J. Smith, William P. Horan, Tatiana Karpouzian, Samantha Abram, Derin Cobia, John G. Csernansky

234. *The Impact of Trauma in Childhood and Adulthood on Clinical and Social Functioning in First Episode Psychosis*

Helen J. Stain, Inge Joa, Tor K. Larsen, Jan Olav Johannessen, Wenche ten Velden Hegelstad, Johannes Langeveld

235. *The Social Consequences for Adults Experiencing Psychosis: Findings from the Second Australian National Survey of Psychosis*

Helen J. Stain, Cherrie Galletly, Scott Clark, Jacqui Wilson, Emily Killen, Lauren Anthes, Linda Campbell, Mary-Claire Hanlon, Carol Harvey

236. *Longitudinal Changes of Psychopathological Symptoms in At-risk Mental State (ARMS) Individuals without Transition to Psychosis*

Erich Studerus, Charlotte Rapp, Jacqueline Aston, Anita Riecher-Rössler

237. *Effect of Supported Employment/Education on Symptom Changes in Young Adults with a First Episode Psychosis*

Manuel Tettamanti, Maryse Badan Bâ, Eric Zbinden, Philippe Rey-Bellet, Marco C. G. Merlo

238. *Facial and Prosodic Emotion Recognition Deficits Predict Specific Dimension of Psychotic Symptoms in Schizophrenia*

Huai-Hsuan Tseng, Yu-Lien Huang, Sue-Huei Chen, Chih-Min Liu, Ming H. Hsieh, Chen-Chung Liu, Jia-Chi Shan, Yi-Ting Lin, Hai-Gwo Hwu

239. *The Effect of Cognitive Remediation Combined with a Comprehensive Psychosocial Programme for Patients with First Episode Schizophrenia: Results of the NEUROCOM Trial*

Lone Vesterager, Torben Christensen, Birthe Olsen, Marianne Melau, Gertrud Krarup, Merete Nordentoft



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

240. *Quality of Life as an Outcome of Psychosis: Implications for Recovery*

Sue M. Cotton, John F. Gleeson, Mario Alvarez-Jimenez, Lisa Henry, Meredith Harris, Simone Farrelly, Susy Harrigan, Patrick McGorry

241. *Obsessive Compulsive Symptoms but not Obsessive Compulsive Disorder are Related to Lower Quality of Life in Schizophrenia*

Alp Uçok, Aysu Tihan, Rasit Tukul

242. *Movement Disorders in the Severely Mentally Ill*

Diederik Tenback, Peter van Harten

243. *Experienced and Anticipated Discrimination in First-episode Psychotic Patients: Pattern, Severity and Relationship with Clinical and Social Factors; Findings from the PICOS Project*

Silvia Zoppi, Antonio Lasalvia, Chiara Bonetto, Doriana Cristofalo, Sarah Tosato, Mariaelena Bertani, Sarah Bissoli, Lorenza Lazzarotto, Gioia Zanatta, Katia De Santi, Enrico Ceccato, Rossana Riolo, Vanna Marangon, Stylianos Nicolau, Ileana Boggian, Mirella Ruggeri

244. *Crucial Elements in Treatment of First-episode Psychosis Patient, Psychosocial Aspects*

Merete Nordentoft, Stephen Austin, Pia Jeppesen, Marianne Melau, Anne Thorup

245. *Prevalence of High Dose Antipsychotic Medication Prescription on Discharge: A Clinical Audit*

Eirini Theochari, Kevin Pankhurst

246. *Long- and Short-term Inpatients with Schizophrenia in China: Implications for Community-Based Service Development*

Guowei Wu, Xuan Ouyang, Bo Yang, Li Li, Zheng Wang, Wenying Yi, Chang Liu, Peng Wang, Zhimin Xue, Robert Rosenheck, Zhening Liu

247. *Longitudinal Medication Adherence Instability and the Risk of Psychiatric Admission in Veterans with Schizophrenia*

John E. Zeber, Eileen M. Stock, Mary Jo V. Pugh, Jack Y. Tsan, Jacqueline A. Pugh, Sandra B. Morissette, Laurel A. Copeland

248. *Evaluating Patient Preferences for Early Intervention Services Using Discrete Choice Conjoint Analysis*

Robert B. Zipursky, Charles E. Cunningham, Peter Bieling, Yvonne Chen, Ivana Furimsky, Lisa Jeffs, Victoria Madsen, Heather Rimas, Fiona Wilson, Bruce Christensen

249. *Cognitive Performance in Cannabis-using Adolescents with a First Episode of Psychosis*

Teresa Sánchez-Gutiérrez, Marta Rapado-Castro, Ana Calvo, Guadalupe Chiclana, Celso Arango

250. *A Multi-centre, Randomised Controlled Trial of a Group Psychological Intervention for Psychosis with Comorbid Cannabis Dependence over the Early Course of Illness*

Kevin Madigan, Elizabeth Lawlor, Daria Brennan, Niall Turner, Anthony Kinsella, John O'Connor, Vincent Russell, John Waddington, Eadbhard O'Callaghan

251. *Substance Use Disorders and Conduct Disorder among Violent Patients with Schizophrenia*

Clare Oakley, Stephanie Harris, Tom Fahy, Declan Murphy, Marco Picchioni

252. *Effect of Cannabis Use on the Course of Schizophrenia in Male Patients: A Prospective Cohort Study*

Daniel van Dijk, Maarten W. J. Koeter, Ronald Hijman, René S. Kahn, Wim van den Brink

253. *Longitudinal Substance Use Trajectories for Persons with Schizophrenia*

Richard A. Van Dorn, Sarah L. Desmarais, M. Scott Young, Beom Lee, Marvin S. Swartz



254. *Sex Differences in Basal and Longitudinal Brain Changes in Early Onset Psychosis*
Marta Rapado-Castro, Santiago Reig, Mara Parellada, Josefina Castro-Fornielles, Ana González-Pinto, Soraya Otero, Inmaculada Baeza, Joost Janssen, Montserrat Graell, Dolores Moreno, Manuel Desco, Celso Arango
255. *Longitudinal Study of Neurological Soft Signs in First Episode Early Onset Psychosis*
María Mayoral, Igor Bombin, Pablo Lobato, Josefina Castro-Fornieles, Ana González-Pinto, Soraya Otero, Mara Parellada, Dolores Moreno, Inmaculada Baeza, Montserrat Graell, Marta Rapado, Celso Arango
256. *Social Cognitive Biases as Moderators and Mediators of Successful Cognitive – Behavioral Therapy in Schizophrenia - Results of the Positive Study*
Stephanie Mehl, Martin W. Landsberg, Anna Schmidt, Andreas Wittorf, Stefan Klingberg, Michael Wagner
257. *Confirmation and Validation of Apolipoprotein H as Novel Biomarker for Schizophrenia*
Tze Jen Chow, Han Chern Loh
258. *A Haplotype Implication Confirms Association Study of AKT1 Genes with Schizophrenia in Malaysian Population*
Han Chern Loh, Tze Jen Chow, Shiau Foon Tee
259. *Gender Differences in the Deficit of Insight in Psychotic Patients*
J. Cobo, L. Nieto, S. Ochoa, J. Usall, I. Baños, B. Gonzalez, I. Ruiz, J. E. Obiols, E. Pousa, A. I. Ruiz
260. *Reduced Reward-Related Probability Learning in Schizophrenia Patients*
Fatma Simsek, Alpaslan Yilmaz, Nazlı B. Ozelik, Ali S. Gonul
261. *Impact of Improving Negative Symptoms on Functioning in Patients with Schizophrenia: A Post-hoc Analysis of a Proof-of-concept Study*
Thomas Blaettler
262. *Specific Default Network Activity and Connectivity Patterns in Adolescent and Young Adult Relatives of Individuals with Bipolar Psychotic Disorder or Schizophrenia*
Heidi W. Thermenos, Susan Whitfield-Gabrieli, Richard Juelich, Nikos M. Makris, Stephen V. Faraone, Ming T. Tsuang, John D. E. Gabrieli, Larry J. Seidman
263. *Homer Expression Modulation by Antipsychotics, Alone or in Combination with Antidepressants: Role of D2-R and Serotonin Occupancy*
Carmine Tomasetti, Felicelasevoli, Federica Marmo, Andrea de Bartolomeis
264. *Default Node network in Young People with Familial Risk for Psychosis*
Tuomas Jukuri, Vesa Kiviniemi, Juha Nikkinen, Jouko Miettunen, Pirjo Mäki, Erika Jääskeläinen, Sari Mikkala, Jenni Koivukangas, Anja Taanila, Irma Moilanen, Markus Heinimaa, Jennifer H. Barnett, Peter B. Jones, Graham K. Murray, Juha Veijola
265. *Computational Approach to Understanding Cortical Circuit Deficits of Schizophrenia*
Peter J. Siekmeier, Tsung-Ung W. Woo
266. *Preliminary 6-month Outcome of a Randomized Controlled Trial of Specialized Early Intervention Treatment in Adult onset First-episode Psychosis (JCEP)*
Eric Y. H. Chen, Christy L. M. Hui, Sherry, K. W. Chan, W. C. Chang, Frendi, W. S. Li, K. F. Leung, S. M. McGhee, P. C. Sham
267. *Evidence that the Combination of Hallucinatory Experiences and Delusional Ideation is a Crucial Indicator of the Early Transition from Vulnerability to Clinical Psychosis*
Feikje Smeets, Tineke Lataster, Maria-De Gracia Dominguez, Ruud van Winkel, Juliëtte Hommes, Roselind Lieb, Hanss-Ullrich Wittchen, Ron de Graaf, Margreet ten Have, Jim van Os
268. *Do Time Perception Networks Mediate Cognitive Dysfunctions in Schizophrenia?*
Felipe Ortuño, José A. Gómez, Francisco Guillen-Grima



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

Index of Presenters and Authors

- Aanesen, K. 120, 126
Aaron, R. 66, 126
Aarts, H. 95, 126
Aas, M. 47, 126, 127
Abayomi, O. 80, 126
Abazyan, B. 4, 60, 126
Abazyan, S. 60, 126
Abbs, B. 4, 63, 126
Abel, K. 91, 126, 127
Abeling, N. 61, 126
Abhishekh, H. 66, 126
Abi-Dargham, A. 24, 126, 127
Abilio, V. ERRORE? (v. Abilio)
Abilio, V. 83, 99, 105, 126
Aboutaleb, N. 78, 126
Abram, S. 123, 126
Achalia, R. 4, 60, 126
Achim, A. 78, 95, 126, 127
Acovski, V. 79, 126
Addington, D. 119, 126
Addington, J. 3, 4, 13, 29, 36, 44, 73, 80, 94, 96, 119, 126, 127
Adelufosi, A. 4, 80, 126
Adeyi, B. 121, 126
Adham, N. 126
Adres, M. 73, 87, 126, 127
Agartz, I. 126, 127
Aggernæs, B. 85, 126, 127
Agid, O. 46, 76, 77, 126, 127
Agrawal, A. 74
Aguglia, E. 114
Aguilar, E. 74, 126, 127
Aguilera, M. 60, 112, 126, 127
Aguirre, C. 91
Ahmad, S. 80
Ahmed, M. 63, 102, 126, 127
Ahn, Y. 120
Ainsworth, J. 88
Aitchison, K. 113, 126, 127
Akdede Kivircik, B. 77
Akdede, B. 77, 93, 118, 119
Akhtar, S. 78
Akib, T. 111
Aktener, A. 4, 77, 93
Alaräsänen, A. 97, 111
Alary, M. 83
Alba-Ferrara, L. 94
Alberati, D. 51, 77
Alberich, S. 73
Alcalde, M. 116
Aleman, A. 62, 74, 84, 103, 106, 108, 110, 116, 117, 118, 126, 127
Alemay, S. 60, 73, 83, 126, 127
Alexander, P. 117
Ali, M. 74
Alizadeh Zendeirood, S. 117
Allain, P. 94
Allegri, F. 30
Allen, P. 62, 63, 103, 108, 126, 127
Allott, K. 40, 78, 79
Almeida, V. 83
Aloj, L. 69
Alonso, C. 71
Alonso-Fernandez, A. 75
Alonso-Solís, A. 105
Alphs, L. 75, 97, 99
Alptekin, K. 4, 75, 77, 93, 118, 119, 126, 127
Altmann, D. 86, 126, 127
Al-Uzri, M. 79
Alvarez Sanchez, R. 77
Alvarez, E. 105, 126, 127
Álvarez, M. 102, 126, 127
Alvarez, P. 101
Alvarez, S. 101
Alvarez-Jimenez, M. 124, 126, 127
Amado, I. 81, 94, 114, 126, 127
Amano, N. 92
Amato, D. 126, 127
Ameller, A. 65
Ammari, N. 65
Amminger, G. 28, 67
Amminger, P. 126, 127
Amzand, S. 65
An, H. 113
An, S. 71, 85, 102, 116, 119, 123
Anacker, C. 121
Anagnostakis, K. 122
Anand, E. 75, 99
Andreas, V. 71
Andreasen, N. 50, 126, 127
Andreassen, O. 126, 127
Andreopoulou, A. 94
Andrés-Perpiñá, S. 65
Annable, L. 100
Anney, R. 113
Anthes, L. 123
Antonelli, M. 121
Antoni, F. 110
Antonio, C. 60
Antonucci, L. 84, 126, 127
Anusha, M. 66
Aoki, S. 107
Aparicio, A. 116, 126, 127
Apter, A. 73, 87, 126, 127
Arai, M. 92
Araki, T. 85
Arango, M.D., Ph.D., C. 3, 4, 36, 63, 65, 87, 99, 124, 125, 126, 127
Arango-Lopez, C. 112
Arenas-Fernandez, R. 75
Arendt, M. 103, 127
Arenovich, T. 83, 101, 127
Arias, B. 60, 91, 99, 127
Armando, M. 41, 57, 127
Arnt, J. 100, 127
Arroyo, S. 100
Arrufat, F. 103
Asabella, A. 63
Ascher-Svanum, H. 77, 78, 92, 98, 121, 127
Ash, D. 80, 127
Askenazy, F. 95
Asmal, L. 76
Aston, J. 63, 64, 123
Atakan, Z. 127
Athanasos, P. 103
Atkinson, R. 86, 127
Attard, A. 52
Attotto, M. 72, 91, 127
Aukes, M. 68, 70, 127
Austin, S. 124
Auther, A. 71, 127
AuYang, C. 80
Averbeck, B. 56
Avvisati, L. 69
Ayan-Oshodi, M. 78
Azcárraga, M. 85
Azorin, J. 75
Baaré, W. 81, 85, 127
Bachmann, S. 63, 127
Backasch, B. 84
Backes, H. 64, 84, 86, 106
Bacon, E. 94, 127
Badan Bâ, M. 81, 123
Bader, V. 45
Badowska, D. 60, 61
Bae, K. 120, 122, 127
Baek, J. 120
Baeza, I. 63, 65, 125, 127
Bahn, S. 49, 61
Bailey, M. 113
Bais, L. 84, 127
Baitz, H. 72
Bak, M. 102
Bak, N. 127
Baker C. 127
Baker, A. 79, 127
Baker, R. 74
Baker, S. 66
Bakker, B. 82
Bakker, R. 82 (Bakker P.R. 127)
Bakker, S. 127
Baklouti, N. 84
Balain, V. 113
Baldwin, P. 88
Ballard, T. 77, 104, 127
Ballespi, S. 60, 82
Banders, A. 103
Banerjee, A. 100, 127
Banken, L. 101
Baños, I. 76, 95
Bansal, R. 86, 127
Banzato, C. 65, 66
Bär, K. 71, 84, 127
Barajas, A. 95
Barbato, M. 94, 96
Barbeito, S. 73, 92, 119
Barbour, J. 101
Bargalló, N. 83
Barker, G. 63, 86, 127
Barker, P. 107
Barnes, A. 107, 127
Barnes, T. 86, 99, 128
Barnett, J. 93, 95, 111, 128
Barr, A. 52, 72, 128
Barrantes-Vidal, N. 60, 82, 98, 112, 117, 128



- | | | | |
|--|---|--|---|
| Barron, D. 79 | Bertsch, J. 77, 121 | Boks, M. 65, 67, 68, 70, 128 | Bridge, J. 96 |
| Barros, B. 65, 66 | Besga, A. 73 | Boksa, P. 83 | Brnabic, A. 78, 128 |
| Barrowclough, C. 88 | Beswick, R. 80 | Bolden, K. 63, 108 | Broadbent, M. 111 |
| Barry, B. 117 | Beszlej, A. 69 | Bombin, I. 65, 125, 128 | Broberg, B. 60, 128 |
| Bartels-Velthuis, A. 65, 96, 128 | Beveridge, N. 4, 70, 91, 128 | Bonaccorso, S. 75 | Brockhaus-Dumke, A. 66, 129 |
| Bartholomeusz, C. 79, 128 | Bhakta, S. 4, 68 | Bonaguro, E. 82 | Broome, M. 62, 129 |
| Bartrés-Faz, D. 65 | Bhatia, T. 68, 74, 112 | Bonet, P. 123 | Brouwer, R. 129 |
| Batassini, C. 60 | Bhattacharyya, S. 32, 45, 128 | Bonetto, C. 93, 95, 124 | Brown, A. 11, 25, 43 |
| Batty, R. 66, 94, 128 | Bhor, M. 70 | Boniatsi, L. 94 | Brown, E. 79, 108 |
| Baumgartner, S. 79, 103, 128 | Biedermann, F. 79, 120, 128 | Booij, J. 128 | Brown, G. 63 |
| Beards, S. 68, 89 | Biedinger, U. 101 | Booij, L. 106 | Brown, V. 72, 85 |
| Beauclair, L. 100 | Bieling, P. 124 | Boomsma, D. 128 | Browne, D. 88 |
| Beaucousin, V. 71, 128 | Bies, R. 122 | Boonstra, N. 66, 119, 128 | Brownstein, L. 117 |
| Beaudet, N. 82 | Bilenberg, N. 87, 89 | Boos, H. 86, 128 | Brüne, M. 79, 129 |
| Beauvillain, C. 94 | Bilkey, D. 60, 128 | Boot, E. 90, 128 | Bruggeman, R. 84, 116, 117, 121, 129 |
| Bebensee, A. 105 | Binder, F. 84 | Bor, W. 23 | Bruns, A. 84 |
| Bechdorf, A. 27, 28, 40, 41, 96, 109, 128 | Biondi, M. 108 | Bora, E. 4, 23, 71 | Bryant, E. 79 |
| Beck, A. 62, 85, 128 | BIOQUE, M. 70, 113 | Borges, S. 67, 89, 90, 111, 112 | Brzozka, M. 60 |
| Becker, H. 98, 110, 115, 128 | Bioque, M. 70, 113 | Borgwardt, S. 28, 37, 63, 64, 108, 128 | Brzózka, M. 61 |
| Bedoya, E. 60, 98 | Birchwood, M. 57, 74, 88, 98, 109, 110, 128 | Borroni, E. 84, 92, 128 | Buchanan, R. 120, 122, 129 |
| Begemann, M. 99, 128 | Bissoli, S. 124 | Borsoi, M. 60 | Buckley, P. 49, 129 |
| Bélanger, M. 99 | Bitner, H. 66 | Bose, A. 11, 55 | Budd, T. 104 |
| Belangero, S. 92, 105 | Bitter, I. 68 | Bossie, C. 75, 96 | Bueno, B. 70 |
| Bell, M. 37, 46, 79, 128 | Bitterman, J. 63 | Bossong, M. 113 | Bugarski-Kirola, D. 96 |
| Bellack, A. 122, 128 | Bittner, R. 84, 128 | Bostoën, T. 96 | Bugra, H. 63, 64, 114 |
| Bellani, M. 108, 128 | Bjelker, B. 60 | Bourdeau, G. 79 | Bulbena, A. 75 |
| Bellantuono, C. 84 | Blackman, R. 4, 60 | Bourque, F. 67, 68, 111 | Bullmore, E. 35, 129 |
| Belles, M. 83 | Blaettler, T. 125 | Boutouyrie-Dumont, B. 77, 100 | Bun, C. 65 |
| Belleville, K. 82 | Blanch, J. 91 | Bowie, C. 100, 128 | Burdick, M. 69 |
| Bellucco, F. 92 | Bland, A. 66 | Bowskill, S. 65, 82, 121 | Burgarski-Kirola, D. 123 |
| Bendall, S. 103 | Blasi, G. 62, 63, 72, 84, 85, 91, 128 | Boyda, H. 128 | Burne, T. 71, 129 |
| Ben-David, S. 89 | Blessing, E. 70 | Boydell, J. 67, 111, 128 | Burns, T. 95 |
| Bendfeldt, K. 64 | Blessing, W. 70 | Boyer, S. 99 | Burshtein, S. 98 |
| Benfenati, F. 105 | Blijd-Hoogewys, E. 65 | Boyette, L. 76 | Busatto, G. 3, 4, 85 |
| Bengoetxea, E. 98 | Bloemen, O. 91 | Boyle, R. 63 | Bushe, C. 75 |
| Benkovits, J. 68 | Blom, J. 106, 119, 128 | Bradshaw, N. 47 | Buzzanca, A. 108 |
| Benning, S. 66 | Blomström, Å. 47 | Braff, D. 3, 110, 128 | Byerley, W. 10, 34 |
| Benros, M. 90 | Bloomfield, M. 84 | Braga, A. 60 | Byun, M. 4, 85, 115 |
| Benson, T. 66, 76, 94 | Blouin, G. 95 | Brain Bank, N. 68 | Cabanis, M. 4, 61, 95 |
| Berge, D. 75, 128 | Bo, Y. 124 | Bralet, M. 74, 128 | Cabrera, B. 70, 113 |
| Berger, G. 128 | Bobes, J. 112 | Brambilla, C. 78, 128 | Cacciani, P. |
| Berger, S. 71, 128 | Bobok, A. 83 | Brambilla, P. 108, 128 | Cachia, A. 92, 102 |
| Berk, M. 66, 128 | Bocxe, J. 78 | Brammer, M. 23, 62, 128 | Cadena, A. 85 |
| Berliner, J. 68 | Bodatsch, M. 66, 88, 109, 128 | Bramon, E. 62, 111, 128 | Cadenhead, K. 63, 108, 129 |
| Bernardo, M. 70, 92, 99, 112, 113, 128 | Boellaard, R. 113 | Brazo, P. 71, 128 | Caforio, G. 62, 63, 72, 83, 84, 90, 129 |
| Bernardo, M. 70, 92, 99, 112, 113, 128 | Boetsch, C. 77, 101 | Breetvelt, E. 68, 128 | Cagney, G. 71, 75, 92 |
| Bertani, M. 124 | Bogers, J. 65, 82, 96, 128 | Brekke, J. 100 | Cahn, W. 61, 67, 86, 108, 113, 129 |
| Bertolino, A. 4, 12, 19, 24, 62, 63, 72, 84, 85, 91, 128 | Boggian, I. 124, 128 | Brenlla Gonzalez, J. 72 | Cairney, I. 102 |
| | Bohbot, V. 73 | Brennan, D. 124 | Cairns, M. 49, 90, 91, 129 |
| | Boivin, M. 75 | Bressan, R. 81, 91, 98, 105 | |
| | | Brett, R. 105, 119, 128 | |



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

- Calabrese, F. 103
Callicott, J. 69, 129
Calvo, M.Sc., A. 124
Calzavara, M. 83, 98, 105
Camerini, B. 98, 105
Campanera, S. 112, 129
Campbell, L. 123
Campbell, P. 9, 21
Cañas, F. 75
Canever, L. 114
Canneva, F. 81
Cannon, D. 63, 101, 129
Cannon, M. 3, 4, 39, 58, 82, 86, 129
Cannon, T. 36, 81, 129
Cantero, M. 102, 104
Cantor, R. 70, 129
Cappe, C. 71
Caramia, F. 108
Carceller, H. 83
Cardarelli, R. 66
Carletti, F. 85, 129
Carlsen, T. 87
Carlson, J. 94
Carr, V. 31, 64, 76, 80, 90, 91, 96, 104, 129
Carrion, R. 4, 71
Carrol, L. 113
Carson, W. 74
Carter, C. 129
Casado, P. 110
Casas-Anguera, E. 79
Cascella, N. 25, 40
Casillas, M. 75, 98
Castelein, S. 110, 129
Castellani, C. 4, 47
Castellanos, F. 105
Castelnovo, A. 74, 77, 88, 96
Castle, D. 3, 79, 98, 110
Castro, M. 84, 105
Castro-Fornieles, J. 65, 125
Catalan, R. 98, 129
Catalán, R. 98, 129
Catalano, L. 109
Cather, C. 63
Catinaud, D. 74
Cattaneo, A. 121
Catts, S. 80, 96, 129
Catts, V. 45
Ceccarini, J. 106, 129
Ceccato, E. 124
Cella, M. 72
Cepeda, C. 101
Cervilla, J. 112
Ceylan, D. 77
Chaddock, C. 37, 45, 62, 129
Chafee, M. 60
Chakirova, G. 72, 85
Champagne-Lavau, M. 79, 94
Chan, C.
Chan, E. 98
Chan, G. 80
Chan, K. 76
Chan, R. 72, 116, 129
Chan, S. 76, 83, 117, 129 CI
Chanen, A. 66
Chang, G. 120
Chang, J. 93, 95,
Chang, R. 108
Chang, V. 113
Chang, W. 76, 80, 117, 129
Chao, Y. 61
Charalambides, M. 89, 90, 129
Charest, A. 94
Chatterjee, A. 107
Chaturvedi, S. 60
Chaves, C. 104
Chen, C. 61, 69, 80, 129
Chen, E. 3, 4, 76, 80, 117, 120, 129
Chen, H. 61, 83
Chen, S. 123
Chen, Y. 80, 124
Cheng, M. 69
Cherubin, P. 95
Cheung, C. 108, 129
Cheung, E. 72, 116
Chia, T. 90, 91
Chia-Hsiang, C. 61, 69, 113
Chiara, B. 93, 95, 124
Chiclana, M.Sc., G. 124
Chiliza, B. 76, 129
Chintoh, A. 83, 99
Chiu, C. 129
Cho, H. 116, 129
Choi, C. 85, 129
Choi, J. 85, 113, 129
Chong Guan, N. 67
Chong, S. 3, 4, 110
Choo, K. 78
Chow, T. 4, 125
Christensen, A. 116
Christensen, B. 73, 124
Christensen, T. 101, 124, 129
Christofolini, D. 91
Chu, E. 86, 129
Chua, S. 74, 83, 106, 108, 122, 129
Chuang, Y. 69
Chui, W. 116
Chun, J. 85, 106, 129
Chung, C. 85
Chung, Y. 74
Cichon, S. 129
Cipriano, A. 105
Ciudad, A. 98, 129
Ciufolini, S. 100, 106, 114
Claes, S. 68, 129
Clark, C. 80
Clark, J. 101
Clark, S. 123
Clark, V. 79
Clarke, G. 61
Clarke, L. 99
Clarke, M. 82, 89, 129
Clarke, N. 61
Clasen, L. 129
Clelland, C. 70
Clelland, J. 70
Clemmensen, L. 67, 87, 109
Clow, A. 79
Coatsworth-Puspoky, R. 101
Cobia, D. 123
Cobo, J. 76, 125, 129
Coen, C. 114
Cohen, B. 101
Cohen, D. 67, 78, 82, 89, 129
Cohen, E. 118
Cohen, M. 129
Cohn, T. 99
Colagiorgio, L. 72, 90
Colibazzi, T. 85
Colijn, M. 93
Colizzi, M. 84, 90, 129
Collier, D. 130
Collin, G. 61, 86
Collinson, S. 71, 73
Collip, D. 106, 130
Coltheart, M. 130
Conley, R. 11, 55, 130
Conrad, A. 76
Consortium, I. 69, 113
Contoreggi, C. 122
Conus, P. 66, 130
Cooper, G. 105
Copeland, L. 66, 80, 124
Corbera, S. 79
Corbière, M. 100, 130
Corcoran, C. 88, 130
Corcoran, R. 115
Cordeiro, S. 62
Cordes, S. 114
Córdova, A. 73
Cornblatt, B. 36, 71, 130
Coromina, M. 94
Correll, C. 36, 52, 68, 77, 87, 99, 130
Corripio, I. 97, 98, 105
Cortese, L. 80
Cortizo, R. 75
Corvin, A. 38, 91, 130
Costafreda, S. 108
Costanzo, E. 84, 105, 130
Costas, J. 112
Côte, A. 65
Cotel, M. 61
Cotter, D. 4, 28, 71, 75, 92, 130
Cotton, S. 66, 95, 124, 130
Couchman, L. 65, 82, 121
Coughlin, J. 39
Couture, S. 78
Craig, T. 111, 130
Craig-Rodriguez, A. 117
Crepon, B. 81
Crews, M. 75
Crichton, J. 80
Crippa, J. 32, 85, 130
Crisp, K. 95
Cristofalo, D. 95, 124
Critchley, H. 64
Croft, R. 64
Crossley, N. 71
Croudace, T. 103
Crow, T. 7, 71, 90, 130
Cryan, J. 61
Csernansky, J. 123
Cucchiari, J. 98, 102, 130
Cuesta, M. 91, 130
Culej, J. 112
Cumming, A. 73
Cunha, P. 85
Cunningham, C. 124
Cunningham, M. 110
Curatolo, E. 108
Curcic, B. 84, 130
Curran, H. 84
Curtis, J. 86, 117
Czaja, S. 81, 94



- Czerski, P. 70, 112
Czobor, P. 68
D'agostino, A. 96
D'Ambrosio, E. 72, 84
D'Imperio, M. 79
D'Souza, D. 4, 35, 131
da Silva Alves, F. 61
da Silva, N. 83
Daalman, K. 57, 76, 118, 119, 130
DaChun, C. 62
Dai, N. 69
Dale, M. 79, 130
Dalman, C. 3, 4, 67, 81, 89, 130
Danaci, A. 79
Daniel, D. 75, 130
Dantas, C. 65, 66
Dark, F. 40
Dashti, S. 78
Dauvermann, M. 61
Dauwan, M. 70
David, A. 58, 62, 67, 100, 109, 130
Davidson, M. 3, 27, 71, 119, 130
Davies, L. 74
Davis, J. 98
Dawson, N. 61, 130
Dazzan, P. 4, 13, 39, 45, 67, 81, 82, 89, 90, 100, 106, 109, 111, 112, 114, 121, 130
de Achával, D. 84, 105, 127, 130
de Bartolomeis, A. 69, 82, 125
de Castro-Manglano, P. 105
de Crespigny, C. 102
De Fazio, P. 80
de Graaf, R. 102, 125, 130
De Haan, L. 61, 66, 76, 87, 90, 95, 97, 101, 104, 107, 109, 110, 115, 119, 130
de Haan, L. 61, 66, 76, 87, 90, 95, 97, 101, 104, 107, 109, 115, 119, 130
De Hert, M. 52, 66, 68, 90, 130
de Jong, S. 68, 74
de Jonge, M. 113, 130
De Koning, M. 45, 90
de la Fuente-Sandoval, C. 85
de la Serna, E. 65, 130
de Leeuw, M. 61
De Luca, R. 114
De Luca, V. 67, 98, 130
de Millas, W. 95
de Quervain, D. 77
De Reus, M. 86
De Santi, K. 124
de Valk, H. 67
de Vos, A. 62
de Wit, N. 67
Deakin, B. 3, 66, 88
Dealberto, M. 49, 88
Decoster, J. 66, 90, 130
DeFries, A. 80, 97, 130
Değirmecioğlu, B. 93
Değirmencioğlu, B. 118
Dekker, C. 98
del Re, E. 92
Del-Bel, E. 99
Delbos, L. 65
Delcroix, N. 83, 130
Delevoye-Turrell, Y. 117
Delfabbro, P. 102
Delger, C. 97
DeLisi, L. 2, 3, 4, 9, 10, 12, 20, 21, 28, 34, 50, 69, 86, 130
DeMartinis, N. 99, 130
Demjaha, A. 70, 130
Dempster, E. 68, 130
Deneve, S. 93
Derks, E. 67, 76, 80, 113, 118, 130
Derom, C. 130
Deroza, P. 105, 114
Deroza, P. 105, 114
Desai, G. 60
Desbonnet, L. 61
Desco, M. 63, 125, 130
Deserno, L. 62
Deshpande, S. 68, 74, 112
Deslauriers, J. 82
Desmarais, C. 75
Desmarais, J. 99
Desmarais, S. 124
Dethmers, A. 117
Detke, H. 75, 77, 99, 121
Detke, M. 118, 130
DeVylder, J. 88
Di Fabio, F. 108
Di Forti, M. 19, 20, 30, 35, 67, 80, 89, 90, 102, 109, 111, 112, 118, 130
Di Giorgio, A. 62, 63, 72, 83, 84, 90, 130
Di Giovambattista, E. 120
di Sarno, E. 95
Diana, M. 105
Díaz-Caneja, C. 87, 98
Dicker, P. 92, 130
Dickerson, D. 60
Dickerson, F. 25
DiClemente, G. 80
Diederer, K. 76, 106, 107, 119, 130
Dieleman, S. 72
Dietsche, B. 64, 84, 86, 106
Diez, A. 110
DiForti, M. 112
Dinan, T. 61
Ding, A. 106
Dingemans, P. 110, 130
Dirks, B. 96, 121
Dmitrzak-Węglarz, M. 4, 70, 71, 112
Dmitrzak-Węglarz, M. 4, 70, 71, 112
Dogterom, C. 65
Dold, M. 99
Dollfus, S. 71, 83, 84, 93, 131
Dolz, M. 94, 131
Domen, P. 86, 106, 114
Domenici, E. 77
Dominguez, M. D. G., 125
Dominguez, T. 97
Domínguez-Martínez, T. 117
Donato, J. 94
Dong, E. 91
Donohoe, G. 91, 131
Doodeman, H. 78
Doody, G. 67, 81, 82, 87, 89, 100, 111, 131
Doriana, C. 95, 124
Dragovic, M. 91
Dragt, S. 110, 115, 131
Drake, R. 115, 131
Drees, J. 122, 131
Drouet, V. 70
Druid, H. 90
Drukker, M. 131
Du Preez, J. 104
Dubois, V. 75
Dubovsky, S. 113, 131
Düring, S. 88
Duffy, L. 96
Dugar, A. 120
Duhig, A. 70
Dumaine, A. 91, 131
Dunn, G. 74, 88, 131
Duque, A. 102
Duran, A. 113
Duran, F. 85
Duran-Sindreu, S. 105
Durstewitz, F. 90
Durstun, S. 131
Ebdrup, B. 84, 99, 131
Eberhardt, C. 67, 87
Eckbo, R. 64
Edden, R. 107
Edgar, C. 117, 131
Edginton, T. 118
Edlinger, M. 78, 80, 102, 131
Edman, G. 91
Edwards, B. 101
Egerton, A. 84, 131
Ehlikes, T. 86
Ek, M. 89
Elberling, H. 87
El-Derey, W. 88
Elisabetsky, E. 99
Elizagarate, E. 73, 97, 131
Elkis, H. 72, 95, 100, 131
Emerencia, A. 118
Emma, R. 91
Emsell, L. 63, 131
Emsley, R. 3, 4, 13, 44, 75, 76, 104, 131
Engler, H. 61
English, J. 71, 75, 92, 131
Eramo, A. 82
Erb, M. 62
Erdem, E. 96
Ereshefsky, L. 77, 131
Erlang, M. 88, 131
Erlenmeyer-Kimling, L. 97
Escandell, M. 79
Escarti, M. 97, 131
Espinosa, R. 104, 131
Esquivel, G. 69
Essig, M. 63, 108
Etard, O. 93
Ettinger, U. 62, 131
Evans, A. 131
Everheart, M. 105
Evins, E. 117, 131
Eyler, L. 63, 108
Eyles, D. 45, 71, 131



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

- Ezcurra, J. 73, 97, 131
Fagerlund, B. 87, 99, 116, 131
Fahy, T. 124
Falcón, C. 83
Falcone, A. 67, 131
Falkai, P. 51, 60, 61, 131
Falkenberg, I. 62, 85
Falkenberg, L. 85
Fañanás, L. 60, 73, 83, 90, 91, 92, 112, 131, 137
Fanning, F. 89
Faraone, S. 109, 125, 131
Faries, D. 97, 131
Farkas, K. 68
Farrelly, L. 71
Farrelly, S. 124
Fatjó-Vilas, M. 60, 73, 90, 91, 92, 112, 131
Fatouros Bergman, H. 72
Favila, R. 85, 131
Fazel, S. 31
Fazio, L. 62, 63, 72, 83, 84, 131
Fear, N. 101
Fearon, P. 12, 19, 67, 81, 82, 89, 100, 111, 131
Feifel, D. 56
Feldman, P. 78, 99
Feldman, S. 122, 131
Feldon, J. 61, 131
Felicetti, F. 120
Feo, C. 100
Ferchiou, A. 91, 131
Fernandes, A. 111
Fernandez, F. 70
Fernandez, I. 100
Fernandez, M. 72, 119
Fernandez-Borregan, C. 75
Ferrante, F. 84, 131
Ferraro, L. 30, 102, 131
Ferrer, I. 69
Fervaha, G. 76
Fett, A. 80, 86, 131
Filia, S. 79
Fillman, S. 114
Fink-Jensen, A. 87
Fischer, D. 121
Fisher, H. 30, 48, 67, 81, 82, 89, 90, 109, 111, 112, 131
Fisher, M. 117, 131
Fitzgerald, P. 64
Flanagan, R. 65, 82, 121
Fleischacker, W. 3, 11, 55, 78, 79, 99, 102, 120, 131
Fleischhcker, W. 80
Fletcher, P. 121
Flett, G. 102
Flohr, A. 77, 92
Floyd, R. 100
Flyckt, L. 91
Föcking, M. 71, 131
Foecking, M. 92
Fohlmann, A. 102, 131
Foix, A. 94
Foley, D. 110
Fone, K. 104, 131
Fonseca, J. 95
Forbes, R. 74
Forchhammer, H. 101
Forchuk, C. 101
Fornito, A. 23, 35, 131
Fors, A. 48
Fortin, G. 100
Fossard, M. 78
Foussias, G. 76, 131
Fraga, D. 105
Fraguas, D. 87
Frajo-Apor, B. 99
Franceschini, A. 102
Francey, S. 78, 131
Francis, A. 66, 69, 86, 93, 131, 132
Francis, H. 102
Franck, N. 93, 132
Frandsen, E. 114
Fransen, A. 81
Frascarelli, M. 108
Freeman, D. 132
Frei, N. 120
French, P. 110
Freudenreich, O. 63, 132
Friedel, E. 85
Friederich, H. 62
Friedman, T. 120
Frissa, S. 101
Frodil, T. 86, 132
Frogley, C. 121, 122
Frydecka, D. 69
Fryssira, H. 94
Fu, C. 62, 132
Fu, D. 75, 96
Fuentenebro, F. 102, 132
Fugger, L. 11, 43
Fujii, T. 70, 132
Fujimoto, S. 64, 107
Fujita, Y. 83
Fukuo, Y. 112, 132
Fukuyama, H. 107
Fulham, W. 104, 105, 132
Fumagalli, F. 103
Fung, S. 132
Furimsky, I. 124
Furuichi, A. 65, 107
Fusar-Poili, P. 64
Fusar-Poli, P. 8, 37, 119, 140
Gabrieli, J. 69, 125, 132
Gadel, R. 114, 132
Gadelha, A. 81, 91, 105
Gaebel, W. 3, 26, 95, 132
Gaillard, r V SOPRA
Gaillard, R. 81, 92, 93, 114
Gajwani, R. 57, 132
Gallagher, L. 113
Galletly, C. 58, 102, 110, 123, 132
Gallo, M. 108
Gama, C. 114
Ganeshan, B. 64
Gangadhar, B. 66, 132
Ganguli, R. 102
Gao, J. 96
Gaoo, C. 132
Garabette, J. 89, 111
Garbett, K. 82, 105
García, A. 98
Garcia, S. 100
garcia, t. 65, 132
García-Amador, M. 98, 132
Garcia-Franco, M. 79
García-García, M. 105
Garcia-Lecumberri, B. 92
García-Martí, G. 74, 132
García-Ribera, C. 76, 132
Garcia-Rizo, C. 92, 113, 132
Garcia-Rizo, C. 92, 113, 132
Gardener, C. 89, 111, 112
Gardiner, E. 91
Gardner, C. 67, 89
Gardner-Sood, P. 75
Garety, P. 119, 132
Garg, K. 68
Garibaldi, G. 77, 96, 123
gariup, m. 65
Garner, B. 103
Garnier, P. 75
Garozzo, A. 93
Garrett, C. 117, 132
Gasse, C. 67, 89
Gasso, P. 113
Gastambide, F. 45
Gastó, C. 73, 83
Gattaz, W. 3
Gauba, D. 112
Gaughran, F. 52, 75
Gautier, C. 74
Gavin, D. 91
Gawęda, & Se Lukasz 72
Gay, O. 92
Gayer-Anderson, C. 4, 67, 82, 89, 90, 111, 112
Gazard, B. 101
Gazi, A. 94
Gedeon R. 11, 55
Geerts, H. 99, 132
Gelao, B. 62, 63, 72, 83, 84, 90, 132
Geml, J. 80
Georgiades, A. 68
Gerret, L. 74
Gerretsen, P. 62
Gershon, A. 98
Gertsik, L. 78, 132
Gettig, E. 68
Geyer, M. 82, 122
Ghedim, F. 105
Giacca, A. 83, 99
Giampietro, V. 62, 132
Giannakopoulos, P. 81
Gicas, K. 72
Giersch, A. 117
Giesbrecht, C. 72
Gilbert-Juan, J. 69, 83
Giles, S. 85
Gill, K. 132
Gill, M. 91, 113, 132
Gillberg, C. 66, 132
Gilleen, J. 100, 132
Giovanolli, S. 61
Girard, T. 73
Girer, J. 79
Giusti, L. 91
Gjestad, R. 102
Glaentzlin, P. 92
Glahn, D. 85
Gleeson, J. 66, 95, 124, 132
Glenthøj, B. 3, 60, 62, 81, 84, 87, 88, 99, 114



- Glenthoj, B. 88, 132
 Gluud, C. 87, 132
 Gobbi, L. 92
 Gochman, P. 87
 Goebel, R. 84, 106, 132
 Goekoop, R. 106
 Goff, D. 11, 26, 31, 55, 63, 132
 Goghari, V. 45, 76, 80, 86
 Gogtay, N. 87, 132
 Gold, J. 109, 132
 Goldberg, T. 71, 132
 Goldberg, X. 73, 83, 92, 112, 132
 Goldstein, J. 63, 132
 Gomar, J. 90, 132
 Gomes, F. 4, 99
 Gomes, S. 99
 Gomez, D. 120, 132
 Gómez-Ansón, B. 105
 Gómez, J. 102, 125
 Gonçalves, C. 60, 99
 Gonçalves, Ó. 88
 Gonçalves, P. 73
 Gong, Q. 116
 Gonul, A. 125
 González Pinto, A. 63, 65, 73, 92, 98, 112, 119, 125, 132
 Gonzalez, B. 76
 González, I. 119
 Gonzalez, J. 66 (JODI), 72 (JULIO), 112 (JOSE)
 Gonzalez-Burgos, G. 51
 González-Oliveros, R. 73
 González-Ortega, I. 73, 119
 Gonzalez-Pinto, A. 63, 65, 73, 92, 98, 112, 119, 125, 132
 González-Pinto, A. V. 3
 Gooding, D. 97
 Goosens, F. 65
 Gopal, S. 75, 98
 Gordon, P. 73
 Goriely, A. 25
 Gorwood, P. 75, 95
 Gosselin, F. 80
 Gourdiér, C. 102
 Grace, A. 3, 4, 13, 45, 50, 56, 132
 Graell, M. 63, 65, 125, 133
 Graf von Reventlow, H. 97, 110, 133
 Graff-Guerrero, A. 62, 85, 122
 Gramfort, A. 63
 Grasa, E. 97, 105
 Gray, R. 79, 133
 Grayson, B. 103, 133
 Grayson, D. 91, 133
 Green, A. 64
 Green, M. 3, 4, 10, 13, 24, 46, 106, 110 (MICHAEL) – 64, 90, 91, 133 (MELISSA)
 Greenawalt, D. 66
 Greenstein, D. 87, 133
 Greenwood, K. 100, 133
 Greenwood, L. 45
 Griffiths, S. 74
 Grignon, S. 82
 Gromann, P. 65, 86
 Gronenschild, E. 86, 133
 Groome, D. 118
 Groot, C. 93
 Gross, G. 11, 55 (GERHARD) – 97 (GEORGINA)
 Gruber, O. 133
 Gruener, D. 117
 Gschwandtner, U. 114, 133
 Guada, J. 100, 133
 Güllmar, D. 87
 Guenette, M. 83
 Gürel, C. 77
 Guerrero-Pedraza, A. 90
 Güttgemanns, J. 109
 Guidotti, A. 91, 133
 Guidotti, G. 103
 Guillen-Grima, F. 102, 125
 Guimarães, F. 99
 Guinjoan, S. 84, 105, 133
 Guitart, M. 112
 Gunther, N. 102
 Gur, R. 74, 112, 133 S
 Gussew, A. 107, 133
 Gutierrez Galve, L. 86
 Gutierrez, M. 73, 97, 119, 133
 Gyertyan, I. 133
 Ha, K. 120
 Haapea, M. 89, 107
 Habets, P. 86, 106, 114, 133
 Haenschel, C. 84, 88, 133
 Hahn, C. 28
 Hahn, M. 76, 83, 99
 Hajima, S. 61
 Hall, G. 65
 Hall, J. 72, 85
 Hall, M. 62, 68, 133
 Hallerbäck, M. 66
 Halpin, S. 76, 133
 Hamaie, Y. 109, 133
 Hämäläinen, M. 63
 Hamilton, G. 113
 Hammer, T. 81, 133
 Hampshire, A. 72
 Handley, R. 67, 89, 90, 112, 133
 Handley, S. 65, 121
 Hanlon, M. 105, 123
 Hannan, A. 30
 Hao, X. 85
 Harder, S. 123
 Hargarter, L. 75, 95, 133
 Hargreaves, A. 91
 Harleston, D. 89, 90, 133
 Harley, M. 133
 Haro, J. 69, 77, 121, 133
 Haro-Abad, J. 112
 Haroutunian, V. 27, 59, 71
 Harrigan, S. 124
 Harris, A. 31, 40, 133
 Harris, M. 80, 124
 Harris, S. 100, 115, 124
 Harrow, M. 76
 Hartmann, M. 100
 Hartung, T. 92
 Harvey, B. 104
 Harvey, C. 123
 Harvey, L. 83
 Harvey, P. 3, 4, 8, 46, 76, 81, 94, 100, 133 – PHILIPPE-OLIVIER 106
 Harvey, R. 61
 Hashemi Sotoobadi, H. 117
 Hashikura, M. 115
 Hashimoto, K. 83,
 Hass, S. 70
 Hassan, S. 102
 Hassman, H. 117, 133
 Hatch, S. 101, 112
 Hattori, K. 70, 92, 115, 133
 Haucke, V. 28
 Hauser, J. 69, 70, 71, 112, 114, 133
 Hausmann, M. 93
 Haut, K. 4, 81
 Hayashi, M. 81
 Haynes, V. 91
 He, Z. 117, 133
 Hedman, A. 115, 133
 Heering, J. 87, 107
 Heinimaa, M. 94, 97, 110, 111, 125, 133
 Heinrichs, W. 65
 Heins, M. 97
 Heinz, A. 62, 85, 87, 109, 110, 133
 Helenius, D. 65
 Hella, P. 95, 133
 Helle, S. 102
 Hellerbach, A. 64, 86
 Helm, M. 113
 Henderson, J. 98
 Henquet, C. 94, 133
 Henry, L. 124
 Henskens, F. 96, 133
 Herdman, K. 73
 Hernandez, J. 103, 133
 Hernaus, D. 106
 Herold, C. 108, 133
 Herrlich, J. 61, 95, 133
 Herrmann, A. 99, 121
 Herrmann, E. 116
 Hervás, G. 104
 Herzig, D. 71, 115
 Herzog, M. 71
 Hewitt, P. 102
 Hides, L. 66
 Higier, R. 38
 Higuchi, T. 115, 133
 Hijman, R. 125
 Hirnstein, M. 93, 115
 Hissee, B. 102
 Hjorthøj, A. 102
 Hjorthøj, C. 46, 102, 115, 133
 Ho, S. 108
 Hochard, C. 74
 Hodgson, D. 104
 Hoe, M. 100
 Hoek, H. 68, 119, 133
 Hoertnagl, C. 79
 Hofer, A. 78, 79, 80, 102, 120, 133
 Hoffman, L. 116, 133
 Hofmann, C. 77, 100
 Holcomb, H. 107
 Holleran, L. 63
 Hollowell, B. 119
 Homberg, J. 104
 Hommes, J. 125
 Honer, M. 92
 Honer, W. 29, 51, 52, 72, 133
 Hong, E. 115



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

- Hong, K. 3, 4, 120
Hooker, C. 106, 134
Hopwood, M. 93, 134
Horan, W. 40, 123
Hori, H. 92, 115 (HIROAKI), 100 (HIKARU), 134
Hori, M. 107
Horn, C. 77
Horti, F. 83
Horvath, S. 105
Hosford, D. 11, 55
Hosheit, M. 86
Hotopf, M. 101, 111, 112
Hough, D. 98
Howes, O. 28, 56, 70, 75, 84, 120, 134
Hradetzky, E. 61
Hsiao, E. 82
Hsieh, M. 123
Hsu, J. 102
Hsu, S. 69
Hu, S. 113
Hua-Hall, M. 62
Huang, M. 80
Huang, Y. 123
Hubbard, K. 89
Huddy, V. 93, 134
Huerta-Ramos, E. 94
Hugdahl, K. 85, 115, 134
Hui, C. 76, 80, 117, 120, 134
Hukic, D. 90
Hulihan, J. 96
Hulshoff Pol, H. 35, 61, 68, 86, 108, 115, 134
Hulsken, S. 104
Hultman, C. 25
Hungria, F. 98, 105
Hunter, M. 104, 134
Hunter, R. 113
Hurst, C. 113
Hurtado-Casanova, A. 75
Hurtig, T. 111, 134
Hutchinson, G. 67, 111, 134
Huttunen, M. 3, 82, 134
Huys, Q. 62
Hwang, J. 108
Hwang, S. 93, 95, 134
Hwu, H. 123, 134
Hyötyläinen, T. 118
Iacoboni, M. 110
Iakimova, G. 94
Iasevoli, F. 69, 82, 120
Ibáñez, M. 60, 91
Idris, N. 103, 134
Ikeda, M. 112, 134
Ikeouchi-Sugita, A. 100
Ikezawa, S. 79
Ilonen, T. 94
Im, C. 88
Imai, N. 91
Incampo, A. 62
Interian, A. 66
Investigators, G. 80, 94, 110
Ira, E. 93
Ishige, Y. 120
Ishima, T. 83
Ishøy, P. 99
Ising, H. 110, 134
Iso, S. 72, 95, 134
Isohanni, I. 97
Isohanni, M. 89, 97, 107, 111, 118
Issy, A. 99
Itokawa, M. 91
Ivorra, J. 69, 112
Iwashiro, N. 85, 116
Iwata, K. 92, 105, 134
Iwata, N. 112, 122, 134
Iyegbe, C. 112
Jaaskelainen, E. 89, 94, 97, 107, 111, 118, 125, 134
Jääskeläinen, E. 89, 94, 97, 107, 111, 118, 125, 134
Jabbar, G. 69, 86
Jablensky, A. 91, 96, 134
Jackson, H. 93
Jackson, M. 58, 134
Jackson, P. 94
Jamain, S. 91, 134
James, A. 71, 134
Jang, J. 85, 108, 115, 134 (JOON HWAN) – 120, 122
Janson, E. 70
Janssen, B. 95
Janssen, J. 63, 125, 134
Janssens, M. 46
Jantzen, P. 87
Jardri, R. 93, 134
Jáuregui, O. 84
Javitt, D. 3, 120, 134
Jeffs, L. 124
Jenner, J. 97, 134
Jensen, J. 103
Jensen, K. 87
Jensen, L. 114
Jeon, I. 71, 100
Jeong, J. 120
Jeppesen, P. 67, 87, 123, 124, 134
Jepsen, J. 87, 109, 116
Jim, J. 82
Jim, O. 80
Jiménez-Arriero, M. 98
Jin, N. 74
Jlidi, A. 74
Joa, I. 123, 134
Joanna, H. 69, 70, 71, 112, 114
Joel, W. 74, 112
Joergensen, T. 87
Johannessen, J. 123
Johnsen, E. 85, 102, 120, 121, 134
Johnson, B. 75
Johnstone, E. 3, 72, 85, 134
Jones, K. 75
Jones, P. 29, 58, 67, 81, 82, 89, 92, 94, 100, 103, 107, 111, 125, 134
Joo, E. 113
Joo, Y. 81, 120, 134
Joober, R. 68, 83, 134
Jörg, F. 117
Jørgensen, H. 102, 120, 121, 134
Joukamaa, M. 111, 134
Jovic, S. 80
Joyce, D. 86
Joyce, E. 4, 13, 47, 86, 134
Juckel, G. 87, 95, 97, 109, 110, 134
Juelich, R. 69, 86, 125, 134
Jukuri, T. 125
Jung, H. 93, 134
Jung, W. 85, 108
Juola, P. 111
Kaakinen, M. 134
Kader, L. 70
Kahn, R. 3, 11, 27, 28, 43, 50, 52, 61, 65, 67, 68, 70, 76, 86, 95, 106, 107, 108, 113, 115, 118, 125, 134
Kaiser, S. 62, 135
Kajio, Y. 112
Kaladindi, S. 62
Kaladjian, A. 114
Kalidindi, S. 68
Kálmán, S. 82
Kalogerakou, S. 94, 135
Kambeitx, J SE KambeitS 135
Kamboj, S. 63
Kamenski, M. 122
Kane, F. 62, 68, 135
Kane, J. 3, 11, 20, 26, 31, 53, 55, 77, 98, 103, 135
Kang, D. 106
Kang, H. 120
Kang, J. 100, 119, 135
Kang, N. 74
Kang, S. 113, 135
Kankulu, B. 101
Kantrowitz, J. 4, 120
Kaon, A. 70
Kapelski, P. 69, 70, 71, 112, 114
Kapur, S. 3, 4, 10, 23, 32, 51, 52, 56, 70, 84, 119, 120, 121, 135
Karabon, L. 69
Karahan, S. 77
Karayiorgou, M. 10, 34, 135
Karci, O. 77
Kärgel, C. 110, 135
Karim Haidar, M. 92
Kariofillis, D. 110
Karl, J. 77
Karlovic, D. 112
Karlsson, H. 81
Karpouzian, T. 123
Kasai, K. 85, 116, 135
Kastner, P. 77
Katagiri, N. 107, 135
Kato, M. 120
Katsuki, A. 100
Katsura, M. 109, 135
Kaufmann, A. 79, 120, 135
Kaushik2, S. 116
Kawada, R. 107
Kawamoto, Y. 115, 135
Kawamura, T. 116
Kawamuro, Y. 116
Kawasaki, Y. 65, 107, 135
Kay-Lambkin, F. 79
Kayo, M. 72, 100, 135
Kearns, A. 122
Kebir, O. 89
Keefe, R. 3, 4, 13, 47, 73, 93, 110, 120, 122, 135
Kehr, J. 103
Keks, N. 26



- Kelin, K. 78, 135
Kelleher, I. 47, 58, 86, 135
Kellendonck, C. 24
Kelly, A. 70
Kelly, C. 105, 135
Kelly, D. 56, 57, 122, 135
Kemmler, G. 78, 80, 99, 102, 135
Kempton, M. 28, 135
Kennedy, D. 108
Kennedy, J. 67, 135
Keraite, A. 89, 90, 112
Kern Sliwa, J. 75, 96
Kern, R. 135
Kesby, J. 71, 135
Keshavan, M. 23, 64, 69, 86, 135
Khan, A. 80, 97, 116, 135
Khandaker, G. 67, 92
Kido, M. 65, 107, 135
Kiejna, A. 69
Kiis, K. 122
Kikinis, Z. 64
Killackey, E. 79, 135
Killen, E. 123
Kim, C. 110, 120, 135
Kim, D. 88
Kim, E. 120, 135
Kim, J. 73, 85, 96, 106, 112, 120, 135
Kim, K. 71, 116, 123, 135
Kim, L. 112
Kim, S. 73, 85, 88, 93, 101, 115, 120, 122, 135
Kim, Y. 93, 95, 112, 120, 135
Kimhy, D. 88
King, J. 73
King, M. 73, 135
King, R. 102
Kingston, T. 88
Kinon, B. 78, 91, 135
Kinoshita, Y. 115, 135
Kinsella, A. 88, 124, 135
Kirby, K. 82
Kircher, T. 4, 61, 64, 84, 86, 95, 102, 106, 107, 135
Kirkbride, J. 90, 135
Kirsch, C. 96, 121
Kishimoto, T. 4, 26, 53, 77
Kiss, B. 83, 103, 135
Kiviniemi, V. 107, 111
Kjelby, E. 121
Klaassen, R. 97, 110, 135
Klauber, D. 87
Kleinlein, P. 117
Kleisas, S. 94, 135
Klingberg, S. 61, 95, 109, 125, 135
Klöhn-Saghatolislam, F. 84
Klosterkoetter, J. 88, 115
Klosterkötter, J. 66, 76, 87, 95, 97, 109, 135
Knegtering, H. 84, 110, 116, 117, 121, 135
Knegtering, R. 84, 135
Knesevich, M. 96
Knop, F. 99
Knott, J. 98, 135
Knowles, E. 112, 135
Knowlton, B. 81
Knudsen, G. 114, 135
Koch, K. 64, 87, 135
Kodama, M. 91, 135
Koenders, L. 107
Koerner, M. 77
Koeter, M. 125
Koethe, D. 135
Koike, S. 85
Koivukangas, J. 107, 111, 125
Kokoszka, A. 72
Kolivakis, T. 99
Kondo, K. 112
Kong, D. 98
Kong, L. 63
Kong, W. 106
Konitsiotis, S. 121
Konrad, C. 84
Kontis, D. 93, 94, 135
Kontson, K. 107
Koo, M. 73, 85
Koo, S. 106
Kopala, L. 135
Koponen, H. 111, 118
Koren, D. 73, 87, 135
Korth, C. 39, 40
Korver-Nieberg, N. 101, 104
Korzechbor, A. 117
Koskela, J. 94
Koskinen, S. 68, 135
Kosten, T. 62
Köther, U. 100
Kott, A. 75
Koutsouleris, N. 37, 136
Kovak-Mufic, A. 112
Koyama, T. 135
Koychev, I. 88
Krabbendam, L. 65, 86, 136
Krarup, G. 124, 136
Kraus, M. 73, 110
Kravariti, E. 62, 68, 136
Krebs, M. 81, 89, 92, 93, 102, 114, 136
krebs, M. 81, 89, 92, 93, 102, 114, 136
Kreftez, D. 117
Kroken, R. 85, 102, 120, 121, 136
Krug, A. 61, 64, 84, 86, 95, 102, 106, 136
Kryzhanovskaya, L. 78
Kubicki, M. 64, 69, 86, 136
Kubota, M. 107
Kuennecke, B. 84
Kuepper, R. 35, 136
Kuipers, E. 31, 53, 136
Kulak, A. 39, 136
Kulcsarova, R. 90
Kumar, V. 99
Kumra, S. 36, 136
Kunugi, H. 70, 92, 115, 136
Kupferschmid, S. 66, 136
Kurachi, M. 65, 136
Kurti, A. 89, 90
Kurtz, M. 44, 94
Kusumawardhani, A. 69
Kwapil, T. 60, 82, 97, 112, 117, 136
Kwok, K. 74
Kwon, J. 3, 4, 13, 45, 71, 85, 96, 108, 115, 119, 120, 136
Kyaga, S. 39
Kyaw, M. 113
Kyllönen, M. 118
Kypraios, D. 94
La Barbera, D. 102, 109, 111, 118
La Cascia, C. 109, 111, 118, 136
Laan, W. 67, 101,
Lafuente, A. 92, 113
Lagodka, A. 93,
Lagopoulos, J. 117
Lahey, P. 101
Lai, D. 61
Lajnef, M. 91
Lako, I. 121
Lalonde, J. 122
Lam, L. 83
Lam, M. 76, 80, 120
Lam, S. 74, 83, 106, 122
Lambert, M. 66, 95
Lambert, T. 74
Lammers, D. 109
Lammertsma, A. 113
Lançon, C. 91
Landau, S. 93
Landín-Romero, R. 90
Landry, J. 99
Landsberg, M. 125
Lane, A. 89
Laneri, D. 64, 86
Lang, D. 72
Langan, C. 63
Langdon, R. 105, 122
Langeveld, J. 123
Langohr, K. 62
Lara, D. 91
Large, M. 31
Larouche, A. 82
Larr, A. 121
Larsen, A. 102
Larsen, T. 121, 123
Laruelle, M. 51
Lasalvia, A. 39, 93, 95, 124
Lässer, M. 108
Lasser, R. 96, 121
Lataster, J. 106
Lataster, T. 94, 122, 125
Latte, G. 69
Lau, J. 74
Laurens, K. 48, 64
Lauriello, J. 99
Laursen, T. 67, 89
Lautenschlager, M. 95
Lavoie, M. 78, 94
Lawford, B. 113
Lawlor, E. 124
Lawrie, S. 37, 61, 72, 85
Lawson, A. 78, 97
Lázaro, L. 91, 112
Lazzarotto, L. 124
Le Gall, E. 94
Le seac'h, A. 93
Leary, C. 61
Leboyer, M. 91
Lecardeur, L. 71
Lecomte, T. 79, 100
Lee, B. 100, 124
Lee, C. 112



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

- Lee, D. 102
Lee, E. 71, 100
Lee, F. 4
Lee, F. 4, 57, 108, 114, 136
Lee, G. 70
Lee, H. 106, 113
Lee, J. 96, 106, 110
Lee, K. 88, 106, 113
Lee, M. 57, 122, 123
Lee, S. 71, 88, 106
Lee, T. 115
Lee, Y. 96, 120, 122
Leeson, V. 86
Leff, J. 111
Lehmkuhl, G. 109
Leibundgut, N. 94
Leicht, S. 97
Leiguarda, R. 105
Lentz, E. 122
Lenz, C. 64
Leonard, S. 47, 62
León-Ortiz, P. 85
Lester, H. 74
Leszczynska-Rodziewicz, A. 69
Leube, D. 84
Leucht, C. 77
Leucht, S. 31, 44, 52, 53, 99
Levin, R. 83
Levine, S. 97, 110
Levitt, J. 64
Leweke, F. M. 32
Lewin, T. 76, 80
Lewis, G. 67, 115
Lewis, S. 29, 74, 88, 109
Leza, J. 70
Li, D. 62
Li, L. 70, 72
Li, Q. 74, 83
Liang, L. 63
Liaño, V. 97
Liao, H. 85
Liddle, P. 62, 86, 113
Lieb, R. 119, 125
Liemburg, E. 106, 110, 116, 121
Lienhart, A. 79
Light, G. 110
Lim, K. 62
Lim, M. 73, 120
Lim, T. 73
Linck, V. 99, 121
Lincoln, S. 106
Lincoln, T. 72, 100
Lindberg, P. 81
Linden, D. 84
Lindenmayer, J. 116, 121
Lindholm, P. 111
Linscott, R. 58
Linszen, D. 61, 87, 90, 97, 109, 110, 115
Linthicum, J.N. 122
Lisa, C. 95
Liu, A. 116
Liu, B. 91
Liu, C. 123
Liu, D. 102
Liu, L. 119
Liu, T. 76
Liu, Y. 98
Liu, Z. 117
Llorca, P. 91
Lo Bianco, L. 63, 84
Lobato, P. 125
Løberg, E. 85, 120
Loebel, A. 98, 102, 120
Loewenstein, D. 81, 94
Loh, H. 125
Lomas, B. 87
Long, C. 112
Looijestijn, J. 106
López, P. 119
Lorente-Rovira, E. 97
Loughland, C. 96, 104
Loukkola, J. 94
Louzã, M. 73
Lublin, H. 99
Lubman, D. 95
Luca, R. 105
Lucacchini, A. 91
Lugnegård, T. 66
Lui, S. 72, 116
Lunardi, P. 60, 99
Lunenburg, M. 98
Luoni, A. 103, 104
Luteijn, B. 65, 97
Lyne, J. 89
Lysaker, P. 74, 79
Ma, T. 60
Ma, Y. 75
Maat, A. 80
Maayan, L. 121
MacCabe, J. 29, 38, 39, 82, 89, 92, 121
MacDonald, A. 86
MacDonald, M.
MacDowell, K. 70
MacEwan, G.W. 72
Machado, M. 81
Machielsen, M. 107, 119
Machin, M. 88
Mackinnon, A. 66, 110
Maddalena, G. 90
Madigan, K. 124
Madsen, G. F. 88
Madsen, K. H. 60
Madsen, V. 124
Maes, J. 97
Magaud, E. 114
Magnusson, C. 89
Magro, C. 75
Maier, W. 95
Mak, H. 108
Makady, S. 81
Mäki, P. 48, 94, 111, 125
Makris, N. 63, 125
Malaspina, D. 25
Malherbe, P. 77
Malhotra, A. 24, 68
Malla, A. 68
Maller, J. 64
Maloney, E. 104
Mamo, D. 62, 122
Mancini, M. 62, 63, 72, 90
Mandl, R. 108
Mane, A. 75
Mann, S. 76, 99
Manschreck, T. 69
Mantua, V. 91
Manuela, R. 102
Manzano, J. 78
Mao, Y. 98
Maples, N. 23, 101
Marangon, V. 124
Marcelis, M. 45, 86, 106, 114
Marconi, M. 120
Marcus, R. 11, 55
Marder, S. 3, 9, 21, 29, 98, 120
Margalit, D. 119
Margolese, H. 99
Marie-José, van Tol, 108
Marinelli, V. 108
Marino, P. 121
Markulev, C. 103
Marmo, F. 82, 125
Marquetand, J. 106
Marsh, P. 40
Martí-Bonmatí, L. 74
Martin, J. 79
Martinez-Cengotitabengoa, M. 92
Martinez-Diaz, J. 75
Martinez-Perez, M. 75
Martin-Facklam, M. 77, 100
Martini, L. 93
Martin-Loeches, M. 110
Martin-Navarro, N. 75
Martins, C. 95, 108
Martins, P. 73
Martins-de-Souza, D. 59
Marzullo, G. 98
Mas, A. 83
Masana, G. 98
Masellis, R. 63, 72, 90
Mason, F. 122
Masramon, H. 102
Mathalon, D. 36
Matheson, S. 64
Matroos, G. 68
Matsuda, Y. 107
Matsumoto, K. 109
Matsuo, J. 115
Matsuoka, H. 109
Matsuzaki, H. 92
Mauri, M. 91
Mavreas, V. 121
Mayoral, F. 103
Mayoral, M. 65, 125
Mazzoncini, R. 93
McFarland, J. 101
McInerney, S. 101
McAlonan, G. 30, 74, 83, 105, 106, 108, 122
McCabe, K. 96, 104
McCarley, R. 9, 21, 47, 50, 64, 85, 88, 92
McCarthy, J. 66
McCarthy, P. 63
McCarthy, S. 38
McCombie, D. 38
McCormick, P. 121
McDonald, C. 63, 101
McDonald, G. 63
McDonnell, D. 77, 99, 121
McDougall, F. 103
McFarland, J. 63
McFarlane, A.
McGorry, P. 3, 23, 27, 66, 67, 103, 124



- McGrath, J. 3, 4, 13, 25, 29,
31, 47, 49, 71, 110
McGuffin, P. 11, 43, 113
McGuire, P. 28, 32, 37, 51, 62,
63, 64, 85, 103, 108
McGurk, S. 116
McIntosh, A. 72, 85
McIntosh, L. 76, 104
McIntyre, R. 99
McKay, M. 98
McKenna, P. 90
McLaughlin, D. 71
McLean, S. 103
McMahon, R. 122
McQuade, R. 74
McQueen, G. 67, 89, 90, 111,
112
McVie, A. 70
Meador-Woodruff, J. 28, 29, 71
Méary, A. 91
Mechelli, A. 103
Medalia, A. 40
Medcalf, R. 101
Medford, N. 64
Medina-Pradas, C. 117
Mehl, S. 125
Mehta, M. 106, 114
Meijer, C. 76, 87, 95, 101, 104,
109, 119
Meijer, J. 101
Meisenzahl, E. 50
Melaragno, M. 91
Melau, M. 91, 101, 123, 124
Melle, I. 23
Mellesdal, L. 121
Menezes, A. 95
Menezes, P. 3, 85
Menon, M. 62
Mentzel, C. 82, 95
Mercatili, M. 96
Merchán-Naranjo, J. 87
Mérida, E. 87
Merlo, M. 81, 123
Merten, J. 72
Meseguer, A. 92
Mestriner, P. 100
Metcalfe, J. 93
Meyer, E. 77
Meyer, U. 30, 61
Meyer-Lindenberg, A. 26, 29,
35, 50, 56
Michail, M. 74
Michel, C. 66, 90, 94, 111, 112
Michel, M. 91
Michel, T. 95
Michie, P. 86, 96, 104
Michielse, S. 86
Miess, S. 115
Miettunen, J. 89, 94, 97, 107,
111, 118, 128
Miewald, J. 64
Mikhailova, I. 92
Miles, A. 65
Mill, J. 68
Milleit, B. 107
Miller, R. 87
Milligan, G. 70
Mills, J. 101
Millward, T. 79
Mimura, M. 77, 122
Min, J. 112
Miñano, M. 112
Mintz, J. 23, 101
Minutko, V. 92
Miralles, M. 112
Miranda, I. 114
Miret, S. 91, 92, 112
Mirigliani, A. 108
Mirnics, K. 82, 105
Mirzakhani, H. 63, 108
Mishra, N. 68
Missonnier, P. 81
Mitchell, S. 122
Mitjavila, M. 60, 82
Miyata, J. 64, 107
Mizuki, Y. 91
Mizuno, M. 107
Model, F. 77
Modinos, G. 62, 103, 108
Modo, M. 121
Mohr, C. 71, 115, 116
Moilanen, I. 94, 111, 125
Moilanen, K. 97
Mojarad, M. 117
Molina, I. 85
Molina, V. 110
Möller, M. 104
Molloy, C.
Moltó, M. 69
Molto, M. 83, 112
Mondelli, V. 67, 89, 90, 112,
114, 121
Monje, A. 69
Monté, G. 90
Montgomery, P. 101
Montrose, D. 64
Moons, T. 68
Moore, L. 113
Moorhead, T. 61, 72, 85
Moran, P. 104
Moreau, J.-L. 84
Morena, J. 100
Moreno, A. 112
Moreno, C. 36
Moreno, D. 63, 87, 125
morer, a. 65
Morgan, C. 4, 39, 49, 67, 80-
82, 89, 90, 100, 101, 104, 109,
111, 112
Morgan, Celia 73, 84
Morgan, K. 67, 79, 81, 82, 89,
100, 11, 118
Morgan, V. 4, 47, 110
Mori, N. 92, 105
Morissette, S. 124
Morita, K. 107
Moritz, S. 10, 24, 72
Morris, B. 61, 70, 113
Morris, C. 113
Morris, D. 91
Morrison, A. 27, 87, 97, 109
Morrison, P. 32, 35
Mortensen, E. 116
Mortensen, P. 3, 11, 43, 89
Morvan, Y. 114
Mosanya, T. 80
Moss, J. 102
Mostawfi, M. 117
Mouchet-Mages, S. 92
Mowry, B. 96
Moya, J. 60
Mozos Ansorena, A. 72
Mrad, V. 105
Mueggler, T. 84
Müller, B. 61, 95, 110
Müller, C. 81
Mueller, D. 37, 116
Müller, H. 95
Mueller, K. 109
Müller, R. 66
Mueller, S. 26
Muggia, E. 20
Mukherjee, P. 72
Mukkala, S. 64, 111, 125
Mulè, A. 12, 19, 20, 64, 109,
111, 118, 125
Mulsant, B. 122
Munkholm, A. 67, 87
Munk-Jørgensen, P. 65
Muñoz, M. 91, 92, 112
Murai, T. 64, 107
Muralidharan, K. 66
Murphy, D. 100, 115, 124
Murray, G. 94, 111, 125
Murray, R. 3, 10, 19, 20, 24,
34, 35, 50, 52, 62, 67, 68, 70,
75, 80-82, 85, 89, 90, 92, 100,
102, 109, 111, 112, 118
Mutschler, D. 62
Myin-Germeys, I. 10, 29, 34,
66, 90, 94, 97, 102, 106, 119,
112
Naber, D. 3, 4, 75, 95, 139
Nacher, J. 69, 83
Nadrich, R. 70
Nagels, A. 106, 107, 139
Nagels, G. 66
Najman, J. 139
Nakamura, J. 100
Nakamura, K. 65, 107, 139
Nakamura, T. 104
Nam, H. 120
Napolitano, I. 95
Nasrallah, H. 96, 121
Natesan, S. 121, 139
Nathou, C. 93
Navarro, M. 112, 139
Nazir, P. 97
Nederveen, A. 61
Neil, A. 80
Neill, E. 73, 96, 118
Neill, J. 103, 139
Nejad, A. 84, 117
Nelson, B. 40, 41, 67, 97, 108,
139
Nemeroff, C. 105
Nemoto, T. 107, 139
Nenadic, I. 73, 87, 139
Nettis, M. 84
Newell, K. 139
Ng, S. 77
Nichols, H. 66, 73, 94
Nicolau, S. 124
Nicole, B. 75
Nicole, L. 75, 139
Nieboer, R. 106, 119, 139
Nielsen, M. 46, 62, 114, 139
Nielssen, O. 31



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

- Nieman, D. 97, 110, 115, 139
Niemi, J. 95, 139
Nienhuis, F. 119, 139
Nieto, L. 76, 125
Nieuwenhuis, M. 86
Nikiforuk, A. 104
Nikkinen, J. 107, 125
Niknazar, S. 117
Nikolaides, A. 88, 115, 139
Nilly, A. 92
Nilsson, L. 90
Nimgaonkar, V. 68, 74, 112
Nishimura, Y. 85
Niznikiewicz, M. 45, 88, 92
Noguchi, K. 65
Nogueira, M. 95
Nolen, W. 62, 106, 139
Nomura, J. 60
Noordsy, D. 4, 48, 139
Noori-Dalooi, M.
Nordentoft, M. 117
Nordgaard, J. 88, 119
Nordstrom, T. 111
Nordström, T. 94
Nori, P. 110
Normand, C. 123
Nothen, M. 139
Novack, R. 71
Novick, D. 77, 121, 139
Nuamah, I. 75, 98
Nuechterlein, K. 29, 81, 139
Nunez, D. 94
Nuñez-Marín, F. 105
Nurjono, M. 96
Nutche, J. 64
O'Callaghan, E. 88
O'Callaghan, E. 89, 90, 124, 139
O'Connell, K. 81
O'Connor, J. 111, 124, 139
O'Daly, O. 106, 139
O'Donnell, P. 4, 51, 66, 115, 139
O'Donoghue, B. 89, 139
O'Donovan, M. 27, 50, 139
O'Donovan, M. 27, 50, 139
O'Hanlon, E. 86
O'Neill, M. 61
O'Toole, B. 80
O'Tuathaigh, C. 61, 140
Oakley, C. 100, 115, 124
Oakman, E. 120
Obiols, J. 125
Ochoa, S. 76, 79, 94, 97, 125
Ochsner, K. 106
Oduola, S. 111
Oelkers-Ax, R. 94
Offord, S. 74
Ogasa, M. 102, 120, 139
Ogo, H. 120
Ogunwale, A. 80
Oh, K. 74
Oishi, N. 64
Ojeda, N. 73, 97, 139
Okahisa, Y. 91, 139
Okubo, Y. 117
Okunji, C. 99, 121
Oldehinkel, M. 84
Olié, J. 92, 139
Olie, J. 92, 139
Oliveres, J. 75, 139
Oliveira, C. 92, 113
Oliveira, G. 72, 95, 117, 139
Oliveira, V. 81
Olsen, B. 101, 124, 139
Olsen, C. 60
Olsen, E. 87
Olsson, E. 90
Olthof, T. 65
Olvet, D. 71
Omer, S. 90
Omuro, N. 109
Onyejiaka, A. 67, 89, 90, 111
Onyjiaka, A. 112
Oorschot, M. 122, 139
Ootsuka, Y. 70
Ophoff, R. 68, 70, 113, 139
Opler, M. 80, 97, 140
Opmeer, E. 106
Oppenheim, C. 92
Oranje, B. 81, 87, 88, 140
Orellana, G. 73
Oresic, M. 118, 140
Orlova, V. 92, 140
Orlovskaya, S. 89
Orozco, I. 70
Orrens, S. 74
Orsolini, G. 91
Ortet, G. 60, 91, 140
Ortiz-Gil, J. 90
Ortuño, F. 102, 125
Ösby, U. 52, 65, 90
Osman, D. 118
Ota, M. 92
Ota, V. 91, 105
Otero, S. 63, 65, 125, 140
Otsa, L. 95, 140
Ott, S. 97
Otte, W. 107
Ottoni, G. 91
Ouyang, X. 124
Owen, A. 72
Owen, M. 140
Owoeye, O. 88
Ozaki, N. 112, 140
Ozcelik, N. 125
Ozkan, B. 96
Ozsoy, S. 96
Pae, C. 112
Pagsberg, A. 87, 116
Pajonk, F. 48
Palaniyappan, L. 4, 45, 62, 86, 113, 140
Palermo, G. 77
Palmer, E. 89
Palmier-Claus, J. 88, 140
Palomo, T. 112
Panenka, W. 72
Pang, S. 108
Pankhurst, K. 124
Pankow, A. 85
Pantano, T. 108
Pantelis, C. 3, 10, 23, 24, 28, 70, 71, 96, 103, 108, 140
Papageorgiou, G. 75, 140
Papaleo, F. 69, 105
Paparelli, A. 67, 111, 140
Papassotiropoulos, A.
Papazacharias, A. 77
Papiol, S. 90, 140
Pappa, S. 121
Pardo, M. 94, 140
Parellada, M. 63, 65, 87, 125, 137, 140
Parente, F. 108
Pariante, C. 67, 89, 90, 106, 109, 112, 114, 121, 140
Park, B. 86
Park, G. 88
Park, H. 73, 85, 106, 108, 115, 140
Park, I. 85, 96, 140
Park, J. 71, 88, 100, 116
Park, S. 62, 66, 73, 76, 81, 93, 94, 96, 110, 140
Park, T. 74
Park, Y. 113
Parker, L. 68
Parnas, J. 87, 88, 119, 140
Paruch, J. 88, 115, 134, 140
Pasternak, O. 45
Patat, A. 77, 100
Patel, M. 65, 82, 121, 140
Paton, C. 98
Patterson, P. 82, 97, 110, 140
Paul, B. 74
Paul, D. 96, 140
Paul, L. 79
Pauli, A. 62
Paulik, G. 86
Pauls, A. 106, 114
Paulson, O. 60
Pawlak, E. 69
Pawlak, J. 69, 71, 114
Pawlbly, S. 106, 114
Pedersen, C. 49, 57, 140
Peel, A. 72
Peeters, S. 106
Pelaez, T. 94, 97
Pelayo-Teran, J. 75, 140
Pellegrino, R. 91
Peña, J. 73, 97, 140
Peña, M. 73
Penadés, R. 44, 92, 98, 140
Peña-Salazar, C. 102
Peng, W. 124
Penn, D. 73, 140
Penttilä, M. 118
Pepper, E. 113
Perälä, J. 68, 140
Peralta, V. 91, 140
Peres, F. 83
Perez Garcia, M. 72
Perez, O. 103, 140
Perez-Sola, V. 112
Perkins, D. 73, 93, 140
Perlini, C. 108, 140
Perongini, M. 120
Perrin, E. 75, 98
Perry, R. 70
Perry, S. 101
Petcu, C. 98
Peterman, J. 62, 76
Peters, E. 20, 57, 74, 119, 140
Peters, J. 92
Peterson, B. 85
Petit, E. 61
Petrides, G. 31



- | | | | |
|--|--------------------------------|---|--|
| Petryshen, T. 92 | Pousada-Casal, A. 109 | Rapagnani, M. 120 | Rius, F. 103 |
| Pettersson-Yeo, W. 103 | Pouzet, B. 77 | Rapisarda, A. 73, 110 | Riva, M. 61, 103, 104 |
| Peuskens, J. 3, 66, 140 | Povedano, E. 75 | Rapoport, J. 87 | Rivolta, D. 115 |
| Pflueger, M. 64, 140 | Powell, J. 111, 112 | Rapp, A. 61, 62, 95 | Rizzo, G. 90 |
| Phassouliotis, C. 103 | Powell, V. 99 | Rapp, C. 63, 64, 108, 114, 123 | Robbins, T. 7 |
| Phillips, L. 103 | Prakash, O. 60 | Rapp, M. 62, 85 | Robenzadeh, A. 77 |
| Phillips, G. 98, 140 | Prasad, K. 23, 64, 112 | Rashidi Nejad, A. 117 | Roberts, D. 37, 117 |
| Phillips, K. 80 | Prat, G. 79, 123 | Rask, C. 87 | Roberts, P. 99 |
| Picard, H. 93 | Pratt, J. 61, 70, 105, 113 | Rasmussen, H. 84, 99, 114 | Roberts, S. 97 |
| Picchioni, M. 62, 85, 100, 115, 121, 122, 124, 140 | Preisler, G. 72 | Rasser, P. 86 | Robertson, S. 119 |
| Pidsley, R. 68 | Prestia, D. 76, 100 | Rassovsky, Y. 110 | Roca, M. 75 |
| Pijnenborg, M. 44, 62, 74, 106, 140 | Price, G. 86 | Rates, S. 60 | Roche, E. 89 |
| Pikalov, A. 98, 102 | Priddle, T. 90 | Rauber, A. 88 | Roddy, S. 86 |
| Pilz, L. 99 | Pringle, D. 90 | Rauch, A. 78, 80 | Roder, C. 72 |
| Pina-Camacho, L. 87, 98 | Prinssen, E. 77 | Razafimandimby, A. 83, 84, 93 | Roder, J. 114 |
| Pinborg, L. 114, 140 | Proal, A. 86 | Read, L. 70 | Roder, V. 116 |
| Pinheiro, A. 88 | Proal, E. 105 | Rebollo-Mesa, I. 68 | Rodriguez Sarmiento, R. 77 |
| Pinho, M. 117 | Proctor, N. 102 | Reeder, C. 23, 93 | Rodriguez, J. 94 |
| Pino, O. 71, 140 | Project (AGP), A. 113 | Reichenbach, J. 64, 87, 107 | Rodriguez-Fonseca, C. 75 |
| Pins, D. 65 | Pronk, J. 65 | Reichenberg, A. 25, 38, 100, 102, 110, 112, 115 (Avi R.); 71, 101, 119 (Abraham R.) | Rodriguez-Huesca, R. 78, 101 |
| Pintore, S. 80 | Pruessner, J. 106 | Reig, S. 63, 125 | Rodríguez-Latorre, P. 87, 98 |
| Piskulic, D. 73, 95, 140 | Pu, W. 4, 63 | Reininghaus, U. 111 | Roebroek, A. 86 |
| Pizzagalli, F. 77 | Pugachova, I. 110 | Remington, G. 4, 67, 76, 77, 83, 99, 121, 132 | Roh, D. 120 |
| Plath, N. 60, 140 | Pugh, J. 124 | Renes, R. 95 | Roiser, J. 63 |
| Platt, B. 63 | Pugh, M. 124 | Reniers, R. 103 | Roivainen, E. 111 |
| Plaze, M. 92 | Puig, O. 65 | Renovell, M. 74, 97 | Rojo, J. 71 |
| Plessen, K. 109 | Pulay, A. 68 | Reocher-Rossler, A. 26 | Roman, P. 108 |
| Pletnikov, M. 25, 59, 60, 140 | Purcell, S. 38 | Réthelyi, J. 68 | Romaniuk, L. 61 |
| Plevier, C. 65 | Puthane, V. 66 | Rettenbacher, M. 102 | Romano, R. 62, 63, 72, 83, 84 |
| Pocelli, A. 62 | Pyka, M. 61, 84 | Rey-Bellet, P. 123 | Romero, M. 103 |
| Polat, S. 118, 119 | Qin, W. 69 | Reznik, N. 73, 87 | Romero, N. 104 |
| Polgár, P. 68 | Quan, M. 4, 64 | Ribeiro-dos-Santos, Â. 91 | Ron, M. 86 |
| Polito, V. 140 | Quarto, T. 62, 83, 84 | Richard, J. 112 | Ron, S. 119 |
| Pollock, B. 62, 122 | Quee, P. 94, 117 | Richards, J. 74 | Ros, A. 60, 82 |
| Pollutri, G. 111 | Quevedo, J. 105 | Richards, M. 103 | Rosa, A. 112 |
| Polsinelli, G. 98 | Rabinowitz, J. 44, 97 | Richards, T. 87 | Rosa, P. 85 |
| Pomarol-Clotet, E. 90, 140 | Racagni, G. 103, 104 | Richardson, C. 122 | Rose, J. 94 |
| Pons, A. 98 | Radulescu, E. 64 | Richetto, J. 47, 61 | Rosen, B. 63 |
| Pontes, L. 95 | Raedler, T. 101 | Richmond, R. 79 | Rosenbaum, S. 117 |
| Popolizio, T. 62, 63, 83, 84, 140 | Raghava, J. 62 | Riecher-Rössler, A. 63, 64, 108, 114, 123 | Rosenheck, R. 124 |
| Popp, D. 118 | Rahman, Z. 74 | Riedel, M. 95 | Ros-Morente, A. 112 |
| Porcelli, A. 72, 90, 140 | Rais, M. 108 | Rietberg, C. 117 | Rossell, S. 66, 73, 81, 93, 96, 101, 118 |
| Portela Traba, B. 72 | Rajewska-Rager, A. 69, 114 | Rietdijk, J. 110 | Rossi, A. 78, 95 |
| Porteous, D. 38, 140 | Rajparia, A. 70 | Rijsdijk, F. 68 | Rossi, R. 69 |
| Posselt, M. 102 | Ramadan, S. 85 | Rimas, H. 124 | Rossner, M. 60, 61 |
| Postmes, L. 114 | Rambaldelli, G. 108 | Riolo, R. 124 | Rostrup, E. 62, 99, 114 |
| Potkin, S. 96, 123, 140 | Rampazzo, A. 93 | Rissanen, I. 111 | Rothman, B. 97 |
| Poulin, J. 64 | Rampino, A. 62, 72, 83, 90 | Risterucci, C. 84 | Roura-Poch, P. 102 |
| Pousa, E. 76, 125 | Ranieri, R. 74, 77, 88, 96 | | Rouwenhorst, M. 109 |
| | Rapado, M. 125 | | Rowland, L. 107 |
| | Rapado-Castro, M. 63, 124, 125 | | Rowlands, C. 102 |



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

- Roy, P. 119
Rubin, L. 57
Rubini, G. 63
Rubinstein, K. 98, 119
Rubio, M. 4, 71
Rudaa, D. 87
Ruggeri, F. 78
Ruggeri, M. 20, 39, 93, 95, 124
Ruhmann, S. 36, 66, 76, 87, 88, 97, 109, 115
Ruiz de Azúa, S. 4, 73
Ruiz de Azua, S. 92, 119
Ruiz, A. 125
Ruiz, I. 76, 125
Rujescu, D. 4, 13, 38, 47
Rumeo, M. 118
Rupp, A. 94
Russell, V. 88, 90, 124
Rutten, B. 29, 69
Rydkjær, J. 87
Ryu, S. 120
Rzanny, R. 107
Saarni, S. 68
Sabbag, S. 76
Sabet-Rasekh, S. 119
Saby, A. 81
Saddichha, S. 4, 78
Saenz-Herrero, M. 92
Saez, A. 69, 83, 112
Saito, J. 107
Saiz-Ruiz, J. 112
Sakamoto, S. 91
Sakinofsky, I. 98
Saks, E. 20, 29
Sakurai, H. 122
Saldeen, A. 87
Salgado, P. 75
Sallet, P. 117
Salokangas, R.
Salvador, R. 87, 97, 109, 110
Salwen, K. 69
San, L. 95
Sanchez, P. 73, 97
Sanchez, R. 74, 77
Sanjuan, J. 69, 74, 97, 98, 112
Santarelli, D. 70
Santarelli, L. 77, 122
Santoro, M. 91, 105
Santos, B. 100
Santos, C. 105
Santos, J. 116
Santos, S. 91
Sarappa, C. 82
Sarma, K. 98
Sarret, P. 82
Sarró, S. 90
Sartory, G. 110
Sasamoto, A. 107
Sasayama, D. 70, 92, 115
Sato, J. 81
Satomura, Y. 85
Sauer, A. 115
Sauer, H. 64, 87, 107
Saunders, J. 75
Savitz, A. 98
Savoia, M. 100
Sawa, A. 25, 39, 60, 66
Sawabe, H. 120
Sawamoto, N. 107
Scala, S. 95, 109
Scanlon, C. 63, 101
Scaramello, N. 120
Scarone, S. 74, 77, 88, 96
Scazufo, M. 85
Scemes, S. 100
Schabetsberger, N. 99
Schacht, A. 98
Schachtzabel, C. 64, 87
Schaefer, A. 66
Schafer, D. 25
Schaffhauser, H. 77, 92
Schal, U. 96
Schall, U. 76, 86, 96, 104, 105
Schalling, M. 90
Schaufelbeger, M. 85
Schaufelberger, M. 85
Scheckner, B. 121
Schedlowski, M. 61
Scheewe, T. 48
Scheggia, D. 105
Scheyer, R. 73, 87
Schimmelmann, B. 66, 76, 90, 94, 111, 112
Schizophrenia Consortium (ISC), I. 113
Schlagenhauf, F. 62, 85
Schlatter, D. 77
Schlösser, R. 64, 87
Schmid, L. 108
Schmidt-Kastner, R. 69
Schmidt, A. 125
Schmidt, C. 99
Schmidt, H. 63, 101
Schmidt, M. 105, 116
Schmitz, N. 61
Schnack, H. 86, 108
Schneider, F. 95
Schnyder, N. 90
Schobel, S. 88
Schoevers, R. 117
Schofield, R. 101
Schooler, N. 26, 120
Schrag, Y. 116
Schreiner, A. 75, 95
Schroeder, J. 63
Schruers, K. 86
Schröder, J. 108
Schubart, C. 65
Schulte, P. 78, 82
Schultz, C. 64, 87,
Schultze-Lutter, F. 66, 76, 87, 90, 94, 97, 109, 110, 111, 112
Schulz, C. 50, 62
Schulz, S. 71
Schulze, K. 68
Schwab, S. 3, 4, 69
Scott, J. 58, 68
Scott, R. 86, 91, 96
Scully, P. 88
Seassau, M. 114
Seidl, U. 108,
Seidman, L. 36, 47, 63, 69, 73, 86, 109, 125
Selimovic, G. 118
Selten, J. 49, 56, 65, 68, 104
Selvaggi, P. 83
Seneviratne, G. 114
Seo, H. 113
serra, c. 65
Serret, S. 94
Seto, H. 65
Sevilmiş, &. 118, 119
Shah, G. 74
Shahbazi, A. 78, 117
Sham, P. 74, 83
Shan, B. 63
Shan, J. 123
Shannon Weickert, C. 3, 4, 49, 114
Sharma, M. 68
Shatapathy, C. 75
Shazad, A. 94
Sheinbaum, T. 60, 82
Shen, T. 78
Shenton, M. 3, 4, 64, 69, 86
Shepherd, A. 64, 88
Shergill, S. 64, 86
Sherin, J. 81
Shim, G. 108, 115
Shimoji, K. 107
Shimozaki, S. 79
Shin, I. 120
Shiraga, N. 107
Shirai, Y. 83
Shotbolt, P. 58
Shum, D. 72, 116
Sibinovic, V. 118
Sideli, L. 30, 11, 118
Siebner, H. 84
Siegwart, M. 66
Sierro, G. 116
Silic, A. 112
Silipo, G. 120
Silk, S. 75
Silva, R. 98, 102
Silverio, A. 105
Silvia, P. 97
Simmonite, M. 113
Simmons, A. 112
Simmons, M.
Simon, A. 64
Simon, G. 93
Simon, J. 62
Simons, C. 70
Sinclair, D. 115
Singer, W. 84, 115
Sinibaldi, L. 63, 83, 84, 90
Sirianni, M. 80
Sitnikova, T. 63
Siu, C. 77, 78, 83, 120
Sivapalan, S. 101
Skibinska, M. 69, 70, 71, 112, 114
Skilleter, A. 63
Skimminge, A. 81
Skovgaard, A. 67, 87
Slachevsky, A. 73
Slavkovic, V. 118
Slooff, C. 121
Slotema, C. 119
Sly, K. 76
Smeets, H. 67, 68
Smeets, F. 125
Smesny, S. 107
Smid, H. 116
Smieskova, R. 64, 108
Smith, E. 94
Smith, M. 91, 105, 123



- | | | | |
|--|------------------------------------|----------------------------------|-----------------------------------|
| Smith, S. 52, 75 | Stewart, M. 120 | Tabisch, J. 86 | Thomas, P. 62, 65, 75, 112 |
| Smyth, N. 79 | Stewart, R. 101, 110, 111 | Takahashi, H. 107, 117 | Thompson, A. 4, 67, 79 |
| Snyder, S. 60 | Steylen, P. 109 | Takahashi, T. 65, 107 | Thomson, D. 61, 70 |
| Soek Mun Yuen, E. 78 | Stieglitz, R. 64 | Takaki, M. 91 | Thomson, I. 110 |
| Sofocleous, C. 94 | Stiekema, A. 117 | Takano, Y. 85 | Thornton, A. 72 |
| Søgaard, L. 60 | Stilo, S. 67, 80, 89, 111, 112 | Takei, N. 3, 92, 105 | Thorup, A. 109, 123, 124 |
| Solano-Ruipérez, R. 116 | Stock, E. 124 | Takizawa, R. 85 | Tiedt, L. 86 |
| Solomon, M. 60 | Stoesser, D. 109 | Tamagni, C. 64, 108, 114 | Tighe, O. 61 |
| Solowij, N. 70 | Storrs, A. 109 | Tamminga, C. 3, 11, 43, 50 | Tihan, A. 124 |
| Somers, M. 70 | Stouten, L. 101 | Tan, E. 81, 101 | Tijssen, M. 82 |
| Sommer, I. 3, 31, 44, 57, 58, 68, 70, 76, 98, 106, 107, 118, 119 | Stowers, C. 79 | Tanaka, H. 92 | Tirkkonen, J. 95 |
| Sommer, J. 64, 86 | Stowkowy, J. 80, 119 | Tanaka, M. 40 | Todd, J. 73, 86, 104, 106 |
| Son, W. 113 | Stratmann, M. 64, 84, 86, 106, 107 | Tanaka, Y. 107 | Tognin, S. 108 |
| Song, L. 72 | Stratta, P. 78 | Tang, J. 76 | Tollenaar, P. 101 |
| Song, Y. 119 | Straube, B. 84, 107 | Tansella, M. 93, 108 | Tomasetti, C. 69, 125 |
| Sørensen, M. 88 | Strauss, G. 4, 97, 109 | Tanskanen, A. 82 | Tooney, P. 70, 90, 91, 96 |
| Soutullo, C. 105 | Stroup, S. 122 | Tao, H. 117 | Torniainen, M. 116 |
| Souza, C. 98, 105 | Studerus, E. 63, 64, 108, 114, 123 | Tapia-Casellas, C. 87, 98 | Torra, M. 98 |
| Souza, R. 105 | Study Group-Presenter Craig | Taricone, I. 20 | Tosato, S. 19, 39, 93, 124 |
| Sowden, S. 67, 89, 112 | Suazo, V. 110 | Tarragó, J. 71 | Tosic-Golubovic, S. 118 |
| Soygur, H. 77 | Subotnik, K. 81 | Tarricone, I. 19, 20, 30, 111 | Touloupoulou, T. 62, 85 |
| Spang, J. 72 | Subramaniam, K. 117 | Tarrier, N. 74 | Towell, T. 79 |
| Specht, K. 85 | Suckling, C. 70 | Tas, C. 79 | Trabajo-Vega, P. 75 |
| Spedding, M. 110 | Suckow, R. 70 | Taurisano, P. 62, 63, 72, 83, 84 | Trapp, E. 117 |
| Sperner-Unterweger, B. 11, 43 | Suga, M. 85 | Taxis, K. 121 | trias, g. 65 |
| Spindola, L. 105 | Sugihara, G. 64 | Taylor, D. 98, 121 | Tricklebank, M. 61 |
| Spiros, A. 99 | Sugurladze, S. 115 | Taylor, H. 112, 114 | Trinidad, P. 94, 97 |
| Sponheim, S. 86 | Suhara, T. 117 | Taylor, L. 66, 76, 93, 117 | Trotta, A. 4, 30, 92, 109 |
| Sporns, O. 35 | Sullivan, E. 115 | Tecic, T. 109 | Tsai, S. 115 |
| Sridhar, N. 121 | Sullivan, S. 115 | Tee, S. 125 | Tsaltas, E. 94 |
| Sriskandarajah, S. 120 | Summerfelt, A. 115 | Tempelaar, W. 65 | Tsan, J. 124 |
| Stain, H. 86, 104, 123 | Sun, J. 81, 116 | ten Have, M. 102, 125 | Tsang, J. 111 |
| Stam, K. 107 | Sun, L. 115 | ten Velden Hegelstad, W. 123 | Tseng, H. 63, 123 |
| Stanfield, A. 85 | Sunakawa, E. 109 | Tenback, D. 82, 95, 124 | Tsoutsoulas1, C. |
| Stauffer, V. 78, 91 | Sussmann, J. 72, 85 | Teo, C. 76, 83, 99 | Tsuang, M. 109, 125 |
| Stefanovic, M. 112 | Sutter, C. 92 | Teraishi, T. 70, 92, 115 | Tsuboi, T. 122 |
| Steinberg, T. 87 | Suvisaari, J. 68, 116, 118 | Terence, M. 95 | Tsujino, N. 107 |
| Steinbusch, H. 69 | Suzuki, K. 105 | Terlevic, R. 108 | Tukel, R. 124 |
| Steiner, J. 59 | Suzuki, M. 65, 107 | Termorshuizen, F. 67 | Tulloch, A. 111 |
| Steinhausen, H. 65, 109 | Suzuki, T. 122 | Tervonen, O. 107 | Tully, L. 4, 106 |
| Stenson, G. 105 | Suzy, A. 71 | Terwisscha van Scheltinga, A. 47 | Tundia, N. 70 |
| Stentebjerg-Olesen, M. 87 | Svarer, C. 114 | Tettamanti, M. 123 | Turkheimer, F. 120 |
| Stephano, S. 85 | Sveltini, A. 75 | Thak, J. 81 | Turkington, D. 10, 23, 24, 37, 74 |
| Sterk, B. 66 | Svisrskis, T., 81 | Thakkar, K. 62 | Turner, K. 71 |
| Sterkaj, F. 118 | Swart, M. 84 | Thanju, A. 116 | Turner, N. 89, 124 |
| Stevens, A. 119 | Swartz, M. 124 | Theochari, E. 94, 124 | Tuulio-Henriksson, A. 116 |
| Stevens, H. 110 | Sytema, S. 66, 118 | Thermenos, H. 69, 86, 109, 125 | Tyllis, P. 102 |
| Stevens, J. 117 | Szczepankiewicz, A. 70, 71, 112 | Thirithalli, J. 66 | Tzouli, S. 121 |
| Stevens, K. 78 | Taanila, A. 94, 111, 125 | Thomann, P. 63, 108 | Uchida, H. 4, 122 |
| Steward, L. 104 | | Thomas, N. 66, 93 | Uchida, T. 109 |
| | | | Uchitomi, Y. 91 |



3rd Schizophrenia International Research Society Conference

Schizophrenia: The Globalization of Research

- Ucok, A. 124
Ugarte, A. 119
Uhlhaas, P. 51, 115
Ujike, H. 91
Ulaş, H. 118, 119
Umbricht, D. 11, 55, 77, 122
Umene-Nakano, W. 100
Uranova, N. 59
Ursini, G. 62, 63, 72, 83, 84, 90
Usall, J. 76, 94, 125
v d Gaag, M. 97
Vakhrusheva, J. 120, 121
Valchera, A. 120
Valdez, G. 116
Valencia, M. 123
Valiente, A. 92, 113
Valiente, C. 102, 104
Vallejo, M. 102
Valli, I. 62
Valmaggia, L. 40
van 't Slot, R. 70
Van Amelsvoort, T. 61, 90
van Amelsvoort, T. 61, 90
van Baal, C. 115
van Baal, G. 108
van Berckel, B. 113
van Bergen, A. 68
van beveren, N. 97
van Buuren, M. 107
Van Dael, F. 119
van Dam, D. 104
van de Fliert, R. 101
van de Ven, V. 106
van den Brink, W. 125
van den Buuse, M. 26
van den Heuvel, E. 35, 61, 86, 116, 121
Van den Heuvel, M. 35, 61, 86
van den Hout, I. 95
van der Doef, T. 113
Van der Gaag, M. 27, 74, 101, 110
van der Heijden, F. 109
Van der Helm, M. 101
van der Krieke, L. 118
van der Leeuw, C. 114
van der Meer, F. 107, 119
van der Meer, J. 61
Van der Meer, L. 61, 62, 84, 106, 117
van der Meer, L. 62, 84, 106, 117
van der Valk, R. 95, 109
Van der Velde, J. 106
van der Ven, E. 65, 68, 104
van der Waerdt, S. 95
van Dijk, D. 82, 116, 125
Van Dorn, R. 124
van Dorsselaer, S. 102, 116
Van Duin, E. 90
van Eijk, K. 68, 70, 116
van Engeland, H. 113, 116
Van Erp, T. 81
van Es, F. 116
van Gasselt, A. 107
van Gastel, W. 65
Van Gool, A. 97, 119
van Haelst, I. 78
van Haren, N. 68, 86, 87, 95, 108, 113, 115
van Harten, P. 68, 82, 95, 124
van Kroonenburgh, M. 114
van Laere, K. 106
van Lutterveld, R. 76, 107
van Nierop, M. 102
Van Os, J. 3, 9, 10, 21, 27, 28, 32, 34, 56, 59, 65, 66, 67, 68, 69, 81, 86, 87, 90, 97, 102, 106, 114, 115, 119, 125
Van Snellenberg, J. 94
van Tricht, M. 115
van Winkel, R. 35, 66, 68, 70, 90, 102, 125
Vancampfort, D. 48
Vanover, K. 11, 55
Var, L. 118, 119
Vargas, G. 77
Vassilouli, S. 94
Vaughan, C. 31, 64, 76, 80, 90, 91, 96, 104
Vawter, M. 49
Vayisoğlu, S. 77
Vázquez, C. 104, 129
Vázquez, M. 98
Vecchio, C. 106, 114
Veen van der, F. 72
Vega, P. 73, 75, 92, 119
Veijola, J. 89, 94, 107, 111, 118, 125
Velehorsch, C. 80
Velikonja, T. 81, 89
Veling, W. 29, 49, 101, 110
Velligan, D. 3, 10, 20, 23, 37, 78, 101
Velthorst, E. 4, 97, 104, 110, 119
Veltman, D. 107
Vendramini, A. 83
Ventura, J. 81
Vercammen, A. 63, 84, 113
Verdecchia, M. 101
Verdurand, M. 114
Verhoeven, W. 109
Verkooijen, S. 118
Vermeulen, L. 95
Vernon, A. 121
Verweij, K. 67
Vesterager, L. 101, 105, 124
Viana, A. 60
Viechtbauer, W. 66
Viertö, S. 68
Vilamala, S. 79
Vila-Rodriguez, F. 72
Villa, H. 60
Villarreal, M. 83, 105
Villavicencio, P. 102, 104
Villella, G. 80
Villeneuve, K. 75
Vingerhoets, C. 107
Vink, M. 61, 107
Vinogradov, S. 36, 117
Vita, A. 3, 4, 19, 44
Vitalis, T. 114
Vizzotto, A. 95
Vogeley, K. 61, 95
Vogt, A. 77
Voisey, J. 113
Vollebergh, W. 97
von Hörsten, S. 81
von Kienlin, M. 84
von Reventlow, H. 87, 97, 109, 110, 133
Vorstman, J. 113
Vossen, H. 92
Vostrikov, V.
Vriend, S. 101
Vrkic, N. 112
Vucurovic, K. 114
Vyas, G. 122
Vyas, N. 46
Waddington, J. 3, 4, 7, 12, 13, 30, 45, 61, 88, 90, 124
Wagner, G. 3, 64, 81, 87
Wagner, M. 95, 122, 125
Wakuda, T. 105
Walker, E. 118
Walkinshaw, M.
Wallace, T. 77
Walling, D. 78
Walshe, M. 62, 68, 111
Walter, A. 64, 108, 114
Walter, H. 61, 65, 95
Wance, D. 116
Wang, J. 80
Wang, K. 72
Wang, L. 80
Wang, P. 124
Wang, Y. 116
Wang, Z. 124
Ward, P. 86, 117, 122
Watanabe, K. 77
Watanabe, T. 116
Waterreus, A. 110
Watkins, A. 117
Watson, S. 99
Watts, G. 110
Weber, M. 62
Webster, M. 70
Wedenoja, J. 116
Wehring, H. 122
Wei, R. 74, 83, 105, 106
Weickert, C. 4, 26, 49, 63, 70, 113, 114, 115
Weickert, T. 4, 26, 63, 113
Weinberger, D. 69, 105
Weis, S. 93
Weisbrod, M. 62, 94
Weiser, M. 3, 4, 27, 40, 41, 58, 71, 98, 119
Welch, K. 72, 85
Welie, H. 67
Wende, K. 107
Wendland, J. 77
Wentzel-Larsen, T. 212
Werbart, A. 72
Werbeloff, N. 46
Werge, T. 87
Wesnes, K. 117
West, J. 107
Westerhausen, R. 85, 115
Wettstein, J. 77, 84, 92
Wexler, B. 79, 85
Whalley, H. 61, 72, 85
Wheeler-Kingshott, C. 86
White, I. 92
White, T. 62
Whitfield-Gabrieli, S. 125
Whitfield-Gabrieli, S. 69



- Whittington, M. 110
Wibral, M. 115
Wicks, S. 81, 89
Widschwendter, C. 79, 102
Wiedemann, G. 61, 95, 109
Wiersma, D. 66, 116, 118, 119, 121
Wigman, J. 47, 57, 97
Wildenauer, D. 69
Wildenauer, M. 69
Wilkins, L. 73
Wilkinson, I.
Wilkosc, M. 70
Willard, D. 93
Williams, G.
Williams, J. 79, 118
Williams, S. 106, 114,
Wilquin, H. 79, 117
Wilson, F. 124
Wilson, J. 123
Winchester, C. 113
Windhorst, A. 113
Winkler, A. 85
Winter, G. 95
Winterer, G. 61
Witcher, J. 78
Wittchen, H. 119, 125
Wittorf, A. 61, 95, 125
Wobrock, T. 95
Wojciak, R. 117
Wolever, T. 99
Wolf, R. 62
Wolf, S. 48, 84, 115
Wolff, A. 60
Wolfinger, T. 78
Wölwer, W. 95
Wondmagegnehu, E. 78
Wong, A. 114
Wong, G. 76, 80, 117, 120
Wong, K. 83
Woo, T. 81
Wood, J. 74, 97, 112
Wood, S. 4, 23, 67, 79, 103, 108
Woodruff, P. 46
Woods, S. 73, 93
Wright, T. 106
Wu, A. 110
Wu, E. 106
Wu, G. 124
Wu, J. 83, 90, 91
Wu, R. 44
Wulff, S. 114
Wunderink, L. 66, 106, 110, 118, 119
Wykes, T. 3, 4, 13, 23, 37, 46, 72, 74, 93
Wyller, R. 111
Wynne, K. 75
Xu, D. 85
Xu, J. 98, 102, 113, 120
Xu, L. 91
Xu, M. 103
Xue, Z. 117, 124
Yağcıoğlu, A. 77
Yağcıoğlu, S. 77
Yahata, N. 116
Yalcin, N. 78, 79, 80
Yalınçetin, B. 118, 119
Yamasue, H. 116
Yang, B. 124
Yang, H. 113
Yang, J. 74
Yang, S. 81
Yang, X. 62
Yao, N. 108
Yaqub, M. 113
Yavaş, E. 118
Yavorsky, C. 80, 97
Yazıcı, M. 77
Yelland, G. 118
Yi, J. 88
Yi, W. 75, 96
Yilmaz, A. 125
Yoffe, R. 110
Yokomizo, J. 117
Yolken, R. 81, 112
Yonamine, C. 81
Yoo, J. 122
Yoon, H. 113
Yoon, J. 120, 122
Yoon, K. 74
Yoshida, H. 107
Yoshimura, R. 100
Yoshitake, T. 103
Young, J. 4, 30, 71, 100, 122
Young, M. 125
Young, R. 113
Yu, K. 108, 116
Yu, W. 68
Yuasa, S. 116
Yu-Chih, S. 113
Yücel, M. 23, 70
Yuen, H. 67, 78
Yung, A. 3, 4, 67, 71, 88, 96, 97, 108, 110, 116, 120, 122, 123
Zai, C. 67, 114
Zaki, J. 79, 92, 106, 112, 140
Zamberletti, E. 46
Zanatta, G. 124
Zandbelt, B. 61, 107
Zanetti, M. 85
Zanoni, M. 93
Zanta, N. 98, 105
Zapico-Merayo, Y. 75
Zararsız, G. 96
Zare Mehrgerdi, F. 117
Zavitsanou, K. 114
Zbinden, E. 83, 123
Zeber, J. 66, 80, 83, 124
Zeramardini, N. 83
Zhan, X. 62, 74, 83, 106, 122
Zhang, H. 63
Zhang, J. 68, 83
Zhang, X. 62, 83, 106, 122
Zhao, J. 63
Zhao, Y. 122
Zheng, L. 78
Zheng, W. 124
Zhou, S. 65
Zhou, X. 82
Zhu, B. 91
Zhu, H. 107
Zimbron, J. 67
Zipursky, R. 77, 124
Zivkov, M. 120
Zoppei, S. 124
Zugno, A. 105, 114
Zugno, A. 105, 114
Zunszain, P. 114
Zuraida Zainal, N. 67



M

DOB: 12/16/1975 F



We're trying to
treat **MARIA.**

So why are we only
testing medications
on **MARY?**

PRINTED IN USA ©2012, Lilly USA, LLC. ALL RIGHTS RESERVED.

Clinical trials are the most important way to evaluate the safety and efficacy of new medicines. We also know that ethnicity, lifestyle and genetics affect how medicines work in individual patients. But only 17% of participants in trials today represent minority populations.¹ This is especially challenging because many trials focus specifically on health conditions that impact minority groups at higher rates.

It's our responsibility to help close the gap. By 2050, minorities will make up 42% of the U.S. population.² We need more diverse representation in clinical trials to ensure treatments are safe and effective for all the people who use them. And we need your help.

For more information, or to learn about becoming an investigator, call 1-877-CTLILLY. Or, visit impact.nmanet.org.

¹ "Participation of Racial/Ethnic Groups in Clinical Trials and Race-Related Labeling: A Review of New Molecular Entities." U.S. Food and Drug Administration. <http://www.fda.gov/downloads/ForConsumers/ByAudience/ForPatientAdvocates/ParticipatinginClinicalTrials/UCM197589.pdf>. Accessed January 4, 2012.

² "United States Population Projections: 2000 to 2050," U.S. Census Bureau, <http://www.census.gov/population/www/projections/analytical-document09.pdf>. Accessed on January 4, 2012.





Otsuka— people creating new products for better health worldwide

The name “Otsuka” translates to “major milestone”. And indeed, for over 85 years, Otsuka’s people have achieved major milestones in their quest to create new products for better health. Otsuka is hard at work investigating potential new treatments, with numerous compounds in various stages of development to treat disorders of the cardiovascular, gastrointestinal, respiratory, renal, and central nervous systems, and to treat cancer and ophthalmic disorders. We’ve funded new research, supported new clinical trials, and pursued the development of new medications – an unfaltering commitment of energy and resources with one goal in mind – to create new products for better health worldwide.



1.800.562.3974 • www.otsuka-us.com

Otsuka America Pharmaceutical, Inc.

Otsuka Pharmaceutical Development & Commercialization, Inc.

Otsuka Maryland Medicinal Laboratories, Inc.